drug,sentence,title,doi,in-vitro evidence
angiotensin,"["" 'the binding of the sars - cov - 2 spike to angiotensin - converting enzyme 2 ( ace2 )  promotes virus entry into the cell.""]",Biosynthetic proteins targeting the SARS-CoV-2 spike as anti-virals.,10.1371/journal.ppat.1010799,"[['1 nm affinities and ec50 of 8 - 18 nm for neutralization of sars - cov - 2.', ' furthermore ,  f9 - c2 and or c2 - foldon effectively neutralized sars - cov - 2 variants ( including delta and omicron variants )  with ec50 values ranging from 13 to 32 nm.']]"
nitrogen,"["" in the nirmatrelvir - bound simulations ,  the nonnative h - bond is correlated with the loss of an important h - bond between glu166 and nirmatrelvir's lactam nitrogen at p1 position.""]",H172Y mutation perturbs the S1 pocket and nirmatrelvir binding of SARS-CoV-2 main protease through a nonnative hydrogen bond.,10.21203/rs.3.rs-1915291/v1,"[[' here we report the molecular dynamics ( md )  simulations as well as the measurements of stability ,  enzyme kinetics of h172y mpro ,  and ic50 value of nir -  matrelvir.']]"
hydrogen,"[' intriguingly ,  a native hydrogen bond ( h - bond )  between phe140 and the n terminus is replaced by a transient h -  bond between phe140 and tyr172.']",H172Y mutation perturbs the S1 pocket and nirmatrelvir binding of SARS-CoV-2 main protease through a nonnative hydrogen bond.,10.21203/rs.3.rs-1915291/v1,"[[' here we report the molecular dynamics ( md )  simulations as well as the measurements of stability ,  enzyme kinetics of h172y mpro ,  and ic50 value of nir -  matrelvir.']]"
nitrogen,"[' in the nirmatrelvir - bound simulations ,  the nonnative h - bond is correlated with the loss of an important h - bond between glu166 and nirmatrelvirs lactam nitrogen at p1 position.']",'H172Y mutation perturbs the S1 pocket and nirmatrelvir binding of SARS CoV-2 main protease through a nonnative hydrogen bond','10.1101/2022.07.31.502215',"[[' here we report the molecular dynamics ( md )  simulations as well as the measurements of stability ,  enzyme kinetics of h172y mpro ,  and ic50 value of nirmatrelvir.']]"
hydrogen,"[' intriguingly ,  a native hydrogen bond ( h - bond )  between phe140 and the n terminus is replaced by a transient h - bond between phe140 and tyr172.']",'H172Y mutation perturbs the S1 pocket and nirmatrelvir binding of SARS CoV-2 main protease through a nonnative hydrogen bond','10.1101/2022.07.31.502215',"[[' here we report the molecular dynamics ( md )  simulations as well as the measurements of stability ,  enzyme kinetics of h172y mpro ,  and ic50 value of nirmatrelvir.']]"
angiotensin,"["" 'sars - cov2 entry is mediated by binding of viral spike - protein( s )  to the transmembrane angiotensin - converting enzyme - 2 ( ace2 )  of the host cell."", ' however ,  ace2 cannot be blocked since its normal function is to convert the angiotensin ii peptide to angiotensin( 1 - 7 )  to reduce hypertension.']",'Recombinant Human ACE2-Fc : A promising therapy for SARS-CoV2 infection','10.1101/2022.07.30.501940',"[[' while maintaining its enzymatic activity ,  the molecule trapped and neutralized sars cov2 virus in vitro with an ic50 of 64 nm.']]"
honokiol,"[' honokiol is a small molecule from magnolia trees ,  for which several biological effects have been reported ,  ,  including anticancer and anti - inflammatory activity.', ' honokiol has also been shown to inhibit several viruses in cell culture.', ' in this study ,  we show that honokiol protected vero e6 cells from sars - cov - 2 - mediated cytopathic effect with an ec50 of 7.', ' in viral load reduction assays we observed that honokiol decreased viral rna copies as well as viral infectious progeny titers.', ' a time - of - addition assay showed that honokiol inhibited virus replication even when added post infection ,  suggesting it acts at a post - entry step of the replication cycle.', ' honokiol was also effective against more recent variants of sars - cov - 2 ,  including omicron and it inhibited other human coronaviruses as well.', ' our study suggests that honokiol is an interesting molecule to evaluate in animal studies and clinical trials to investigate its effect on virus replication and pathogenic ( inflammatory )  host responses.']",'Honokiol inhibits SARS-CoV-2 replication in cell culture','10.1101/2022.07.26.501656',"[[' in this study ,  we show that honokiol protected vero e6 cells from sars - cov - 2 - mediated cytopathic effect with an ec50 of 7.8 {micro}m.']]"
nystatin,"["" 'backgroundthere has been much speculation that polyene macrolide antibiotics ,  such as amphotericin b ( amb )  and nystatin ( nys )  may have antiviral activity against several viruses including sars - cov - 2.""]",'Determining the antiviral activity of two polyene macrolide antibiotics following treatment in Kidney Cells infected with SARS-CoV-2','10.1101/2022.07.23.501242',"[['  results and conclusionsamphotericin b ( amb )  showed a significant reduction in the tcid50 titer ,  with the 50% effective concentration ( ec50 )  of 1.24 {micro}m ,  which was 2.5 times lower than the cytotoxicity concentration.', ' in addition ,  when measuring viral inhibition by immunoassay ,  amb was significantly more potent than remdesivir ( ec50 31.8 nm vs.']]"
remdesivir,"[' in a second study ,  amb and remdesivir were incubated in kidney cells infected with the virus and inhibition of the virus was determined by an immunoassay.', ' in addition ,  when measuring viral inhibition by immunoassay ,  amb was significantly more potent than remdesivir ( ec50 31.']",'Determining the antiviral activity of two polyene macrolide antibiotics following treatment in Kidney Cells infected with SARS-CoV-2','10.1101/2022.07.23.501242',"[['  results and conclusionsamphotericin b ( amb )  showed a significant reduction in the tcid50 titer ,  with the 50% effective concentration ( ec50 )  of 1.24 {micro}m ,  which was 2.5 times lower than the cytotoxicity concentration.', ' in addition ,  when measuring viral inhibition by immunoassay ,  amb was significantly more potent than remdesivir ( ec50 31.8 nm vs.']]"
irbesartan,"['  methodsa serial dilution of amb ,  nys ,  and irbesartan ( a drug known to bind to the ace - 2 receptor as a positive control )  were then added ( n=4 at each concentration )  to the infected vero76 kidney cells in 100 {micro}l media.', ' nys and irbesartan both exhibited substantially less active and would not be considered a suitable choice for further investigations.']",'Determining the antiviral activity of two polyene macrolide antibiotics following treatment in Kidney Cells infected with SARS-CoV-2','10.1101/2022.07.23.501242',"[['  results and conclusionsamphotericin b ( amb )  showed a significant reduction in the tcid50 titer ,  with the 50% effective concentration ( ec50 )  of 1.24 {micro}m ,  which was 2.5 times lower than the cytotoxicity concentration.', ' in addition ,  when measuring viral inhibition by immunoassay ,  amb was significantly more potent than remdesivir ( ec50 31.8 nm vs.']]"
water,"[' using vero e6 cells ,  we measured the in vitro efficacy ( ic50 )  of stored ( frozen )  dried - leaf hot - water a.', ' annua hot - water extracts ( tea infusions )  could potentially provide a cost - effective approach to help stave off this pandemic virus and its rapidly evolving variants.']",'SARS-CoV-2 omicron variants succumb in vitro to Artemisia annua hot water extracts','10.1101/2022.07.22.501141',"[[' using vero e6 cells ,  we measured the in vitro efficacy ( ic50 )  of stored ( frozen )  dried - leaf hot - water a.', ' ic50 values normalized to the extract artemisinin ( art )  content ranged from 0.5 - 16.5 {micro}m art.', ' although ic50 values for these new variants are slightly higher than those reported for previously tested variants ,  they were within limits of assay variation.']]"
artemisinin,[' ic50 values normalized to the extract artemisinin ( art )  content ranged from 0.'],'SARS-CoV-2 omicron variants succumb in vitro to Artemisia annua hot water extracts','10.1101/2022.07.22.501141',"[[' using vero e6 cells ,  we measured the in vitro efficacy ( ic50 )  of stored ( frozen )  dried - leaf hot - water a.', ' ic50 values normalized to the extract artemisinin ( art )  content ranged from 0.5 - 16.5 {micro}m art.', ' although ic50 values for these new variants are slightly higher than those reported for previously tested variants ,  they were within limits of assay variation.']]"
eltrombopag,"[' through screening of a custom clinical compound library ,  we identified eltrombopag ( ddl - 701 )  ,  a thrombopoietin receptor agonist ,  as having plpro inhibitory activity that is sustained in the presence of the mpro inhibitor nirmatrelvir.']",'Identification of a Papain-Like Protease Inhibitor with Potential for Repurposing in Combination with an Mpro Protease Inhibitor for Treatment of SARS-CoV-2','10.1101/2022.07.18.500363',[[' ddl - 701 is already approved for treatment of thrombocytopenia and has previously been shown to achieve human plasma levels after oral dosing that is above the ic50 needed for it to exert its plpro inhibitory activity in vivo.']]
thrombopoietin,"[' through screening of a custom clinical compound library ,  we identified eltrombopag ( ddl - 701 )  ,  a thrombopoietin receptor agonist ,  as having plpro inhibitory activity that is sustained in the presence of the mpro inhibitor nirmatrelvir.']",'Identification of a Papain-Like Protease Inhibitor with Potential for Repurposing in Combination with an Mpro Protease Inhibitor for Treatment of SARS-CoV-2','10.1101/2022.07.18.500363',[[' ddl - 701 is already approved for treatment of thrombocytopenia and has previously been shown to achieve human plasma levels after oral dosing that is above the ic50 needed for it to exert its plpro inhibitory activity in vivo.']]
papain,"["" 'sars - cov - 2 requires two cysteine proteases for viral polypeptide processing to allow maturation and replication: the 3c - like protease also known as the main protease ( mpro )  and the papain - like protease ( plpro ) .""]",'Identification of a Papain-Like Protease Inhibitor with Potential for Repurposing in Combination with an Mpro Protease Inhibitor for Treatment of SARS-CoV-2','10.1101/2022.07.18.500363',[[' ddl - 701 is already approved for treatment of thrombocytopenia and has previously been shown to achieve human plasma levels after oral dosing that is above the ic50 needed for it to exert its plpro inhibitory activity in vivo.']]
cysteine,"["" 'sars - cov - 2 requires two cysteine proteases for viral polypeptide processing to allow maturation and replication: the 3c - like protease also known as the main protease ( mpro )  and the papain - like protease ( plpro ) .""]",'Identification of a Papain-Like Protease Inhibitor with Potential for Repurposing in Combination with an Mpro Protease Inhibitor for Treatment of SARS-CoV-2','10.1101/2022.07.18.500363',[[' ddl - 701 is already approved for treatment of thrombocytopenia and has previously been shown to achieve human plasma levels after oral dosing that is above the ic50 needed for it to exert its plpro inhibitory activity in vivo.']]
nitazoxanide,"[' herein we show that the anti - infective drug nitazoxanide has a potent antiviral activity against three human endemic coronaviruses ,  the alpha - coronaviruses hcov - 229e and hcov - nl63 ,  and the beta - coronavirus hcov - oc43 in cell culture with ic50 ranging between 0.', ' we found that nitazoxanide does not affect hcov adsorption ,  entry or uncoating ,  but acts at postentry level and interferes with the spike glycoprotein maturation ,  hampering its terminal glycosylation at an endoglycosidase h - sensitive stage.', ' altogether the results indicate that nitazoxanide ,  due to its broad - spectrum anti - coronavirus activity ,  may represent a readily available useful tool in the treatment of seasonal coronavirus infections.']",'Nitazoxanide is a potent inhibitor of human seasonal coronaviruses acting at postentry level: effect on viral spike glycoprotein','10.1101/2022.07.13.499346',"[[' herein we show that the anti - infective drug nitazoxanide has a potent antiviral activity against three human endemic coronaviruses ,  the alpha - coronaviruses hcov - 229e and hcov - nl63 ,  and the beta - coronavirus hcov - oc43 in cell culture with ic50 ranging between 0.05 and 0.15 g ml ,  and high selectivity indexes.']]"
cysteine,"["" 'using the regioselective cyanobenzothiazole condensation reaction with the n - terminal cysteine and the chloroacetamide reaction with an internal cysteine ,  a phage - displayed macrocyclic 12 - mer peptide library was constructed and subsequently validated."", ' the current study demonstrates that two kinetically - controlled reactions toward n - terminal and internal cysteines ,  respectively ,  are highly effective in the construction of phage - displayed macrocyclic peptides ,  and the selection based on the sars - cov - 2 spike epitopes is a promising methodology in the identification of peptidyl antivirals.']",'A Novel Regioselective Approach to Cyclize Phage-Displayed Peptides in Combination with Epitope-Directed Selection to Identify a Potent Neutralizing Macrocyclic Peptide for SARS-CoV-2','10.1101/2022.07.06.498864',"[[' antiviral tests against sars - cov - 2 showed that one macrocyclic peptide is highly potent against viral reproduction in vero e6 cells with an ec50 value of 3.1 micromolar.'], [' the alphalisa - detected ic50 value for this macrocyclic peptide was 0.3 micromolar.']]"
angiotensin,"["" 'the binding of the sars - cov - 2 spike to angiotensin - converting enzyme 2 ( ace2 )  promotes virus entry into the cell."", '  author summarythe entry of sars - cov - 2 in permissive cells is mediated by the binding of its spike to angiotensin - converting enzyme 2 ( ace2 )  on the cell surface.']",'Biosynthetic proteins targeting the SARS-CoV-2 spike as anti-virals','10.1101/2022.05.10.491295',"[['1 nm affinities and ec50 of 8 - 18 nm for neutralization of sars - cov - 2.', ' furthermore ,  f9 - c2 and or c2 - foldon effectively neutralized sars - cov - 2 variants ( including delta and omicron variants )  with ec50 values ranging from 13 to 32 nm.']]"
angiotensin,[' it could block angiotensin - converting enzyme 2 ( ace2 )  binding to the rbd in the s protein trimer via steric hindrance.'],'A cocktail containing two synergetic antibodies broadly neutralizes SARS-CoV-2 and its variants including Omicron BA.1 and BA.2','10.1101/2022.04.26.489529',"[[' importantly ,  an antibody cocktail containing 55a8 and 58g6 ( 2 - cocktail )  showed synergetic neutralizing activity with a half - maximal inhibitory concentration ( ic50 )  in the picomolar range in vitro and prophylactic efficacy in hamsters challenged with omicron ( ba.1 )  through intranasal delivery at an extraordinarily low dosage ( 25 g of each antibody daily )  at 3 days post - infection.']]"
remdesivir,"[' remdesivir ( rdv ,  veklury( r )  )  is a nucleoside analog prodrug and the first fda - approved antiviral treatment of covid - 19.']","'Remdesivir and GS-441524 retain antiviral activity against Delta, Omicron, and other emergent SARS-CoV-2 variants'",'10.1101/2022.02.09.479840',"[[' delta and omicron variants remained susceptible to rdv and gs - 441524 ,  with ec50 values 0.31 to 0.62 - fold of those observed against the ancestral wa1 isolate.', ' all other tested variants exhibited ec50 values ranging from 0.15 to 2.3 - fold of the observed ec50 values against wa1.']]"
remdesivir,"["" 'in vitro selection of remdesivir - resistant sars - cov - 2 revealed the emergence of a v166l substitution ,  located outside of the polymerase active site of the nsp12 protein ,  after 9 passages.""]",'In Vitro Selection of Remdesivir-Resistant SARS-CoV-2 Demonstrates High Barrier to Resistance.','10.1101/2022.02.07.479493',"[['3 - fold increase in ec50.', '5 - fold increase in ec50 was observed ,  indicating a high in vitro barrier to rdv resistance.']]"
papain,[' the main protease ( mpro )  and papain - like protease ( plpro )  are attractive drug targets among coronaviruses due to their essential role in processing the polyproteins translated from the viral rna.'],'Structure-based identification of naphthoquinones and derivatives as novel inhibitors of main protease Mpro and papain-like protease PLpro of SARS-CoV-2','10.1101/2022.01.05.475095',"[[' four compounds inhibited mpro with half - maximal inhibitory concentration ( ic50 )  values between 0.41 {micro}m and 66 {micro}m.', ' in addition ,  eight compounds inhibited plpro with ic50 ranging from 1.7 {micro}m to 46 {micro}m.']]"
remdesivir,"["" 'the in vitro effect of gs - 441524 ,  remdesivir ,  eidd - 1931 ,  molnupiravir and nirmatrelvir against the various sars - cov - 2 vocs ,  including omicron ,  was determined."", '  our results indicate that gs - 441524 ,  remdesivir ,  eidd - 1931 ,  molnupiravir and nirmatrelvir retain their activity against the vocs alpha ,  beta ,  gamma ,  delta and omicron.']","'Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern.'",'10.1101/2021.12.27.474275',"[[' the number of fluorescent pixels of gfp signal ,  determined by high - content imaging on day 4 post - infection ,  was used as read - out ,  and the ec50 of each compound on a viral isolate of each voc was calculated.']]"
glycine,"[' it inhibits the sars - cov - 2 main protease ( mpro )  and contains an  - ketoamide warhead ,  a p1 {beta} - cyclobutylalanyl moiety ,  a p2 dimethylcyclopropylproline ,  a p3 tert - butyl - glycine ,  and a p4 n - terminal tert - butylcarbamide.']",'The N-Terminal Carbamate is Key to High Cellular and Antiviral Potency for Boceprevir-Based SARS-CoV-2 Main Protease Inhibitors','10.1101/2021.12.18.473330',[[' they all have high potency with ec50 values around 1 m.']]
boceprevir,"["" 'boceprevir is an hcv nsp3 inhibitor that has been explored as a repurposed drug for covid - 19."", ' by introducing modifications at all four positions ,  we synthesized 20 boceprevir - based mpro inhibitors including pf - 07321332 and characterized their mpro inhibition potency in test tubes ( in vitro )  and human host cells ( in cellulo ) .', ' the original moieties at p2 ,  p3 and the p4 n - terminal cap positions in boceprevir are better than other tested chemical moieties for high in vitro potency.', ' based on all observations ,  we conclude that a p4 n - terminal carbamate in a boceprevir derivative is key for high antiviral potency against sars - cov - 2.']",'The N-Terminal Carbamate is Key to High Cellular and Antiviral Potency for Boceprevir-Based SARS-CoV-2 Main Protease Inhibitors','10.1101/2021.12.18.473330',[[' they all have high potency with ec50 values around 1 m.']]
carbamide,"[' it inhibits the sars - cov - 2 main protease ( mpro )  and contains an  - ketoamide warhead ,  a p1 {beta} - cyclobutylalanyl moiety ,  a p2 dimethylcyclopropylproline ,  a p3 tert - butyl - glycine ,  and a p4 n - terminal tert - butylcarbamide.', ' the p1 opal residue ,  p2 dimethylcyclopropylproline and p4 n - terminal tert - butylcarbamide make strong hydrophobic interactions with mpro ,  explaining high in vitro potency of inhibitors that contain these moieties.', ' all inhibitors including pf - 07321332 with a p4 n - terminal carbamide or amide have low in cellulo potency.']",'The N-Terminal Carbamate is Key to High Cellular and Antiviral Potency for Boceprevir-Based SARS-CoV-2 Main Protease Inhibitors','10.1101/2021.12.18.473330',[[' they all have high potency with ec50 values around 1 m.']]
alanine,"[' in its mpro complex structure ,  the p4 n - terminal isovaleramide is tucked deep in a small pocket of mpro that originally recognizes a p4 alanine side chain in a substrate.']",'The N-Terminal Carbamate is Key to High Cellular and Antiviral Potency for Boceprevir-Based SARS-CoV-2 Main Protease Inhibitors','10.1101/2021.12.18.473330',[[' they all have high potency with ec50 values around 1 m.']]
threonine,[' the installation of a p3 o - tert - butyl - threonine improves in cellulo potency.'],'The N-Terminal Carbamate is Key to High Cellular and Antiviral Potency for Boceprevir-Based SARS-CoV-2 Main Protease Inhibitors','10.1101/2021.12.18.473330',[[' they all have high potency with ec50 values around 1 m.']]
remdesivir,"["" 'the portfolio of sars - cov - 2 small molecule drugs is currently limited to a handful that are either approved ( remdesivir )  ,  emergency approved ( dexamethasone ,  baricitinib )  or in advanced clinical trials.""]",'Vandetanib Reduces Inflammatory Cytokines and Ameliorates COVID-19 in Infected Mice','10.1101/2021.12.16.472155',"[[' vandetanib ,  which targets the vascular endothelial growth factor receptor ( vegfr )  ,  the epidermal growth factor receptor ( egfr )  ,  and the ret - tyrosine kinase showed the most promising results on inhibition versus toxic effect on sars - cov - 2 - infected caco - 2 and a549 - hace2 cells ( ic50 0.79 um )  while also showing a reduction of > 3 log tcid50 ml for hcov - 229e.']]"
dexamethasone,"["" 'the portfolio of sars - cov - 2 small molecule drugs is currently limited to a handful that are either approved ( remdesivir )  ,  emergency approved ( dexamethasone ,  baricitinib )  or in advanced clinical trials.""]",'Vandetanib Reduces Inflammatory Cytokines and Ameliorates COVID-19 in Infected Mice','10.1101/2021.12.16.472155',"[[' vandetanib ,  which targets the vascular endothelial growth factor receptor ( vegfr )  ,  the epidermal growth factor receptor ( egfr )  ,  and the ret - tyrosine kinase showed the most promising results on inhibition versus toxic effect on sars - cov - 2 - infected caco - 2 and a549 - hace2 cells ( ic50 0.79 um )  while also showing a reduction of > 3 log tcid50 ml for hcov - 229e.']]"
baricitinib,"["" 'the portfolio of sars - cov - 2 small molecule drugs is currently limited to a handful that are either approved ( remdesivir )  ,  emergency approved ( dexamethasone ,  baricitinib )  or in advanced clinical trials.""]",'Vandetanib Reduces Inflammatory Cytokines and Ameliorates COVID-19 in Infected Mice','10.1101/2021.12.16.472155',"[[' vandetanib ,  which targets the vascular endothelial growth factor receptor ( vegfr )  ,  the epidermal growth factor receptor ( egfr )  ,  and the ret - tyrosine kinase showed the most promising results on inhibition versus toxic effect on sars - cov - 2 - infected caco - 2 and a549 - hace2 cells ( ic50 0.79 um )  while also showing a reduction of > 3 log tcid50 ml for hcov - 229e.']]"
vandetanib,"[' vandetanib ,  which targets the vascular endothelial growth factor receptor ( vegfr )  ,  the epidermal growth factor receptor ( egfr )  ,  and the ret - tyrosine kinase showed the most promising results on inhibition versus toxic effect on sars - cov - 2 - infected caco - 2 and a549 - hace2 cells ( ic50 0.', ' the in vivo efficacy of vandetanib was assessed in a mouse model of sars - cov - 2 infection and statistically significantly reduced the levels of il - 6 ,  il - 10 ,  tnf - a; ,  and mitigated inflammatory cell infiltrates in the lungs of infected animals but did not reduce viral load.', ' vandetanib rescued the decreased ifn - 1b; caused by sars - cov - 2 infection in mice to levels similar to that in uninfected animals.', ' our results indicate that the fda - approved vandetanib is a potential therapeutic candidate for covid - 19 positioned for follow up in clinical trials either alone or in combination with other drugs to address the cytokine storm associated with this viral infection.']",'Vandetanib Reduces Inflammatory Cytokines and Ameliorates COVID-19 in Infected Mice','10.1101/2021.12.16.472155',"[[' vandetanib ,  which targets the vascular endothelial growth factor receptor ( vegfr )  ,  the epidermal growth factor receptor ( egfr )  ,  and the ret - tyrosine kinase showed the most promising results on inhibition versus toxic effect on sars - cov - 2 - infected caco - 2 and a549 - hace2 cells ( ic50 0.79 um )  while also showing a reduction of > 3 log tcid50 ml for hcov - 229e.']]"
tyrosine,"[' vandetanib ,  which targets the vascular endothelial growth factor receptor ( vegfr )  ,  the epidermal growth factor receptor ( egfr )  ,  and the ret - tyrosine kinase showed the most promising results on inhibition versus toxic effect on sars - cov - 2 - infected caco - 2 and a549 - hace2 cells ( ic50 0.']",'Vandetanib Reduces Inflammatory Cytokines and Ameliorates COVID-19 in Infected Mice','10.1101/2021.12.16.472155',"[[' vandetanib ,  which targets the vascular endothelial growth factor receptor ( vegfr )  ,  the epidermal growth factor receptor ( egfr )  ,  and the ret - tyrosine kinase showed the most promising results on inhibition versus toxic effect on sars - cov - 2 - infected caco - 2 and a549 - hace2 cells ( ic50 0.79 um )  while also showing a reduction of > 3 log tcid50 ml for hcov - 229e.']]"
merimepodib,"[' we identified four molecules ,  including the broad - spectrum antiviral merimepodib vx - 497 ,  which show anti - nsp5 activity and inhibit sars - cov - 2 replication in a549 - ace2 cells with ic50 values in the 4 - 21 micromolar range.']",'A highly sensitive cell-based luciferase assay for high-throughput automated screening of SARS-CoV-2 nsp5/3CLpro inhibitors','10.1101/2021.12.18.473303',"[[' we identified four molecules ,  including the broad - spectrum antiviral merimepodib vx - 497 ,  which show anti - nsp5 activity and inhibit sars - cov - 2 replication in a549 - ace2 cells with ic50 values in the 4 - 21 micromolar range.']]"
threonine,"[' inhibitors that showed high in cellulo potency all contain o - tert - butyl - threonine at the p3 site.', ' based on the current and a previous study ,  we conclude that o - tert - butyl - threonine at the p3 site is a key component to achieve high cellular and antiviral potency for peptidyl aldehyde inhibitors of mpro.']",'The P3 O-Tert-Butyl-Threonine is Key to High Cellular and Antiviral Potency for Aldehyde-Based SARS-CoV-2 Main Protease Inhibitors','10.1101/2021.12.18.473326',"[[' these inhibitors have a large variation of determined ic50 values that range from 4.8 to 650 nm.', ' the determined ic50 values reveal that relatively small side chains at both p2 and p3 sites are favorable for achieving high in vitro mpro inhibition potency ,  the p3 site is tolerable toward unnatural amino acids with two alkyl substituents on the  - carbon ,  and the inhibition potency is sensitive toward the n - terminal protection group.']]"
cysteine,[' a covalent interaction between the active site cysteine and a bound inhibitor was observed in all structures.'],'The P3 O-Tert-Butyl-Threonine is Key to High Cellular and Antiviral Potency for Aldehyde-Based SARS-CoV-2 Main Protease Inhibitors','10.1101/2021.12.18.473326',"[[' these inhibitors have a large variation of determined ic50 values that range from 4.8 to 650 nm.', ' the determined ic50 values reveal that relatively small side chains at both p2 and p3 sites are favorable for achieving high in vitro mpro inhibition potency ,  the p3 site is tolerable toward unnatural amino acids with two alkyl substituents on the  - carbon ,  and the inhibition potency is sensitive toward the n - terminal protection group.']]"
carbon,"[' the determined ic50 values reveal that relatively small side chains at both p2 and p3 sites are favorable for achieving high in vitro mpro inhibition potency ,  the p3 site is tolerable toward unnatural amino acids with two alkyl substituents on the  - carbon ,  and the inhibition potency is sensitive toward the n - terminal protection group.']",'The P3 O-Tert-Butyl-Threonine is Key to High Cellular and Antiviral Potency for Aldehyde-Based SARS-CoV-2 Main Protease Inhibitors','10.1101/2021.12.18.473326',"[[' these inhibitors have a large variation of determined ic50 values that range from 4.8 to 650 nm.', ' the determined ic50 values reveal that relatively small side chains at both p2 and p3 sites are favorable for achieving high in vitro mpro inhibition potency ,  the p3 site is tolerable toward unnatural amino acids with two alkyl substituents on the  - carbon ,  and the inhibition potency is sensitive toward the n - terminal protection group.']]"
remdesivir,"[' the antiviral drug remdesivir was used as control.', '88 m for both virus variants ,  that of remdesivir between 1.']",'The Petasites hybridus CO2-extract (Ze 339) blocks SARS-CoV-2 replication in vitro','10.1101/2021.12.03.471068',"[[' pre - treatment with ze 339 in sars - cov - 2 infected vero e6 cells with either virus variant significantly inhibited virus replication with ic50 values of 0.10 and 0.40 g ml ,  repectively.', ' the ic50 values obtained for isopetasin ranged between 0.37 - 0.88 m for both virus variants ,  that of remdesivir between 1.53 - 2.37 m.']]"
papain,"[' however ,  the development of papain - like protease ( plpro )  inhibitors faces several obstacles.']",'Drug repurposing screening identified tropifexor as a SARS-CoV-2 papain-like protease inhibitor','10.1101/2021.12.02.471030',"[[' gratifyingly ,  tropifexor showed antiviral activity against sars - cov - 2 in calu - 3 cells with an ec50 of 4.03 {micro}m ,  a 7.8 - fold increase compared to grl0617 ( ec50 = 31.4 {micro}m ) .'], [' in this study ,  we conducted a drug - repurposing screening of plpro against the medchemexpress bioactive compound library and identified three hits ,  eacc ,  ky - 226 ,  and tropifexor ,  as potent plpro inhibitors with ic50 values ranging from 3.39 to 8.28 {micro}m.', ' in addition ,  tropifexor inhibited the cellular plpro activity in the flipgfp assay with an ic50 of 10.6 {micro}m.']]"
tropifexor,"[' in this study ,  we conducted a drug - repurposing screening of plpro against the medchemexpress bioactive compound library and identified three hits ,  eacc ,  ky - 226 ,  and tropifexor ,  as potent plpro inhibitors with ic50 values ranging from 3.', ' in addition ,  tropifexor inhibited the cellular plpro activity in the flipgfp assay with an ic50 of 10.', ' gratifyingly ,  tropifexor showed antiviral activity against sars - cov - 2 in calu - 3 cells with an ec50 of 4.', ' overall ,  tropifexor represents a novel plpro inhibitor that can be further developed as sars - cov - 2 antivirals.']",'Drug repurposing screening identified tropifexor as a SARS-CoV-2 papain-like protease inhibitor','10.1101/2021.12.02.471030',"[[' gratifyingly ,  tropifexor showed antiviral activity against sars - cov - 2 in calu - 3 cells with an ec50 of 4.03 {micro}m ,  a 7.8 - fold increase compared to grl0617 ( ec50 = 31.4 {micro}m ) .'], [' in this study ,  we conducted a drug - repurposing screening of plpro against the medchemexpress bioactive compound library and identified three hits ,  eacc ,  ky - 226 ,  and tropifexor ,  as potent plpro inhibitors with ic50 values ranging from 3.39 to 8.28 {micro}m.', ' in addition ,  tropifexor inhibited the cellular plpro activity in the flipgfp assay with an ic50 of 10.6 {micro}m.']]"
angiotensin,"["" 'soluble angiotensin - converting enzyme 2 ( ace2 )  constitutes an attractive antiviral capable of targeting a wide range of coronaviruses utilizing ace2 as their receptor."", ' these ace2 - fcs harbor structurally validated mutations that enhance spike ( s )  binding and remove angiotensin enzymatic activity.']",'Engineered ACE2-Fc counters murine lethal SARS-CoV-2 infection through direct neutralization and Fc-effector activities','10.1101/2021.11.24.469776',"[[' the lead variant bound tightly to s ,  mediated in vitro neutralization of sars - cov - 2 variants of concern ( vocs )  with sub - nanomolar ic50 and was capable of robust fc - effector functions ,  including antibody - dependent - cellular cytotoxicity ,  phagocytosis and complement deposition.']]"
moxidectin,"[' here ,  in vitro antiviral activity of the avermectins ( ivermectin and selamectin )  and milbemycins ( moxidectin and milbemycin oxime )  were assessed against a clinical isolate from a chu montpellier patient infected with sars - cov - 2 in 2020.', ' similarly ,  the other macrocyclic lactones moxidectin ,  milbemycin oxime and selamectin reduced sars - cov - 2 replication in vitro ( with ec50 of 2 - 5 m ) .', ' immunofluorescence assays with ivermectin and moxidectin showed a reduction in the number of infected and polynuclear cells suggesting a drug action on viral cell fusion.']",'Low selectivity index of ivermectin and macrocyclic lactones on SARS-CoV2 replication in vitro argues against their therapeutic use for COVID-19.','10.1101/2021.11.01.466865',"[[' ivermectin demonstrated anti - sars - cov - 2 activity in vitro in human pulmonary cells in comparison to veroe6 ( with ec50 of 1 - 3 m ) .', ' similarly ,  the other macrocyclic lactones moxidectin ,  milbemycin oxime and selamectin reduced sars - cov - 2 replication in vitro ( with ec50 of 2 - 5 m ) .']]"
ivermectin,"[' ivermectin was first approved for human use as an endectocide in the 1980s.', ' here ,  in vitro antiviral activity of the avermectins ( ivermectin and selamectin )  and milbemycins ( moxidectin and milbemycin oxime )  were assessed against a clinical isolate from a chu montpellier patient infected with sars - cov - 2 in 2020.', ' ivermectin demonstrated anti - sars - cov - 2 activity in vitro in human pulmonary cells in comparison to veroe6 ( with ec50 of 1 - 3 m ) .', ' immunofluorescence assays with ivermectin and moxidectin showed a reduction in the number of infected and polynuclear cells suggesting a drug action on viral cell fusion.', ' this is discussed in regards to recent clinical covid studies on ivermectin.']",'Low selectivity index of ivermectin and macrocyclic lactones on SARS-CoV2 replication in vitro argues against their therapeutic use for COVID-19.','10.1101/2021.11.01.466865',"[[' ivermectin demonstrated anti - sars - cov - 2 activity in vitro in human pulmonary cells in comparison to veroe6 ( with ec50 of 1 - 3 m ) .', ' similarly ,  the other macrocyclic lactones moxidectin ,  milbemycin oxime and selamectin reduced sars - cov - 2 replication in vitro ( with ec50 of 2 - 5 m ) .']]"
selamectin,"[' here ,  in vitro antiviral activity of the avermectins ( ivermectin and selamectin )  and milbemycins ( moxidectin and milbemycin oxime )  were assessed against a clinical isolate from a chu montpellier patient infected with sars - cov - 2 in 2020.', ' similarly ,  the other macrocyclic lactones moxidectin ,  milbemycin oxime and selamectin reduced sars - cov - 2 replication in vitro ( with ec50 of 2 - 5 m ) .']",'Low selectivity index of ivermectin and macrocyclic lactones on SARS-CoV2 replication in vitro argues against their therapeutic use for COVID-19.','10.1101/2021.11.01.466865',"[[' ivermectin demonstrated anti - sars - cov - 2 activity in vitro in human pulmonary cells in comparison to veroe6 ( with ec50 of 1 - 3 m ) .', ' similarly ,  the other macrocyclic lactones moxidectin ,  milbemycin oxime and selamectin reduced sars - cov - 2 replication in vitro ( with ec50 of 2 - 5 m ) .']]"
ribose,"["" 'we recently published a preliminary assessment of the activity of a poly ( adp - ribose )  polymerase ( parp )  inhibitor ,  stenoparib ,  also known as 2x - 121 ,  which inhibits viral replication by affecting pathways of the host."", ' stenoparib is an inhibitor of mammalian poly ( adp - ribose )  polymerases ( parps ) .', ' stenoparib is an inhibitor of mammalian poly ( adp - ribose )  polymerases ( parps ) .']","'Stenoparib, an inhibitor of cellular poly (ADP-ribose) polymerases (PARPs), blocks in vitro replication of SARS-CoV-2 variants'",'10.1101/2021.11.03.467186',"[['1 )  in vitro ,  with 50% effective concentration ( ec50 )  estimates of 4.1 m ,  8.5 m ,  24.2 m and 13.6 m ,  respectively.']]"
remdesivir,"['5 m remdesivir resulted in over 90% inhibition of the alpha ( b.', '7 )  variant ,  which is substantially greater than what was achieved with stenoparib or remdesivir alone at these concentrations.', ' to date ,  only two antiviral drugs ,  remdesivir and molnupiravir ,  or treatment with monoclonal antibodies ,  have been approved by the united states food and drug administration as covid - 19 therapies in certain situations.', ' a host - targeting therapeutic like stenoparib could be a significant benefit for covid - 19 patients as a standalone therapy ,  or especially as part of a combinatorial covid - 19 treatment strategy with an antiviral drug such as remdesivir or molnupiravir.']","'Stenoparib, an inhibitor of cellular poly (ADP-ribose) polymerases (PARPs), blocks in vitro replication of SARS-CoV-2 variants'",'10.1101/2021.11.03.467186',"[['1 )  in vitro ,  with 50% effective concentration ( ec50 )  estimates of 4.1 m ,  8.5 m ,  24.2 m and 13.6 m ,  respectively.']]"
rhamnose,"['7 kda is composed of rhamnose ,  galacturonic acid ,  galactose and arabinose in the molar ratio of 8.', ' there are four branches attached to c - 1 or c4 position of rhamnose glycosyl residues on the backbone.']",'Novel pectin from crude polysaccharide of Syzygium aromaticum against SARS-CoV-2 activities by targeting 3CLpro','10.1101/2021.10.27.466067',[['9% ( ec50 : 0.90 m ) .']]
pectin,"[' hence ,  we hypothesize that negative charged pectin glycan may also impede the virus replication.', ' the structure characterization demonstrated that 922211 is a homogalacturonan linked to rg - i pectin polysaccharide.']",'Novel pectin from crude polysaccharide of Syzygium aromaticum against SARS-CoV-2 activities by targeting 3CLpro','10.1101/2021.10.27.466067',[['9% ( ec50 : 0.90 m ) .']]
galactose,"['7 kda is composed of rhamnose ,  galacturonic acid ,  galactose and arabinose in the molar ratio of 8.']",'Novel pectin from crude polysaccharide of Syzygium aromaticum against SARS-CoV-2 activities by targeting 3CLpro','10.1101/2021.10.27.466067',[['9% ( ec50 : 0.90 m ) .']]
melittin,"[' in this study ,  we describe the anti - sars - cov - 2 activity of gramicidin s and melittin peptides obtained from bacillus brevis and bee venom respectively.', ' the ec50 values for gramicidin s and melittin are calculated as 1.', ' based on proteome analysis it was found that more than 250 proteins were found to be differentially regulated in the gramicidin s and melittin treated sars - cov - 2 infected vero cells against control sars - cov - 2 infected vero cells after 24 and 48 hours post infection.']",'Gramicidin S and Melittin - Potential anti-viral therapeutic peptides to treat SARS-CoV-2 infection','10.1101/2021.10.21.465254',[[' the ec50 values for gramicidin s and melittin are calculated as 1.571g and 0.656g respectively.']]
gramicidin,"[' in this study ,  we describe the anti - sars - cov - 2 activity of gramicidin s and melittin peptides obtained from bacillus brevis and bee venom respectively.', ' the ec50 values for gramicidin s and melittin are calculated as 1.', ' based on proteome analysis it was found that more than 250 proteins were found to be differentially regulated in the gramicidin s and melittin treated sars - cov - 2 infected vero cells against control sars - cov - 2 infected vero cells after 24 and 48 hours post infection.']",'Gramicidin S and Melittin - Potential anti-viral therapeutic peptides to treat SARS-CoV-2 infection','10.1101/2021.10.21.465254',[[' the ec50 values for gramicidin s and melittin are calculated as 1.571g and 0.656g respectively.']]
nystatin,"[' the viral envelope may be challenged by polyene antibiotics ,  such as nystatin ,  which has strong affinity to sterols.', ' nystatin may block the establishment of the virus - host cell connection ,  too.', ' in this study ,  the nystatin was investigated ,  as antiviral agent to sars - cov - 2.', ' we demonstrated by tests in vero e6 cell based cytopathic assay ,  nystatin blocked the replication of sars - cov - 2 in concentration 62.', ' nystatin might be the first one with emergency use authorization ,  either ,  as a safe and efficient non - systemic antiviral drug ,  with well - established use ,  since decades.']",'Repurposed nystatin to inhibit SARS-CoV-2 and mutants in the GI tract','10.1101/2021.10.19.464931',[['5 g ml ( ic50 )  at wuhan and british mutant strains.']]
pyronaridine,"[' out of these we previously identified pyronaridine ,  which inhibited the sars - cov - 2 replication in a549 - ace2 cells.', ' herein ,  the in vivo efficacy of pyronaridine has now been assessed in a k18 - hace transgenic mouse model of covid - 19.', ' pyronaridine treatment demonstrated a statistically significant reduction of viral load in the lungs of sars cov - 2 infected mice.', ' furthermore ,  the pyronaridine treated group reduced lung pathology ,  which was also associated with significant reduction in the levels of pro - inflammatory cytokines chemokine and cell infiltration.', ' notably ,  pyronaridine inhibited the viral plpro activity in vitro ( ic50 of 1.', ' interestingly ,  pyronaridine also selectively inhibits the host kinase camk1 ( ic50 of 2.', ' we have also generated several pyronaridine analogs to assist in understanding the structure activity relationship for plpro inhibition.', ' our results indicate that pyronaridine is a potential therapeutic candidate for covid - 19.', ' pyronaridine ,  an antiviral drug with in vitro activity against ebola ,  marburg and sars - cov - 2 has now statistically significantly reduced the viral load in mice along with il - 6 ,  tnf -  ,  and ifn - {beta} ultimately demonstrating a protective effect against lung damage by infection to provide a new potential treatment for testing clinically.']",'Pyronaridine Protects Against SARS-CoV-2 in Mouse','10.1101/2021.09.30.462449',"[[' notably ,  pyronaridine inhibited the viral plpro activity in vitro ( ic50 of 1.8 {micro}m )  without any effect on mpro ,  indicating a possible molecular mechanism involved in its ability to inhibit sars - cov - 2 replication.', ' interestingly ,  pyronaridine also selectively inhibits the host kinase camk1 ( ic50 of 2.4 {micro}m ) .']]"
remdesivir,"[' one of these is remdesivir ,  which was originally repurposed from its use against ebola and functions by causing early rna chain termination.']",'Pyronaridine Protects Against SARS-CoV-2 in Mouse','10.1101/2021.09.30.462449',"[[' notably ,  pyronaridine inhibited the viral plpro activity in vitro ( ic50 of 1.8 {micro}m )  without any effect on mpro ,  indicating a possible molecular mechanism involved in its ability to inhibit sars - cov - 2 replication.', ' interestingly ,  pyronaridine also selectively inhibits the host kinase camk1 ( ic50 of 2.4 {micro}m ) .']]"
disulfiram,"["" 'disulfiram is a 70 - year - old anti - alcoholism drug ,  while copper( ii )  gluconate ( cu( glu ) 2 )  is a commonly used food additive or copper supplement."", ' here we disclose that the combination of disulfiram and copper( ii )  gluconate drastically enhances the anti - sars - cov - 2 activity at the cellular level as compared to disulfiram or copper( ii )  gluconate alone.', ' a 1:1 mixture of disulfiram and copper( ii )  gluconate shows an ec50 value of 154 nm against sars - cov - 2 at the cellular level ,  much lower than the 17.', '45 m reported for disulfiram alone.']",'Copper(II) Gluconate Boosts the Anti-SARS-CoV-2 Effect of Disulfiram in Vitro','10.1101/2021.09.17.460613',"[[' a 1:1 mixture of disulfiram and copper( ii )  gluconate shows an ec50 value of 154 nm against sars - cov - 2 at the cellular level ,  much lower than the 17.45 m reported for disulfiram alone.']]"
copper,"["" 'disulfiram is a 70 - year - old anti - alcoholism drug ,  while copper( ii )  gluconate ( cu( glu ) 2 )  is a commonly used food additive or copper supplement."", ' here we disclose that the combination of disulfiram and copper( ii )  gluconate drastically enhances the anti - sars - cov - 2 activity at the cellular level as compared to disulfiram or copper( ii )  gluconate alone.', ' a 1:1 mixture of disulfiram and copper( ii )  gluconate shows an ec50 value of 154 nm against sars - cov - 2 at the cellular level ,  much lower than the 17.']",'Copper(II) Gluconate Boosts the Anti-SARS-CoV-2 Effect of Disulfiram in Vitro','10.1101/2021.09.17.460613',"[[' a 1:1 mixture of disulfiram and copper( ii )  gluconate shows an ec50 value of 154 nm against sars - cov - 2 at the cellular level ,  much lower than the 17.45 m reported for disulfiram alone.']]"
remdesivir,"[' the in vitro safety and anti - sars - cov - 2 activity of plant extracts were performed in veroe6 cells using remdesivir as positive control.', ' the percentage of sars - cov - 2 inhibition for atri - cov - e4 was better than remdesivir.', ' for e gene and n gene ,  remdesivir showed ic50 of 0.']","'In silico, In vitro Screening of Plant Extracts for Anti-SARS-CoV-2 Activity and Evaluation of Their Acute and Sub-Acute Toxicity'",'10.1101/2021.09.07.459230',"[[' for e gene and n gene ,  remdesivir showed ic50 of 0.15 {micro}m and 0.11 {micro}m respectively ,  for e gene and n gene ,  atri - cov - e4 showed ic50 of 1.18 {micro}g and 1.16 {micro}g respectively.']]"
water,"['  materials and methodsusing vero e6 cells ,  we measured anti - sars - cov - 2 activity of dried - leaf hot - water a.', ' annua hot - water extracts ( tea infusions )  ,  could provide a cost - effective therapy to help stave off the rapid global spread of these variants ,  buying time for broader implementation of vaccines.']",'Artemisia annua hot-water extracts show potent activity in vitro against Covid-19 variants including delta','10.1101/2021.09.08.459260',"[[' ic50 and ic90 values based on measured artemisinin content ranged from 0.3 - 8.4 m and 1.4 - 25.0 m ,  respectively.', ' the ic50 and ic90 values based on dried leaf weight ( dw )  used to make the tea infusions ranged from 11.0 - 67.7 g dw and 59.5 - 160.6 g dw ,  respectively.']]"
artemisinin,"[' this medicinal plant is effective against numerous infectious microbial and viral diseases and is used by many global communities as a source of artemisinin derivatives that are first - line drugs to treat malaria.', ' ic50 and ic90 values based on measured artemisinin content ranged from 0.']",'Artemisia annua hot-water extracts show potent activity in vitro against Covid-19 variants including delta','10.1101/2021.09.08.459260',"[[' ic50 and ic90 values based on measured artemisinin content ranged from 0.3 - 8.4 m and 1.4 - 25.0 m ,  respectively.', ' the ic50 and ic90 values based on dried leaf weight ( dw )  used to make the tea infusions ranged from 11.0 - 67.7 g dw and 59.5 - 160.6 g dw ,  respectively.']]"
hydrogen,"[' furthermore ,  the l452r mutation in rbd of delta variant forms an additional hydrogen bond with the hydroxy group of t30 of nb22 ,  leading to the increased neutralization potency of nb22 against delta variant.']",'Increased neutralization of SARS-CoV-2 Delta variant by nanobody (Nb22) and the structural basis','10.1101/2021.09.06.459055',[['4 - fold increased neutralization potency against delta variant with an ic50 value of 0.41 ng ml ( 5.13 pm )  relative to alpha variant.']]
leucine,"[' structural analysis of mpro complexed with a selenoether analogue of the highest - affinity peptide revealed key binding interactions ,  including glutamine and leucine residues in sites s1 and s2 ,  respectively ,  and a binding epitope straddling both protein chains in the physiological dimer.']",'Discovery of Antiviral Cyclic Peptides Targeting the Main Protease of SARS-CoV-2 via mRNA Display','10.1101/2021.08.23.457419',[[' several of these mpro peptide inhibitors possessed antiviral activity against sars - cov - 2 in vitro with ec50 values in the low micromolar range.']]
glutamine,"[' structural analysis of mpro complexed with a selenoether analogue of the highest - affinity peptide revealed key binding interactions ,  including glutamine and leucine residues in sites s1 and s2 ,  respectively ,  and a binding epitope straddling both protein chains in the physiological dimer.']",'Discovery of Antiviral Cyclic Peptides Targeting the Main Protease of SARS-CoV-2 via mRNA Display','10.1101/2021.08.23.457419',[[' several of these mpro peptide inhibitors possessed antiviral activity against sars - cov - 2 in vitro with ec50 values in the low micromolar range.']]
angiotensin,[' 2022 binds two non - overlapping epitopes simultaneously on the rbd of the sars - cov - 2 spike protein and blocks the binding of rbd to human angiotensin - converting enzyme 2 ( ace2 ) .'],'An ultrapotent neutralizing bispecific antibody with broad spectrum against SARS-CoV-2 variants','10.1101/2021.08.10.455627',"[[' the half - maximum inhibitory concentration ( ic50 )  of 2022 is 270 pm ,  30 pm ,  20 pm ,  and 1 pm ,  for wild - type ,  alpha ,  beta ,  and delta pseudovirus ,  respectively.', ' in the live virus assay ,  2022 has an ic50 of 26.4 pm ,  13.3 pm ,  and 88.6 pm ,  for wild - type ,  beta ,  and delta live virus ,  respectively.']]"
angiotensin,"[' we hypothesized that competitive enzyme linked immunoassays ( elisas )  based on sars - cov - 2 spike proteins receptor binding domain ( rbd )  attachment to its host receptor ,  the angiotensin converting enzyme 2 receptor ( ace2r )  ,  would correlate with prnt ,  given the central role of rbd - ace2r interactions in infection and published studies to date ,  and enable evaluation of vaccine responses.']",'Development and utilization of a surrogate SARS-CoV-2 viral neutralization assay to assess mRNA vaccine responses.','10.1101/2021.08.05.21261616',"[[' when the competitive elisa was used to evaluate n=32 samples from covid - 19 patients previously tested by prnt ,  excellent correlation in ic50 results were observed ( rs= .83 ,  p < 0.0001 ) .']]"
chloroquine,"[' antimalarial drugs ,  such as chloroquine ( cq )  hydroxychloroquine ( hcq )  and mefloquine have emerged as potential anti - sars - cov - 2 antivirals.']","'Unlike Chloroquine, mefloquine inhibits SARS-CoV-2 infection in physiologically relevant cells and does not induce viral variants.'",'10.1101/2021.07.21.451321',"[[' mefloquine inhibited sars - cov - 2 replication ,  including the gamma variant ,  in calu - 3 cells with low cytotoxicity and ec50 and ec90 values of 1.2 and 5.3 um ,  respectively.']]"
hydroxychloroquine,"[' antimalarial drugs ,  such as chloroquine ( cq )  hydroxychloroquine ( hcq )  and mefloquine have emerged as potential anti - sars - cov - 2 antivirals.']","'Unlike Chloroquine, mefloquine inhibits SARS-CoV-2 infection in physiologically relevant cells and does not induce viral variants.'",'10.1101/2021.07.21.451321',"[[' mefloquine inhibited sars - cov - 2 replication ,  including the gamma variant ,  in calu - 3 cells with low cytotoxicity and ec50 and ec90 values of 1.2 and 5.3 um ,  respectively.']]"
mefloquine,"[' antimalarial drugs ,  such as chloroquine ( cq )  hydroxychloroquine ( hcq )  and mefloquine have emerged as potential anti - sars - cov - 2 antivirals.', ' importantly ,  mefloquine is not a 4 - aminoquinoline like cq and hcq and has been previously repurposed for other respiratory diseases.', ' unlike the 4 - aminoquinolines that accumulate in the high ph of intracellular lysosomes of the lung ,  the high respiratory tract penetration of mefloquine is driven by its high lipophilicity.', ' accordingly ,  here we report the anti - sars - cov - 2 activity of mefloquine in calu - 3 type ii pneumocytes and primary human monocytes.', ' mefloquine inhibited sars - cov - 2 replication ,  including the gamma variant ,  in calu - 3 cells with low cytotoxicity and ec50 and ec90 values of 1.', ' in addition ,  mefloquine reduced up to 68% the sars - cov - 2 rna levels in infected monocytes ,  reducing viral - induced inflammation.', ' mefloquine blocked early steps of the sars - cov - 2 replicative cycle and was less prone than cq to induce drug - associated viral mutations and synergized with rna polymerase inhibitor.', ' the pharmacological parameters of mefloquine are consistent with its plasma exposure in humans and its tissue - to - plasma predicted coefficient points that this drug may accumulate in the lungs.', ' these data indicate that mefloquine could represent an orally available clinically approved drug option against covid - 19 and should not be neglected on the basis of the failure of cq and hcq.']","'Unlike Chloroquine, mefloquine inhibits SARS-CoV-2 infection in physiologically relevant cells and does not induce viral variants.'",'10.1101/2021.07.21.451321',"[[' mefloquine inhibited sars - cov - 2 replication ,  including the gamma variant ,  in calu - 3 cells with low cytotoxicity and ec50 and ec90 values of 1.2 and 5.3 um ,  respectively.']]"
remdesivir,"[' using this assay ,  we measured a half maximal inhibitory concentration ( ic50 )  for remdesivir of 9.']",'A SARS-CoV-2 nucleocapsid protein TR-FRET assay amenable to high-throughput screening','10.1101/2021.07.03.450938',"[[' using this assay ,  we measured a half maximal inhibitory concentration ( ic50 )  for remdesivir of 9.3 m against infection with sars - cov - 2 usa wa1 2020 ( wa - 1 ) .']]"
dihydroquercetin,"["" the docking simulation results predicted that (  +  )  - dihydrokaempferol ,  (  +  )  - dihydroquercetin ,  (  +  )  - dihydromyricetin ,  kaempferol ,  quercetin ,  myricentin ,  isoquercetin ,  and rutin could bind to at least two subsites ( s1 ,  s1' ,  s2 ,  and s4 )  in the binding pocket and inhibit the activity of sars - cov - 2 mpro.""]",'Flavonols and dihydroflavonols inhibit the main protease activity of SARS-CoV-2 and the replication of human coronavirus 229E','10.1101/2021.07.01.450756',[[' in vitro inhibition assays showed that seven available compounds effectively inhibited the sars - cov - 2 mpro activity and their ic50 values ranged from 0.125 to 12.9 um.']]
rutin,"["" the docking simulation results predicted that (  +  )  - dihydrokaempferol ,  (  +  )  - dihydroquercetin ,  (  +  )  - dihydromyricetin ,  kaempferol ,  quercetin ,  myricentin ,  isoquercetin ,  and rutin could bind to at least two subsites ( s1 ,  s1' ,  s2 ,  and s4 )  in the binding pocket and inhibit the activity of sars - cov - 2 mpro.""]",'Flavonols and dihydroflavonols inhibit the main protease activity of SARS-CoV-2 and the replication of human coronavirus 229E','10.1101/2021.07.01.450756',[[' in vitro inhibition assays showed that seven available compounds effectively inhibited the sars - cov - 2 mpro activity and their ic50 values ranged from 0.125 to 12.9 um.']]
quercetin,"["" the docking simulation results predicted that (  +  )  - dihydrokaempferol ,  (  +  )  - dihydroquercetin ,  (  +  )  - dihydromyricetin ,  kaempferol ,  quercetin ,  myricentin ,  isoquercetin ,  and rutin could bind to at least two subsites ( s1 ,  s1' ,  s2 ,  and s4 )  in the binding pocket and inhibit the activity of sars - cov - 2 mpro.""]",'Flavonols and dihydroflavonols inhibit the main protease activity of SARS-CoV-2 and the replication of human coronavirus 229E','10.1101/2021.07.01.450756',[[' in vitro inhibition assays showed that seven available compounds effectively inhibited the sars - cov - 2 mpro activity and their ic50 values ranged from 0.125 to 12.9 um.']]
kaempferol,"["" the docking simulation results predicted that (  +  )  - dihydrokaempferol ,  (  +  )  - dihydroquercetin ,  (  +  )  - dihydromyricetin ,  kaempferol ,  quercetin ,  myricentin ,  isoquercetin ,  and rutin could bind to at least two subsites ( s1 ,  s1' ,  s2 ,  and s4 )  in the binding pocket and inhibit the activity of sars - cov - 2 mpro.""]",'Flavonols and dihydroflavonols inhibit the main protease activity of SARS-CoV-2 and the replication of human coronavirus 229E','10.1101/2021.07.01.450756',[[' in vitro inhibition assays showed that seven available compounds effectively inhibited the sars - cov - 2 mpro activity and their ic50 values ranged from 0.125 to 12.9 um.']]
isoquercetin,"["" the docking simulation results predicted that (  +  )  - dihydrokaempferol ,  (  +  )  - dihydroquercetin ,  (  +  )  - dihydromyricetin ,  kaempferol ,  quercetin ,  myricentin ,  isoquercetin ,  and rutin could bind to at least two subsites ( s1 ,  s1' ,  s2 ,  and s4 )  in the binding pocket and inhibit the activity of sars - cov - 2 mpro.""]",'Flavonols and dihydroflavonols inhibit the main protease activity of SARS-CoV-2 and the replication of human coronavirus 229E','10.1101/2021.07.01.450756',[[' in vitro inhibition assays showed that seven available compounds effectively inhibited the sars - cov - 2 mpro activity and their ic50 values ranged from 0.125 to 12.9 um.']]
dihydromyricetin,"["" the docking simulation results predicted that (  +  )  - dihydrokaempferol ,  (  +  )  - dihydroquercetin ,  (  +  )  - dihydromyricetin ,  kaempferol ,  quercetin ,  myricentin ,  isoquercetin ,  and rutin could bind to at least two subsites ( s1 ,  s1' ,  s2 ,  and s4 )  in the binding pocket and inhibit the activity of sars - cov - 2 mpro.""]",'Flavonols and dihydroflavonols inhibit the main protease activity of SARS-CoV-2 and the replication of human coronavirus 229E','10.1101/2021.07.01.450756',[[' in vitro inhibition assays showed that seven available compounds effectively inhibited the sars - cov - 2 mpro activity and their ic50 values ranged from 0.125 to 12.9 um.']]
chloroquine,"[' we used this assay to analyze 30 literature reported mpro inhibitors including mpi1 - 9 that were newly developed aldehyde - based reversible covalent inhibitors of mpro ,  gc376 and 11a that are two investigational drugs undergoing clinical trials for the treatment of covid - 19 patients in united states ,  boceprevir ,  calpain inhibitor ii ,  calpain inhibitor xii ,  ebselen ,  bepridil that is an antianginal drug with potent anti - sars - cov - 2 activity ,  and chloroquine and hydroxychloroquine that were previously shown to inhibit mpro.', ' chloroquine and hydroxychloroquine showed close to undetectable cellular potency to inhibit mpro.']",'Cellular Activities of SARS-CoV-2 Main Protease Inhibitors Reveal Their Unique Characteristics','10.1101/2021.06.08.447613',"[[' our results also revealed that mpi5 ,  6 ,  7 ,  and 8 have high cellular and antiviral potency with both ic50 and ec50 values respectively below 1 m.', ' as the one with the highest cellular and antiviral potency among all tested compounds ,  mpi8 has a remarkable cellular mpro inhibition ic50 value of 31 nm that matches closely to its strong antiviral effect with an ec50 value of 30 nm.'], [' our results also revealed that mpi5 ,  6 ,  7 ,  and 8 have high cellular and antiviral potency with both ic50 and ec50 values respectively below 1 m.', ' as the one with the highest cellular and antiviral potency among all tested compounds ,  mpi8 has a remarkable cellular mpro inhibition ic50 value of 31 nm that matches closely to its strong antiviral effect with an ec50 value of 30 nm.']]"
boceprevir,"[' we used this assay to analyze 30 literature reported mpro inhibitors including mpi1 - 9 that were newly developed aldehyde - based reversible covalent inhibitors of mpro ,  gc376 and 11a that are two investigational drugs undergoing clinical trials for the treatment of covid - 19 patients in united states ,  boceprevir ,  calpain inhibitor ii ,  calpain inhibitor xii ,  ebselen ,  bepridil that is an antianginal drug with potent anti - sars - cov - 2 activity ,  and chloroquine and hydroxychloroquine that were previously shown to inhibit mpro.']",'Cellular Activities of SARS-CoV-2 Main Protease Inhibitors Reveal Their Unique Characteristics','10.1101/2021.06.08.447613',"[[' our results also revealed that mpi5 ,  6 ,  7 ,  and 8 have high cellular and antiviral potency with both ic50 and ec50 values respectively below 1 m.', ' as the one with the highest cellular and antiviral potency among all tested compounds ,  mpi8 has a remarkable cellular mpro inhibition ic50 value of 31 nm that matches closely to its strong antiviral effect with an ec50 value of 30 nm.'], [' our results also revealed that mpi5 ,  6 ,  7 ,  and 8 have high cellular and antiviral potency with both ic50 and ec50 values respectively below 1 m.', ' as the one with the highest cellular and antiviral potency among all tested compounds ,  mpi8 has a remarkable cellular mpro inhibition ic50 value of 31 nm that matches closely to its strong antiviral effect with an ec50 value of 30 nm.']]"
hydroxychloroquine,"[' we used this assay to analyze 30 literature reported mpro inhibitors including mpi1 - 9 that were newly developed aldehyde - based reversible covalent inhibitors of mpro ,  gc376 and 11a that are two investigational drugs undergoing clinical trials for the treatment of covid - 19 patients in united states ,  boceprevir ,  calpain inhibitor ii ,  calpain inhibitor xii ,  ebselen ,  bepridil that is an antianginal drug with potent anti - sars - cov - 2 activity ,  and chloroquine and hydroxychloroquine that were previously shown to inhibit mpro.', ' chloroquine and hydroxychloroquine showed close to undetectable cellular potency to inhibit mpro.']",'Cellular Activities of SARS-CoV-2 Main Protease Inhibitors Reveal Their Unique Characteristics','10.1101/2021.06.08.447613',"[[' our results also revealed that mpi5 ,  6 ,  7 ,  and 8 have high cellular and antiviral potency with both ic50 and ec50 values respectively below 1 m.', ' as the one with the highest cellular and antiviral potency among all tested compounds ,  mpi8 has a remarkable cellular mpro inhibition ic50 value of 31 nm that matches closely to its strong antiviral effect with an ec50 value of 30 nm.'], [' our results also revealed that mpi5 ,  6 ,  7 ,  and 8 have high cellular and antiviral potency with both ic50 and ec50 values respectively below 1 m.', ' as the one with the highest cellular and antiviral potency among all tested compounds ,  mpi8 has a remarkable cellular mpro inhibition ic50 value of 31 nm that matches closely to its strong antiviral effect with an ec50 value of 30 nm.']]"
bepridil,"[' we used this assay to analyze 30 literature reported mpro inhibitors including mpi1 - 9 that were newly developed aldehyde - based reversible covalent inhibitors of mpro ,  gc376 and 11a that are two investigational drugs undergoing clinical trials for the treatment of covid - 19 patients in united states ,  boceprevir ,  calpain inhibitor ii ,  calpain inhibitor xii ,  ebselen ,  bepridil that is an antianginal drug with potent anti - sars - cov - 2 activity ,  and chloroquine and hydroxychloroquine that were previously shown to inhibit mpro.', ' on contrary to their strong antiviral effects ,  11a ,  calpain inhibitor ii ,  calpain xii ,  ebselen ,  and bepridil showed relatively weak to undetectable cellular mpro inhibition potency implicating their roles in interfering with key steps other than just the mpro catalysis in the sars - cov - 2 life cycle to convene potent antiviral effects.']",'Cellular Activities of SARS-CoV-2 Main Protease Inhibitors Reveal Their Unique Characteristics','10.1101/2021.06.08.447613',"[[' our results also revealed that mpi5 ,  6 ,  7 ,  and 8 have high cellular and antiviral potency with both ic50 and ec50 values respectively below 1 m.', ' as the one with the highest cellular and antiviral potency among all tested compounds ,  mpi8 has a remarkable cellular mpro inhibition ic50 value of 31 nm that matches closely to its strong antiviral effect with an ec50 value of 30 nm.'], [' our results also revealed that mpi5 ,  6 ,  7 ,  and 8 have high cellular and antiviral potency with both ic50 and ec50 values respectively below 1 m.', ' as the one with the highest cellular and antiviral potency among all tested compounds ,  mpi8 has a remarkable cellular mpro inhibition ic50 value of 31 nm that matches closely to its strong antiviral effect with an ec50 value of 30 nm.']]"
ebselen,"[' we used this assay to analyze 30 literature reported mpro inhibitors including mpi1 - 9 that were newly developed aldehyde - based reversible covalent inhibitors of mpro ,  gc376 and 11a that are two investigational drugs undergoing clinical trials for the treatment of covid - 19 patients in united states ,  boceprevir ,  calpain inhibitor ii ,  calpain inhibitor xii ,  ebselen ,  bepridil that is an antianginal drug with potent anti - sars - cov - 2 activity ,  and chloroquine and hydroxychloroquine that were previously shown to inhibit mpro.', ' on contrary to their strong antiviral effects ,  11a ,  calpain inhibitor ii ,  calpain xii ,  ebselen ,  and bepridil showed relatively weak to undetectable cellular mpro inhibition potency implicating their roles in interfering with key steps other than just the mpro catalysis in the sars - cov - 2 life cycle to convene potent antiviral effects.']",'Cellular Activities of SARS-CoV-2 Main Protease Inhibitors Reveal Their Unique Characteristics','10.1101/2021.06.08.447613',"[[' our results also revealed that mpi5 ,  6 ,  7 ,  and 8 have high cellular and antiviral potency with both ic50 and ec50 values respectively below 1 m.', ' as the one with the highest cellular and antiviral potency among all tested compounds ,  mpi8 has a remarkable cellular mpro inhibition ic50 value of 31 nm that matches closely to its strong antiviral effect with an ec50 value of 30 nm.'], [' our results also revealed that mpi5 ,  6 ,  7 ,  and 8 have high cellular and antiviral potency with both ic50 and ec50 values respectively below 1 m.', ' as the one with the highest cellular and antiviral potency among all tested compounds ,  mpi8 has a remarkable cellular mpro inhibition ic50 value of 31 nm that matches closely to its strong antiviral effect with an ec50 value of 30 nm.']]"
papain,"[' one of the two enzymes ,  papain - like protease or plpro ,  also possesses deubiquitination and deisgylation activities that suppresses host innate immune responses toward sars - cov - 2 infection.']",'Drug Repurposing for the SARS-CoV-2 Papain-Like Protease','10.1101/2021.06.04.447160',"[[' more comprehensive characterizations revealed 7 inhibitors grl0617 ,  sjb2 - 043 ,  tcid ,  dub - in - 1 ,  dub - in - 3 ,  pr - 619 ,  and s130 with an ic50 value below 60 m and four inhibitors grl0617 ,  sjb2 - 043 ,  tcid ,  and pr - 619 with an ic50 value below 10 m.', ' among four inhibitors with an ic50 value below 10 m ,  sjb2 - 043 is the most unique in that it doesnt fully inhibit plpro but has an outstanding ic50 value of 0.56 m.']]"
cysteine,"["" 'as the pathogen of covid - 19 ,  sars - cov - 2 encodes two essential cysteine proteases that process the pathogens two large polypeptide translates orf1a and orf1ab in human host cells to form 15 functionally important ,  mature nonstructural proteins."", ' to repurpose drugs for plpro ,  we experimentally screened 33 deubiquitinase and 37 cysteine protease inhibitors on their inhibition of plpro.', ' our results showed that 15 deubiquitinase and 1 cysteine protease inhibitors exhibit potent inhibition of plpro at 200 m.']",'Drug Repurposing for the SARS-CoV-2 Papain-Like Protease','10.1101/2021.06.04.447160',"[[' more comprehensive characterizations revealed 7 inhibitors grl0617 ,  sjb2 - 043 ,  tcid ,  dub - in - 1 ,  dub - in - 3 ,  pr - 619 ,  and s130 with an ic50 value below 60 m and four inhibitors grl0617 ,  sjb2 - 043 ,  tcid ,  and pr - 619 with an ic50 value below 10 m.', ' among four inhibitors with an ic50 value below 10 m ,  sjb2 - 043 is the most unique in that it doesnt fully inhibit plpro but has an outstanding ic50 value of 0.56 m.']]"
angiotensin,"[' further analysis identified allosteric binders to host receptor angiotensin - converting enzyme 2 ,  which were able to inhibit the entry of pseudoparticles bearing spike protein of wild type sars - cov - 2 as well as south african b.']",'A hybrid in silico approach reveals novel inhibitors of multiple SARS-CoV-2 variants','10.1101/2021.06.04.447130',"[[' experimental testing with live virus provided 100 ( ~16% of predicted hits )  active compounds ( efficacy > 30% ,  ic50 [&le;] 15 m ) .']]"
nafamostat,"[' similarly ,  inhibition of tmprss2 protease activity by camostat mesylate or nafamostat mesylate prevents infection mediated by the tmprss2 - dependent and cathepsin - independent pathway.', ' here ,  we combined the use of apilimod with camostat mesylate or nafamostat mesylate and found an unexpected ~5 - 10 fold increase in their effectiveness to prevent sars - cov - 2 infection in different cell types.', ' they include apilimod ,  an inhibitor of pikfyve kinase and camostat mesylate and nafamostat mesylate ,  inhibitors of tmprss2 protease.', ' our research is significant for having uncovered an unexpected synergism in the effective inhibitory activity of apilimod used together with camostat mesylate or with nafamostat mesylate.']",'Synergistic inhibition of two host factors that facilitate entry of Severe Acute Respiratory Syndrome Coronavirus 2','10.1101/2021.06.01.446623',[[' the substantial ~5 fold or more decrease of half maximal effective concentrations ( ec50 values )  suggests a plausible treatment strategy based on the combined use of these inhibitors.']]
camostat,"[' similarly ,  inhibition of tmprss2 protease activity by camostat mesylate or nafamostat mesylate prevents infection mediated by the tmprss2 - dependent and cathepsin - independent pathway.', ' here ,  we combined the use of apilimod with camostat mesylate or nafamostat mesylate and found an unexpected ~5 - 10 fold increase in their effectiveness to prevent sars - cov - 2 infection in different cell types.', ' they include apilimod ,  an inhibitor of pikfyve kinase and camostat mesylate and nafamostat mesylate ,  inhibitors of tmprss2 protease.', ' our research is significant for having uncovered an unexpected synergism in the effective inhibitory activity of apilimod used together with camostat mesylate or with nafamostat mesylate.']",'Synergistic inhibition of two host factors that facilitate entry of Severe Acute Respiratory Syndrome Coronavirus 2','10.1101/2021.06.01.446623',[[' the substantial ~5 fold or more decrease of half maximal effective concentrations ( ec50 values )  suggests a plausible treatment strategy based on the combined use of these inhibitors.']]
apilimod,"[' the pikfyve kinase inhibitor apilimod interferes with late endosomal viral traffic ,  and through an ill - defined mechanism prevents in vitro infection through late endosomes mediated by cathepsin.', ' here ,  we combined the use of apilimod with camostat mesylate or nafamostat mesylate and found an unexpected ~5 - 10 fold increase in their effectiveness to prevent sars - cov - 2 infection in different cell types.', ' they include apilimod ,  an inhibitor of pikfyve kinase and camostat mesylate and nafamostat mesylate ,  inhibitors of tmprss2 protease.', ' our research is significant for having uncovered an unexpected synergism in the effective inhibitory activity of apilimod used together with camostat mesylate or with nafamostat mesylate.']",'Synergistic inhibition of two host factors that facilitate entry of Severe Acute Respiratory Syndrome Coronavirus 2','10.1101/2021.06.01.446623',[[' the substantial ~5 fold or more decrease of half maximal effective concentrations ( ec50 values )  suggests a plausible treatment strategy based on the combined use of these inhibitors.']]
angiotensin,"[' angiotensin - converting enzyme 2 ( ace2 )  ,  as a key receptor for sars - cov - 2 infections ,  has been proposed as a potential therapeutic target in covid - 19 patients.']",'High level production and characterization of truncated human angiotensin converting enzyme 2 in Nicotiana benthamiana plant as a potential therapeutic target in COVID-19','10.1101/2021.05.17.444533',"[[' the ic50 values of glycosylated and deglycosylated aec2 were 0.4 and 24 g ml ,  respectively ,  for the pre - entry infection ,  when incubated with 100tcid50 of sars - cov - 2.']]"
camostat,"[' utilizing rational structure - based drug design ( sbdd )  coupled to substrate specificity screening of tmprss2 ,  we have discovered a novel class of small molecule ketobenzothiazole tmprss2 inhibitors with significantly improved activity over existing irreversible inhibitors camostat and nafamostat.']",'A novel class of TMPRSS2 inhibitors potently block SARS-CoV-2 and MERS-CoV viral entry and protect human epithelial lung cells','10.1101/2021.05.06.442935',"[[' lead compound mm3122 ( 4 )  has an ic50 of 340 pm against recombinant full - length tmprss2 protein ,  an ec50 of 430 pm in blocking host cell entry into calu - 3 human lung epithelial cells of a newly developed vsv sars - cov - 2 chimeric virus ,  and an ec50 of 74 nm in inhibiting cytopathic effects induced by sars - cov - 2 virus in calu - 3 cells.', ' further ,  mm3122 blocks middle east respiratory syndrome coronavirus ( mers - cov )  cell entry with an ec50 of 870 pm.'], [' lead compound mm3122 ( 4 )  has an ic50 of 340 pm against recombinant full - length tmprss2 protein ,  an ec50 of 430 pm in blocking host cell entry into calu - 3 human lung epithelial cells of a newly developed vsv sars - cov - 2 chimeric virus ,  and an ec50 of 74 nm in inhibiting cytopathic effects induced by sars - cov - 2 virus in calu - 3 cells.']]"
serine,"["" 'the host cell serine protease tmprss2 is an attractive therapeutic target for covid - 19 drug discovery.""]",'A novel class of TMPRSS2 inhibitors potently block SARS-CoV-2 and MERS-CoV viral entry and protect human epithelial lung cells','10.1101/2021.05.06.442935',"[[' lead compound mm3122 ( 4 )  has an ic50 of 340 pm against recombinant full - length tmprss2 protein ,  an ec50 of 430 pm in blocking host cell entry into calu - 3 human lung epithelial cells of a newly developed vsv sars - cov - 2 chimeric virus ,  and an ec50 of 74 nm in inhibiting cytopathic effects induced by sars - cov - 2 virus in calu - 3 cells.', ' further ,  mm3122 blocks middle east respiratory syndrome coronavirus ( mers - cov )  cell entry with an ec50 of 870 pm.'], [' lead compound mm3122 ( 4 )  has an ic50 of 340 pm against recombinant full - length tmprss2 protein ,  an ec50 of 430 pm in blocking host cell entry into calu - 3 human lung epithelial cells of a newly developed vsv sars - cov - 2 chimeric virus ,  and an ec50 of 74 nm in inhibiting cytopathic effects induced by sars - cov - 2 virus in calu - 3 cells.']]"
resveratrol,"[' here we screened 512 pure compounds derived from natural products using a high - throughput rbd ace2 binding assay and identified (  -  )  - hopeaphenol ,  a resveratrol tetramer ,  in addition to vatalbinoside a and vaticanol b ,  as potent and selective inhibitors of rbd ace2 binding and viral entry.']","'The natural stilbenoid (-)-hopeaphenol inhibits cellular entry of SARS-CoV-2 USA-WA1/2020, B.1.1.7 and B.1.351 variants'",'10.1101/2021.04.29.442010',"[[' for example ,  (  -  )  - hopeaphenol disrupted rbd ace2 binding with a 50% inhibitory concentration ( ic50 )  of 0.11 um in contrast to an ic50 of 28.3 um against the unrelated host ligand receptor binding pair pd - 1 pd - l1 ( selectivity index = 257.3 ) .', ' when assessed against the usa - wa1 2020 variant ,  (  -  )  - hopeaphenol also inhibited entry of a vsvdeltag - gfp reporter pseudovirus expressing sars - cov - 2 spike into ace2 - expressing vero - e6 cells and in vitro replication of infectious virus in cytopathic effect assays ( ic50 = 10.2 um )  without cytotoxicity.']]"
hopeaphenol,"[' here we screened 512 pure compounds derived from natural products using a high - throughput rbd ace2 binding assay and identified (  -  )  - hopeaphenol ,  a resveratrol tetramer ,  in addition to vatalbinoside a and vaticanol b ,  as potent and selective inhibitors of rbd ace2 binding and viral entry.', ' for example ,  (  -  )  - hopeaphenol disrupted rbd ace2 binding with a 50% inhibitory concentration ( ic50 )  of 0.', ' when assessed against the usa - wa1 2020 variant ,  (  -  )  - hopeaphenol also inhibited entry of a vsvdeltag - gfp reporter pseudovirus expressing sars - cov - 2 spike into ace2 - expressing vero - e6 cells and in vitro replication of infectious virus in cytopathic effect assays ( ic50 = 10.', ' notably ,  (  -  )  - hopeaphenol also inhibited two emerging variants of concern originating from the united kingdom ( b.', ' these results identify (  -  )  - hopeaphenol and related stilbenoid analogues as potent and selective inhibitors of viral entry across multiple sars - cov - 2 variants including those with increased infectivity and or reduced susceptibility to existing vaccines.']","'The natural stilbenoid (-)-hopeaphenol inhibits cellular entry of SARS-CoV-2 USA-WA1/2020, B.1.1.7 and B.1.351 variants'",'10.1101/2021.04.29.442010',"[[' for example ,  (  -  )  - hopeaphenol disrupted rbd ace2 binding with a 50% inhibitory concentration ( ic50 )  of 0.11 um in contrast to an ic50 of 28.3 um against the unrelated host ligand receptor binding pair pd - 1 pd - l1 ( selectivity index = 257.3 ) .', ' when assessed against the usa - wa1 2020 variant ,  (  -  )  - hopeaphenol also inhibited entry of a vsvdeltag - gfp reporter pseudovirus expressing sars - cov - 2 spike into ace2 - expressing vero - e6 cells and in vitro replication of infectious virus in cytopathic effect assays ( ic50 = 10.2 um )  without cytotoxicity.']]"
remdesivir,"[' finally ,  we found that mu - unmc - 2 is highly synergistic with remdesivir ( rdv )  ,  suggesting that minimal amounts are needed when used in combination with rdv ,  and has the potential to develop as a potential entry inhibitor for covid - 19.']",'Discovery and in-vitro evaluation of potent SARS-CoV-2 entry inhibitors','10.1101/2021.04.02.438204',"[[' of these ,  two compounds ( mu - unmc - 1 and mu - unmc - 2 )  blocked sars - cov - 2 replication at sub - micromolar ic50 in human bronchial epithelial cells ( uncn1t )  and vero cells.']]"
galidesivir,"['  here ,  we summarise available evidence on 29 fda - approved compounds ,  from in vitro results to clinical trials ,  focussing on remdesivir ,  galidesivir and favipiravir ,  and test 29 antiviral compounds activity in vitro.', ' in vitro studies identified ten drug candidates with demonstrable anti - sars - cov - 2 activity ,  including favipiravir ,  remdesivir ,  and galidesivir.', ' we report the difference in ic50 from published data using wuhan1 wash1 strains with phe2 and gla1 ,  including ic50 values below 100m for galidesivir in wild - type virus.']",'COVID-19: A need for new rather than repurposed antiviral drugs.','10.1101/2021.03.25.436935',"[[' we report the difference in ic50 from published data using wuhan1 wash1 strains with phe2 and gla1 ,  including ic50 values below 100m for galidesivir in wild - type virus.']]"
remdesivir,"['  here ,  we summarise available evidence on 29 fda - approved compounds ,  from in vitro results to clinical trials ,  focussing on remdesivir ,  galidesivir and favipiravir ,  and test 29 antiviral compounds activity in vitro.', ' in vitro studies identified ten drug candidates with demonstrable anti - sars - cov - 2 activity ,  including favipiravir ,  remdesivir ,  and galidesivir.']",'COVID-19: A need for new rather than repurposed antiviral drugs.','10.1101/2021.03.25.436935',"[[' we report the difference in ic50 from published data using wuhan1 wash1 strains with phe2 and gla1 ,  including ic50 values below 100m for galidesivir in wild - type virus.']]"
favipiravir,"['  here ,  we summarise available evidence on 29 fda - approved compounds ,  from in vitro results to clinical trials ,  focussing on remdesivir ,  galidesivir and favipiravir ,  and test 29 antiviral compounds activity in vitro.', ' in vitro studies identified ten drug candidates with demonstrable anti - sars - cov - 2 activity ,  including favipiravir ,  remdesivir ,  and galidesivir.']",'COVID-19: A need for new rather than repurposed antiviral drugs.','10.1101/2021.03.25.436935',"[[' we report the difference in ic50 from published data using wuhan1 wash1 strains with phe2 and gla1 ,  including ic50 values below 100m for galidesivir in wild - type virus.']]"
lenvatinib,"[' another hit ,  lenvatinib ( approved for use in humans as an anti - cancer treatment )  ,  could not be validated as a sars - cov - 2 3cl main protease inhibitor in vitro ,  but serendipitously exhibited a striking functional synergy with the approved nucleoside analogue remdesivir to inhibit sars - cov - 2 replication in vero - ccl81 cells.', ' lenvatinib is a broadly - acting host receptor tyrosine kinase ( rtk )  inhibitor ,  but the synergistic effect with remdesivir was not observed with other approved rtk inhibitors ( such as pazopanib or sunitinib )  ,  suggesting that the mechanism - of - action is independent of host rtks.', ' furthermore ,  time - of - addition studies revealed that lenvatinib remdesivir synergy probably targets sars - cov - 2 replication subsequent to host - cell entry.', ' future studies should aim at understanding and optimizing the lenvatinib remdesivir synergistic mechanism as a therapeutic option.', ' however ,  our approach serendipitously identified lenvatinib ( an anti - cancer drug approved for use in humans )  as a potent inhibitor of sars - cov - 2 replication when combined with the existing approved antiviral drug ,  remdesivir.', ' our findings raise the possibility that future studies to understand the molecular mechanisms underlying the lenvatinib remdesivir synergy could uncover new therapeutic principles for treatment of covid - 19 or similar viral diseases.']",'Combined computational and cellular screening identifies synergistic inhibition of SARS-CoV-2 by lenvatinib and remdesivir','10.1101/2021.03.19.435806',"[[' one hit ,  diclazuril ( an investigational anti - protozoal compound )  ,  was validated as a sars - cov - 2 3cl main protease inhibitor in vitro ( ic50 value of 29 m )  and modestly inhibited sars - cov - 2 replication in vero - ccl81 cells.']]"
tyrosine,"[' lenvatinib is a broadly - acting host receptor tyrosine kinase ( rtk )  inhibitor ,  but the synergistic effect with remdesivir was not observed with other approved rtk inhibitors ( such as pazopanib or sunitinib )  ,  suggesting that the mechanism - of - action is independent of host rtks.']",'Combined computational and cellular screening identifies synergistic inhibition of SARS-CoV-2 by lenvatinib and remdesivir','10.1101/2021.03.19.435806',"[[' one hit ,  diclazuril ( an investigational anti - protozoal compound )  ,  was validated as a sars - cov - 2 3cl main protease inhibitor in vitro ( ic50 value of 29 m )  and modestly inhibited sars - cov - 2 replication in vero - ccl81 cells.']]"
remdesivir,"[' another hit ,  lenvatinib ( approved for use in humans as an anti - cancer treatment )  ,  could not be validated as a sars - cov - 2 3cl main protease inhibitor in vitro ,  but serendipitously exhibited a striking functional synergy with the approved nucleoside analogue remdesivir to inhibit sars - cov - 2 replication in vero - ccl81 cells.', ' lenvatinib is a broadly - acting host receptor tyrosine kinase ( rtk )  inhibitor ,  but the synergistic effect with remdesivir was not observed with other approved rtk inhibitors ( such as pazopanib or sunitinib )  ,  suggesting that the mechanism - of - action is independent of host rtks.', ' furthermore ,  time - of - addition studies revealed that lenvatinib remdesivir synergy probably targets sars - cov - 2 replication subsequent to host - cell entry.', ' future studies should aim at understanding and optimizing the lenvatinib remdesivir synergistic mechanism as a therapeutic option.', ' however ,  our approach serendipitously identified lenvatinib ( an anti - cancer drug approved for use in humans )  as a potent inhibitor of sars - cov - 2 replication when combined with the existing approved antiviral drug ,  remdesivir.', ' our findings raise the possibility that future studies to understand the molecular mechanisms underlying the lenvatinib remdesivir synergy could uncover new therapeutic principles for treatment of covid - 19 or similar viral diseases.']",'Combined computational and cellular screening identifies synergistic inhibition of SARS-CoV-2 by lenvatinib and remdesivir','10.1101/2021.03.19.435806',"[[' one hit ,  diclazuril ( an investigational anti - protozoal compound )  ,  was validated as a sars - cov - 2 3cl main protease inhibitor in vitro ( ic50 value of 29 m )  and modestly inhibited sars - cov - 2 replication in vero - ccl81 cells.']]"
pazopanib,"[' lenvatinib is a broadly - acting host receptor tyrosine kinase ( rtk )  inhibitor ,  but the synergistic effect with remdesivir was not observed with other approved rtk inhibitors ( such as pazopanib or sunitinib )  ,  suggesting that the mechanism - of - action is independent of host rtks.']",'Combined computational and cellular screening identifies synergistic inhibition of SARS-CoV-2 by lenvatinib and remdesivir','10.1101/2021.03.19.435806',"[[' one hit ,  diclazuril ( an investigational anti - protozoal compound )  ,  was validated as a sars - cov - 2 3cl main protease inhibitor in vitro ( ic50 value of 29 m )  and modestly inhibited sars - cov - 2 replication in vero - ccl81 cells.']]"
chymotrypsin,"[' here ,  we screened by high - throughput docking 6 , 000 compounds within the drugbank library for their potential to bind and inhibit the sars - cov - 2 3cl main protease ,  a chymotrypsin - like enzyme that is essential for viral replication.']",'Combined computational and cellular screening identifies synergistic inhibition of SARS-CoV-2 by lenvatinib and remdesivir','10.1101/2021.03.19.435806',"[[' one hit ,  diclazuril ( an investigational anti - protozoal compound )  ,  was validated as a sars - cov - 2 3cl main protease inhibitor in vitro ( ic50 value of 29 m )  and modestly inhibited sars - cov - 2 replication in vero - ccl81 cells.']]"
diclazuril,"[' one hit ,  diclazuril ( an investigational anti - protozoal compound )  ,  was validated as a sars - cov - 2 3cl main protease inhibitor in vitro ( ic50 value of 29 m )  and modestly inhibited sars - cov - 2 replication in vero - ccl81 cells.', ' while we found that diclazuril ( an investigational human drug already approved for use in animals )  inhibited this viral enzyme in vitro ,  it only showed modest ability to inhibit sars - cov - 2 replication in cells.']",'Combined computational and cellular screening identifies synergistic inhibition of SARS-CoV-2 by lenvatinib and remdesivir','10.1101/2021.03.19.435806',"[[' one hit ,  diclazuril ( an investigational anti - protozoal compound )  ,  was validated as a sars - cov - 2 3cl main protease inhibitor in vitro ( ic50 value of 29 m )  and modestly inhibited sars - cov - 2 replication in vero - ccl81 cells.']]"
sunitinib,"[' lenvatinib is a broadly - acting host receptor tyrosine kinase ( rtk )  inhibitor ,  but the synergistic effect with remdesivir was not observed with other approved rtk inhibitors ( such as pazopanib or sunitinib )  ,  suggesting that the mechanism - of - action is independent of host rtks.']",'Combined computational and cellular screening identifies synergistic inhibition of SARS-CoV-2 by lenvatinib and remdesivir','10.1101/2021.03.19.435806',"[[' one hit ,  diclazuril ( an investigational anti - protozoal compound )  ,  was validated as a sars - cov - 2 3cl main protease inhibitor in vitro ( ic50 value of 29 m )  and modestly inhibited sars - cov - 2 replication in vero - ccl81 cells.']]"
papain,"["" 'the papain - like protease ( plpro )  of sars - cov - 2 is a validated antiviral drug target.""]",'Discovery of SARS-CoV-2 papain-like protease inhibitors through a combination of high-throughput screening and FlipGFP-based reporter assay','10.1101/2021.03.15.435551',"[[' two compounds selected from the flipgfp - plpro assay ,  jun9 - 53 - 2 and jun9 - 72 - 2 ,  inhibited sars - cov - 2 replication in caco - 2 hace2 cells with ec50 values of 8.89 and 8.32 {micro}m ,  respectively ,  which were 3 - fold more potent than grl0617 ( ec50 = 25.1 {micro}m ) .'], [' through a fret - based high - throughput screening ,  several hits were identified as plpro inhibitors with ic50 values at the single - digit micromolar range.', ' subsequent lead optimization led to potent inhibitors with ic50 values ranging from 0.56 to 0.90 {micro}m.']]"
rottlerin,"[' experimentally validated inhibitors using a ligand activity assay include natural compounds with available prior knowledge on safety and bioavailability properties ,  such as the natural compound rottlerin ( ic50 = 37 m )  ,  and synthetic compounds previously not characterized ( e.']",'A pharmacophore model for SARS-CoV-2 3CLpro small molecule inhibitors and in vitro experimental validation of computationally screened inhibitors','10.1101/2021.03.02.433618',"[[' experimentally validated inhibitors using a ligand activity assay include natural compounds with available prior knowledge on safety and bioavailability properties ,  such as the natural compound rottlerin ( ic50 = 37 m )  ,  and synthetic compounds previously not characterized ( e.', ' compound cid 46897844 ,  ic50 = 31 m ) .']]"
remdesivir,"[' very few targeted therapeutics for covid - 19 currently exist ,  such as remdesivir.', '5 {micro}m ,  comparable to ic50 value of remdesivir ( 1.', ' further ,  we demonstrated that the combination of doses of sf2523 and remdesivir is highly synergistic: it allows for the reduction of doses of sf2523 and remdesivir by 25 - fold and 4 - fold ,  respectively ,  to achieve the same potency observed for a single inhibitor.', ' because sf2523 inhibits two sars - cov - 2 driven pathogenesis mechanisms involving brd2 brd4 and mtor signaling ,  our data suggest that sf2523 alone or in combination with remdesivir could be a novel and efficient therapeutic strategy to block sars - cov - 2 infection and hence be beneficial in preventing severe covid - 19 disease evolution.', '  one sentence summaryevidence of in silico designed chemotype ( sf2523 )  targeting pi3k -  mtor brd4 inhibits sars - cov - 2 infection and is highly synergistic with remdesivir.']",'Blockade of SARS-CoV-2 infection in-vitro by highly potent PI3K-/mTOR/BRD4 inhibitor','10.1101/2021.03.02.433604',"[[' our results demonstrate that sf2523 effectively blocks sars - cov - 2 replication in lung bronchial epithelial cells in vitro ,  showing an ic50 value of 1.5 {micro}m ,  comparable to ic50 value of remdesivir ( 1.1 {micro}m ) .']]"
papain,[' viral replication and assembly are entirely dependent on two viral cysteine proteases: 3c - like protease ( 3clpro )  and the papain - like protease ( plpro ) .'],"'Potent, Novel SARS-CoV-2 PLpro Inhibitors Block Viral Replication in Monkey and Human Cell Cultures'",'10.1101/2021.02.13.431008',"[[' a high - throughput screen of biased and unbiased libraries gave a low hit rate ,  identifying only cpi - 169 and the positive control ,  grl0617 ,  as inhibitors with good potency ( ic50 < 10 {micro}m ) .']]"
cysteine,"[' viral replication and assembly are entirely dependent on two viral cysteine proteases: 3c - like protease ( 3clpro )  and the papain - like protease ( plpro ) .', ' 3clpro is inhibited by many known cysteine protease inhibitors ,  whereas plpro is a relatively unusual cysteine protease ,  being resistant to blockade by such inhibitors.', ' the high potency and slow inhibitor off - rate were rationalized by newly identified ligand interactions with a ""bl2 groove"" that is distal from the active site cysteine.']","'Potent, Novel SARS-CoV-2 PLpro Inhibitors Block Viral Replication in Monkey and Human Cell Cultures'",'10.1101/2021.02.13.431008',"[[' a high - throughput screen of biased and unbiased libraries gave a low hit rate ,  identifying only cpi - 169 and the positive control ,  grl0617 ,  as inhibitors with good potency ( ic50 < 10 {micro}m ) .']]"
guanosine,[' non - structural protein ( nsp )  14 is one of the 16 nsps in sars - cov - 2 and catalyzes the methylation of the viral rna at n7 - guanosine in the cap formation process.'],'Probing the SAM Binding Site of SARS-CoV-2 nsp14 in vitro Using SAM Competitive Inhibitors Guides Developing Selective bi-substrate Inhibitors','10.1101/2021.02.19.424337',"[[' among seven identified screening hits ,  ss148 inhibited nsp14 mt activity with an ic50 value of 70 { +   - } 6 nm and was selective against 20 human protein lysine methyltransferases indicating significant differences in sam binding sites.', ' interestingly ,  ds0464 with ic50 value of 1.1 { +   - } 0.2 m showed a bi - substrate competitive inhibitor mechanism of action.']]"
lysine,"[' among seven identified screening hits ,  ss148 inhibited nsp14 mt activity with an ic50 value of 70 { +   - } 6 nm and was selective against 20 human protein lysine methyltransferases indicating significant differences in sam binding sites.']",'Probing the SAM Binding Site of SARS-CoV-2 nsp14 in vitro Using SAM Competitive Inhibitors Guides Developing Selective bi-substrate Inhibitors','10.1101/2021.02.19.424337',"[[' among seven identified screening hits ,  ss148 inhibited nsp14 mt activity with an ic50 value of 70 { +   - } 6 nm and was selective against 20 human protein lysine methyltransferases indicating significant differences in sam binding sites.', ' interestingly ,  ds0464 with ic50 value of 1.1 { +   - } 0.2 m showed a bi - substrate competitive inhibitor mechanism of action.']]"
proline,"[' here we tested the immunogenicity of the trimeric ,  full length spike protein with 2 proline mutations to preserve its prefusion conformation.']",'Potent neutralization antibodies induced by a recombinant trimeric Spike protein vaccine candidate containing PIKA adjuvant for COVID-19','10.1101/2021.02.17.431647',"[[' the titer of neutralization reached more than 1000 in average when tested by a pseudo - virus system ,  using monoclonal antibodies ( 40592 - mm57 and 40591 - mm43 )  with neutralizing ic50 at 1 g ml as standards.']]"
cotton,[' respiratory syncytial virus ( rsv )  titer is reduced by drug treatment in cotton rats.'],"'From COVID-19 to the Common Cold: Novel Host-Targeted, Pan-Respiratory Antiviral Small Molecule Therapeutics'",'10.1101/2021.01.17.426875',"[[' efficacy is observed against the six viral families causing most human respiratory viral disease ,  irrespective of strain ,  including both influenza ( fluv )  and sars - cov - 2 ,  with cell culture ec50 at or below 100 nm.']]"
phospholipids,[' the superfamily of phospholipases a2 ( pla2s )  consists of a large number of members that catalyze the hydrolysis of phospholipids at a specific position.'],'Snake venom phospholipases A2 possess a strong virucidal activity against SARS-CoV-2 in vitro and block the cell fusion mediated by spike glycoprotein interaction with the ACE2 receptor','10.1101/2021.01.12.426042',"[[' here we show that secreted pla2s from the venom of various snakes protect to varying degrees the vero e6 cells widely used for the replication of viruses with evident cytopathic action ,  from sars - cov - 2 infection pla2s showed low cytotoxicity to vero e6 cells and the high antiviral activity against sars - cov - 2 with ic50 values ranged from 0.06 to 7.71 g ml.']]"
sulfate,[' investigation has confirmed that polysaccharide heparan sulfate can bind to the spike protein and block sars - cov - 2 infection.'],'Structural characterization of cocktail-like targeting polysaccharides from Ecklonia kurome Okam and their anti-SARS-CoV-2 activities in vitro','10.1101/2021.01.14.426521',"[[' very interestingly ,  37502 also can potently disturb spike protein binding to ace2 receptor ( ec50 ,  2.01 m ) .', ' importantly ,  polysaccharide 375 shows good anti - sars - cov - 2 infection activity in cell culture with ec50 values of 27 nm ( 99.9 % inhibiting rate at the concentration of 20 g ml )  ,  low toxicity ( ld50: 136 mg kg on mice ) .'], [' by high throughput screening to target 3clpro enzyme ,  a key enzyme that plays a pivotal role in the viral replication and transcription using nature polysaccharides library ,  we discover the mixture polysaccharide 375 from seaweed ecklonia kurome completely block 3clpro enzymatic activity ( ic50 ,  0.48 m ) .']]"
mannose,"[' the structure study based on monosaccharide composition ,  methylation ,  nmr spectrum analysis suggest that 375 contains guluronic acid ,  mannuronic acid ,  mannose ,  rhamnose ,  glucouronic acid ,  galacturonic acid ,  glucose ,  galactose ,  xylose and fucose with ratio of 1.']",'Structural characterization of cocktail-like targeting polysaccharides from Ecklonia kurome Okam and their anti-SARS-CoV-2 activities in vitro','10.1101/2021.01.14.426521',"[[' very interestingly ,  37502 also can potently disturb spike protein binding to ace2 receptor ( ec50 ,  2.01 m ) .', ' importantly ,  polysaccharide 375 shows good anti - sars - cov - 2 infection activity in cell culture with ec50 values of 27 nm ( 99.9 % inhibiting rate at the concentration of 20 g ml )  ,  low toxicity ( ld50: 136 mg kg on mice ) .'], [' by high throughput screening to target 3clpro enzyme ,  a key enzyme that plays a pivotal role in the viral replication and transcription using nature polysaccharides library ,  we discover the mixture polysaccharide 375 from seaweed ecklonia kurome completely block 3clpro enzymatic activity ( ic50 ,  0.48 m ) .']]"
galactose,"[' the structure study based on monosaccharide composition ,  methylation ,  nmr spectrum analysis suggest that 375 contains guluronic acid ,  mannuronic acid ,  mannose ,  rhamnose ,  glucouronic acid ,  galacturonic acid ,  glucose ,  galactose ,  xylose and fucose with ratio of 1.']",'Structural characterization of cocktail-like targeting polysaccharides from Ecklonia kurome Okam and their anti-SARS-CoV-2 activities in vitro','10.1101/2021.01.14.426521',"[[' very interestingly ,  37502 also can potently disturb spike protein binding to ace2 receptor ( ec50 ,  2.01 m ) .', ' importantly ,  polysaccharide 375 shows good anti - sars - cov - 2 infection activity in cell culture with ec50 values of 27 nm ( 99.9 % inhibiting rate at the concentration of 20 g ml )  ,  low toxicity ( ld50: 136 mg kg on mice ) .'], [' by high throughput screening to target 3clpro enzyme ,  a key enzyme that plays a pivotal role in the viral replication and transcription using nature polysaccharides library ,  we discover the mixture polysaccharide 375 from seaweed ecklonia kurome completely block 3clpro enzymatic activity ( ic50 ,  0.48 m ) .']]"
fucose,"[' the structure study based on monosaccharide composition ,  methylation ,  nmr spectrum analysis suggest that 375 contains guluronic acid ,  mannuronic acid ,  mannose ,  rhamnose ,  glucouronic acid ,  galacturonic acid ,  glucose ,  galactose ,  xylose and fucose with ratio of 1.']",'Structural characterization of cocktail-like targeting polysaccharides from Ecklonia kurome Okam and their anti-SARS-CoV-2 activities in vitro','10.1101/2021.01.14.426521',"[[' very interestingly ,  37502 also can potently disturb spike protein binding to ace2 receptor ( ec50 ,  2.01 m ) .', ' importantly ,  polysaccharide 375 shows good anti - sars - cov - 2 infection activity in cell culture with ec50 values of 27 nm ( 99.9 % inhibiting rate at the concentration of 20 g ml )  ,  low toxicity ( ld50: 136 mg kg on mice ) .'], [' by high throughput screening to target 3clpro enzyme ,  a key enzyme that plays a pivotal role in the viral replication and transcription using nature polysaccharides library ,  we discover the mixture polysaccharide 375 from seaweed ecklonia kurome completely block 3clpro enzymatic activity ( ic50 ,  0.48 m ) .']]"
glucose,"[' the structure study based on monosaccharide composition ,  methylation ,  nmr spectrum analysis suggest that 375 contains guluronic acid ,  mannuronic acid ,  mannose ,  rhamnose ,  glucouronic acid ,  galacturonic acid ,  glucose ,  galactose ,  xylose and fucose with ratio of 1.']",'Structural characterization of cocktail-like targeting polysaccharides from Ecklonia kurome Okam and their anti-SARS-CoV-2 activities in vitro','10.1101/2021.01.14.426521',"[[' very interestingly ,  37502 also can potently disturb spike protein binding to ace2 receptor ( ec50 ,  2.01 m ) .', ' importantly ,  polysaccharide 375 shows good anti - sars - cov - 2 infection activity in cell culture with ec50 values of 27 nm ( 99.9 % inhibiting rate at the concentration of 20 g ml )  ,  low toxicity ( ld50: 136 mg kg on mice ) .'], [' by high throughput screening to target 3clpro enzyme ,  a key enzyme that plays a pivotal role in the viral replication and transcription using nature polysaccharides library ,  we discover the mixture polysaccharide 375 from seaweed ecklonia kurome completely block 3clpro enzymatic activity ( ic50 ,  0.48 m ) .']]"
xylose,"[' the structure study based on monosaccharide composition ,  methylation ,  nmr spectrum analysis suggest that 375 contains guluronic acid ,  mannuronic acid ,  mannose ,  rhamnose ,  glucouronic acid ,  galacturonic acid ,  glucose ,  galactose ,  xylose and fucose with ratio of 1.']",'Structural characterization of cocktail-like targeting polysaccharides from Ecklonia kurome Okam and their anti-SARS-CoV-2 activities in vitro','10.1101/2021.01.14.426521',"[[' very interestingly ,  37502 also can potently disturb spike protein binding to ace2 receptor ( ec50 ,  2.01 m ) .', ' importantly ,  polysaccharide 375 shows good anti - sars - cov - 2 infection activity in cell culture with ec50 values of 27 nm ( 99.9 % inhibiting rate at the concentration of 20 g ml )  ,  low toxicity ( ld50: 136 mg kg on mice ) .'], [' by high throughput screening to target 3clpro enzyme ,  a key enzyme that plays a pivotal role in the viral replication and transcription using nature polysaccharides library ,  we discover the mixture polysaccharide 375 from seaweed ecklonia kurome completely block 3clpro enzymatic activity ( ic50 ,  0.48 m ) .']]"
rhamnose,"[' the structure study based on monosaccharide composition ,  methylation ,  nmr spectrum analysis suggest that 375 contains guluronic acid ,  mannuronic acid ,  mannose ,  rhamnose ,  glucouronic acid ,  galacturonic acid ,  glucose ,  galactose ,  xylose and fucose with ratio of 1.']",'Structural characterization of cocktail-like targeting polysaccharides from Ecklonia kurome Okam and their anti-SARS-CoV-2 activities in vitro','10.1101/2021.01.14.426521',"[[' very interestingly ,  37502 also can potently disturb spike protein binding to ace2 receptor ( ec50 ,  2.01 m ) .', ' importantly ,  polysaccharide 375 shows good anti - sars - cov - 2 infection activity in cell culture with ec50 values of 27 nm ( 99.9 % inhibiting rate at the concentration of 20 g ml )  ,  low toxicity ( ld50: 136 mg kg on mice ) .'], [' by high throughput screening to target 3clpro enzyme ,  a key enzyme that plays a pivotal role in the viral replication and transcription using nature polysaccharides library ,  we discover the mixture polysaccharide 375 from seaweed ecklonia kurome completely block 3clpro enzymatic activity ( ic50 ,  0.48 m ) .']]"
water,"[' hot - water leaf extracts based on artemisinin ,  total flavonoids ,  or dry leaf mass showed antiviral activity with ic50 values of 0.', ' while all hot water extracts were effective ,  concentrations of artemisinin and total flavonoids varied by nearly 100 - fold in the extracts and antiviral efficacy was inversely correlated to artemisinin and total flavonoid contents.']",'Artemisia annua L. extracts prevent in vitro replication of SARS-CoV-2','10.1101/2021.01.08.425825',"[[' hot - water leaf extracts based on artemisinin ,  total flavonoids ,  or dry leaf mass showed antiviral activity with ic50 values of 0.1 - 8.7 m ,  0.01 - 0.14 g ,  and 23.4 - 57.4 g ,  respectively.', ' artemisinin alone showed an estimated ic50 of about 70 m ,  and antimalarial artemisinin derivatives artesunate ,  artemether ,  and dihydroartemisinin were ineffective or cytotoxic at elevated micromolar concentrations.', ' in contrast ,  the antimalarial drug amodiaquine had an ic50 = 5.8 m.']]"
artemisinin,"[' ,  which produces the antimalarial drug artemisinin ,  prevents sars - cov - 2 replication in vitro.', ' hot - water leaf extracts based on artemisinin ,  total flavonoids ,  or dry leaf mass showed antiviral activity with ic50 values of 0.', ' while all hot water extracts were effective ,  concentrations of artemisinin and total flavonoids varied by nearly 100 - fold in the extracts and antiviral efficacy was inversely correlated to artemisinin and total flavonoid contents.', ' artemisinin alone showed an estimated ic50 of about 70 m ,  and antimalarial artemisinin derivatives artesunate ,  artemether ,  and dihydroartemisinin were ineffective or cytotoxic at elevated micromolar concentrations.', ' results suggest the active component in the extracts is likely something besides artemisinin or is a combination of components acting synergistically to block post - entry viral infection.']",'Artemisia annua L. extracts prevent in vitro replication of SARS-CoV-2','10.1101/2021.01.08.425825',"[[' hot - water leaf extracts based on artemisinin ,  total flavonoids ,  or dry leaf mass showed antiviral activity with ic50 values of 0.1 - 8.7 m ,  0.01 - 0.14 g ,  and 23.4 - 57.4 g ,  respectively.', ' artemisinin alone showed an estimated ic50 of about 70 m ,  and antimalarial artemisinin derivatives artesunate ,  artemether ,  and dihydroartemisinin were ineffective or cytotoxic at elevated micromolar concentrations.', ' in contrast ,  the antimalarial drug amodiaquine had an ic50 = 5.8 m.']]"
amodiaquine,"[' in contrast ,  the antimalarial drug amodiaquine had an ic50 = 5.']",'Artemisia annua L. extracts prevent in vitro replication of SARS-CoV-2','10.1101/2021.01.08.425825',"[[' hot - water leaf extracts based on artemisinin ,  total flavonoids ,  or dry leaf mass showed antiviral activity with ic50 values of 0.1 - 8.7 m ,  0.01 - 0.14 g ,  and 23.4 - 57.4 g ,  respectively.', ' artemisinin alone showed an estimated ic50 of about 70 m ,  and antimalarial artemisinin derivatives artesunate ,  artemether ,  and dihydroartemisinin were ineffective or cytotoxic at elevated micromolar concentrations.', ' in contrast ,  the antimalarial drug amodiaquine had an ic50 = 5.8 m.']]"
artemether,"[' artemisinin alone showed an estimated ic50 of about 70 m ,  and antimalarial artemisinin derivatives artesunate ,  artemether ,  and dihydroartemisinin were ineffective or cytotoxic at elevated micromolar concentrations.']",'Artemisia annua L. extracts prevent in vitro replication of SARS-CoV-2','10.1101/2021.01.08.425825',"[[' hot - water leaf extracts based on artemisinin ,  total flavonoids ,  or dry leaf mass showed antiviral activity with ic50 values of 0.1 - 8.7 m ,  0.01 - 0.14 g ,  and 23.4 - 57.4 g ,  respectively.', ' artemisinin alone showed an estimated ic50 of about 70 m ,  and antimalarial artemisinin derivatives artesunate ,  artemether ,  and dihydroartemisinin were ineffective or cytotoxic at elevated micromolar concentrations.', ' in contrast ,  the antimalarial drug amodiaquine had an ic50 = 5.8 m.']]"
remdesivir,"[' besides remdesivir ,  there are no approved small molecule - based therapeutics.']",'Artemisia annua L. extracts prevent in vitro replication of SARS-CoV-2','10.1101/2021.01.08.425825',"[[' hot - water leaf extracts based on artemisinin ,  total flavonoids ,  or dry leaf mass showed antiviral activity with ic50 values of 0.1 - 8.7 m ,  0.01 - 0.14 g ,  and 23.4 - 57.4 g ,  respectively.', ' artemisinin alone showed an estimated ic50 of about 70 m ,  and antimalarial artemisinin derivatives artesunate ,  artemether ,  and dihydroartemisinin were ineffective or cytotoxic at elevated micromolar concentrations.', ' in contrast ,  the antimalarial drug amodiaquine had an ic50 = 5.8 m.']]"
artesunate,"[' artemisinin alone showed an estimated ic50 of about 70 m ,  and antimalarial artemisinin derivatives artesunate ,  artemether ,  and dihydroartemisinin were ineffective or cytotoxic at elevated micromolar concentrations.']",'Artemisia annua L. extracts prevent in vitro replication of SARS-CoV-2','10.1101/2021.01.08.425825',"[[' hot - water leaf extracts based on artemisinin ,  total flavonoids ,  or dry leaf mass showed antiviral activity with ic50 values of 0.1 - 8.7 m ,  0.01 - 0.14 g ,  and 23.4 - 57.4 g ,  respectively.', ' artemisinin alone showed an estimated ic50 of about 70 m ,  and antimalarial artemisinin derivatives artesunate ,  artemether ,  and dihydroartemisinin were ineffective or cytotoxic at elevated micromolar concentrations.', ' in contrast ,  the antimalarial drug amodiaquine had an ic50 = 5.8 m.']]"
dihydroartemisinin,"[' artemisinin alone showed an estimated ic50 of about 70 m ,  and antimalarial artemisinin derivatives artesunate ,  artemether ,  and dihydroartemisinin were ineffective or cytotoxic at elevated micromolar concentrations.']",'Artemisia annua L. extracts prevent in vitro replication of SARS-CoV-2','10.1101/2021.01.08.425825',"[[' hot - water leaf extracts based on artemisinin ,  total flavonoids ,  or dry leaf mass showed antiviral activity with ic50 values of 0.1 - 8.7 m ,  0.01 - 0.14 g ,  and 23.4 - 57.4 g ,  respectively.', ' artemisinin alone showed an estimated ic50 of about 70 m ,  and antimalarial artemisinin derivatives artesunate ,  artemether ,  and dihydroartemisinin were ineffective or cytotoxic at elevated micromolar concentrations.', ' in contrast ,  the antimalarial drug amodiaquine had an ic50 = 5.8 m.']]"
angiotensin,"[' here ,  we used a yeast surface - display library of human naive antibodies to isolate and characterize three novel neutralizing antibodies that target the rbd: one that blocks interaction with angiotensin - converting enzyme 2 ( ace2 )  ,  the human receptor for sars - cov - 2 ,  and two that target other epitopes on the rbd.']",'Neutralizing antibodies targeting the SARS-CoV-2 receptor binding domain isolated from a naive human antibody library','10.1101/2021.01.07.425806',[[' these three antibodies neutralized sars - cov - 2 spike - pseudotyped lentivirus with ic50 values as low as 60 ng ml in vitro.']]
yeast,"[' here ,  we used a yeast surface - display library of human naive antibodies to isolate and characterize three novel neutralizing antibodies that target the rbd: one that blocks interaction with angiotensin - converting enzyme 2 ( ace2 )  ,  the human receptor for sars - cov - 2 ,  and two that target other epitopes on the rbd.']",'Neutralizing antibodies targeting the SARS-CoV-2 receptor binding domain isolated from a naive human antibody library','10.1101/2021.01.07.425806',[[' these three antibodies neutralized sars - cov - 2 spike - pseudotyped lentivirus with ic50 values as low as 60 ng ml in vitro.']]
water,"[' clinical studies revealed that some traditional chinese medicines ,  such as lianhua qingwen capsule and huoxiang zhengqi water ,  exhibited excellent therapeutic effect on covid - 19.']",'A novel fermented Yi traditional medicine efficiently suppresses the replication of SARS-CoV-2 in vitro','10.1101/2020.12.29.424534',[[' the in vitro data showed that jb10 could significantly suppresses the replication of the sars - cov - 2 with an ec50 of 769.1 times dilution and a selection index of 42.68.']]
remdesivir,"[' remdesivir is currently approved by the fda for the treatment of covid - 19 ,  but the who declared that remdesivir is almost ineffective against covid - 19.']",'A novel fermented Yi traditional medicine efficiently suppresses the replication of SARS-CoV-2 in vitro','10.1101/2020.12.29.424534',[[' the in vitro data showed that jb10 could significantly suppresses the replication of the sars - cov - 2 with an ec50 of 769.1 times dilution and a selection index of 42.68.']]
cysteine,[' cathepsin l is a key host cysteine protease utilized by coronaviruses for cell entry and is recognized as a promising drug target.'],'Potent in vitro anti-SARS-CoV-2 activity by gallinamide A and analogues via inhibition of cathepsin L','10.1101/2020.12.23.424111',"[[' we demonstrate that gallinamide a and two lead analogues potently inhibit sars - cov - 2 infection in vitro ,  with ec50 values in the nanomolar range ,  thus further highlighting the potential of cathepsin l as a covid - 19 antiviral drug target.'], [' the marine natural product ,  gallinamide a and several synthetic analogues ,  were identified as potent inhibitors of cathepsin l activity with ic50 values in the picomolar range.']]"
boceprevir,"[' several mpro inhibitors have been reported with potent enzymatic inhibition and cellular antiviral activity ,  including gc376 ,  boceprevir ,  calpain inhibitors ii and xii ,  each containing a reactive warhead that covalently modifies the catalytic cys145.']",'An expedited approach towards the rationale design of non-covalent SARS-CoV-2 main protease inhibitors with in vitro antiviral activity','10.1101/2020.12.19.423537',"[['31 microm and ec50 of 1.27 microm ,  respectively.'], [' lead optimization led to the discovery of 23r ,  which inhibits sars - cov - 2 mpro and sars - cov - 2 viral replication with an ic50 of 0.31 microm and ec50 of 1.27 microm ,  respectively.']]"
cepharanthine,"[' antiviral tests using native sars - cov - 2 in vero e6 cells confirmed that four of the drugs ( sc9 cepharanthine ,  sc161 hernandezine ,  sc171 ,  and sc185 neferine )  reduced cytopathic effect and supernatant viral rna load.', ' among them ,  cepharanthine showed the strongest anti - sars - cov - 2 activity.']",'Identification of bis-benzylisoquinoline alkaloids as SARS-CoV-2 entry inhibitors from a library of natural products in vitro','10.1101/2020.12.13.420406',"[[' using this system ,  we identified nine compounds ,  specifically ,  bis - benzylisoquinoline alkaloids ,  that potently inhibited sars - cov - 2 pseudovirus entry ,  with ec50 values of 0.1 - 10 m.']]"
calcium,"[' mechanistic studies showed that these compounds ,  reported as calcium channel blockers ( ccbs )  ,  inhibited ca2 +  - mediated membrane fusion and consequently suppressed coronavirus entry.']",'Identification of bis-benzylisoquinoline alkaloids as SARS-CoV-2 entry inhibitors from a library of natural products in vitro','10.1101/2020.12.13.420406',"[[' using this system ,  we identified nine compounds ,  specifically ,  bis - benzylisoquinoline alkaloids ,  that potently inhibited sars - cov - 2 pseudovirus entry ,  with ec50 values of 0.1 - 10 m.']]"
hernandezine,"[' antiviral tests using native sars - cov - 2 in vero e6 cells confirmed that four of the drugs ( sc9 cepharanthine ,  sc161 hernandezine ,  sc171 ,  and sc185 neferine )  reduced cytopathic effect and supernatant viral rna load.']",'Identification of bis-benzylisoquinoline alkaloids as SARS-CoV-2 entry inhibitors from a library of natural products in vitro','10.1101/2020.12.13.420406',"[[' using this system ,  we identified nine compounds ,  specifically ,  bis - benzylisoquinoline alkaloids ,  that potently inhibited sars - cov - 2 pseudovirus entry ,  with ec50 values of 0.1 - 10 m.']]"
neferine,"[' antiviral tests using native sars - cov - 2 in vero e6 cells confirmed that four of the drugs ( sc9 cepharanthine ,  sc161 hernandezine ,  sc171 ,  and sc185 neferine )  reduced cytopathic effect and supernatant viral rna load.']",'Identification of bis-benzylisoquinoline alkaloids as SARS-CoV-2 entry inhibitors from a library of natural products in vitro','10.1101/2020.12.13.420406',"[[' using this system ,  we identified nine compounds ,  specifically ,  bis - benzylisoquinoline alkaloids ,  that potently inhibited sars - cov - 2 pseudovirus entry ,  with ec50 values of 0.1 - 10 m.']]"
myricetin,"[' the x - ray crystal structure of the complex of myricetin and sars - cov - 2 3cl - pro was solved at a resolution of 1.', '77 [a] ,  showing that myricetin is covalently bound to the catalytic cys145 and therefore inhibiting its enzymatic activity.']",'Identification of inhibitors of SARS-CoV-2 3CL-Pro enzymatic activity using a small molecule in-vitro repurposing screen','10.1101/2020.12.16.422677',"[[' we confirmed previously reported inhibitors of 3cl - pro ,  and have identified 62 additional compounds with ic50 values below 1 m and profiled their selectivity towards chymotrypsin and 3cl - pro from the mers virus.']]"
chymotrypsin,"[' we confirmed previously reported inhibitors of 3cl - pro ,  and have identified 62 additional compounds with ic50 values below 1 m and profiled their selectivity towards chymotrypsin and 3cl - pro from the mers virus.']",'Identification of inhibitors of SARS-CoV-2 3CL-Pro enzymatic activity using a small molecule in-vitro repurposing screen','10.1101/2020.12.16.422677',"[[' we confirmed previously reported inhibitors of 3cl - pro ,  and have identified 62 additional compounds with ic50 values below 1 m and profiled their selectivity towards chymotrypsin and 3cl - pro from the mers virus.']]"
emetine,"["" 'emetine is a fda - approved drug for the treatment of amebiasis."", ' in the recent times we had also demonstrated the antiviral efficacy of emetine against some rna and dna viruses.', ' following emergence of the covid - 19 ,  we further evaluated thein vitro antiviral activity of emetine against severe acute respiratory syndrome coronavirus 2 ( sars - cov - 2 ) .', ' the therapeutic index of emetine was determined to be 10910.', 'besides ,  we also demonstrated the protective efficacy of emetine against lethal challenge with infectious bronchitis virus ( ibv; a chicken coronavirus )  in the embryonated chicken egg infection model.', ' emetine treatment was shown to decrease viral rna and protein synthesis without affecting other steps of viral life cycle such as attachment ,  entry and budding.', 'in a chromatin immunoprecipitation ( chip )  assay ,  emetine was shown to disrupt the binding of sars - cov - 2 rna with eif4e ( eukaryotic translation initiation factor 4e ,  a cellular cap - binding protein required for initiation ofprotein translation ) .', ' to conclude ,  emetine targets sars - cov - 2 protein synthesis which is mediated via inhibiting the interaction of sars - cov - 2 rna with eif4e.', ' this is a novel mechanistic insight on the antiviral efficacy of emetine.', ' in vitro antiviral efficacy against sars - cov - 2 and its ability to protect chicken embryos against ibv suggests that emetine could be repurposed to treat covid - 19.']",'Emetine as an antiviral agent suppresses SARS-CoV-2 replication by inhibiting interaction of viral mRNA with eIF4E: An in vitro study','10.1101/2020.11.29.401984',"[['8 nm and effective concentration 50 ( ec50 )  of 0.147 nm.'], ['4 ,  at a cytotoxic concentration 50 ( cc50 )  of 1603.8 nm and effective concentration 50 ( ec50 )  of 0.147 nm.']]"
thein,"[' following emergence of the covid - 19 ,  we further evaluated thein vitro antiviral activity of emetine against severe acute respiratory syndrome coronavirus 2 ( sars - cov - 2 ) .']",'Emetine as an antiviral agent suppresses SARS-CoV-2 replication by inhibiting interaction of viral mRNA with eIF4E: An in vitro study','10.1101/2020.11.29.401984',"[['8 nm and effective concentration 50 ( ec50 )  of 0.147 nm.'], ['4 ,  at a cytotoxic concentration 50 ( cc50 )  of 1603.8 nm and effective concentration 50 ( ec50 )  of 0.147 nm.']]"
chicken,"['besides ,  we also demonstrated the protective efficacy of emetine against lethal challenge with infectious bronchitis virus ( ibv; a chicken coronavirus )  in the embryonated chicken egg infection model.', ' in vitro antiviral efficacy against sars - cov - 2 and its ability to protect chicken embryos against ibv suggests that emetine could be repurposed to treat covid - 19.']",'Emetine as an antiviral agent suppresses SARS-CoV-2 replication by inhibiting interaction of viral mRNA with eIF4E: An in vitro study','10.1101/2020.11.29.401984',"[['8 nm and effective concentration 50 ( ec50 )  of 0.147 nm.'], ['4 ,  at a cytotoxic concentration 50 ( cc50 )  of 1603.8 nm and effective concentration 50 ( ec50 )  of 0.147 nm.']]"
angiotensin,[' viral entry via binding of the receptor binding domain ( rbd )  located within the s1 subunit of the sars - cov - 2 spike ( s )  protein to its target receptor angiotensin converting enzyme ( ace )  2 is a key step in cell infection.'],'LL-37 fights SARS-CoV-2: The Vitamin D-Inducible Peptide LL-37 Inhibits Binding of SARS-CoV-2 Spike Protein to its Cellular Receptor Angiotensin Converting Enzyme 2 In Vitro','10.1101/2020.12.02.408153',"[[' further ,  inhibition of the binding of s - strep ( ic50 = 735 nm )  ,  s1e ( ic50 = 168 nm )  ,  and rbd ( ic50 = 126 nm )  to hace2 by ll - 37 was demonstrated.']]"
voxilaprevir,"[' among macrocyclic pi simeprevir ,  paritaprevir ,  grazoprevir ,  glecaprevir ,  voxilaprevir ,  vaniprevir ,  danoprevir and deldeprevir ,  simeprevir had the highest ( ec50 15 m )  and glecaprevir the lowest ( ec50 >178 m )  potency.']",'Hepatitis C Virus Protease Inhibitors Show Differential Efficacy and Interactions with Remdesivir for Treatment of SARS-CoV-2 in Vitro','10.1101/2020.12.02.408112',"[[' linear pi boceprevir ,  telaprevir and narlaprevir had 50% effective concentrations ( ec50 )  of ~40 m.', ' among macrocyclic pi simeprevir ,  paritaprevir ,  grazoprevir ,  glecaprevir ,  voxilaprevir ,  vaniprevir ,  danoprevir and deldeprevir ,  simeprevir had the highest ( ec50 15 m )  and glecaprevir the lowest ( ec50 >178 m )  potency.', ' acyclic pi asunaprevir and faldaprevir had ec50 of 72 and 23 m ,  respectively.', ' ach - 806 ,  an hcv ns3 protease co - factor ns4a inhibitor ,  had ec50 of 46 m.', ' treatment of infected cultures with equipotent concentrations ( 1 - fold ec50 )  of hcv pi revealed minor differences in barrier to sars - cov - 2 escape.', ' complete viral suppression was achieved treating with [&ge;]3 - fold ec50 boceprevir or combination of 1 - fold ec50 simeprevir with 0.4 - fold ec50 remdesivir ,  not leading to significant viral suppression in single treatments.']]"
grazoprevir,"[' among macrocyclic pi simeprevir ,  paritaprevir ,  grazoprevir ,  glecaprevir ,  voxilaprevir ,  vaniprevir ,  danoprevir and deldeprevir ,  simeprevir had the highest ( ec50 15 m )  and glecaprevir the lowest ( ec50 >178 m )  potency.', ' in combination with remdesivir ,  linear pi boceprevir and narlaprevir showed antagonism ,  while macrocyclic pi simeprevir ,  paritaprevir and grazoprevir showed synergism with drug reduction indexes of up to 27 for simeprevir.']",'Hepatitis C Virus Protease Inhibitors Show Differential Efficacy and Interactions with Remdesivir for Treatment of SARS-CoV-2 in Vitro','10.1101/2020.12.02.408112',"[[' linear pi boceprevir ,  telaprevir and narlaprevir had 50% effective concentrations ( ec50 )  of ~40 m.', ' among macrocyclic pi simeprevir ,  paritaprevir ,  grazoprevir ,  glecaprevir ,  voxilaprevir ,  vaniprevir ,  danoprevir and deldeprevir ,  simeprevir had the highest ( ec50 15 m )  and glecaprevir the lowest ( ec50 >178 m )  potency.', ' acyclic pi asunaprevir and faldaprevir had ec50 of 72 and 23 m ,  respectively.', ' ach - 806 ,  an hcv ns3 protease co - factor ns4a inhibitor ,  had ec50 of 46 m.', ' treatment of infected cultures with equipotent concentrations ( 1 - fold ec50 )  of hcv pi revealed minor differences in barrier to sars - cov - 2 escape.', ' complete viral suppression was achieved treating with [&ge;]3 - fold ec50 boceprevir or combination of 1 - fold ec50 simeprevir with 0.4 - fold ec50 remdesivir ,  not leading to significant viral suppression in single treatments.']]"
telaprevir,"[' linear pi boceprevir ,  telaprevir and narlaprevir had 50% effective concentrations ( ec50 )  of ~40 m.']",'Hepatitis C Virus Protease Inhibitors Show Differential Efficacy and Interactions with Remdesivir for Treatment of SARS-CoV-2 in Vitro','10.1101/2020.12.02.408112',"[[' linear pi boceprevir ,  telaprevir and narlaprevir had 50% effective concentrations ( ec50 )  of ~40 m.', ' among macrocyclic pi simeprevir ,  paritaprevir ,  grazoprevir ,  glecaprevir ,  voxilaprevir ,  vaniprevir ,  danoprevir and deldeprevir ,  simeprevir had the highest ( ec50 15 m )  and glecaprevir the lowest ( ec50 >178 m )  potency.', ' acyclic pi asunaprevir and faldaprevir had ec50 of 72 and 23 m ,  respectively.', ' ach - 806 ,  an hcv ns3 protease co - factor ns4a inhibitor ,  had ec50 of 46 m.', ' treatment of infected cultures with equipotent concentrations ( 1 - fold ec50 )  of hcv pi revealed minor differences in barrier to sars - cov - 2 escape.', ' complete viral suppression was achieved treating with [&ge;]3 - fold ec50 boceprevir or combination of 1 - fold ec50 simeprevir with 0.4 - fold ec50 remdesivir ,  not leading to significant viral suppression in single treatments.']]"
remdesivir,"[' we evaluated the efficacy of clinically relevant hepatitis c virus ( hcv )  ns3 protease inhibitors ( pi )  against sars - cov - 2 and their interactions with remdesivir ,  the only antiviral approved for treatment of covid - 19.', ' in combination with remdesivir ,  linear pi boceprevir and narlaprevir showed antagonism ,  while macrocyclic pi simeprevir ,  paritaprevir and grazoprevir showed synergism with drug reduction indexes of up to 27 for simeprevir.', '4 - fold ec50 remdesivir ,  not leading to significant viral suppression in single treatments.', ' considering potency ,  human plasma concentrations and synergism with remdesivir ,  simeprevir seemed the most promising compound for optimization of future antiviral treatments of covid - 19.']",'Hepatitis C Virus Protease Inhibitors Show Differential Efficacy and Interactions with Remdesivir for Treatment of SARS-CoV-2 in Vitro','10.1101/2020.12.02.408112',"[[' linear pi boceprevir ,  telaprevir and narlaprevir had 50% effective concentrations ( ec50 )  of ~40 m.', ' among macrocyclic pi simeprevir ,  paritaprevir ,  grazoprevir ,  glecaprevir ,  voxilaprevir ,  vaniprevir ,  danoprevir and deldeprevir ,  simeprevir had the highest ( ec50 15 m )  and glecaprevir the lowest ( ec50 >178 m )  potency.', ' acyclic pi asunaprevir and faldaprevir had ec50 of 72 and 23 m ,  respectively.', ' ach - 806 ,  an hcv ns3 protease co - factor ns4a inhibitor ,  had ec50 of 46 m.', ' treatment of infected cultures with equipotent concentrations ( 1 - fold ec50 )  of hcv pi revealed minor differences in barrier to sars - cov - 2 escape.', ' complete viral suppression was achieved treating with [&ge;]3 - fold ec50 boceprevir or combination of 1 - fold ec50 simeprevir with 0.4 - fold ec50 remdesivir ,  not leading to significant viral suppression in single treatments.']]"
boceprevir,"[' linear pi boceprevir ,  telaprevir and narlaprevir had 50% effective concentrations ( ec50 )  of ~40 m.', ' in combination with remdesivir ,  linear pi boceprevir and narlaprevir showed antagonism ,  while macrocyclic pi simeprevir ,  paritaprevir and grazoprevir showed synergism with drug reduction indexes of up to 27 for simeprevir.', ' complete viral suppression was achieved treating with [&ge;]3 - fold ec50 boceprevir or combination of 1 - fold ec50 simeprevir with 0.']",'Hepatitis C Virus Protease Inhibitors Show Differential Efficacy and Interactions with Remdesivir for Treatment of SARS-CoV-2 in Vitro','10.1101/2020.12.02.408112',"[[' linear pi boceprevir ,  telaprevir and narlaprevir had 50% effective concentrations ( ec50 )  of ~40 m.', ' among macrocyclic pi simeprevir ,  paritaprevir ,  grazoprevir ,  glecaprevir ,  voxilaprevir ,  vaniprevir ,  danoprevir and deldeprevir ,  simeprevir had the highest ( ec50 15 m )  and glecaprevir the lowest ( ec50 >178 m )  potency.', ' acyclic pi asunaprevir and faldaprevir had ec50 of 72 and 23 m ,  respectively.', ' ach - 806 ,  an hcv ns3 protease co - factor ns4a inhibitor ,  had ec50 of 46 m.', ' treatment of infected cultures with equipotent concentrations ( 1 - fold ec50 )  of hcv pi revealed minor differences in barrier to sars - cov - 2 escape.', ' complete viral suppression was achieved treating with [&ge;]3 - fold ec50 boceprevir or combination of 1 - fold ec50 simeprevir with 0.4 - fold ec50 remdesivir ,  not leading to significant viral suppression in single treatments.']]"
narlaprevir,"[' linear pi boceprevir ,  telaprevir and narlaprevir had 50% effective concentrations ( ec50 )  of ~40 m.', ' in combination with remdesivir ,  linear pi boceprevir and narlaprevir showed antagonism ,  while macrocyclic pi simeprevir ,  paritaprevir and grazoprevir showed synergism with drug reduction indexes of up to 27 for simeprevir.']",'Hepatitis C Virus Protease Inhibitors Show Differential Efficacy and Interactions with Remdesivir for Treatment of SARS-CoV-2 in Vitro','10.1101/2020.12.02.408112',"[[' linear pi boceprevir ,  telaprevir and narlaprevir had 50% effective concentrations ( ec50 )  of ~40 m.', ' among macrocyclic pi simeprevir ,  paritaprevir ,  grazoprevir ,  glecaprevir ,  voxilaprevir ,  vaniprevir ,  danoprevir and deldeprevir ,  simeprevir had the highest ( ec50 15 m )  and glecaprevir the lowest ( ec50 >178 m )  potency.', ' acyclic pi asunaprevir and faldaprevir had ec50 of 72 and 23 m ,  respectively.', ' ach - 806 ,  an hcv ns3 protease co - factor ns4a inhibitor ,  had ec50 of 46 m.', ' treatment of infected cultures with equipotent concentrations ( 1 - fold ec50 )  of hcv pi revealed minor differences in barrier to sars - cov - 2 escape.', ' complete viral suppression was achieved treating with [&ge;]3 - fold ec50 boceprevir or combination of 1 - fold ec50 simeprevir with 0.4 - fold ec50 remdesivir ,  not leading to significant viral suppression in single treatments.']]"
danoprevir,"[' among macrocyclic pi simeprevir ,  paritaprevir ,  grazoprevir ,  glecaprevir ,  voxilaprevir ,  vaniprevir ,  danoprevir and deldeprevir ,  simeprevir had the highest ( ec50 15 m )  and glecaprevir the lowest ( ec50 >178 m )  potency.']",'Hepatitis C Virus Protease Inhibitors Show Differential Efficacy and Interactions with Remdesivir for Treatment of SARS-CoV-2 in Vitro','10.1101/2020.12.02.408112',"[[' linear pi boceprevir ,  telaprevir and narlaprevir had 50% effective concentrations ( ec50 )  of ~40 m.', ' among macrocyclic pi simeprevir ,  paritaprevir ,  grazoprevir ,  glecaprevir ,  voxilaprevir ,  vaniprevir ,  danoprevir and deldeprevir ,  simeprevir had the highest ( ec50 15 m )  and glecaprevir the lowest ( ec50 >178 m )  potency.', ' acyclic pi asunaprevir and faldaprevir had ec50 of 72 and 23 m ,  respectively.', ' ach - 806 ,  an hcv ns3 protease co - factor ns4a inhibitor ,  had ec50 of 46 m.', ' treatment of infected cultures with equipotent concentrations ( 1 - fold ec50 )  of hcv pi revealed minor differences in barrier to sars - cov - 2 escape.', ' complete viral suppression was achieved treating with [&ge;]3 - fold ec50 boceprevir or combination of 1 - fold ec50 simeprevir with 0.4 - fold ec50 remdesivir ,  not leading to significant viral suppression in single treatments.']]"
glecaprevir,"[' among macrocyclic pi simeprevir ,  paritaprevir ,  grazoprevir ,  glecaprevir ,  voxilaprevir ,  vaniprevir ,  danoprevir and deldeprevir ,  simeprevir had the highest ( ec50 15 m )  and glecaprevir the lowest ( ec50 >178 m )  potency.']",'Hepatitis C Virus Protease Inhibitors Show Differential Efficacy and Interactions with Remdesivir for Treatment of SARS-CoV-2 in Vitro','10.1101/2020.12.02.408112',"[[' linear pi boceprevir ,  telaprevir and narlaprevir had 50% effective concentrations ( ec50 )  of ~40 m.', ' among macrocyclic pi simeprevir ,  paritaprevir ,  grazoprevir ,  glecaprevir ,  voxilaprevir ,  vaniprevir ,  danoprevir and deldeprevir ,  simeprevir had the highest ( ec50 15 m )  and glecaprevir the lowest ( ec50 >178 m )  potency.', ' acyclic pi asunaprevir and faldaprevir had ec50 of 72 and 23 m ,  respectively.', ' ach - 806 ,  an hcv ns3 protease co - factor ns4a inhibitor ,  had ec50 of 46 m.', ' treatment of infected cultures with equipotent concentrations ( 1 - fold ec50 )  of hcv pi revealed minor differences in barrier to sars - cov - 2 escape.', ' complete viral suppression was achieved treating with [&ge;]3 - fold ec50 boceprevir or combination of 1 - fold ec50 simeprevir with 0.4 - fold ec50 remdesivir ,  not leading to significant viral suppression in single treatments.']]"
simeprevir,"[' among macrocyclic pi simeprevir ,  paritaprevir ,  grazoprevir ,  glecaprevir ,  voxilaprevir ,  vaniprevir ,  danoprevir and deldeprevir ,  simeprevir had the highest ( ec50 15 m )  and glecaprevir the lowest ( ec50 >178 m )  potency.', ' in combination with remdesivir ,  linear pi boceprevir and narlaprevir showed antagonism ,  while macrocyclic pi simeprevir ,  paritaprevir and grazoprevir showed synergism with drug reduction indexes of up to 27 for simeprevir.', ' complete viral suppression was achieved treating with [&ge;]3 - fold ec50 boceprevir or combination of 1 - fold ec50 simeprevir with 0.', ' considering potency ,  human plasma concentrations and synergism with remdesivir ,  simeprevir seemed the most promising compound for optimization of future antiviral treatments of covid - 19.']",'Hepatitis C Virus Protease Inhibitors Show Differential Efficacy and Interactions with Remdesivir for Treatment of SARS-CoV-2 in Vitro','10.1101/2020.12.02.408112',"[[' linear pi boceprevir ,  telaprevir and narlaprevir had 50% effective concentrations ( ec50 )  of ~40 m.', ' among macrocyclic pi simeprevir ,  paritaprevir ,  grazoprevir ,  glecaprevir ,  voxilaprevir ,  vaniprevir ,  danoprevir and deldeprevir ,  simeprevir had the highest ( ec50 15 m )  and glecaprevir the lowest ( ec50 >178 m )  potency.', ' acyclic pi asunaprevir and faldaprevir had ec50 of 72 and 23 m ,  respectively.', ' ach - 806 ,  an hcv ns3 protease co - factor ns4a inhibitor ,  had ec50 of 46 m.', ' treatment of infected cultures with equipotent concentrations ( 1 - fold ec50 )  of hcv pi revealed minor differences in barrier to sars - cov - 2 escape.', ' complete viral suppression was achieved treating with [&ge;]3 - fold ec50 boceprevir or combination of 1 - fold ec50 simeprevir with 0.4 - fold ec50 remdesivir ,  not leading to significant viral suppression in single treatments.']]"
paritaprevir,"[' among macrocyclic pi simeprevir ,  paritaprevir ,  grazoprevir ,  glecaprevir ,  voxilaprevir ,  vaniprevir ,  danoprevir and deldeprevir ,  simeprevir had the highest ( ec50 15 m )  and glecaprevir the lowest ( ec50 >178 m )  potency.', ' in combination with remdesivir ,  linear pi boceprevir and narlaprevir showed antagonism ,  while macrocyclic pi simeprevir ,  paritaprevir and grazoprevir showed synergism with drug reduction indexes of up to 27 for simeprevir.']",'Hepatitis C Virus Protease Inhibitors Show Differential Efficacy and Interactions with Remdesivir for Treatment of SARS-CoV-2 in Vitro','10.1101/2020.12.02.408112',"[[' linear pi boceprevir ,  telaprevir and narlaprevir had 50% effective concentrations ( ec50 )  of ~40 m.', ' among macrocyclic pi simeprevir ,  paritaprevir ,  grazoprevir ,  glecaprevir ,  voxilaprevir ,  vaniprevir ,  danoprevir and deldeprevir ,  simeprevir had the highest ( ec50 15 m )  and glecaprevir the lowest ( ec50 >178 m )  potency.', ' acyclic pi asunaprevir and faldaprevir had ec50 of 72 and 23 m ,  respectively.', ' ach - 806 ,  an hcv ns3 protease co - factor ns4a inhibitor ,  had ec50 of 46 m.', ' treatment of infected cultures with equipotent concentrations ( 1 - fold ec50 )  of hcv pi revealed minor differences in barrier to sars - cov - 2 escape.', ' complete viral suppression was achieved treating with [&ge;]3 - fold ec50 boceprevir or combination of 1 - fold ec50 simeprevir with 0.4 - fold ec50 remdesivir ,  not leading to significant viral suppression in single treatments.']]"
vaniprevir,"[' among macrocyclic pi simeprevir ,  paritaprevir ,  grazoprevir ,  glecaprevir ,  voxilaprevir ,  vaniprevir ,  danoprevir and deldeprevir ,  simeprevir had the highest ( ec50 15 m )  and glecaprevir the lowest ( ec50 >178 m )  potency.']",'Hepatitis C Virus Protease Inhibitors Show Differential Efficacy and Interactions with Remdesivir for Treatment of SARS-CoV-2 in Vitro','10.1101/2020.12.02.408112',"[[' linear pi boceprevir ,  telaprevir and narlaprevir had 50% effective concentrations ( ec50 )  of ~40 m.', ' among macrocyclic pi simeprevir ,  paritaprevir ,  grazoprevir ,  glecaprevir ,  voxilaprevir ,  vaniprevir ,  danoprevir and deldeprevir ,  simeprevir had the highest ( ec50 15 m )  and glecaprevir the lowest ( ec50 >178 m )  potency.', ' acyclic pi asunaprevir and faldaprevir had ec50 of 72 and 23 m ,  respectively.', ' ach - 806 ,  an hcv ns3 protease co - factor ns4a inhibitor ,  had ec50 of 46 m.', ' treatment of infected cultures with equipotent concentrations ( 1 - fold ec50 )  of hcv pi revealed minor differences in barrier to sars - cov - 2 escape.', ' complete viral suppression was achieved treating with [&ge;]3 - fold ec50 boceprevir or combination of 1 - fold ec50 simeprevir with 0.4 - fold ec50 remdesivir ,  not leading to significant viral suppression in single treatments.']]"
faldaprevir,"[' acyclic pi asunaprevir and faldaprevir had ec50 of 72 and 23 m ,  respectively.']",'Hepatitis C Virus Protease Inhibitors Show Differential Efficacy and Interactions with Remdesivir for Treatment of SARS-CoV-2 in Vitro','10.1101/2020.12.02.408112',"[[' linear pi boceprevir ,  telaprevir and narlaprevir had 50% effective concentrations ( ec50 )  of ~40 m.', ' among macrocyclic pi simeprevir ,  paritaprevir ,  grazoprevir ,  glecaprevir ,  voxilaprevir ,  vaniprevir ,  danoprevir and deldeprevir ,  simeprevir had the highest ( ec50 15 m )  and glecaprevir the lowest ( ec50 >178 m )  potency.', ' acyclic pi asunaprevir and faldaprevir had ec50 of 72 and 23 m ,  respectively.', ' ach - 806 ,  an hcv ns3 protease co - factor ns4a inhibitor ,  had ec50 of 46 m.', ' treatment of infected cultures with equipotent concentrations ( 1 - fold ec50 )  of hcv pi revealed minor differences in barrier to sars - cov - 2 escape.', ' complete viral suppression was achieved treating with [&ge;]3 - fold ec50 boceprevir or combination of 1 - fold ec50 simeprevir with 0.4 - fold ec50 remdesivir ,  not leading to significant viral suppression in single treatments.']]"
asunaprevir,"[' acyclic pi asunaprevir and faldaprevir had ec50 of 72 and 23 m ,  respectively.']",'Hepatitis C Virus Protease Inhibitors Show Differential Efficacy and Interactions with Remdesivir for Treatment of SARS-CoV-2 in Vitro','10.1101/2020.12.02.408112',"[[' linear pi boceprevir ,  telaprevir and narlaprevir had 50% effective concentrations ( ec50 )  of ~40 m.', ' among macrocyclic pi simeprevir ,  paritaprevir ,  grazoprevir ,  glecaprevir ,  voxilaprevir ,  vaniprevir ,  danoprevir and deldeprevir ,  simeprevir had the highest ( ec50 15 m )  and glecaprevir the lowest ( ec50 >178 m )  potency.', ' acyclic pi asunaprevir and faldaprevir had ec50 of 72 and 23 m ,  respectively.', ' ach - 806 ,  an hcv ns3 protease co - factor ns4a inhibitor ,  had ec50 of 46 m.', ' treatment of infected cultures with equipotent concentrations ( 1 - fold ec50 )  of hcv pi revealed minor differences in barrier to sars - cov - 2 escape.', ' complete viral suppression was achieved treating with [&ge;]3 - fold ec50 boceprevir or combination of 1 - fold ec50 simeprevir with 0.4 - fold ec50 remdesivir ,  not leading to significant viral suppression in single treatments.']]"
pyronaridine,"[' we have previously repurposed pyronaridine ,  tilorone and quinacrine ( from malaria ,  influenza ,  and antiprotozoal uses ,  respectively )  as inhibitors of ebola and marburg virus in vitro in hela cells and of mouse adapted ebola virus in mouse in vivo.', ' we found that tilorone and pyronaridine inhibited the virus replication in a549 - ace2 cells with ic50 values of 180 nm and ic50 198 nm ,  respectively.', ' human cmax for pyronaridine and quinacrine is greater than the ic50 hence justifying in vivo evaluation.']","'Repurposing the Ebola and Marburg Virus Inhibitors Tilorone, Quinacrine and Pyronaridine: In vitro Activity Against SARS-CoV-2 and Potential Mechanisms'",'10.1101/2020.12.01.407361',"[[' we found that tilorone and pyronaridine inhibited the virus replication in a549 - ace2 cells with ic50 values of 180 nm and ic50 198 nm ,  respectively.', ' human cmax for pyronaridine and quinacrine is greater than the ic50 hence justifying in vivo evaluation.']]"
quinacrine,"[' we have previously repurposed pyronaridine ,  tilorone and quinacrine ( from malaria ,  influenza ,  and antiprotozoal uses ,  respectively )  as inhibitors of ebola and marburg virus in vitro in hela cells and of mouse adapted ebola virus in mouse in vivo.', ' human cmax for pyronaridine and quinacrine is greater than the ic50 hence justifying in vivo evaluation.']","'Repurposing the Ebola and Marburg Virus Inhibitors Tilorone, Quinacrine and Pyronaridine: In vitro Activity Against SARS-CoV-2 and Potential Mechanisms'",'10.1101/2020.12.01.407361',"[[' we found that tilorone and pyronaridine inhibited the virus replication in a549 - ace2 cells with ic50 values of 180 nm and ic50 198 nm ,  respectively.', ' human cmax for pyronaridine and quinacrine is greater than the ic50 hence justifying in vivo evaluation.']]"
remdesivir,[' most notably the rna polymerase targeting remdesivir demonstrated activity in vitro and efficacy in the early stage of the disease in humans.'],"'Repurposing the Ebola and Marburg Virus Inhibitors Tilorone, Quinacrine and Pyronaridine: In vitro Activity Against SARS-CoV-2 and Potential Mechanisms'",'10.1101/2020.12.01.407361',"[[' we found that tilorone and pyronaridine inhibited the virus replication in a549 - ace2 cells with ic50 values of 180 nm and ic50 198 nm ,  respectively.', ' human cmax for pyronaridine and quinacrine is greater than the ic50 hence justifying in vivo evaluation.']]"
remdesivir,"[' approved drugs including hydroxychloroquine ,  remdesivir or interferon were reported to inhibit the infection or propagation of severe acute respiratory syndrome - related coronavirus 2 ( sars - cov - 2 )  ,  however ,  their clinical efficacies have not yet been well demonstrated.']",'Anti-severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) potency of Mefloquine as an entry inhibitor in vitro','10.1101/2020.11.19.389726',"[[' mefloquine showed higher anti - sars - cov - 2 activity than hydroxychloroquine in veroe6 tmprss2 and calu - 3 cells ,  with ic50 = 1.28 m ,  ic90 = 2.31 m ,  and ic99 = 4.39 m in veroe6 tmprss2 cells.']]"
hydroxychloroquine,"[' approved drugs including hydroxychloroquine ,  remdesivir or interferon were reported to inhibit the infection or propagation of severe acute respiratory syndrome - related coronavirus 2 ( sars - cov - 2 )  ,  however ,  their clinical efficacies have not yet been well demonstrated.', ' mefloquine showed higher anti - sars - cov - 2 activity than hydroxychloroquine in veroe6 tmprss2 and calu - 3 cells ,  with ic50 = 1.']",'Anti-severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) potency of Mefloquine as an entry inhibitor in vitro','10.1101/2020.11.19.389726',"[[' mefloquine showed higher anti - sars - cov - 2 activity than hydroxychloroquine in veroe6 tmprss2 and calu - 3 cells ,  with ic50 = 1.28 m ,  ic90 = 2.31 m ,  and ic99 = 4.39 m in veroe6 tmprss2 cells.']]"
mefloquine,"[' to identify drugs with higher antiviral potency ,  we screened approved anti - parasitic anti - protozoal drugs and identified an anti - malarial drug ,  mefloquine ,  which showed the highest anti - sars - cov - 2 activity among the tested compounds.', ' mefloquine showed higher anti - sars - cov - 2 activity than hydroxychloroquine in veroe6 tmprss2 and calu - 3 cells ,  with ic50 = 1.', ' mefloquine inhibited viral entry after viral attachment to the target cell.', ' combined treatment with mefloquine and nelfinavir ,  a replication inhibitor ,  showed synergistic antiviral activity.', ' our mathematical modeling based on the drug concentration in the lung predicted that mefloquine administration at a standard treatment dosage could decline viral dynamics in patients ,  reduce cumulative viral load to 7% and shorten the time until virus elimination by 6.', ' these data cumulatively underscore mefloquine as an anti - sars - cov - 2 entry inhibitor.']",'Anti-severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) potency of Mefloquine as an entry inhibitor in vitro','10.1101/2020.11.19.389726',"[[' mefloquine showed higher anti - sars - cov - 2 activity than hydroxychloroquine in veroe6 tmprss2 and calu - 3 cells ,  with ic50 = 1.28 m ,  ic90 = 2.31 m ,  and ic99 = 4.39 m in veroe6 tmprss2 cells.']]"
nelfinavir,"[' combined treatment with mefloquine and nelfinavir ,  a replication inhibitor ,  showed synergistic antiviral activity.']",'Anti-severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) potency of Mefloquine as an entry inhibitor in vitro','10.1101/2020.11.19.389726',"[[' mefloquine showed higher anti - sars - cov - 2 activity than hydroxychloroquine in veroe6 tmprss2 and calu - 3 cells ,  with ic50 = 1.28 m ,  ic90 = 2.31 m ,  and ic99 = 4.39 m in veroe6 tmprss2 cells.']]"
chloroquine,"[' chloroquine ( cq )  and hydroxychloroquine ( hcq )  have been challenged in treating covid - 19 patients and still under debate due to the uncertainty regarding the effectiveness and safety ,  and there is still lack of the systematic study on the toxicity of these two drugs.']",Cytotoxicity Evaluation of Chloroquine and Hydroxychloroquine in Multiple Cell Lines and Tissues by Dynamic Imaging System and Physiologically Based Pharmacokinetic Model,10.3389/fphar.2020.574720,[[' cc50 and the ratio of tissue trough concentrations to cc50 ( rttcc )  were brought into predicted toxicity profiles.']]
hydroxychloroquine,"[' chloroquine ( cq )  and hydroxychloroquine ( hcq )  have been challenged in treating covid - 19 patients and still under debate due to the uncertainty regarding the effectiveness and safety ,  and there is still lack of the systematic study on the toxicity of these two drugs.']",Cytotoxicity Evaluation of Chloroquine and Hydroxychloroquine in Multiple Cell Lines and Tissues by Dynamic Imaging System and Physiologically Based Pharmacokinetic Model,10.3389/fphar.2020.574720,[[' cc50 and the ratio of tissue trough concentrations to cc50 ( rttcc )  were brought into predicted toxicity profiles.']]
angiotensin,[' structural analysis and evidences have been indicated that interaction between a segment of receptor binding domain ( rbd )  from s protein of virus and human angiotensin - converting enzyme 2 ( hace2 )  is essential for cellular entry of virus.'],Inhibition of S-protein RBD and hACE2 Interaction for Control of SARSCoV-2 Infection (COVID-19).,10.2174/1389557520666201117111259,"[[' moreover ,  some recently identified rbd - hace2 interaction inhibitors have also been described with their protein binding pattern and potencies ( ic50 values )  which will help for further improvement in the selectivity.']]"
itraconazole,"[' itraconazole ,  an antifungal agent ,  has been reported to have potential activity against animal coronaviruses.', '  methodsusing cell - based phenotypic assays ,  the in vitro antiviral activity of itraconazole and 17 - oh itraconazole was assessed against clinical isolates from a german and belgian patient infected with sars - cov - 2.', '  resultsitraconazole demonstrated antiviral activity in human caco - 2 cells ( ec50 = 2.', ' similarly ,  its primary metabolite ,  17 - oh itraconazole ,  showed inhibition of sars - cov - 2 activity ( ec50 = 3.', ' itraconazole and 17 - oh itraconazole resulted in a viral yield reduction in vitro of approximately 2 - log10 and approximately 1 - log10 ,  as measured in both caco - 2 cells and veroe6 - egfp cells ,  respectively.', '  discussionitraconazole and 17 - oh itraconazole exert in vitro low micromolar activity against sars - cov - 2.', ' despite the in vitro antiviral activity ,  itraconazole did not result in a beneficial effect in hospitalized covid - 19 patients in a clinical study ( eudract number: 2020 - 001243 - 15 ) .', '  highlightso_liitraconazole exerted in vitro low micromolar activity against sars - cov - 2 ( ec50 = 2.']",'In Vitro Activity of Itraconazole Against SARS-CoV-2','10.1101/2020.11.13.381194',"[['  resultsitraconazole demonstrated antiviral activity in human caco - 2 cells ( ec50 = 2.3 m; mtt assay ) .', ' similarly ,  its primary metabolite ,  17 - oh itraconazole ,  showed inhibition of sars - cov - 2 activity ( ec50 = 3.6 m ) .', ' remdesivir inhibited viral replication with an ec50 = 0.4 m.', '  highlightso_liitraconazole exerted in vitro low micromolar activity against sars - cov - 2 ( ec50 = 2.']]"
remdesivir,"[' remdesivir inhibited viral replication with an ec50 = 0.', ' the viral yield reduction brought about by remdesivir or gs - 441524 ( parent nucleoside of the antiviral prodrug remdesivir; positive control )  was more pronounced ,  with an approximately 3 log10 drop and >4 log10 drop in caco - 2 cells and veroe6 - egfp cells ,  respectively.']",'In Vitro Activity of Itraconazole Against SARS-CoV-2','10.1101/2020.11.13.381194',"[['  resultsitraconazole demonstrated antiviral activity in human caco - 2 cells ( ec50 = 2.3 m; mtt assay ) .', ' similarly ,  its primary metabolite ,  17 - oh itraconazole ,  showed inhibition of sars - cov - 2 activity ( ec50 = 3.6 m ) .', ' remdesivir inhibited viral replication with an ec50 = 0.4 m.', '  highlightso_liitraconazole exerted in vitro low micromolar activity against sars - cov - 2 ( ec50 = 2.']]"
quinacrine,"[' the results described in this study demonstrate the inhibitory potential of quinacrine and suramin against sars - cov - 2 main protease ( 3clpro ) .', ' quinacrine and suramin molecules present a competitive and non - competitive mode of inhibition ,  respectively ,  with ic50 and kd values in low m range.', ' our results suggested that suramin in combination with quinacrine showed promising synergistic efficacy to inhibit sars - cov - 2 3clpro.']",'The repurposed drugs suramin and quinacrine inhibit cooperatively in vitro SARS-CoV-2 3CLpro','10.1101/2020.11.11.378018',"[[' quinacrine and suramin molecules present a competitive and non - competitive mode of inhibition ,  respectively ,  with ic50 and kd values in low m range.']]"
suramin,"[' the results described in this study demonstrate the inhibitory potential of quinacrine and suramin against sars - cov - 2 main protease ( 3clpro ) .', ' quinacrine and suramin molecules present a competitive and non - competitive mode of inhibition ,  respectively ,  with ic50 and kd values in low m range.', ' our results suggested that suramin in combination with quinacrine showed promising synergistic efficacy to inhibit sars - cov - 2 3clpro.']",'The repurposed drugs suramin and quinacrine inhibit cooperatively in vitro SARS-CoV-2 3CLpro','10.1101/2020.11.11.378018',"[[' quinacrine and suramin molecules present a competitive and non - competitive mode of inhibition ,  respectively ,  with ic50 and kd values in low m range.']]"
remdesivir,"[' compared to remdesivir ,  which inhibits viral replication downstream of cell entry ,  stenoparib impedes entry and post - entry processes as determined by time - of - addition ( toa )  experiments.', '5 m remdesivir suppressed coronavirus growth by more than 90% ,  indicating a potentially synergistic effect for this drug combination.', ' stenoparib as a standalone or as part of combinatorial therapy with remdesivir should be a valuable addition to the arsenal against covid - 19.']","'Stenoparib, an inhibitor of cellular poly (ADP-ribose) polymerase (PARP), blocks replication of the SARS-CoV-2 human coronavirus in vitro.'",'10.1101/2020.11.12.380394',"[['5 m half - maximally effective concentration ( ec50 )  ,  combined with 0.5 m remdesivir suppressed coronavirus growth by more than 90% ,  indicating a potentially synergistic effect for this drug combination.']]"
ivermectin,"[' ivermectin ,  an anti - helminthic drug is also being proposed for treatment and prevention of covid - 19.', ' ivermectin has demonstrated broad spectrum antiviral activity against both dna and rna viruses.', ' however ,  in - vitro to in - vivo extrapolation studies indicate an inability to achieve the desired ic50 levels of ivermectin after oral administration of doses up to 10 times higher than the approved anti - helminthic dose.', ' it is hypothesised that inhaled formulation of ivermectin may be effective against sars - cov - 2.', ' therefore ,  ivermectin administered via inhalational route needs to be explored for potential beneficial role in covid - 19 in preclinical and clinical studies.']",Inhaled route and anti-inflammatory action of ivermectin: do they hold promise in fighting against COVID-19?,10.1016/j.mehy.2020.110364,"[[' however ,  in - vitro to in - vivo extrapolation studies indicate an inability to achieve the desired ic50 levels of ivermectin after oral administration of doses up to 10 times higher than the approved anti - helminthic dose.']]"
remdesivir,"[' the fda has recently approved remdesivir ,  an inhibitor of sars - cov - 2 replication ,  to treat covid - 19 ,  though recent data from the who shows little to no benefit with use of this anti - viral agent.']",'Ethacridine inhibits SARS-CoV-2 by inactivating viral particles in cellular models','10.1101/2020.10.28.359042',"[[' here we report the discovery of ethacridine ,  a safe antiseptic use in humans ,  as a potent drug for use against sars - cov - 2 ( ec50 ~ 0.08 m ) .']]"
bortezomib,"[' interestingly in cancer cells ,  the formation of sg is correlated to drug - resistance and blocking sg formation has been shown to reestablish the efficacy of the anticancer drug bortezomib.', ' changes in the cytotoxicity of bortezomib were measured.', ' results: bortezomib cytotoxicity in breast cancer cell lines changed with a 22 fold decrease in its ic50 for t47d and a 7 fold decrease for mcf7 cells.', ' as a result ,  it increases the cytotoxicity of the fda approved drug ,  bortezomib.', ' in addition ,  the increased cytotoxicity appears to correlate to improved bortezomib selectivity when compared to control cell lines.']","Role of Chikungunya nsP3 in Regulating G3BP1 Activity, Stress Granule Formation and Drug Efficacy",10.1016/j.arcmed.2020.10.002,[[' results: bortezomib cytotoxicity in breast cancer cell lines changed with a 22 fold decrease in its ic50 for t47d and a 7 fold decrease for mcf7 cells.']]
lopinavir,"[' from the clinical studies in covid - 19 ,  it has shown rapid viral clearance as compared to lopinavir ritonavir and superior recovery rate than umifenovir.']",Role of favipiravir in the treatment of COVID-19,10.1016/j.ijid.2020.10.069,"[[' it has a wide therapeutic safety margin indicated by wide cc50 ec50 ratio for high dose.'], [' it has a wide therapeutic safety margin indicated by wide cc50 ec50 ratio for high dose.']]"
favipiravir,"[' favipiravir is one such oral drug that was approved for new and re - emerging pandemic influenza in japan in 2014 and has shown potent in vitro activity against sars cov - 2.', ' overall ,  favipiravir has shown promising results in clinical studies in china ,  russia ,  and japan ,  and more trials are underway in multiple countries including usa ,  uk ,  india.', ' recently ,  treatment guidelines from many countries and some states from india have included favipiravir in the treatment protocol.', ' this review provides insights on the evidence based evolving role of favipiravir in the management covid - 19 infection with emphasis on benefits of initiating an early antiviral therapy with special focus on favipiravir ,  its pharmacodynamic ,  pharmacokinetic ,  in vitro ,  clinical data and inclusion in the treatment protocols of covid - 19.']",Role of favipiravir in the treatment of COVID-19,10.1016/j.ijid.2020.10.069,"[[' it has a wide therapeutic safety margin indicated by wide cc50 ec50 ratio for high dose.'], [' it has a wide therapeutic safety margin indicated by wide cc50 ec50 ratio for high dose.']]"
ritonavir,"[' from the clinical studies in covid - 19 ,  it has shown rapid viral clearance as compared to lopinavir ritonavir and superior recovery rate than umifenovir.']",Role of favipiravir in the treatment of COVID-19,10.1016/j.ijid.2020.10.069,"[[' it has a wide therapeutic safety margin indicated by wide cc50 ec50 ratio for high dose.'], [' it has a wide therapeutic safety margin indicated by wide cc50 ec50 ratio for high dose.']]"
heparin,"[' heparin ( delivered systemically )  is currently used to treat anticoagulant anomalies in covid - 19 patients.', ' in addition ,  in the uk ,  brazil and australia ,  nebulised unfractionated heparin ( ufh )  is being trialled in covid - 19 patients as a potential treatment.', ' a systematic comparison of the potential antiviral effect of various heparin preparations on live wild - type sars - cov - 2 ,  in vitro ,  is needed.', ' experimental approach: seven different heparin preparations including ufh and low molecular weight heparins ( lmwh )  of porcine or bovine origin were screened for antiviral activity against live sars - cov - 2 ( australia vic01 2020 )  using a plaque inhibition assay with vero e6 cells.', ' interaction of heparin with spike protein rbd was studied using differential scanning fluorimetry ,  and the inhibition of rbd binding to human ace2 protein using elisa assays was examined.', ' mechanistically we observed that heparin binds and destabilizes the rbd protein ,  and furthermore we show heparin directly inhibits the binding of rbd to the human ace2 protein receptor.', ' conclusions and implications: this comparison of clinically relevant heparins shows ufh has significantly stronger sars - cov - 2 antiviral activity compared to lmwhs.']",Unfractionated heparin inhibits live wildtype SARSCoV2 cell infectivity at therapeutically relevant concentrations,10.1111/bph.15304,"[[' key results: all the ufh preparations had potent antiviral effects ,  with ic50 values ranging between 25 - 41 g ml - 1 whereas lmwhs were less inhibitory by ~150 - fold ( ic50 range 3.4  -  7.8 mg ml - 1  ) .']]"
baloxavir,"[' this study aims to evaluate the clinical outcomes and plasma concentrations of baloxavir acid and favipiravir in covid - 19 patients.', ' methods: favipiravir and baloxavir acid were evaluated for their antiviral activity against sars - cov - 2 in vitro before the trial initiation.', ' patients were randomized assigned in a 1:1:1 ratio into baloxavir marboxil group ,  favipiravir group ,  and control group.', ' results: baloxavir acid showed antiviral activity in vitro with the half - maximal effective concentration ( ec50 )  of 5.', ' the percentage of patients who turned viral negative after 14 - day treatment was 70% ,  77% ,  and 100% in the baloxavir marboxil ,  favipiravir ,  and control group respectively ,  with the medians of time from randomization to clinical improvement was 14 ,  14 and 15 days ,  respectively.', ' one of the limitations of this study is the time from symptom onset to randomization ,  especially in the baloxavir marboxil and control groups ,  which is higher than the favipiravir group.', ' conclusions: our findings could not prove a benefit of addition of either baloxavir marboxil or favipiravir under the trial dosages to the existing standard treatment.']","Clinical Outcomes and Plasma Concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 Patients: An Exploratory Randomized, Controlled Trial",10.1016/j.ejps.2020.105631,"[["" results: baloxavir acid showed antiviral activity in vitro with the half - maximal effective concentration ( ec50 )  of 5.48 m comparable to arbidol and lopinavir ,  but favipiravir didn't demonstrate significant antiviral activity up to 100 m.""]]"
arbidol,"[""48 m comparable to arbidol and lopinavir ,  but favipiravir didn't demonstrate significant antiviral activity up to 100 m.""]","Clinical Outcomes and Plasma Concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 Patients: An Exploratory Randomized, Controlled Trial",10.1016/j.ejps.2020.105631,"[["" results: baloxavir acid showed antiviral activity in vitro with the half - maximal effective concentration ( ec50 )  of 5.48 m comparable to arbidol and lopinavir ,  but favipiravir didn't demonstrate significant antiviral activity up to 100 m.""]]"
favipiravir,"[' this study aims to evaluate the clinical outcomes and plasma concentrations of baloxavir acid and favipiravir in covid - 19 patients.', ' methods: favipiravir and baloxavir acid were evaluated for their antiviral activity against sars - cov - 2 in vitro before the trial initiation.', ' patients were randomized assigned in a 1:1:1 ratio into baloxavir marboxil group ,  favipiravir group ,  and control group.', ""48 m comparable to arbidol and lopinavir ,  but favipiravir didn't demonstrate significant antiviral activity up to 100 m."", ' the percentage of patients who turned viral negative after 14 - day treatment was 70% ,  77% ,  and 100% in the baloxavir marboxil ,  favipiravir ,  and control group respectively ,  with the medians of time from randomization to clinical improvement was 14 ,  14 and 15 days ,  respectively.', ' one of the limitations of this study is the time from symptom onset to randomization ,  especially in the baloxavir marboxil and control groups ,  which is higher than the favipiravir group.', ' conclusions: our findings could not prove a benefit of addition of either baloxavir marboxil or favipiravir under the trial dosages to the existing standard treatment.']","Clinical Outcomes and Plasma Concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 Patients: An Exploratory Randomized, Controlled Trial",10.1016/j.ejps.2020.105631,"[["" results: baloxavir acid showed antiviral activity in vitro with the half - maximal effective concentration ( ec50 )  of 5.48 m comparable to arbidol and lopinavir ,  but favipiravir didn't demonstrate significant antiviral activity up to 100 m.""]]"
lopinavir,"[""48 m comparable to arbidol and lopinavir ,  but favipiravir didn't demonstrate significant antiviral activity up to 100 m.""]","Clinical Outcomes and Plasma Concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 Patients: An Exploratory Randomized, Controlled Trial",10.1016/j.ejps.2020.105631,"[["" results: baloxavir acid showed antiviral activity in vitro with the half - maximal effective concentration ( ec50 )  of 5.48 m comparable to arbidol and lopinavir ,  but favipiravir didn't demonstrate significant antiviral activity up to 100 m.""]]"
papain,"[' k777 did not inhibit activity of the papain - like cysteine protease and 3cl cysteine protease ,  encoded by sars - cov - 2 at concentrations of  100 m.']",A cysteine protease inhibitor blocks SARS-CoV-2 infection of human and monkey cells.,10.1101/2020.10.23.347534,"[[' k777 reduced viral infectivity with ec50 values of inhibition of viral infection of: 74 nm for vero e6 ,  <80 nm for a549 ace2 ,  and 4 nm for hela ace2 cells.', ' in contrast ,  calu - 3 and caco - 2 cells had ec50 values in the low micromolar range.']]"
cysteine,"[' k777 did not inhibit activity of the papain - like cysteine protease and 3cl cysteine protease ,  encoded by sars - cov - 2 at concentrations of  100 m.', ' these results suggested that k777 exerts its potent anti - viral activity by inactivation of mammalian cysteine proteases which are essential to viral infectivity.']",A cysteine protease inhibitor blocks SARS-CoV-2 infection of human and monkey cells.,10.1101/2020.10.23.347534,"[[' k777 reduced viral infectivity with ec50 values of inhibition of viral infection of: 74 nm for vero e6 ,  <80 nm for a549 ace2 ,  and 4 nm for hela ace2 cells.', ' in contrast ,  calu - 3 and caco - 2 cells had ec50 values in the low micromolar range.']]"
papain,"[' k777 did not inhibit activity of the papain - like cysteine protease and 3cl cysteine protease ,  encoded by sars - cov - 2 at concentrations of [&le;] 100 m.']",'A cysteine protease inhibitor blocks SARS-CoV-2 infection of human and monkey cells','10.1101/2020.10.23.347534',"[[' k777 reduced viral infectivity with ec50 values of inhibition of viral infection of: 74 nm for vero e6 ,  <80 nm for a549 ace2 ,  and 4 nm for hela ace2 cells.', ' in contrast ,  calu - 3 and caco - 2 cells had ec50 values in the low micromolar range.']]"
cysteine,"[' k777 did not inhibit activity of the papain - like cysteine protease and 3cl cysteine protease ,  encoded by sars - cov - 2 at concentrations of [&le;] 100 m.', ' these results suggested that k777 exerts its potent anti - viral activity by inactivation of mammalian cysteine proteases which are essential to viral infectivity.']",'A cysteine protease inhibitor blocks SARS-CoV-2 infection of human and monkey cells','10.1101/2020.10.23.347534',"[[' k777 reduced viral infectivity with ec50 values of inhibition of viral infection of: 74 nm for vero e6 ,  <80 nm for a549 ace2 ,  and 4 nm for hela ace2 cells.', ' in contrast ,  calu - 3 and caco - 2 cells had ec50 values in the low micromolar range.']]"
acetamide,"['5]dec - 4 - yl ) acetamide ( 4f )  inhibited human coronavirus 229e ,  at ec50 values of 9.']",New spirothiazolidinone derivatives: Synthesis and antiviral evaluation,10.1080/10426507.2020.1828886,"[['5]decan - 4 - yl ) benzamide ( 3d )  exhibited strong activity against influenza a h3n2 virus ,  at ec50 values of 0.5 and 0.2 um and a selectivity index of about 50.', '5]dec - 4 - yl ) acetamide ( 4f )  inhibited human coronavirus 229e ,  at ec50 values of 9.8 and 8.6 um ,  and a favorable selectivity index for 4f.']]"
hydroxychloroquine,[' hydroxychloroquine ( hcq )  is commonly used in the treatment of malaria and rheumatic diseases.'],A multiscale absorption and transit model for oral delivery of hydroxychloroquine: Pharmacokinetic modeling and intestinal concentration prediction to assess toxicity and druginduced damage in healthy subjects,10.1002/cnm.3403,"[[' the simulated stomach and intestinal fluid and enterocyte concentrations were compared with the in vitro cc50 values.', ' while the peak enterocyte concentrations were several orders lower than the in vitro cc50 values ,  the peak stomach and the intestinal fluid concentrations were only one order smaller than the in vitro cc50 values.', ' in particular ,  the peak stomach and the duodenum fluid concentrations were just 3 smaller than the in vitro cc50 values.']]"
benzophenone,[' benzophenone derivatives could also be identified among the most potent screening hits.'],Biochemical screening for SARS-CoV-2 main protease inhibitors,10.1371/journal.pone.0240079,[[' these screens led to the identification of 13 inhibitors with ic50 values ranging from 0.2 m to 23 m.']]
thimerosal,"[' the screens confirmed several known sars - cov mpro inhibitors as inhibitors of sars - cov - 2 mpro ,  such as the organo - mercuric compounds thimerosal and phenylmercuric acetate.']",Biochemical screening for SARS-CoV-2 main protease inhibitors,10.1371/journal.pone.0240079,[[' these screens led to the identification of 13 inhibitors with ic50 values ranging from 0.2 m to 23 m.']]
cysteine,"["" this cysteine protease acts by processing the viruses' precursor polyproteins.""]",Biochemical screening for SARS-CoV-2 main protease inhibitors,10.1371/journal.pone.0240079,[[' these screens led to the identification of 13 inhibitors with ic50 values ranging from 0.2 m to 23 m.']]
artemether,"[' we report in vitro efficacy of artemisia annua extracts as well as artemisinin ,  artesunate ,  and artemether against sars - cov - 2.', ' in treatment assays ,  artesunate ( 50% effective concentration ( ec50 ) : 7 g ml )  was more potent than the tested plant extracts ( 128 - 260 g ml )  or artemisinin ( 151 g ml )  and artemether ( >179 g ml )  ,  while generally ec50 in pretreatment assays were slightly higher.', ' the selectivity index ( si )  ,  calculated based on treatment and cell viability assays ,  was highest for artemisinin ( 54 )  ,  and roughly equal for the extracts ( 5 - 10 )  ,  artesunate ( 6 )  and artemether ( <7 ) .']",'In vitro efficacy of Artemisinin-based treatments against SARS-CoV-2','10.1101/2020.10.05.326637',"[[' in treatment assays ,  artesunate ( 50% effective concentration ( ec50 ) : 7 g ml )  was more potent than the tested plant extracts ( 128 - 260 g ml )  or artemisinin ( 151 g ml )  and artemether ( >179 g ml )  ,  while generally ec50 in pretreatment assays were slightly higher.', ' peak plasma concentrations of artesunate exceeding ec50 values can be achieved.']]"
artemisinin,"[' we report in vitro efficacy of artemisia annua extracts as well as artemisinin ,  artesunate ,  and artemether against sars - cov - 2.', ' subsequent concentration - response studies using a high - throughput antiviral assay ,  based on immunostaining of sars - cov - 2 spike glycoprotein ,  revealed that pretreatment and treatment with extracts ,  artemisinin ,  and artesunate inhibited sars - cov - 2 infection of veroe6 cells.', ' in treatment assays ,  artesunate ( 50% effective concentration ( ec50 ) : 7 g ml )  was more potent than the tested plant extracts ( 128 - 260 g ml )  or artemisinin ( 151 g ml )  and artemether ( >179 g ml )  ,  while generally ec50 in pretreatment assays were slightly higher.', ' the selectivity index ( si )  ,  calculated based on treatment and cell viability assays ,  was highest for artemisinin ( 54 )  ,  and roughly equal for the extracts ( 5 - 10 )  ,  artesunate ( 6 )  and artemether ( <7 ) .']",'In vitro efficacy of Artemisinin-based treatments against SARS-CoV-2','10.1101/2020.10.05.326637',"[[' in treatment assays ,  artesunate ( 50% effective concentration ( ec50 ) : 7 g ml )  was more potent than the tested plant extracts ( 128 - 260 g ml )  or artemisinin ( 151 g ml )  and artemether ( >179 g ml )  ,  while generally ec50 in pretreatment assays were slightly higher.', ' peak plasma concentrations of artesunate exceeding ec50 values can be achieved.']]"
artesunate,"[' we report in vitro efficacy of artemisia annua extracts as well as artemisinin ,  artesunate ,  and artemether against sars - cov - 2.', ' subsequent concentration - response studies using a high - throughput antiviral assay ,  based on immunostaining of sars - cov - 2 spike glycoprotein ,  revealed that pretreatment and treatment with extracts ,  artemisinin ,  and artesunate inhibited sars - cov - 2 infection of veroe6 cells.', ' in treatment assays ,  artesunate ( 50% effective concentration ( ec50 ) : 7 g ml )  was more potent than the tested plant extracts ( 128 - 260 g ml )  or artemisinin ( 151 g ml )  and artemether ( >179 g ml )  ,  while generally ec50 in pretreatment assays were slightly higher.', ' the selectivity index ( si )  ,  calculated based on treatment and cell viability assays ,  was highest for artemisinin ( 54 )  ,  and roughly equal for the extracts ( 5 - 10 )  ,  artesunate ( 6 )  and artemether ( <7 ) .', ' peak plasma concentrations of artesunate exceeding ec50 values can be achieved.']",'In vitro efficacy of Artemisinin-based treatments against SARS-CoV-2','10.1101/2020.10.05.326637',"[[' in treatment assays ,  artesunate ( 50% effective concentration ( ec50 ) : 7 g ml )  was more potent than the tested plant extracts ( 128 - 260 g ml )  or artemisinin ( 151 g ml )  and artemether ( >179 g ml )  ,  while generally ec50 in pretreatment assays were slightly higher.', ' peak plasma concentrations of artesunate exceeding ec50 values can be achieved.']]"
artemether,"[' we report in vitro efficacy of artemisia annua extracts as well as artemisinin ,  artesunate ,  and artemether against sars - cov - 2.', ' in treatment assays ,  artesunate ( 50% effective concentration ( ec50 ) : 7 g ml )  was more potent than the tested plant extracts ( 128 - 260 g ml )  or artemisinin ( 151 g ml )  and artemether ( >179 g ml )  ,  while generally ec50 in pretreatment assays were slightly higher.', ' the selectivity index ( si )  ,  calculated based on treatment and cell viability assays ,  was highest for artemisinin ( 54 )  ,  and roughly equal for the extracts ( 5 - 10 )  ,  artesunate ( 6 )  and artemether ( <7 ) .']",In vitro efficacy of Artemisinin-based treatments against SARS-CoV-2,10.1101/2020.10.05.326637,"[[' in treatment assays ,  artesunate ( 50% effective concentration ( ec50 ) : 7 g ml )  was more potent than the tested plant extracts ( 128 - 260 g ml )  or artemisinin ( 151 g ml )  and artemether ( >179 g ml )  ,  while generally ec50 in pretreatment assays were slightly higher.', ' peak plasma concentrations of artesunate exceeding ec50 values can be achieved.']]"
artemisinin,"[' we report in vitro efficacy of artemisia annua extracts as well as artemisinin ,  artesunate ,  and artemether against sars - cov - 2.', ' subsequent concentration - response studies using a high - throughput antiviral assay ,  based on immunostaining of sars - cov - 2 spike glycoprotein ,  revealed that pretreatment and treatment with extracts ,  artemisinin ,  and artesunate inhibited sars - cov - 2 infection of veroe6 cells.', ' in treatment assays ,  artesunate ( 50% effective concentration ( ec50 ) : 7 g ml )  was more potent than the tested plant extracts ( 128 - 260 g ml )  or artemisinin ( 151 g ml )  and artemether ( >179 g ml )  ,  while generally ec50 in pretreatment assays were slightly higher.', ' the selectivity index ( si )  ,  calculated based on treatment and cell viability assays ,  was highest for artemisinin ( 54 )  ,  and roughly equal for the extracts ( 5 - 10 )  ,  artesunate ( 6 )  and artemether ( <7 ) .']",In vitro efficacy of Artemisinin-based treatments against SARS-CoV-2,10.1101/2020.10.05.326637,"[[' in treatment assays ,  artesunate ( 50% effective concentration ( ec50 ) : 7 g ml )  was more potent than the tested plant extracts ( 128 - 260 g ml )  or artemisinin ( 151 g ml )  and artemether ( >179 g ml )  ,  while generally ec50 in pretreatment assays were slightly higher.', ' peak plasma concentrations of artesunate exceeding ec50 values can be achieved.']]"
artesunate,"[' we report in vitro efficacy of artemisia annua extracts as well as artemisinin ,  artesunate ,  and artemether against sars - cov - 2.', ' subsequent concentration - response studies using a high - throughput antiviral assay ,  based on immunostaining of sars - cov - 2 spike glycoprotein ,  revealed that pretreatment and treatment with extracts ,  artemisinin ,  and artesunate inhibited sars - cov - 2 infection of veroe6 cells.', ' in treatment assays ,  artesunate ( 50% effective concentration ( ec50 ) : 7 g ml )  was more potent than the tested plant extracts ( 128 - 260 g ml )  or artemisinin ( 151 g ml )  and artemether ( >179 g ml )  ,  while generally ec50 in pretreatment assays were slightly higher.', ' the selectivity index ( si )  ,  calculated based on treatment and cell viability assays ,  was highest for artemisinin ( 54 )  ,  and roughly equal for the extracts ( 5 - 10 )  ,  artesunate ( 6 )  and artemether ( <7 ) .', ' peak plasma concentrations of artesunate exceeding ec50 values can be achieved.']",In vitro efficacy of Artemisinin-based treatments against SARS-CoV-2,10.1101/2020.10.05.326637,"[[' in treatment assays ,  artesunate ( 50% effective concentration ( ec50 ) : 7 g ml )  was more potent than the tested plant extracts ( 128 - 260 g ml )  or artemisinin ( 151 g ml )  and artemether ( >179 g ml )  ,  while generally ec50 in pretreatment assays were slightly higher.', ' peak plasma concentrations of artesunate exceeding ec50 values can be achieved.']]"
nitazoxanide,"[' two compounds ,  nitazoxanide and jib - 04 inhibited sars - cov - 2 replication in vero e6 cells with an ec50 of 4.', ' these results highlight the potential utility of nitazoxanide and jib - 04 as antiviral agents against sars - cov - 2 and other viral pathogens.']",'Nitazoxanide and JIB-04 have broad-spectrum antiviral activity and inhibit SARS-CoV-2 replication in cell culture and coronavirus pathogenesis in a pig model','10.1101/2020.09.24.312165',"[[' two compounds ,  nitazoxanide and jib - 04 inhibited sars - cov - 2 replication in vero e6 cells with an ec50 of 4.90 m and 0.69 m ,  respectively ,  with specificity indices of greater than 150.']]"
acrylamide,[' application of the protocol to an existing sars - cov - 1 mpro reversible inhibitor led to a new acrylamide inhibitor series with low micromolar ic50 against sars - cov - 2 mpro.'],'An automatic pipeline for the design of irreversible derivatives identifies a potent SARS-CoV-2 Mpro inhibitor.','10.1101/2020.09.21.299776',"[[' in prospective evaluation against a panel of kinases ,  five out of nine predicted covalent inhibitors showed ic50 between 155 nm  -  4.2 m.', ' application of the protocol to an existing sars - cov - 1 mpro reversible inhibitor led to a new acrylamide inhibitor series with low micromolar ic50 against sars - cov - 2 mpro.']]"
cysteine,"[' we use covalent docking ,  to dock these tailored covalent libraries and to find those that can bind covalently to a nearby cysteine while keeping some of the main interactions of the original molecule.', ' we found ~11 , 000 cysteines in close proximity to a ligand across 8 , 386 protein - ligand complexes in the pdb.']",'An automatic pipeline for the design of irreversible derivatives identifies a potent SARS-CoV-2 Mpro inhibitor.','10.1101/2020.09.21.299776',"[[' in prospective evaluation against a panel of kinases ,  five out of nine predicted covalent inhibitors showed ic50 between 155 nm  -  4.2 m.', ' application of the protocol to an existing sars - cov - 1 mpro reversible inhibitor led to a new acrylamide inhibitor series with low micromolar ic50 against sars - cov - 2 mpro.']]"
angiotensin,"[' using a multiplex in vitro binding assay we showed that eight of the selected nbs effectively block the interaction between rbd ,  s1 - domain and homotrimeric spike protein with the angiotensin converting enzyme 2 ( ace2 )  as the viral docking site on human cells.']",'NeutrobodyPlex - Nanobodies to monitor a SARS-CoV-2 neutralizing immune response','10.1101/2020.09.22.308338',"[[' according to competitive binding analysis and detailed epitope mapping ,  we grouped all nbs blocking the rbd:ace2 interaction in three distinct nb - sets and demonstrated their neutralizing effect with ic50 values in the low nanomolar range in a cell - based sars - cov - 2 neutralization assay.', ' tested nb combinations from different sets showed substantially lower ic50 values in both functional assays indicating a profound synergistic effect of nbs simultaneously targeting different epitopes within the rbd.']]"
angiotensin,"[' kim - 1 positive cells express less angiotensin - converting enzyme 2 ( ace2 )  ,  the well - known receptor for sars - cov - 2.']",KIM-1/TIM-1 is a Receptor for SARS-CoV-2 in Lung and Kidney.,10.1101/2020.09.16.20190694,"[[' using microscale thermophoresis ,  the ec50 for kim - 1 - sars - cov - 2 spike protein ,  and receptor binding domain ( rbd )  interactions ,  were 19 and 10 nm respectively.']]"
disulfiram,"[' in this study ,  we investigated the mechanism of action of six previously reported mpro inhibitors ,  ebselen ,  disulfiram ,  tideglusib ,  carmofur ,  shikonin ,  and px - 12 using a consortium of techniques including fret - based enzymatic assay ,  thermal shift assay ,  native mass spectrometry ,  cellular antiviral assays ,  and molecular dynamics simulations.', ' overall ,  we provide compelling evidence suggesting that ebselen ,  disulfiram ,  tideglusib ,  carmofur ,  shikonin ,  and px - 12 are non - specific sars - cov - 2 mpro inhibitors ,  and urge the scientific community to be stringent with hit validation.']","'Ebselen, disulfiram, carmofur, PX-12, tideglusib, and shikonin are non-specific promiscuous SARS-CoV-2 main protease inhibitors'",'10.1101/2020.09.15.299164',"[[' however ,  none of the compounds inhibits the viral replication of ev - a71 or ev - d68 ,  suggesting that the enzymatic inhibition potency ic50 values obtained in the absence of dtt cannot be used to faithfully predict their cellular antiviral activity.']]"
tideglusib,"[' in this study ,  we investigated the mechanism of action of six previously reported mpro inhibitors ,  ebselen ,  disulfiram ,  tideglusib ,  carmofur ,  shikonin ,  and px - 12 using a consortium of techniques including fret - based enzymatic assay ,  thermal shift assay ,  native mass spectrometry ,  cellular antiviral assays ,  and molecular dynamics simulations.', ' overall ,  we provide compelling evidence suggesting that ebselen ,  disulfiram ,  tideglusib ,  carmofur ,  shikonin ,  and px - 12 are non - specific sars - cov - 2 mpro inhibitors ,  and urge the scientific community to be stringent with hit validation.']","'Ebselen, disulfiram, carmofur, PX-12, tideglusib, and shikonin are non-specific promiscuous SARS-CoV-2 main protease inhibitors'",'10.1101/2020.09.15.299164',"[[' however ,  none of the compounds inhibits the viral replication of ev - a71 or ev - d68 ,  suggesting that the enzymatic inhibition potency ic50 values obtained in the absence of dtt cannot be used to faithfully predict their cellular antiviral activity.']]"
glutamine,"[' in addition ,  mpro has a unique substrate preference for glutamine in the p1 position.']","'Ebselen, disulfiram, carmofur, PX-12, tideglusib, and shikonin are non-specific promiscuous SARS-CoV-2 main protease inhibitors'",'10.1101/2020.09.15.299164',"[[' however ,  none of the compounds inhibits the viral replication of ev - a71 or ev - d68 ,  suggesting that the enzymatic inhibition potency ic50 values obtained in the absence of dtt cannot be used to faithfully predict their cellular antiviral activity.']]"
cysteine,"[' mpro is a cysteine protease that hydrolyzes the viral polyprotein at more than 11 sites and it is highly conserved among coronaviruses.', ' in the absence of dtt ,  these six compounds not only inhibit mpro ,  but also a panel of viral cysteine proteases including sars - cov - 2 papain - like protease ,  the 2apro and 3cpro from enterovirus a71 ( ev - a71 )  and ev - d68.']","'Ebselen, disulfiram, carmofur, PX-12, tideglusib, and shikonin are non-specific promiscuous SARS-CoV-2 main protease inhibitors'",'10.1101/2020.09.15.299164',"[[' however ,  none of the compounds inhibits the viral replication of ev - a71 or ev - d68 ,  suggesting that the enzymatic inhibition potency ic50 values obtained in the absence of dtt cannot be used to faithfully predict their cellular antiviral activity.']]"
ebselen,"[' in this study ,  we investigated the mechanism of action of six previously reported mpro inhibitors ,  ebselen ,  disulfiram ,  tideglusib ,  carmofur ,  shikonin ,  and px - 12 using a consortium of techniques including fret - based enzymatic assay ,  thermal shift assay ,  native mass spectrometry ,  cellular antiviral assays ,  and molecular dynamics simulations.', ' overall ,  we provide compelling evidence suggesting that ebselen ,  disulfiram ,  tideglusib ,  carmofur ,  shikonin ,  and px - 12 are non - specific sars - cov - 2 mpro inhibitors ,  and urge the scientific community to be stringent with hit validation.']","'Ebselen, disulfiram, carmofur, PX-12, tideglusib, and shikonin are non-specific promiscuous SARS-CoV-2 main protease inhibitors'",'10.1101/2020.09.15.299164',"[[' however ,  none of the compounds inhibits the viral replication of ev - a71 or ev - d68 ,  suggesting that the enzymatic inhibition potency ic50 values obtained in the absence of dtt cannot be used to faithfully predict their cellular antiviral activity.']]"
carmofur,"[' in this study ,  we investigated the mechanism of action of six previously reported mpro inhibitors ,  ebselen ,  disulfiram ,  tideglusib ,  carmofur ,  shikonin ,  and px - 12 using a consortium of techniques including fret - based enzymatic assay ,  thermal shift assay ,  native mass spectrometry ,  cellular antiviral assays ,  and molecular dynamics simulations.', ' overall ,  we provide compelling evidence suggesting that ebselen ,  disulfiram ,  tideglusib ,  carmofur ,  shikonin ,  and px - 12 are non - specific sars - cov - 2 mpro inhibitors ,  and urge the scientific community to be stringent with hit validation.']","'Ebselen, disulfiram, carmofur, PX-12, tideglusib, and shikonin are non-specific promiscuous SARS-CoV-2 main protease inhibitors'",'10.1101/2020.09.15.299164',"[[' however ,  none of the compounds inhibits the viral replication of ev - a71 or ev - d68 ,  suggesting that the enzymatic inhibition potency ic50 values obtained in the absence of dtt cannot be used to faithfully predict their cellular antiviral activity.']]"
papain,"[' in the absence of dtt ,  these six compounds not only inhibit mpro ,  but also a panel of viral cysteine proteases including sars - cov - 2 papain - like protease ,  the 2apro and 3cpro from enterovirus a71 ( ev - a71 )  and ev - d68.']","'Ebselen, disulfiram, carmofur, PX-12, tideglusib, and shikonin are non-specific promiscuous SARS-CoV-2 main protease inhibitors'",'10.1101/2020.09.15.299164',"[[' however ,  none of the compounds inhibits the viral replication of ev - a71 or ev - d68 ,  suggesting that the enzymatic inhibition potency ic50 values obtained in the absence of dtt cannot be used to faithfully predict their cellular antiviral activity.']]"
shikonin,"[' in this study ,  we investigated the mechanism of action of six previously reported mpro inhibitors ,  ebselen ,  disulfiram ,  tideglusib ,  carmofur ,  shikonin ,  and px - 12 using a consortium of techniques including fret - based enzymatic assay ,  thermal shift assay ,  native mass spectrometry ,  cellular antiviral assays ,  and molecular dynamics simulations.', ' overall ,  we provide compelling evidence suggesting that ebselen ,  disulfiram ,  tideglusib ,  carmofur ,  shikonin ,  and px - 12 are non - specific sars - cov - 2 mpro inhibitors ,  and urge the scientific community to be stringent with hit validation.']","'Ebselen, disulfiram, carmofur, PX-12, tideglusib, and shikonin are non-specific promiscuous SARS-CoV-2 main protease inhibitors'",'10.1101/2020.09.15.299164',"[[' however ,  none of the compounds inhibits the viral replication of ev - a71 or ev - d68 ,  suggesting that the enzymatic inhibition potency ic50 values obtained in the absence of dtt cannot be used to faithfully predict their cellular antiviral activity.']]"
remdesivir,"["" 'background and objectivesremdesivir and hydroxychloroquine are or were among the most promising therapeutic options to tackle the current sars - cov - 2 pandemic."", ' besides the use of the prodrug remdesivir itself ,  the direct administration of gs - 441 524 ,  the resulting main metabolite of remdesivir ,  could be advantageous and even more effective.', ' in vitro experiments were conducted to investigate the degradation of remdesivir in human plasma and blood.', ' furthermore ,  we could demonstrate a high tissue distribution of gs - 441 524 even if not administered as the prodrug remdesivir.']",'Mouse model for testing SARS-CoV-2 antivirals: Pharmacokinetics','10.1101/2020.09.16.299537',"[[' for gs - 441 524 ,  measured tissue concentrations exceeded the reported in vitro ec50 values by more than 10 - fold and in consideration of its high efficacy against feline infectious peritonitis ,  gs - 441 524 could indeed be effective against sars - cov - 2 in vivo.', ' for hcq ,  relatively high in vitro ec50 values are reported ,  which were not reached in all tissues.']]"
hydroxychloroquine,"["" 'background and objectivesremdesivir and hydroxychloroquine are or were among the most promising therapeutic options to tackle the current sars - cov - 2 pandemic.""]",'Mouse model for testing SARS-CoV-2 antivirals: Pharmacokinetics','10.1101/2020.09.16.299537',"[[' for gs - 441 524 ,  measured tissue concentrations exceeded the reported in vitro ec50 values by more than 10 - fold and in consideration of its high efficacy against feline infectious peritonitis ,  gs - 441 524 could indeed be effective against sars - cov - 2 in vivo.', ' for hcq ,  relatively high in vitro ec50 values are reported ,  which were not reached in all tissues.']]"
angiotensin,[' cell entry of sars - cov - 2 mainly depends on binding of the viral spike ( s )  proteins to angiotensin converting enzyme 2 ( ace2 )  on host cells.'],'Ceftazidime Is a Potential Drug to Inhibit SARS-CoV-2 Infection In Vitro by Blocking Spike Protein-ACE2 Interaction','10.1101/2020.09.14.295956',"[[' the inhibitory concentration ( ic50 )  was 113.2 m ,  which is far below the blood concentration ( over 300 m )  of ceftazidime in patients when clinically treated with recommended dose.']]"
ceftazidime,"[' using a high - throughput screening system to investigate the interaction between spike receptor binding domain ( s - rbd )  and ace2 extracellular domain ,  we screened 3581 fda - approved drugs and natural small molecules and identified ceftazidime as a potent compound to inhibit s - rbd - ace2 interaction by binding to s - rbd.', ' in addition to significantly inhibit s - rbd binding to hpaepic cells ,  ceftazidime efficiently prevented sars - cov - 2 pseudovirus to infect ace2 - expressing 293t cells.', '2 m ,  which is far below the blood concentration ( over 300 m )  of ceftazidime in patients when clinically treated with recommended dose.', ' notably ,  ceftazidime is a drug clinically used for the treatment of pneumonia with minimal side effects compared with other antiviral drugs.', ' thus ,  ceftazidime has both anti - bacterial and anti - sars - cov - 2 effects ,  which should be the first - line antibiotics used for the clinical treatment of covid - 19.']",'Ceftazidime Is a Potential Drug to Inhibit SARS-CoV-2 Infection In Vitro by Blocking Spike Protein-ACE2 Interaction','10.1101/2020.09.14.295956',"[[' the inhibitory concentration ( ic50 )  was 113.2 m ,  which is far below the blood concentration ( over 300 m )  of ceftazidime in patients when clinically treated with recommended dose.']]"
histamine,"['  findingsthe computational approach with four independent queries identified major drug families ,  most often and in overlapping fashion anti - infective ,  anti - inflammatory ,  anti - hypertensive ,  anti - histamine and neuroactive drugs.', ' azelastine ,  an histamine 1 receptor - blocker ,  was predicted in multiple screens ,  and based on its attractive safety profile and availability in nasal formulation ,  was selected for experimental testing.', '  interpretationsazelastine ,  an anti - histamine ,  available in nasal sprays developed against allergic rhinitis may be considered as a topical prevention or treatment of nasal colonization with sars - cov - 2.']","'The Anti-histamine Azelastine, Identified by Computational Drug Repurposing, Inhibits SARS-CoV-2 Infection in Reconstituted Human Nasal Tissue In Vitro'",'10.1101/2020.09.15.296228',[[' azelastine significantly reduced cytopathic effect and sars - cov - 2 infection of vero e6 cells with an ec50 of [~]6 m both in a preventive and treatment setting.']]
azelastine,"[' antiviral activity of a predicted drug ,  azelastine ,  was tested in vitro in sars - cov - 2 infection assays with vero e6 monkey kidney epithelial cells and reconstituted human nasal tissue.', ' azelastine ,  an histamine 1 receptor - blocker ,  was predicted in multiple screens ,  and based on its attractive safety profile and availability in nasal formulation ,  was selected for experimental testing.', ' azelastine significantly reduced cytopathic effect and sars - cov - 2 infection of vero e6 cells with an ec50 of [~]6 m both in a preventive and treatment setting.', ' furthermore ,  azelastine in a commercially available nasal spray tested at 5 - fold dilution was highly potent in inhibiting viral propagation in sars - cov - 2 infected reconstituted human nasal tissue.', '  interpretationsazelastine ,  an anti - histamine ,  available in nasal sprays developed against allergic rhinitis may be considered as a topical prevention or treatment of nasal colonization with sars - cov - 2.']","'The Anti-histamine Azelastine, Identified by Computational Drug Repurposing, Inhibits SARS-CoV-2 Infection in Reconstituted Human Nasal Tissue In Vitro'",'10.1101/2020.09.15.296228',[[' azelastine significantly reduced cytopathic effect and sars - cov - 2 infection of vero e6 cells with an ec50 of [~]6 m both in a preventive and treatment setting.']]
masitinib,"[' we investigated the mechanism of action for these and found that masitinib ,  a drug originally developed as a tyrosine - kinase inhibitor for cancer treatment ,  strongly inhibited the activity of the sars - cov - 2 main protease 3clpro.', ' x - ray crystallography revealed that masitinib directly binds to the active site of 3clpro ,  thereby blocking its enzymatic activity.', ' thus ,  our results show that masitinib has broad anti - viral activity against two distinct beta - coronaviruses and multiple picornaviruses that cause human disease and is a strong candidate for clinical trials to treat sars - cov - 2 infection.']",'Drug repurposing screen identifies masitinib as a 3CLpro inhibitor that blocks replication of SARS-CoV-2 in vitro','10.1101/2020.08.31.274639',"[[' 20 of the 26 drugs significantly inhibited sars - cov - 2 replication in human lung cells ( a549 epithelial cell line )  ,  with ec50 values ranging from 0.1 to 8 micromolar.']]"
tyrosine,"[' we investigated the mechanism of action for these and found that masitinib ,  a drug originally developed as a tyrosine - kinase inhibitor for cancer treatment ,  strongly inhibited the activity of the sars - cov - 2 main protease 3clpro.']",'Drug repurposing screen identifies masitinib as a 3CLpro inhibitor that blocks replication of SARS-CoV-2 in vitro','10.1101/2020.08.31.274639',"[[' 20 of the 26 drugs significantly inhibited sars - cov - 2 replication in human lung cells ( a549 epithelial cell line )  ,  with ec50 values ranging from 0.1 to 8 micromolar.']]"
ribavirin,[' two retrospective matched - cohort studies reported the use of lopinavir ritonavir in combination with ribavirin for sars patients.'],"Lopinavir/ritonavir for the treatment of SARS, MERS and COVID-19: a systematic review.",10.26355/eurrev_202008_22659,[[' three additional in - vitro studies reported the ec50 of the antiviral activity of lopinavir ritonavir in mers.']]
lopinavir,"[' objective: lopinavir ritonavir has been used for the treatment of severe acute respiratory syndrome ( sars )  and middle east respiratory syndrome ( mers )  coronavirus infections.', ' materials and methods: we performed a systematic review of the literature regarding the use of lopinavir ritonavir for the treatment of these three infections.', ' we systematically searched the pubmed database from inception to april 30th ,  2020 ,  to identify in - vitro and animal studies and any reports of human use of lopinavir ritonavir for the treatment of sars ,  mers and covid - 19.', ' results: five in - vitro studies evaluated the effect of lopinavir ritonavir in sars.', ' three additional in - vitro studies reported the ec50 of the antiviral activity of lopinavir ritonavir in mers.', ' we identified no in vitro studies evaluating the effect of lopinavir ritonavir on the novel coronavirus.', ' two retrospective matched - cohort studies reported the use of lopinavir ritonavir in combination with ribavirin for sars patients.', ' three case reports and one retrospective study described the use of lopinavir ritonavir in mers.', ' twenty - two papers describe the use of lopinavir ritonavir in adult patients with covid - 19.', ' conclusions: the existing literature does not suffice for assessing whether lopinavir ritonavir has any benefit in sars ,  mers or covid - 19.']","Lopinavir/ritonavir for the treatment of SARS, MERS and COVID-19: a systematic review.",10.26355/eurrev_202008_22659,[[' three additional in - vitro studies reported the ec50 of the antiviral activity of lopinavir ritonavir in mers.']]
ritonavir,"[' objective: lopinavir ritonavir has been used for the treatment of severe acute respiratory syndrome ( sars )  and middle east respiratory syndrome ( mers )  coronavirus infections.', ' materials and methods: we performed a systematic review of the literature regarding the use of lopinavir ritonavir for the treatment of these three infections.', ' we systematically searched the pubmed database from inception to april 30th ,  2020 ,  to identify in - vitro and animal studies and any reports of human use of lopinavir ritonavir for the treatment of sars ,  mers and covid - 19.', ' results: five in - vitro studies evaluated the effect of lopinavir ritonavir in sars.', ' three additional in - vitro studies reported the ec50 of the antiviral activity of lopinavir ritonavir in mers.', ' we identified no in vitro studies evaluating the effect of lopinavir ritonavir on the novel coronavirus.', ' two retrospective matched - cohort studies reported the use of lopinavir ritonavir in combination with ribavirin for sars patients.', ' three case reports and one retrospective study described the use of lopinavir ritonavir in mers.', ' twenty - two papers describe the use of lopinavir ritonavir in adult patients with covid - 19.', ' conclusions: the existing literature does not suffice for assessing whether lopinavir ritonavir has any benefit in sars ,  mers or covid - 19.']","Lopinavir/ritonavir for the treatment of SARS, MERS and COVID-19: a systematic review.",10.26355/eurrev_202008_22659,[[' three additional in - vitro studies reported the ec50 of the antiviral activity of lopinavir ritonavir in mers.']]
masitinib,"[' we investigated the mechanism of action for these and found that masitinib ,  a drug originally developed as a tyrosine - kinase inhibitor for cancer treatment ,  strongly inhibited the activity of the sars - cov - 2 main protease 3clpro.', ' x - ray crystallography revealed that masitinib directly binds to the active site of 3clpro ,  thereby blocking its enzymatic activity.', ' thus ,  our results show that masitinib has broad anti - viral activity against two distinct beta - coronaviruses and multiple picornaviruses that cause human disease and is a strong candidate for clinical trials to treat sars - cov - 2 infection.']",Drug repurposing screen identifies masitinib as a 3CLpro inhibitor that blocks replication of SARS-CoV-2 in vitro.,10.1101/2020.08.31.274639,"[[' 20 of the 26 drugs significantly inhibited sars - cov - 2 replication in human lung cells ( a549 epithelial cell line )  ,  with ec50 values ranging from 0.1 to 8 micromolar.']]"
tyrosine,"[' we investigated the mechanism of action for these and found that masitinib ,  a drug originally developed as a tyrosine - kinase inhibitor for cancer treatment ,  strongly inhibited the activity of the sars - cov - 2 main protease 3clpro.']",Drug repurposing screen identifies masitinib as a 3CLpro inhibitor that blocks replication of SARS-CoV-2 in vitro.,10.1101/2020.08.31.274639,"[[' 20 of the 26 drugs significantly inhibited sars - cov - 2 replication in human lung cells ( a549 epithelial cell line )  ,  with ec50 values ranging from 0.1 to 8 micromolar.']]"
remdesivir,"[' the replication was drastically inhibited by remdesivir ,  an rna polymerase inhibitor for sars - cov - 2.', ' the ic50 of remdesivir in this study was 0.']",'A PCR amplicon-based SARS-CoV-2 replicon for antiviral screening','10.1101/2020.08.28.267567',"[[' the ic50 of remdesivir in this study was 0.29 m ,  generally consistent to the ic50 obtained using infectious sars - cov - 2 in a previous study ( 0.77 m ) .']]"
chloroquine,"[' we confirmed that it does so in a concentration - dependent manner with a low micromolar half - maximal inhibitory concentration ( ic50 = 3 m )  in our protein - based elisa - type setup ,  while chloroquine ,  siramesine ,  and suramin showed no inhibitory activity in this assay.']",'Methylene Blue Inhibits In Vitro the SARS-CoV-2 Spike - ACE2 Protein-Protein Interaction - A Mechanism That Can Contribute to Its Antiviral Activity Against COVID-19','10.1101/2020.08.29.273441',"[[' we confirmed that it does so in a concentration - dependent manner with a low micromolar half - maximal inhibitory concentration ( ic50 = 3 m )  in our protein - based elisa - type setup ,  while chloroquine ,  siramesine ,  and suramin showed no inhibitory activity in this assay.']]"
suramin,"[' we confirmed that it does so in a concentration - dependent manner with a low micromolar half - maximal inhibitory concentration ( ic50 = 3 m )  in our protein - based elisa - type setup ,  while chloroquine ,  siramesine ,  and suramin showed no inhibitory activity in this assay.']",'Methylene Blue Inhibits In Vitro the SARS-CoV-2 Spike - ACE2 Protein-Protein Interaction - A Mechanism That Can Contribute to Its Antiviral Activity Against COVID-19','10.1101/2020.08.29.273441',"[[' we confirmed that it does so in a concentration - dependent manner with a low micromolar half - maximal inhibitory concentration ( ic50 = 3 m )  in our protein - based elisa - type setup ,  while chloroquine ,  siramesine ,  and suramin showed no inhibitory activity in this assay.']]"
phenothiazine,"[' as part of this ,  we found that methylene blue ,  a tricyclic phenothiazine compound approved by the fda for the treatment of methemoglobinemia and used for other medical applications ( including the inactivation of viruses in blood products prior to transfusion when activated by light )  ,  inhibits this interaction.']",'Methylene Blue Inhibits In Vitro the SARS-CoV-2 Spike - ACE2 Protein-Protein Interaction - A Mechanism That Can Contribute to Its Antiviral Activity Against COVID-19','10.1101/2020.08.29.273441',"[[' we confirmed that it does so in a concentration - dependent manner with a low micromolar half - maximal inhibitory concentration ( ic50 = 3 m )  in our protein - based elisa - type setup ,  while chloroquine ,  siramesine ,  and suramin showed no inhibitory activity in this assay.']]"
siramesine,"[' we confirmed that it does so in a concentration - dependent manner with a low micromolar half - maximal inhibitory concentration ( ic50 = 3 m )  in our protein - based elisa - type setup ,  while chloroquine ,  siramesine ,  and suramin showed no inhibitory activity in this assay.']",'Methylene Blue Inhibits In Vitro the SARS-CoV-2 Spike - ACE2 Protein-Protein Interaction - A Mechanism That Can Contribute to Its Antiviral Activity Against COVID-19','10.1101/2020.08.29.273441',"[[' we confirmed that it does so in a concentration - dependent manner with a low micromolar half - maximal inhibitory concentration ( ic50 = 3 m )  in our protein - based elisa - type setup ,  while chloroquine ,  siramesine ,  and suramin showed no inhibitory activity in this assay.']]"
suramin,"[' moreover ,  based on this system ,  we have demonstrated that an aqueous extract from the chinese herb prunella vulgaris ( chpv )  and a compound ,  suramin ,  displayed potent inhibitory effects on both wild type and mutant ( g614 )  scov - 2 sp pseudotyped virus ( scov - 2 - sp - pvs )  - mediated infection.', ' the 50% inhibitory concentration ( ic50 )  for chpv and suramin on scov - 2 - sp - pvs are 30 ,  and 40 g ml ,  respectively.', ' to define the mechanisms of their actions ,  we demonstrated that both chpv and suramin are able to directly interrupt scov - 2 - sp binding to its receptor ace2 and block the viral entry step.', ' importantly ,  our results also showed that chpv or suramin can efficiently reduce levels of cytopathic effect caused by sars - cov - 2 virus ( hcov - 19 canada on - vido - 01 2020 )  infection in vero cells.', ' furthermore ,  our results demonstrated that the combination of chpv suramin with an anti - sars - cov - 2 neutralizing antibody mediated more potent blocking effect against scov2 - sp - pvs.', ' overall ,  this study provides evidence that chpv and suramin has anti - sars - cov - 2 activity and may be developed as a novel antiviral approach against sars - cov - 2 infection.']",'Prunella vulgaris extract and suramin block SARS-coronavirus 2 virus Spike protein D614 and G614 variants mediated receptor association and virus entry in cell culture system','10.1101/2020.08.28.270306',"[[' the 50% inhibitory concentration ( ic50 )  for chpv and suramin on scov - 2 - sp - pvs are 30 ,  and 40 g ml ,  respectively.']]"
efonidipine,"['7 m )  ,  and efonidipine ( 38.']",'Identification of 14 Known Drugs as Inhibitors of the Main Protease of SARS-CoV-2','10.1101/2020.08.28.271957',"[[' remarkably 14 of the compounds at 100 - m concentration were found to reduce the enzymatic activity and 5 provided ic50 values below 40 m: manidipine ( 4.8 m )  ,  boceprevir ( 5.4 m )  ,  lercanidipine ( 16.2 m )  ,  bedaquiline ( 18.7 m )  ,  and efonidipine ( 38.5 m ) .']]"
bedaquiline,"['2 m )  ,  bedaquiline ( 18.']",'Identification of 14 Known Drugs as Inhibitors of the Main Protease of SARS-CoV-2','10.1101/2020.08.28.271957',"[[' remarkably 14 of the compounds at 100 - m concentration were found to reduce the enzymatic activity and 5 provided ic50 values below 40 m: manidipine ( 4.8 m )  ,  boceprevir ( 5.4 m )  ,  lercanidipine ( 16.2 m )  ,  bedaquiline ( 18.7 m )  ,  and efonidipine ( 38.5 m ) .']]"
boceprevir,"['8 m )  ,  boceprevir ( 5.']",'Identification of 14 Known Drugs as Inhibitors of the Main Protease of SARS-CoV-2','10.1101/2020.08.28.271957',"[[' remarkably 14 of the compounds at 100 - m concentration were found to reduce the enzymatic activity and 5 provided ic50 values below 40 m: manidipine ( 4.8 m )  ,  boceprevir ( 5.4 m )  ,  lercanidipine ( 16.2 m )  ,  bedaquiline ( 18.7 m )  ,  and efonidipine ( 38.5 m ) .']]"
manidipine,[' remarkably 14 of the compounds at 100 - m concentration were found to reduce the enzymatic activity and 5 provided ic50 values below 40 m: manidipine ( 4.'],'Identification of 14 Known Drugs as Inhibitors of the Main Protease of SARS-CoV-2','10.1101/2020.08.28.271957',"[[' remarkably 14 of the compounds at 100 - m concentration were found to reduce the enzymatic activity and 5 provided ic50 values below 40 m: manidipine ( 4.8 m )  ,  boceprevir ( 5.4 m )  ,  lercanidipine ( 16.2 m )  ,  bedaquiline ( 18.7 m )  ,  and efonidipine ( 38.5 m ) .']]"
lercanidipine,"['4 m )  ,  lercanidipine ( 16.']",'Identification of 14 Known Drugs as Inhibitors of the Main Protease of SARS-CoV-2','10.1101/2020.08.28.271957',"[[' remarkably 14 of the compounds at 100 - m concentration were found to reduce the enzymatic activity and 5 provided ic50 values below 40 m: manidipine ( 4.8 m )  ,  boceprevir ( 5.4 m )  ,  lercanidipine ( 16.2 m )  ,  bedaquiline ( 18.7 m )  ,  and efonidipine ( 38.5 m ) .']]"
suramin,"[' moreover ,  based on this system ,  we have demonstrated that an aqueous extract from the chinese herb prunella vulgaris ( chpv )  and a compound ,  suramin ,  displayed potent inhibitory effects on both wild type and mutant ( g614 )  scov - 2 sp pseudotyped virus ( scov - 2 - sp - pvs )  - mediated infection.', ' the 50% inhibitory concentration ( ic50 )  for chpv and suramin on scov - 2 - sp - pvs are 30 ,  and 40 g ml ,  respectively.', ' to define the mechanisms of their actions ,  we demonstrated that both chpv and suramin are able to directly interrupt scov - 2sp binding to its receptor ace2 and block the viral entry step.', ' importantly ,  our results also showed that chpv or suramin can efficiently reduce levels of cytopathic effect caused by sars - cov - 2 virus ( hcov - 19 canada on - vido - 01 2020 )  infection in vero cells.', ' furthermore ,  our results demonstrated that the combination of chpv suramin with an anti - sars - cov - 2 neutralizing antibody mediated more potent blocking effect against scov2 - sp - pvs.', ' overall ,  this study provides evidence that chpv and suramin has anti - sars - cov - 2 activity and may be developed as a novel antiviral approach against sars - cov - 2 infection.']",Prunella vulgaris extract and suramin block SARS-coronavirus 2 virus Spike protein D614 and G614 variants mediated receptor association and virus entry in cell culture system,10.1101/2020.08.28.270306,"[[' the 50% inhibitory concentration ( ic50 )  for chpv and suramin on scov - 2 - sp - pvs are 30 ,  and 40 g ml ,  respectively.']]"
angiotensin,"["" 'in the light of the recent accumulated knowledge on sars - cov - 2 and its mode of human cells invasion ,  the binding of viral spike glycoprotein to human angiotensin converting enzyme 2 ( hace2 )  receptor plays a central role in cell entry.""]",'An hACE2 peptide mimic blocks SARS-CoV-2 Pulmonary Cell Infection','10.1101/2020.08.24.264077',[[' our best peptide mimics bind to the virus spike protein with high affinity and are able to block sars - cov - 2 human pulmonary cell infection with an inhibitory concentration ( ic50 )  in the nanomolar range.']]
carrageenan,"[' the aim of this study was to investigate the broad spectrum antiviral activity of a naturally existing sulfated polysaccharide ,  lambda - carrageenan ( {lambda} - cgn )  ,  purified from marine red algae.']",'Antiviral activity of lambda-carrageenan against influenza viruses in mice and severe acute respiratory syndrome coronavirus 2 in vitro','10.1101/2020.08.23.255364',"[[' cell culture - based assays revealed that the macromolecule efficiently inhibited both influenza a and b viruses ,  as well as currently circulating severe acute respiratory syndrome coronavirus 2 ( sars - cov - 2 )  ,  with ec50 values ranging from 0.3 - 1.4 g ml.']]"
cucumber,"[' in the present study ,  4 marine sulfated polysaccharides were screened for their inhibitory activity against sars - cov - 2 ,  including sea cucumber sulfated polysaccharide ( scsp )  ,  fucoidan from brown algae ,  iota - carrageenan from red algae ,  and chondroitin sulfate c from sharks ( cs ) .']",Inhibitory activities of marine sulfated polysaccharides against SARS-CoV-2,10.1039/d0fo02017f,[[' scsp exhibited the strongest inhibitory activity with ic50 of 9.10 g ml - 1.']]
carrageenan,"[' in the present study ,  4 marine sulfated polysaccharides were screened for their inhibitory activity against sars - cov - 2 ,  including sea cucumber sulfated polysaccharide ( scsp )  ,  fucoidan from brown algae ,  iota - carrageenan from red algae ,  and chondroitin sulfate c from sharks ( cs ) .', ' of them ,  scsp ,  fucoidan ,  and carrageenan showed significant antiviral activities at concentrations of 3.']",Inhibitory activities of marine sulfated polysaccharides against SARS-CoV-2,10.1039/d0fo02017f,[[' scsp exhibited the strongest inhibitory activity with ic50 of 9.10 g ml - 1.']]
sulfate,"[' in the present study ,  4 marine sulfated polysaccharides were screened for their inhibitory activity against sars - cov - 2 ,  including sea cucumber sulfated polysaccharide ( scsp )  ,  fucoidan from brown algae ,  iota - carrageenan from red algae ,  and chondroitin sulfate c from sharks ( cs ) .']",Inhibitory activities of marine sulfated polysaccharides against SARS-CoV-2,10.1039/d0fo02017f,[[' scsp exhibited the strongest inhibitory activity with ic50 of 9.10 g ml - 1.']]
fucoidan,"[' in the present study ,  4 marine sulfated polysaccharides were screened for their inhibitory activity against sars - cov - 2 ,  including sea cucumber sulfated polysaccharide ( scsp )  ,  fucoidan from brown algae ,  iota - carrageenan from red algae ,  and chondroitin sulfate c from sharks ( cs ) .', ' of them ,  scsp ,  fucoidan ,  and carrageenan showed significant antiviral activities at concentrations of 3.']",Inhibitory activities of marine sulfated polysaccharides against SARS-CoV-2,10.1039/d0fo02017f,[[' scsp exhibited the strongest inhibitory activity with ic50 of 9.10 g ml - 1.']]
sulfate,[' further studies will confirm if astodrimer sodium binds to sars - cov - 2 spike protein and physically blocks initial association of the virus with heparan sulfate proteoglycans on the host cell.'],"'Astodrimer sodium, dendrimer antiviral, inhibits replication of SARS-CoV-2 in vitro'",'10.1101/2020.08.20.260190',"[[' we report that astodrimer sodium inhibits replication of sars - cov - 2 in vero e6 cells when added to cells 1 - hour prior to or 1 - hour post infection ,  with 50% effective concentrations reducing virus - induced cytopathic effect ( ec50 )  ranging from 0.090 to 0.742 m ( 0.002 to 0.012 mg ml ) .', ' astodrimer sodium was also effective in a virucidal evaluation when mixed with virus for 1 hour prior to infection of cells ( ec50 1.83 m [0.030 mg ml] ) .']]"
astodrimer,"[' the current studies were conducted to evaluate the in vitro sars - cov - 2 antiviral activity of astodrimer sodium ,  a dendrimer with broad spectrum antimicrobial activity ,  including against enveloped viruses in in vitro and in vivo models ,  that is marketed for antiviral and antibacterial applications.', ' we report that astodrimer sodium inhibits replication of sars - cov - 2 in vero e6 cells when added to cells 1 - hour prior to or 1 - hour post infection ,  with 50% effective concentrations reducing virus - induced cytopathic effect ( ec50 )  ranging from 0.', ' astodrimer sodium was also effective in a virucidal evaluation when mixed with virus for 1 hour prior to infection of cells ( ec50 1.', ' the data were similar for all investigations and were consistent with the potent antiviral activity of astodrimer sodium being due to inhibition of virus - host cell interactions ,  as previously demonstrated for other viruses.', ' further studies will confirm if astodrimer sodium binds to sars - cov - 2 spike protein and physically blocks initial association of the virus with heparan sulfate proteoglycans on the host cell.', ' given the in vitro effectiveness and significantly high si ,  astodrimer sodium warrants further investigation for potential as a nasally administered or inhaled antiviral agent for sars - cov - 2 prevention and treatment applications.']","'Astodrimer sodium, dendrimer antiviral, inhibits replication of SARS-CoV-2 in vitro'",'10.1101/2020.08.20.260190',"[[' we report that astodrimer sodium inhibits replication of sars - cov - 2 in vero e6 cells when added to cells 1 - hour prior to or 1 - hour post infection ,  with 50% effective concentrations reducing virus - induced cytopathic effect ( ec50 )  ranging from 0.090 to 0.742 m ( 0.002 to 0.012 mg ml ) .', ' astodrimer sodium was also effective in a virucidal evaluation when mixed with virus for 1 hour prior to infection of cells ( ec50 1.83 m [0.030 mg ml] ) .']]"
angiotensin,"[' we constructed a vh - phage library and targeted a known neutralizing site ,  the angiotensin - converting enzyme 2 ( ace2 )  binding interface of the trimeric sars - cov - 2 spike receptor - binding domain ( spike - rbd ) .']",'Bi-paratopic and multivalent human VH domains neutralize SARS-CoV-2 by targeting distinct epitopes within the ACE2 binding interface of Spike','10.1101/2020.08.08.242511',"[[' the most potent binder ,  a trivalent vh ,  neutralized authentic sars - cov - 2 with half - minimal inhibitory concentration ( ic50 )  of 4.0 nm ( 180 ng ml ) .']]"
ptc299,"[' here ,  we describe the anti - covid - 19 potential of ptc299 ,  an orally available compound that is a potent inhibitor of dihydroorotate dehydrogenase ( dhodh )  ,  the rate - limiting enzyme of the de novo pyrimidine biosynthesis pathway.', ' in tissue culture ,  ptc299 manifests robust ,  dose - dependent ,  and dhodh - dependent inhibition of sars cov - 2 replication ( ec50 range ,  2.', ' ptc299 also blocked replication of other rna viruses ,  including ebola virus.', ' consistent with known dhodh requirements for immunomodulatory cytokine production ,  ptc299 inhibited the production of interleukin ( il )  - 6 ,  il - 17a ( also called il - 17 )  ,  il - 17f ,  and vascular endothelial growth factor ( vegf )  in tissue culture models.', ' the combination of anti - sars - cov - 2 activity ,  cytokine inhibitory activity ,  and previously established favorable pharmacokinetic and human safety profiles render ptc299 a promising therapeutic for covid - 19.']",'The DHODH Inhibitor PTC299 Arrests SARS-CoV-2 Replication and Suppresses Induction of Inflammatory Cytokines','10.1101/2020.08.05.238394',"[[' in tissue culture ,  ptc299 manifests robust ,  dose - dependent ,  and dhodh - dependent inhibition of sars cov - 2 replication ( ec50 range ,  2.0 to 31.6 nm )  with a selectivity index >3 , 800.']]"
angiotensin,"["" 'an essential mechanism for sars - cov - 1 and  - 2 infection begins with the viral spike protein binding to the human receptor protein angiotensin - converting enzyme ii ( ace2 ) .""]",'Engineered ACE2 receptor traps potently neutralize SARS-CoV-2','10.1101/2020.07.31.231746',"[[' with the addition of the natural ace2 collectrin domain and fusion to a human fc domain for increased stabilization and avidity ,  the most optimal ace2 receptor traps neutralized sars - cov - 2 pseudotyped lentivirus and authentic sars - cov - 2 virus with half - maximal inhibitory concentrations ( ic50 )  in the 10 - 100 ng ml range.']]"
yeast,[' these designed receptor variants were affinity matured an additional 14 - fold by random mutagenesis and selection using yeast surface display.'],'Engineered ACE2 receptor traps potently neutralize SARS-CoV-2','10.1101/2020.07.31.231746',"[[' with the addition of the natural ace2 collectrin domain and fusion to a human fc domain for increased stabilization and avidity ,  the most optimal ace2 receptor traps neutralized sars - cov - 2 pseudotyped lentivirus and authentic sars - cov - 2 virus with half - maximal inhibitory concentrations ( ic50 )  in the 10 - 100 ng ml range.']]"
sinefungin,"[' further ,  we determined the ic50 value of sinefungin ( 286 { +   - } 66 nm )  to illustrate the value of our approach for inhibitor screening.']",'Substrate specificity of SARS-CoV-2 nsp10-nsp16 methyltransferase','10.1101/2020.07.30.228478',"[[' further ,  we determined the ic50 value of sinefungin ( 286 { +   - } 66 nm )  to illustrate the value of our approach for inhibitor screening.']]"
angiotensin,[' an essential mechanism for sars - cov - 1 and  - 2 infection begins with the viral spike protein binding to the human receptor protein angiotensin - converting enzyme ii ( ace2 ) .'],Engineered ACE2 receptor traps potently neutralize SARS-CoV-2.,10.1101/2020.07.31.231746,"[[' with the addition of the natural ace2 collectrin domain and fusion to a human fc domain for increased stabilization and avidity ,  the most optimal ace2 receptor traps neutralized sars - cov - 2 pseudotyped lentivirus and authentic sars - cov - 2 virus with half - maximal inhibitory concentrations ( ic50 )  in the tens of ng ml range.']]"
yeast,[' these designed receptor variants were affinity matured an additional 14 - fold by random mutagenesis and selection using yeast surface display.'],Engineered ACE2 receptor traps potently neutralize SARS-CoV-2.,10.1101/2020.07.31.231746,"[[' with the addition of the natural ace2 collectrin domain and fusion to a human fc domain for increased stabilization and avidity ,  the most optimal ace2 receptor traps neutralized sars - cov - 2 pseudotyped lentivirus and authentic sars - cov - 2 virus with half - maximal inhibitory concentrations ( ic50 )  in the tens of ng ml range.']]"
chloroquine,"[' abstract \xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0 chloroquine is the first line of medicine in the treatment of malaria.', ' besides being antimalaria ,  the chloroquine also can be used as the anti - inflammation in the medicine of arthritis rheumatoid arthritis and lupus erythematosus discoid.', ' hydroxychloroquine sulfate is 4 - aminoquinolin with hydroxylated chloroquine analog ,  having the same pharmacokinetic as chloroquine which is given orally in hydroxychloroquine sulfate form ,  processed by gastrointestinal absorption and very faster kidney elimination.', ' the effectiveness of chloroquine and hydroxychloroquine towards covid - 19 in the in vitro experiment showed it could inhibit the duplication of the sars - cov - 2 virus.', ' the chloroquine function is to stop covid - 19 infection with ( ec50 )  1 , 13 m and ( cc50 )  larger than 100 m.', ' meanwhile ,  the hydroxychloroquine function is to inhibit the attachment and entry of the virus into the hosts cell by enzymatic activation which is the lysosome acidification disorder and antigen presentation as the result of ph increase.', ' based on the clinical study ,  the 10 of 12 patients who have lopinavir ritonavir therapy by virology ,  the chloroquine group showed rt - pcr negative on day 7 ,  10 ,  and 14 in compare to lopinavir ritonavir that showed rt - pcr negative on day 14.', ' on the 9 th day ,  60% of the patients of chloroquine group showed the ct scan of lungs image normal instead of the lopinavir ritonavir at 25%.', ' in the day 14 based on the ct test result ,  the pulmonary improvement increased twice rather than chloroquine group ( rate ratio 2.', ' it proved that the chloroquine role showed the result of the medicine has a significant effect by cleaning the virus or other clinical matters.', ' the purpose of this literature review is to know the effectiveness quinoline class of drugs which is chloroquine and hydroxychloroquine in covid - 19 disease.', ' keywords: effectiveness ,  chloroquine ,  covid - 19 correspondence : dedydermawan555@gmail.']",The Level of Effectiveness Use of Quinoline Drugs in COVID-19: A Literature Review,10.30651/jqm.v4i2.4998,"[[' the chloroquine function is to stop covid - 19 infection with ( ec50 )  1 , 13 m and ( cc50 )  larger than 100 m.'], [' the chloroquine function is to stop covid - 19 infection with ( ec50 )  1 , 13 m and ( cc50 )  larger than 100 m.']]"
sulfate,"[' hydroxychloroquine sulfate is 4 - aminoquinolin with hydroxylated chloroquine analog ,  having the same pharmacokinetic as chloroquine which is given orally in hydroxychloroquine sulfate form ,  processed by gastrointestinal absorption and very faster kidney elimination.']",The Level of Effectiveness Use of Quinoline Drugs in COVID-19: A Literature Review,10.30651/jqm.v4i2.4998,"[[' the chloroquine function is to stop covid - 19 infection with ( ec50 )  1 , 13 m and ( cc50 )  larger than 100 m.'], [' the chloroquine function is to stop covid - 19 infection with ( ec50 )  1 , 13 m and ( cc50 )  larger than 100 m.']]"
lopinavir,"[' based on the clinical study ,  the 10 of 12 patients who have lopinavir ritonavir therapy by virology ,  the chloroquine group showed rt - pcr negative on day 7 ,  10 ,  and 14 in compare to lopinavir ritonavir that showed rt - pcr negative on day 14.', ' on the 9 th day ,  60% of the patients of chloroquine group showed the ct scan of lungs image normal instead of the lopinavir ritonavir at 25%.']",The Level of Effectiveness Use of Quinoline Drugs in COVID-19: A Literature Review,10.30651/jqm.v4i2.4998,"[[' the chloroquine function is to stop covid - 19 infection with ( ec50 )  1 , 13 m and ( cc50 )  larger than 100 m.'], [' the chloroquine function is to stop covid - 19 infection with ( ec50 )  1 , 13 m and ( cc50 )  larger than 100 m.']]"
hydroxychloroquine,"[' hydroxychloroquine sulfate is 4 - aminoquinolin with hydroxylated chloroquine analog ,  having the same pharmacokinetic as chloroquine which is given orally in hydroxychloroquine sulfate form ,  processed by gastrointestinal absorption and very faster kidney elimination.', ' the effectiveness of chloroquine and hydroxychloroquine towards covid - 19 in the in vitro experiment showed it could inhibit the duplication of the sars - cov - 2 virus.', ' meanwhile ,  the hydroxychloroquine function is to inhibit the attachment and entry of the virus into the hosts cell by enzymatic activation which is the lysosome acidification disorder and antigen presentation as the result of ph increase.', ' the purpose of this literature review is to know the effectiveness quinoline class of drugs which is chloroquine and hydroxychloroquine in covid - 19 disease.']",The Level of Effectiveness Use of Quinoline Drugs in COVID-19: A Literature Review,10.30651/jqm.v4i2.4998,"[[' the chloroquine function is to stop covid - 19 infection with ( ec50 )  1 , 13 m and ( cc50 )  larger than 100 m.'], [' the chloroquine function is to stop covid - 19 infection with ( ec50 )  1 , 13 m and ( cc50 )  larger than 100 m.']]"
ritonavir,"[' based on the clinical study ,  the 10 of 12 patients who have lopinavir ritonavir therapy by virology ,  the chloroquine group showed rt - pcr negative on day 7 ,  10 ,  and 14 in compare to lopinavir ritonavir that showed rt - pcr negative on day 14.', ' on the 9 th day ,  60% of the patients of chloroquine group showed the ct scan of lungs image normal instead of the lopinavir ritonavir at 25%.']",The Level of Effectiveness Use of Quinoline Drugs in COVID-19: A Literature Review,10.30651/jqm.v4i2.4998,"[[' the chloroquine function is to stop covid - 19 infection with ( ec50 )  1 , 13 m and ( cc50 )  larger than 100 m.'], [' the chloroquine function is to stop covid - 19 infection with ( ec50 )  1 , 13 m and ( cc50 )  larger than 100 m.']]"
camostat,"[' compared to the inhibitor camostat mesylate ( ec50 26000 ng ml )  ,  it is 270 times more potent.']","Metadichol, a Novel Nano Lipid Formulation that Inhibits SARS-COV-2 and a Multitude of Pathological Viruses in vitro",10.21203/rs.3.rs-34021/v5,"[['< p><p>results< p><p>metadichol ,  a nano lipid formulation of long - chain alcohols ,  has been shown to inhibit tmprss2 ( ec50 96 ng ml ) .', ' compared to the inhibitor camostat mesylate ( ec50 26000 ng ml )  ,  it is 270 times more potent.']]"
serine,[' sars - cov - 2 uses the receptor ace2 for entry and the serine protease tmprss2 for s protein priming.'],"Metadichol, a Novel Nano Lipid Formulation that Inhibits SARS-COV-2 and a Multitude of Pathological Viruses in vitro",10.21203/rs.3.rs-34021/v5,"[['< p><p>results< p><p>metadichol ,  a nano lipid formulation of long - chain alcohols ,  has been shown to inhibit tmprss2 ( ec50 96 ng ml ) .', ' compared to the inhibitor camostat mesylate ( ec50 26000 ng ml )  ,  it is 270 times more potent.']]"
carrageenan,"[' here ,  we show that iota - carrageenan can inhibit the cell entry of sspl in a dose dependent manner.', '6 microgram ml iota - carrageenan.', ' in vitro data on iota - carrageenan against various rhino -  and coronaviruses showed similar ic50 values and translated readily into clinical effectiveness when a nasal spray containing iota - carrageenan demonstrated a reduction in severity and duration of symptoms of common cold caused by various respiratory viruses.', ' accordingly ,  our in vitro data on sspl suggest that administration of iota - carrageenan may be an effective and safe prophylaxis or treatment for sars - cov - 2 infections.']",'SARS-CoV-2 in-vitro neutralization assay reveals inhibition of virus entry by iota-carrageenan','10.1101/2020.07.28.224733',"[[' sspl particles were efficiently neutralized with an ic50 value of 2.6 microgram ml iota - carrageenan.', ' in vitro data on iota - carrageenan against various rhino -  and coronaviruses showed similar ic50 values and translated readily into clinical effectiveness when a nasal spray containing iota - carrageenan demonstrated a reduction in severity and duration of symptoms of common cold caused by various respiratory viruses.']]"
cysteine,"[' guided by previous medicinal chemistry studies about sars - cov - 1 main protease ( sc1mpro )  ,  we have designed and synthesized a series of sc2mpro inhibitors that contain beta - ( s - 2 - oxopyrrolidin - 3 - yl )  - alaninal ( opal )  for the formation of a reversible covalent bond with the sc2mpro active site cysteine c145.']",'A Speedy Route to Multiple Highly Potent SARS-CoV-2 Main Protease Inhibitors','10.1101/2020.07.28.223784',"[[' all inhibitors display high potency with ic50 values at or below 100 nm.', ' the most potent compound mpi3 has as an ic50 value as 8.5 nm.']]"
angiotensin,[' we have isolated several nanobodies that bind to the sars - cov - 2 spike protein receptor binding domain and block spike protein interaction with the angiotensin converting enzyme 2 ( ace2 )  receptor.'],'High Affinity Nanobodies Block SARS-CoV-2 Spike Receptor Binding Domain Interaction with Human Angiotensin Converting Enzyme','10.1101/2020.07.24.219857',[['02 micrograms ml ec50 ( 1.1 nm ) .']]
hydroxocobalamin,"['26 m )  ,  hydroxocobalamin ( ic50 = 3.']",'Identification of SARS-CoV-2 3CL Protease Inhibitors by a Quantitative High-throughput Screening','10.1101/2020.07.17.207019',"[['  key resultstwenty - seven small molecule inhibitors of sars - cov - 2 3clpro have been identified with ic50s ranging from 0.26 to 27.1 m with a greater than 80% maximal inhibition.', ' walrycin b ( ic50 = 0.26 m )  ,  hydroxocobalamin ( ic50 = 3.29 m )  ,  suramin sodium ( ic50 = 6.50 m )  ,  z - devd - fmk ( ic50 = 6.81 m )  ,  and lll - 12 ( ic50 = 9.84 m )  are the most potent 3clpro inhibitors with ic50s under 10 m.']]"
suramin,"['29 m )  ,  suramin sodium ( ic50 = 6.']",'Identification of SARS-CoV-2 3CL Protease Inhibitors by a Quantitative High-throughput Screening','10.1101/2020.07.17.207019',"[['  key resultstwenty - seven small molecule inhibitors of sars - cov - 2 3clpro have been identified with ic50s ranging from 0.26 to 27.1 m with a greater than 80% maximal inhibition.', ' walrycin b ( ic50 = 0.26 m )  ,  hydroxocobalamin ( ic50 = 3.29 m )  ,  suramin sodium ( ic50 = 6.50 m )  ,  z - devd - fmk ( ic50 = 6.81 m )  ,  and lll - 12 ( ic50 = 9.84 m )  are the most potent 3clpro inhibitors with ic50s under 10 m.']]"
papain,"[' the sars - cov - 2 papain - like cysteine protease has been implicated in virus maturation ,  dysregulation of host inflammation and antiviral immune responses.']",'Structural basis for the inhibition of the papain-like protease of SARS-CoV-2 by small molecules','10.1101/2020.07.17.208959',[[' inhibitor grl0617 showed a promising ic50 of 2.1 m.']]
cysteine,"[' the sars - cov - 2 papain - like cysteine protease has been implicated in virus maturation ,  dysregulation of host inflammation and antiviral immune responses.']",'Structural basis for the inhibition of the papain-like protease of SARS-CoV-2 by small molecules','10.1101/2020.07.17.208959',[[' inhibitor grl0617 showed a promising ic50 of 2.1 m.']]
lopinavir,"[' we investigated the association between lopinavir ( lpv )  and hydroxychloroquine ( hcq )  plasma concentrations and the values of acute phase inflammation marker c - reactive protein ( crp ) .', ' lopinavir ritonavir was administered 12 hourly ,  800 200 mg on day 1 ,  and 400 100 mg on day 2 until day 5 or 7.']",'Effect of Systemic Inflammatory Response to SARS-CoV-2 on Lopinavir and Hydroxychloroquine Plasma Concentrations','10.1101/2020.07.05.20146878',[[' the ratio of calculated unbound drug fraction to published sars - cov2 ec50 values indicated insufficient lpv concentrations in the lung.']]
hydroxychloroquine,[' we investigated the association between lopinavir ( lpv )  and hydroxychloroquine ( hcq )  plasma concentrations and the values of acute phase inflammation marker c - reactive protein ( crp ) .'],'Effect of Systemic Inflammatory Response to SARS-CoV-2 on Lopinavir and Hydroxychloroquine Plasma Concentrations','10.1101/2020.07.05.20146878',[[' the ratio of calculated unbound drug fraction to published sars - cov2 ec50 values indicated insufficient lpv concentrations in the lung.']]
tocilizumab,"['001 )  ,  and were significantly lower when tocilizumab was preadministrated.']",'Effect of Systemic Inflammatory Response to SARS-CoV-2 on Lopinavir and Hydroxychloroquine Plasma Concentrations','10.1101/2020.07.05.20146878',[[' the ratio of calculated unbound drug fraction to published sars - cov2 ec50 values indicated insufficient lpv concentrations in the lung.']]
ritonavir,"[' lopinavir ritonavir was administered 12 hourly ,  800 200 mg on day 1 ,  and 400 100 mg on day 2 until day 5 or 7.']",'Effect of Systemic Inflammatory Response to SARS-CoV-2 on Lopinavir and Hydroxychloroquine Plasma Concentrations','10.1101/2020.07.05.20146878',[[' the ratio of calculated unbound drug fraction to published sars - cov2 ec50 values indicated insufficient lpv concentrations in the lung.']]
telaprevir,"['10m )  ,  and telaprevir ( 15.']",'A drug repurposing screen identifies hepatitis C antivirals as inhibitors of the SARS-CoV-2 main protease.','10.1101/2020.07.10.197889',"[[' subsequent dose validation studies demonstrated 8 dose responsive hits with an ic50 [&le;] 50 m.', ' hits from our screen are enriched with hepatitis c ns3 4a protease targeting drugs including boceprevir ( ic50=0.95 m )  ,  ciluprevir ( 20.77m ) .', ' narlaprevir ( ic50=1.10m )  ,  and telaprevir ( 15.25m ) .']]"
boceprevir,"[' hits from our screen are enriched with hepatitis c ns3 4a protease targeting drugs including boceprevir ( ic50=0.', ' taken together this work suggests previous large - scale commercial drug development initiatives targeting hepatitis c ns3 4a viral protease should be revisited because some previous lead compounds may be more potent against sars - cov - 2 mpro than boceprevir and suitable for rapid repurposing.']",'A drug repurposing screen identifies hepatitis C antivirals as inhibitors of the SARS-CoV-2 main protease.','10.1101/2020.07.10.197889',"[[' subsequent dose validation studies demonstrated 8 dose responsive hits with an ic50 [&le;] 50 m.', ' hits from our screen are enriched with hepatitis c ns3 4a protease targeting drugs including boceprevir ( ic50=0.95 m )  ,  ciluprevir ( 20.77m ) .', ' narlaprevir ( ic50=1.10m )  ,  and telaprevir ( 15.25m ) .']]"
narlaprevir,[' narlaprevir ( ic50=1.'],'A drug repurposing screen identifies hepatitis C antivirals as inhibitors of the SARS-CoV-2 main protease.','10.1101/2020.07.10.197889',"[[' subsequent dose validation studies demonstrated 8 dose responsive hits with an ic50 [&le;] 50 m.', ' hits from our screen are enriched with hepatitis c ns3 4a protease targeting drugs including boceprevir ( ic50=0.95 m )  ,  ciluprevir ( 20.77m ) .', ' narlaprevir ( ic50=1.10m )  ,  and telaprevir ( 15.25m ) .']]"
ciluprevir,"['95 m )  ,  ciluprevir ( 20.']",'A drug repurposing screen identifies hepatitis C antivirals as inhibitors of the SARS-CoV-2 main protease.','10.1101/2020.07.10.197889',"[[' subsequent dose validation studies demonstrated 8 dose responsive hits with an ic50 [&le;] 50 m.', ' hits from our screen are enriched with hepatitis c ns3 4a protease targeting drugs including boceprevir ( ic50=0.95 m )  ,  ciluprevir ( 20.77m ) .', ' narlaprevir ( ic50=1.10m )  ,  and telaprevir ( 15.25m ) .']]"
hydroxychloroquine,['1 m against sars - cov - 2 in vero e6 cells and was 4 - fold more potent than hydroxychloroquine [hcq].'],'Tafenoquine inhibits replication of SARS-Cov-2 at pharmacologically relevant concentrations in vitro','10.1101/2020.07.12.199059',"[["" 'tafenoquine [tq] exhibited ec50 90s of ~ 2.6 5.1 m against sars - cov - 2 in vero e6 cells and was 4 - fold more potent than hydroxychloroquine [hcq].""]]"
oleandrin,"[' here ,  we tested in vitro oleandrin ,  derived from the nerium oleander plant and shown previously to have inhibitory activity against several viruses.', ' using vero cells ,  we found that prophylactic oleandrin administration at concentrations down to 0.', ' the potent prophylactic and therapeutic antiviral activities demonstrated here strongly support the further development of oleandrin to reduce the severity of covid - 19 and potentially also to reduce spread by persons diagnosed early after infection.', ' we tested oleandrin ,  derived from the nerium oleander plant and shown previously to reduce the replication of several viruses ,  against sars - cov - 2 infection of vero cells.', ' when administered both before and after virus infection ,  nanogram doses of oleandrin significantly inhibited replication by up to 3 , 000 - fold ,  indicating the potential to prevent disease and virus spread in persons recently exposed to sars - cov - 2 ,  as well as to prevent severe disease in persons at high risk.', ' these results indicate that oleandrin should be tested in animal models and in humans exposed to infection to determine its medical usefulness in controlling the pandemic.']",'Prophylactic and Therapeutic Inhibition of In Vitro SARS-CoV-2 Replication by Oleandrin','10.1101/2020.07.15.203489',"[[' the ec50 values were 11.98ng ml when virus output was measured at 24 hours post - infection ,  and 7.07ng ml measured at 48 hours post - infection.']]"
camostat,"[' compared to the inhibitor camostat mesylate ( ec50 26000 ng ml )  ,  it is 270 times more potent.']","Metadichol a novel nano lipid that inhibits In Vitro, SARS-COV-2 and a multitude of pathological viruses",10.21203/rs.3.rs-34021/v4,"[['< p><p>metadichol ,  a nano lipid formulation of long - chain alcohols ,  has been shown to inhibit tmprss2 ( ec50 96 ng ml ) .', ' compared to the inhibitor camostat mesylate ( ec50 26000 ng ml )  ,  it is 270 times more potent.']]"
serine,[' sars - cov - 2 uses the receptor ace2 for entry and the serine protease tmprss2 for s protein priming.'],"Metadichol a novel nano lipid that inhibits In Vitro, SARS-COV-2 and a multitude of pathological viruses",10.21203/rs.3.rs-34021/v4,"[['< p><p>metadichol ,  a nano lipid formulation of long - chain alcohols ,  has been shown to inhibit tmprss2 ( ec50 96 ng ml ) .', ' compared to the inhibitor camostat mesylate ( ec50 26000 ng ml )  ,  it is 270 times more potent.']]"
nitazoxanide,"[' one drug that has shown promising results in vitro is nitazoxanide.', ' unlike other postulated drugs ,  nitazoxanide shows a high ratio of maximum plasma concentration ( cmax )  ,  after 1 day of 500\u2009mg twice daily ( bd )  ,  to the concentration required to inhibit 50% replication ( ec50 )  of severe acute respiratory syndrome coronavirus 2 ( sars - cov - 2 )  ( cmax:\xa0ec50roughly equal to 14:1 ) .', ' as such ,  it is important to investigate the safety of nitazoxanide for further trials.', ' we aimed to conduct a review of the safety of nitazoxanide for any prior indication and calculate its minimum costs of production.', ' methods a review of nitazoxanide clinical research was conducted using embase and medline databases ,  supplemented by clinicaltrials.', ' we searched for phase 2 or 3 randomised controlled trials ( rcts )  comparing nitazoxanide with placebo or active control for 514 days in participants experiencing acute infections of any kind.', ' results nine rcts of nitazoxanide were identified for inclusion.', ' based on a weighted - mean cost of us $61 kg ,  a 14 - day course of treatment with nitazoxanide 500\u2009mg bd would cost $1.', ' conclusion nitazoxanide demonstrates a good safety profile at approved doses.', ' we estimate that it would be possible to manufacture nitazoxanide as generic for $1.', ' if efficacy against sars - cov - 2 is demonstrated in clinical studies ,  nitazoxanide may represent a safe and affordable treatment in the ongoing pandemic.']",Review of safety and minimum pricing of nitazoxanide for potential treatment of COVID-19,10.1016/s2055-6640(20)30017-0,"[[' unlike other postulated drugs ,  nitazoxanide shows a high ratio of maximum plasma concentration ( cmax )  ,  after 1 day of 500\u2009mg twice daily ( bd )  ,  to the concentration required to inhibit 50% replication ( ec50 )  of severe acute respiratory syndrome coronavirus 2 ( sars - cov - 2 )  ( cmax:\xa0ec50roughly equal to 14:1 ) .']]"
tafenoquine,[' abstract tafenoquine [tq] exhibited ec50 90s of ~ 2.'],Tafenoquine inhibits replication of SARS-Cov-2 at pharmacologically relevant concentrations in vitro,10.1101/2020.07.12.199059,[[' abstract tafenoquine [tq] exhibited ec50 90s of ~ 2.6 5.1 m against sars - cov - 2 in vero e6 cells and was 4 - fold more potent than hydroxychloroquine [hcq].']]
hydroxychloroquine,['1 m against sars - cov - 2 in vero e6 cells and was 4 - fold more potent than hydroxychloroquine [hcq].'],Tafenoquine inhibits replication of SARS-Cov-2 at pharmacologically relevant concentrations in vitro,10.1101/2020.07.12.199059,[[' abstract tafenoquine [tq] exhibited ec50 90s of ~ 2.6 5.1 m against sars - cov - 2 in vero e6 cells and was 4 - fold more potent than hydroxychloroquine [hcq].']]
telaprevir,"['10m )  ,  and telaprevir ( 15.']",A drug repurposing screen identifies hepatitis C antivirals as inhibitors of the SARS-CoV-2 main protease,10.1101/2020.07.10.197889,"[[' subsequent dose validation studies demonstrated 8 dose responsive hits with an ic50  50 m.', ' hits from our screen are enriched with hepatitis c ns3 4a protease targeting drugs including boceprevir ( ic50=0.95 m )  ,  ciluprevir ( 20.77m ) .', ' narlaprevir ( ic50=1.10m )  ,  and telaprevir ( 15.25m ) .']]"
boceprevir,"[' hits from our screen are enriched with hepatitis c ns3 4a protease targeting drugs including boceprevir ( ic50=0.', ' taken together this work suggests previous large - scale commercial drug development initiatives targeting hepatitis c ns3 4a viral protease should be revisited because some previous lead compounds may be more potent against sars - cov - 2 mpro than boceprevir and suitable for rapid repurposing.']",A drug repurposing screen identifies hepatitis C antivirals as inhibitors of the SARS-CoV-2 main protease,10.1101/2020.07.10.197889,"[[' subsequent dose validation studies demonstrated 8 dose responsive hits with an ic50  50 m.', ' hits from our screen are enriched with hepatitis c ns3 4a protease targeting drugs including boceprevir ( ic50=0.95 m )  ,  ciluprevir ( 20.77m ) .', ' narlaprevir ( ic50=1.10m )  ,  and telaprevir ( 15.25m ) .']]"
narlaprevir,[' narlaprevir ( ic50=1.'],A drug repurposing screen identifies hepatitis C antivirals as inhibitors of the SARS-CoV-2 main protease,10.1101/2020.07.10.197889,"[[' subsequent dose validation studies demonstrated 8 dose responsive hits with an ic50  50 m.', ' hits from our screen are enriched with hepatitis c ns3 4a protease targeting drugs including boceprevir ( ic50=0.95 m )  ,  ciluprevir ( 20.77m ) .', ' narlaprevir ( ic50=1.10m )  ,  and telaprevir ( 15.25m ) .']]"
ciluprevir,"['95 m )  ,  ciluprevir ( 20.']",A drug repurposing screen identifies hepatitis C antivirals as inhibitors of the SARS-CoV-2 main protease,10.1101/2020.07.10.197889,"[[' subsequent dose validation studies demonstrated 8 dose responsive hits with an ic50  50 m.', ' hits from our screen are enriched with hepatitis c ns3 4a protease targeting drugs including boceprevir ( ic50=0.95 m )  ,  ciluprevir ( 20.77m ) .', ' narlaprevir ( ic50=1.10m )  ,  and telaprevir ( 15.25m ) .']]"
angiotensin,[' the viral spike glycoprotein is very likely to interact with host angiotensin - converting enzyme 2 ( ace2 )  and transmits its genetic materials and hijacks host machinery with extreme fidelity for self propagation.'],Energetics and IC50 based epitope screening in SARS CoV-2 (COVID 19) spike protein by immunoinformatic analysis implicating for a suitable vaccine development,10.1186/s12967-020-02435-4,"[[' we verified their structure quality ( swiss - model ,  phyre2 ,  and pymol )  topology ( profunc )  ,  motifs ( meme suite ,  glam2scan )  ,  gene ontology based conserved domain ( interpro database )  and screened several epitopes ( svmtrip )  of sars cov - 2 based on their energetics ,  ic50 and antigenicity with regard to their possible glycosylation and mhc paratope binding ( vaxigen v2.0 ,  hawkdock ,  zdock server )  effects.', ' results: we screened here few pairs of spike protein epitopic regions and selected their energetic ,  inhibitory concentration50 ( ic50 )  ,  mhc ii reactivity and found some of those to be very good target for vaccination.']]"
lopinavir,"[' we investigated the association between lopinavir ( lpv )  and hydroxychloroquine ( hcq )  plasma concentrations and the values of acute phase inflammation marker c - reactive protein ( crp ) .', ' lopinavir ritonavir was administered 12 hourly ,  800 200 mg on day 1 ,  and 400 100 mg on day 2 until day 5 or 7.']",Effect of Systemic Inflammatory Response to SARS-CoV-2 on Lopinavir and Hydroxychloroquine Plasma Concentrations,10.1101/2020.07.05.20146878,[[' the ratio of calculated unbound drug fraction to published sars - cov2 ec50 values indicated insufficient lpv concentrations in the lung.']]
hydroxychloroquine,[' we investigated the association between lopinavir ( lpv )  and hydroxychloroquine ( hcq )  plasma concentrations and the values of acute phase inflammation marker c - reactive protein ( crp ) .'],Effect of Systemic Inflammatory Response to SARS-CoV-2 on Lopinavir and Hydroxychloroquine Plasma Concentrations,10.1101/2020.07.05.20146878,[[' the ratio of calculated unbound drug fraction to published sars - cov2 ec50 values indicated insufficient lpv concentrations in the lung.']]
tocilizumab,"['001 )  ,  and were significantly lower when tocilizumab was preadministrated.']",Effect of Systemic Inflammatory Response to SARS-CoV-2 on Lopinavir and Hydroxychloroquine Plasma Concentrations,10.1101/2020.07.05.20146878,[[' the ratio of calculated unbound drug fraction to published sars - cov2 ec50 values indicated insufficient lpv concentrations in the lung.']]
ritonavir,"[' lopinavir ritonavir was administered 12 hourly ,  800 200 mg on day 1 ,  and 400 100 mg on day 2 until day 5 or 7.']",Effect of Systemic Inflammatory Response to SARS-CoV-2 on Lopinavir and Hydroxychloroquine Plasma Concentrations,10.1101/2020.07.05.20146878,[[' the ratio of calculated unbound drug fraction to published sars - cov2 ec50 values indicated insufficient lpv concentrations in the lung.']]
angiotensin,[' the viral spike glycoprotein is very likely to interact with host angiotensin - converting enzyme 2 ( ace2 )  and transmits its genetic materials and hijacks host machinery with extreme fidelity for self propagation.'],'Energetics based epitope screening in SARS CoV-2 (COVID 19) spike glycoprotein by Immuno-informatic analysis aiming to a suitable vaccine development.','10.1101/2020.04.02.021725',"[[' we verified their structure quality ( swiss - model ,  phyre2 ,  pymol )  topology ( profunc )  ,  motifs ( meme suite ,  glam2scan )  ,  gene ontology based conserved domain ( interpro database )  and screened several epitopes ( svmtrip )  of sars cov - 2 based on their energetics ,  ic50 and antigenicity with regard to their possible glycosylation and mhc paratopic binding ( vaxigen v2.0 ,  hawkdock ,  zdock server )  effects.', ' we screened here few pairs of spike protein epitopic regions and selected their energetic ,  ic50 ,  mhc ii reactivity and found some of those to be very good target for vaccination.']]"
carmofur,"["" 'the antineoplastic drug carmofur was shown to inhibit sars - cov - 2 main protease ( mpro ) ."", ' here the x - ray crystal structure of mpro in complex with carmofur reveals that the carbonyl reactive group of carmofur is covalently bound to catalytic cys145 ,  whereas its fatty acid tail occupies the hydrophobic s2 subsite.', ' carmofur inhibits viral replication in cells ( ec50 = 24.']","'Structural basis for the inhibition of COVID-19 virus main protease by carmofur, an antineoplastic drug'",'10.1101/2020.04.09.033233',[[' carmofur inhibits viral replication in cells ( ec50 = 24.30 m )  and it is a promising lead compound to develop new antiviral treatment for covid - 19.']]
auranofin,"[' herein ,  we report that the clinical approved auranofin could perfectly inhibit the activity of 3 - chymotrypsin - like cysteine protease ( mpro or 3clpro )  of sars - cov - 2.', ' for mpro inhibition ,  ic50 of auranofin ,  vitamin k3 ,  phenyl isothiocyanate ,  gold cluster are about 0.', ' especially for fda approved auranofin ,  it is an anti - inflammation drug in clinic ,  thus it may with strong potential to inhibit virus replication and suppress the inflammation damage in covid - 19 patients.']",'Molecules inhibit the enzyme activity of 3-chymotrypsin-like cysteine protease of SARS-CoV-2 virus','10.1101/2020.05.28.120642',"[[' for mpro inhibition ,  ic50 of auranofin ,  vitamin k3 ,  phenyl isothiocyanate ,  gold cluster are about 0.51m ,  7.96m ,  10.13m ,  1.61m ,  respectively.']]"
cysteine,"[' herein ,  we report that the clinical approved auranofin could perfectly inhibit the activity of 3 - chymotrypsin - like cysteine protease ( mpro or 3clpro )  of sars - cov - 2.']",'Molecules inhibit the enzyme activity of 3-chymotrypsin-like cysteine protease of SARS-CoV-2 virus','10.1101/2020.05.28.120642',"[[' for mpro inhibition ,  ic50 of auranofin ,  vitamin k3 ,  phenyl isothiocyanate ,  gold cluster are about 0.51m ,  7.96m ,  10.13m ,  1.61m ,  respectively.']]"
chymotrypsin,"[' herein ,  we report that the clinical approved auranofin could perfectly inhibit the activity of 3 - chymotrypsin - like cysteine protease ( mpro or 3clpro )  of sars - cov - 2.']",'Molecules inhibit the enzyme activity of 3-chymotrypsin-like cysteine protease of SARS-CoV-2 virus','10.1101/2020.05.28.120642',"[[' for mpro inhibition ,  ic50 of auranofin ,  vitamin k3 ,  phenyl isothiocyanate ,  gold cluster are about 0.51m ,  7.96m ,  10.13m ,  1.61m ,  respectively.']]"
vortioxetine,"[' four compounds ,  clomiphene ( citrate )  ,  vortioxetine ,  vortioxetine ( hydrobromide )  and asenapine ( hydrochloride )  ,  showed potent inhibitory effects in both pseudovirus and authentic virus assay.', ' the combination of clomiphene ( citrate )  ,  vortioxetine and asenapine ( hydrochloride )  is much more potent than used alone ,  with ic50 of 0.']",'Several FDA-approved drugs effectively inhibit SARS-CoV-2 infection in vitro','10.1101/2020.06.05.135996',"[[' the combination of clomiphene ( citrate )  ,  vortioxetine and asenapine ( hydrochloride )  is much more potent than used alone ,  with ic50 of 0.34 m.']]"
clomiphene,"[' four compounds ,  clomiphene ( citrate )  ,  vortioxetine ,  vortioxetine ( hydrobromide )  and asenapine ( hydrochloride )  ,  showed potent inhibitory effects in both pseudovirus and authentic virus assay.', ' the combination of clomiphene ( citrate )  ,  vortioxetine and asenapine ( hydrochloride )  is much more potent than used alone ,  with ic50 of 0.']",'Several FDA-approved drugs effectively inhibit SARS-CoV-2 infection in vitro','10.1101/2020.06.05.135996',"[[' the combination of clomiphene ( citrate )  ,  vortioxetine and asenapine ( hydrochloride )  is much more potent than used alone ,  with ic50 of 0.34 m.']]"
asenapine,"[' four compounds ,  clomiphene ( citrate )  ,  vortioxetine ,  vortioxetine ( hydrobromide )  and asenapine ( hydrochloride )  ,  showed potent inhibitory effects in both pseudovirus and authentic virus assay.', ' the combination of clomiphene ( citrate )  ,  vortioxetine and asenapine ( hydrochloride )  is much more potent than used alone ,  with ic50 of 0.']",'Several FDA-approved drugs effectively inhibit SARS-CoV-2 infection in vitro','10.1101/2020.06.05.135996',"[[' the combination of clomiphene ( citrate )  ,  vortioxetine and asenapine ( hydrochloride )  is much more potent than used alone ,  with ic50 of 0.34 m.']]"
angiotensin,"[' in addition to its well - documented interaction with its receptor ,  human angiotensin converting enzyme 2 ( hace2 )  ,  sgp has been found to bind to glycosaminoglycans like heparan sulfate ,  which is found on the surface of virtually all mammalian cells.']",'Effective Inhibition of SARS-CoV-2 Entry by Heparin and Enoxaparin Derivatives','10.1101/2020.06.08.140236',"[[' concentration - response curves showed that plv - s particles were efficiently neutralized by a range of concentrations of unfractionated heparin ( ufh )  ,  enoxaparin ,  6 - o - desulfated ufh and 6 - o - desulfated enoxaparin with an ic50 of 599 ng l ,  108 g l ,  177 ng l ,  and 586 g l respectively.']]"
sulfate,"[' in addition to its well - documented interaction with its receptor ,  human angiotensin converting enzyme 2 ( hace2 )  ,  sgp has been found to bind to glycosaminoglycans like heparan sulfate ,  which is found on the surface of virtually all mammalian cells.', ' here ,  we pseudotyped sars - cov - 2 sgp on a third generation lentiviral ( plv )  vector and tested the impact of various sulfated polysaccharides on transduction efficiency in mammalian cells.', ' various sulfated polysaccharides potently neutralized plv - s pseudotyped virus with clear structure - based differences in anti - viral activity and affinity to sgp.', ' concentration - response curves showed that plv - s particles were efficiently neutralized by a range of concentrations of unfractionated heparin ( ufh )  ,  enoxaparin ,  6 - o - desulfated ufh and 6 - o - desulfated enoxaparin with an ic50 of 599 ng l ,  108 g l ,  177 ng l ,  and 586 g l respectively.']",'Effective Inhibition of SARS-CoV-2 Entry by Heparin and Enoxaparin Derivatives','10.1101/2020.06.08.140236',"[[' concentration - response curves showed that plv - s particles were efficiently neutralized by a range of concentrations of unfractionated heparin ( ufh )  ,  enoxaparin ,  6 - o - desulfated ufh and 6 - o - desulfated enoxaparin with an ic50 of 599 ng l ,  108 g l ,  177 ng l ,  and 586 g l respectively.']]"
heparin,"[' concentration - response curves showed that plv - s particles were efficiently neutralized by a range of concentrations of unfractionated heparin ( ufh )  ,  enoxaparin ,  6 - o - desulfated ufh and 6 - o - desulfated enoxaparin with an ic50 of 599 ng l ,  108 g l ,  177 ng l ,  and 586 g l respectively.']",'Effective Inhibition of SARS-CoV-2 Entry by Heparin and Enoxaparin Derivatives','10.1101/2020.06.08.140236',"[[' concentration - response curves showed that plv - s particles were efficiently neutralized by a range of concentrations of unfractionated heparin ( ufh )  ,  enoxaparin ,  6 - o - desulfated ufh and 6 - o - desulfated enoxaparin with an ic50 of 599 ng l ,  108 g l ,  177 ng l ,  and 586 g l respectively.']]"
enoxaparin,"[' concentration - response curves showed that plv - s particles were efficiently neutralized by a range of concentrations of unfractionated heparin ( ufh )  ,  enoxaparin ,  6 - o - desulfated ufh and 6 - o - desulfated enoxaparin with an ic50 of 599 ng l ,  108 g l ,  177 ng l ,  and 586 g l respectively.']",'Effective Inhibition of SARS-CoV-2 Entry by Heparin and Enoxaparin Derivatives','10.1101/2020.06.08.140236',"[[' concentration - response curves showed that plv - s particles were efficiently neutralized by a range of concentrations of unfractionated heparin ( ufh )  ,  enoxaparin ,  6 - o - desulfated ufh and 6 - o - desulfated enoxaparin with an ic50 of 599 ng l ,  108 g l ,  177 ng l ,  and 586 g l respectively.']]"
chymotrypsin,[' the chymotrypsin - like protease of sars - cov - 2 shares structure similarity with hcv and hiv proteases.'],'First Clinical Study Using HCV Protease Inhibitor Danoprevir to Treat Naive and Experienced COVID-19 Patients','10.1101/2020.03.22.20034041',"[[' danoprevir ( ganovo )  is a potent hcv protease ( ns3 4a )  inhibitor ( ic50 = 0.29 nm )  ,  which was approved and marketed in china since 2018 to treat chronic hepatitis c patients.']]"
danoprevir,"[' we reported here the first clinical study using hepatitis c virus ( hcv )  protease inhibitor ,  danoprevir ,  to treat covid - 19 patients.', ' danoprevir ( ganovo )  is a potent hcv protease ( ns3 4a )  inhibitor ( ic50 = 0.', ' ritonavir is a cyp3a4 inhibitor to enhance plasma concentration of danoprevir while it also acts as a human immunodeficiency virus ( hiv )  protease inhibitor at high doses.', ' in the current clinical study ( nct04291729 )  conducted at the nineth hospital of nanchang ,  we evaluated therapeutic effects of danoprevir ,  boosted by ritonavir ,  on treatment naive and experienced covid - 19 patients.', ' the data from this small - sample clinical study showed that danoprevir boosted by ritonavir is safe and well tolerated in all patients.', ' after 4 to 12 - day treatment of danoprevir boosted by ritonavir ,  all eleven patients enrolled ,  two naive and nine experienced ,  were discharged from the hospital as they met all four conditions as follows: ( 1 )  normal body temperature for at least 3 days; ( 2 )  significantly improved respiratory symptoms; ( 3 )  lung imaging shows obvious absorption and recovery of acute exudative lesion; and ( 4 )  two consecutive rt - pcr negative tests of sars - cov - 2 nucleotide acid ( respiratory track sampling with interval at least one day ) .', ' our findings suggest that repurposing danoprevir for covid - 19 is a promising therapeutic option.']",'First Clinical Study Using HCV Protease Inhibitor Danoprevir to Treat Naive and Experienced COVID-19 Patients','10.1101/2020.03.22.20034041',"[[' danoprevir ( ganovo )  is a potent hcv protease ( ns3 4a )  inhibitor ( ic50 = 0.29 nm )  ,  which was approved and marketed in china since 2018 to treat chronic hepatitis c patients.']]"
ritonavir,"[' ritonavir is a cyp3a4 inhibitor to enhance plasma concentration of danoprevir while it also acts as a human immunodeficiency virus ( hiv )  protease inhibitor at high doses.', ' in the current clinical study ( nct04291729 )  conducted at the nineth hospital of nanchang ,  we evaluated therapeutic effects of danoprevir ,  boosted by ritonavir ,  on treatment naive and experienced covid - 19 patients.', ' the data from this small - sample clinical study showed that danoprevir boosted by ritonavir is safe and well tolerated in all patients.', ' after 4 to 12 - day treatment of danoprevir boosted by ritonavir ,  all eleven patients enrolled ,  two naive and nine experienced ,  were discharged from the hospital as they met all four conditions as follows: ( 1 )  normal body temperature for at least 3 days; ( 2 )  significantly improved respiratory symptoms; ( 3 )  lung imaging shows obvious absorption and recovery of acute exudative lesion; and ( 4 )  two consecutive rt - pcr negative tests of sars - cov - 2 nucleotide acid ( respiratory track sampling with interval at least one day ) .']",'First Clinical Study Using HCV Protease Inhibitor Danoprevir to Treat Naive and Experienced COVID-19 Patients','10.1101/2020.03.22.20034041',"[[' danoprevir ( ganovo )  is a potent hcv protease ( ns3 4a )  inhibitor ( ic50 = 0.29 nm )  ,  which was approved and marketed in china since 2018 to treat chronic hepatitis c patients.']]"
baloxavir,"[' this study aims to evaluate the clinical outcomes and plasma concentrations of baloxavir marboxil and favipiravir in covid - 19 patients.', ' methods: favipiravir and baloxavir acid were evaluated for their antiviral activity against sars - cov - 2 in vitro before the trial initiation.', ' patients were randomized assigned in a 1:1:1 ratio into baloxavir marboxil group ,  favipiravir group ,  and control group.', ' results: baloxavir showed antiviral activity in vitro with the half - maximal effective concentration ( ec50 )  of 5.', ' the percentage of patients who turned viral negative after 14 - day treatment was 70% ,  77% ,  and 100% in the baloxavir ,  favipiravir ,  and control group respectively ,  with the medians of time from randomization to clinical improvement was 14 ,  14 and 15 days ,  respectively.', ' conclusions: our findings do not support that adding either baloxavir or favipiravir under the trial dosages to the existing standard treatment.']","'Clinical Outcomes and Plasma Concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 Patients: an Exploratory Randomized, Controlled Trial'",'10.1101/2020.04.29.20085761',"[[' results: baloxavir showed antiviral activity in vitro with the half - maximal effective concentration ( ec50 )  of 5.48 m comparable to arbidol and lopinavir ,  but favipiravir did not demonstrate significant antiviral activity up to 100 m.']]"
arbidol,"['48 m comparable to arbidol and lopinavir ,  but favipiravir did not demonstrate significant antiviral activity up to 100 m.']","'Clinical Outcomes and Plasma Concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 Patients: an Exploratory Randomized, Controlled Trial'",'10.1101/2020.04.29.20085761',"[[' results: baloxavir showed antiviral activity in vitro with the half - maximal effective concentration ( ec50 )  of 5.48 m comparable to arbidol and lopinavir ,  but favipiravir did not demonstrate significant antiviral activity up to 100 m.']]"
favipiravir,"[' this study aims to evaluate the clinical outcomes and plasma concentrations of baloxavir marboxil and favipiravir in covid - 19 patients.', ' methods: favipiravir and baloxavir acid were evaluated for their antiviral activity against sars - cov - 2 in vitro before the trial initiation.', ' patients were randomized assigned in a 1:1:1 ratio into baloxavir marboxil group ,  favipiravir group ,  and control group.', '48 m comparable to arbidol and lopinavir ,  but favipiravir did not demonstrate significant antiviral activity up to 100 m.', ' the percentage of patients who turned viral negative after 14 - day treatment was 70% ,  77% ,  and 100% in the baloxavir ,  favipiravir ,  and control group respectively ,  with the medians of time from randomization to clinical improvement was 14 ,  14 and 15 days ,  respectively.', ' conclusions: our findings do not support that adding either baloxavir or favipiravir under the trial dosages to the existing standard treatment.']","'Clinical Outcomes and Plasma Concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 Patients: an Exploratory Randomized, Controlled Trial'",'10.1101/2020.04.29.20085761',"[[' results: baloxavir showed antiviral activity in vitro with the half - maximal effective concentration ( ec50 )  of 5.48 m comparable to arbidol and lopinavir ,  but favipiravir did not demonstrate significant antiviral activity up to 100 m.']]"
lopinavir,"['48 m comparable to arbidol and lopinavir ,  but favipiravir did not demonstrate significant antiviral activity up to 100 m.']","'Clinical Outcomes and Plasma Concentrations of Baloxavir Marboxil and Favipiravir in COVID-19 Patients: an Exploratory Randomized, Controlled Trial'",'10.1101/2020.04.29.20085761',"[[' results: baloxavir showed antiviral activity in vitro with the half - maximal effective concentration ( ec50 )  of 5.48 m comparable to arbidol and lopinavir ,  but favipiravir did not demonstrate significant antiviral activity up to 100 m.']]"
dipyridamole,[' we screened an fda approved drug library and found that an anticoagulant agent dipyridamole ( dip )  suppressed hcov - 19 replication at an ec50 of 100 nm in vitro.'],'Therapeutic effects of dipyridamole on COVID-19 patients with coagulation dysfunction','10.1101/2020.02.27.20027557',[[' we screened an fda approved drug library and found that an anticoagulant agent dipyridamole ( dip )  suppressed hcov - 19 replication at an ec50 of 100 nm in vitro.']]
ebselen,[' ebselen also exhibited promising antiviral activity in cell - based assays.'],"'Structure-based drug design, virtual screening and high-throughput screening rapidly identify antiviral leads targeting COVID-19'",'10.1101/2020.02.26.964882',[[' six of these inhibit mpro with ic50 values ranging from 0.67 to 21.4 m.']]
ebastine,"[' three medicines pimozide ,  ebastine ,  and bepridil are basic small molecules that are expected to exert a similar effect as hydroxychloroquine in raising endosomal ph for slowing down the sars - cov - 2 entry into human cell hosts.']",'Targeting the SARS-CoV-2 Main Protease to Repurpose Drugs for COVID-19','10.1101/2020.05.23.112235',"[[' of these tested small molecule medicines ,  six displayed an ic50 value in inhibiting mpro below 100 m.']]"
bepridil,"[' three medicines pimozide ,  ebastine ,  and bepridil are basic small molecules that are expected to exert a similar effect as hydroxychloroquine in raising endosomal ph for slowing down the sars - cov - 2 entry into human cell hosts.', ' bepridil has been previously explored in a high dose as 100 mg kg for treating diseases.', ' therefore ,  the current study urges serious considerations of using bepridil in covid - 19 clinical tests.']",'Targeting the SARS-CoV-2 Main Protease to Repurpose Drugs for COVID-19','10.1101/2020.05.23.112235',"[[' of these tested small molecule medicines ,  six displayed an ic50 value in inhibiting mpro below 100 m.']]"
hydroxychloroquine,"[' three medicines pimozide ,  ebastine ,  and bepridil are basic small molecules that are expected to exert a similar effect as hydroxychloroquine in raising endosomal ph for slowing down the sars - cov - 2 entry into human cell hosts.']",'Targeting the SARS-CoV-2 Main Protease to Repurpose Drugs for COVID-19','10.1101/2020.05.23.112235',"[[' of these tested small molecule medicines ,  six displayed an ic50 value in inhibiting mpro below 100 m.']]"
pimozide,"[' three medicines pimozide ,  ebastine ,  and bepridil are basic small molecules that are expected to exert a similar effect as hydroxychloroquine in raising endosomal ph for slowing down the sars - cov - 2 entry into human cell hosts.']",'Targeting the SARS-CoV-2 Main Protease to Repurpose Drugs for COVID-19','10.1101/2020.05.23.112235',"[[' of these tested small molecule medicines ,  six displayed an ic50 value in inhibiting mpro below 100 m.']]"
azithromycine,"[' several drugs ,  such as azithromycine ,  opipramol ,  quinidine or omeprazol present antiviral potency with 2<ec50<20{micro}m.']",'In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication','10.1101/2020.04.03.023846',"[[' the hits were sorted according to their chemical composition and their known therapeutic effect ,  then ec50 and cc50 were determined for a subset of compounds.', ' several drugs ,  such as azithromycine ,  opipramol ,  quinidine or omeprazol present antiviral potency with 2<ec50<20{micro}m.'], [' the hits were sorted according to their chemical composition and their known therapeutic effect ,  then ec50 and cc50 were determined for a subset of compounds.']]"
chloroquine,"[' the robustness of the screen was assessed by the identification of drugs ,  such as chloroquine derivatives and protease inhibitors ,  already in clinical trials.']",'In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication','10.1101/2020.04.03.023846',"[[' the hits were sorted according to their chemical composition and their known therapeutic effect ,  then ec50 and cc50 were determined for a subset of compounds.', ' several drugs ,  such as azithromycine ,  opipramol ,  quinidine or omeprazol present antiviral potency with 2<ec50<20{micro}m.'], [' the hits were sorted according to their chemical composition and their known therapeutic effect ,  then ec50 and cc50 were determined for a subset of compounds.']]"
quinidine,"[' several drugs ,  such as azithromycine ,  opipramol ,  quinidine or omeprazol present antiviral potency with 2<ec50<20{micro}m.']",'In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication','10.1101/2020.04.03.023846',"[[' the hits were sorted according to their chemical composition and their known therapeutic effect ,  then ec50 and cc50 were determined for a subset of compounds.', ' several drugs ,  such as azithromycine ,  opipramol ,  quinidine or omeprazol present antiviral potency with 2<ec50<20{micro}m.'], [' the hits were sorted according to their chemical composition and their known therapeutic effect ,  then ec50 and cc50 were determined for a subset of compounds.']]"
omeprazol,"[' several drugs ,  such as azithromycine ,  opipramol ,  quinidine or omeprazol present antiviral potency with 2<ec50<20{micro}m.']",'In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication','10.1101/2020.04.03.023846',"[[' the hits were sorted according to their chemical composition and their known therapeutic effect ,  then ec50 and cc50 were determined for a subset of compounds.', ' several drugs ,  such as azithromycine ,  opipramol ,  quinidine or omeprazol present antiviral potency with 2<ec50<20{micro}m.'], [' the hits were sorted according to their chemical composition and their known therapeutic effect ,  then ec50 and cc50 were determined for a subset of compounds.']]"
opipramol,"[' several drugs ,  such as azithromycine ,  opipramol ,  quinidine or omeprazol present antiviral potency with 2<ec50<20{micro}m.']",'In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication','10.1101/2020.04.03.023846',"[[' the hits were sorted according to their chemical composition and their known therapeutic effect ,  then ec50 and cc50 were determined for a subset of compounds.', ' several drugs ,  such as azithromycine ,  opipramol ,  quinidine or omeprazol present antiviral potency with 2<ec50<20{micro}m.'], [' the hits were sorted according to their chemical composition and their known therapeutic effect ,  then ec50 and cc50 were determined for a subset of compounds.']]"
hydroxychloroquine,"["" 'aimswe investigate mechanisms for potential pro - arrhythmic effects of hydroxychloroquine ( hcq )  alone ,  or combined with azithromycin ( azm )  ,  in covid - 19 management supplementing the limited available experimental cardiac safety data.""]",'Mechanistic insights into ventricular arrhythmogenesis of hydroxychloroquine and azithromycin for the treatment of COVID-19','10.1101/2020.05.21.108605',"[['  methodswe integrated patch - clamp studies utilizing in vitro proarrhythmia assay ( cipa )  schema ic50 paradigms ,  molecular modelling ,  cardiac multi - electrode array and voltage ( rh237 )  mapping ,  ecg studies ,  and ca2 +  ( rhod - 2 am )  mapping in isolated langendorff - perfused guinea - pig hearts with human in - silico ion current modelling.', '  resultshcq blocked ikr and ik1 with ic50s ( 10{ +   - }0.6 and 34{ +   - }5.0 m )  within clinical therapeutic ranges ,  ina and ical at higher ic50s ,  leaving ito and iks unaffected.', ' hcq + azm combined inhibited ikr and ik1 with ic50s of 7.7{ +   - }0.8 m and 30.4{ +   - }3.0 m ,  sparing ina ,  ical and ito.']]"
azithromycin,"["" 'aimswe investigate mechanisms for potential pro - arrhythmic effects of hydroxychloroquine ( hcq )  alone ,  or combined with azithromycin ( azm )  ,  in covid - 19 management supplementing the limited available experimental cardiac safety data.""]",'Mechanistic insights into ventricular arrhythmogenesis of hydroxychloroquine and azithromycin for the treatment of COVID-19','10.1101/2020.05.21.108605',"[['  methodswe integrated patch - clamp studies utilizing in vitro proarrhythmia assay ( cipa )  schema ic50 paradigms ,  molecular modelling ,  cardiac multi - electrode array and voltage ( rh237 )  mapping ,  ecg studies ,  and ca2 +  ( rhod - 2 am )  mapping in isolated langendorff - perfused guinea - pig hearts with human in - silico ion current modelling.', '  resultshcq blocked ikr and ik1 with ic50s ( 10{ +   - }0.6 and 34{ +   - }5.0 m )  within clinical therapeutic ranges ,  ina and ical at higher ic50s ,  leaving ito and iks unaffected.', ' hcq + azm combined inhibited ikr and ik1 with ic50s of 7.7{ +   - }0.8 m and 30.4{ +   - }3.0 m ,  sparing ina ,  ical and ito.']]"
niclosamide,"[' in particular ,  two fda - approved drugs  -  niclosamide and ciclesonide  -  were notable in some respects.']",'Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs','10.1101/2020.03.20.999730',[['1 m < ic50 < 10 m )  against sars - cov - 2.']]
ciclesonide,"[' in particular ,  two fda - approved drugs  -  niclosamide and ciclesonide  -  were notable in some respects.']",'Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs','10.1101/2020.03.20.999730',[['1 m < ic50 < 10 m )  against sars - cov - 2.']]
chloroquine,"[' moreover ,  we have evaluated two of these ,  chloroquine and chlorpromazine ,  in vivo using a mouse - adapted sars - cov model and found both drugs protect mice from clinical disease.']",'FDA approved drugs with broad anti-coronaviral activity inhibit SARS-CoV-2 in vitro','10.1101/2020.03.25.008482',[[' we found that 17 of these inhibit sars - cov - 2 at a range of ic50 values at non - cytotoxic concentrations.']]
chlorpromazine,"[' moreover ,  we have evaluated two of these ,  chloroquine and chlorpromazine ,  in vivo using a mouse - adapted sars - cov model and found both drugs protect mice from clinical disease.']",'FDA approved drugs with broad anti-coronaviral activity inhibit SARS-CoV-2 in vitro','10.1101/2020.03.25.008482',[[' we found that 17 of these inhibit sars - cov - 2 at a range of ic50 values at non - cytotoxic concentrations.']]
cobicistat,"[' prezcobix rezolsta is a fixed - dose combination of 800 mg of the hiv protease inhibitor darunavir ( drv )  and 150 mg cobicistat ,  a cyp3a4 inhibitor ,  which is indicated in combination with other antiretroviral agents for the treatment of hiv infection.', ' there are currently no definitive data on the safety and efficacy of drv cobicistat for treatment of covid - 19.']",'Lack of Antiviral Activity of Darunavir against SARS-CoV-2','10.1101/2020.04.03.20052548',"[[' drv showed no activity against sars - cov - 2 at clinically relevant concentrations ( ec50 >100 m ) .', ' remdesivir ,  used as a positive control ,  showed potent antiviral activity ( ec50 = 0.38 m ) .']]"
darunavir,"[' prezcobix rezolsta is a fixed - dose combination of 800 mg of the hiv protease inhibitor darunavir ( drv )  and 150 mg cobicistat ,  a cyp3a4 inhibitor ,  which is indicated in combination with other antiretroviral agents for the treatment of hiv infection.', ' the in vitro antiviral activity of darunavir against a clinical isolate from a patient infected with sars - cov - 2 was assessed.']",'Lack of Antiviral Activity of Darunavir against SARS-CoV-2','10.1101/2020.04.03.20052548',"[[' drv showed no activity against sars - cov - 2 at clinically relevant concentrations ( ec50 >100 m ) .', ' remdesivir ,  used as a positive control ,  showed potent antiviral activity ( ec50 = 0.38 m ) .']]"
remdesivir,"[' remdesivir ,  used as a positive control ,  showed potent antiviral activity ( ec50 = 0.']",'Lack of Antiviral Activity of Darunavir against SARS-CoV-2','10.1101/2020.04.03.20052548',"[[' drv showed no activity against sars - cov - 2 at clinically relevant concentrations ( ec50 >100 m ) .', ' remdesivir ,  used as a positive control ,  showed potent antiviral activity ( ec50 = 0.38 m ) .']]"
baicalein,"[' baicalensis ,  baicalein strongly inhibits sars - cov - 2 3clpro activity with an ic50 of 0.', ' we further identified four baicalein analogue compounds from other herbs that inhibit sars - cov - 2 3clpro activity at microm concentration.', ' baicalensis has effective anti - sars - cov - 2 activity and baicalein and analogue compounds are strong sars - cov - 2 3clpro inhibitors.']",'Scutellaria baicalensis extract and baicalein inhibit replication of SARS-CoV-2 and its 3C-like protease in vitro','10.1101/2020.04.10.035824',"[[' baicalensis inhibits sars - cov - 2 3clpro activity in vitro and the replication of sars - cov - 2 in vero cells with an ec50 of 0.74 g ml.'], [' baicalensis ,  baicalein strongly inhibits sars - cov - 2 3clpro activity with an ic50 of 0.39 m.']]"
huangqin,"[' scutellariae radix ( huangqin in chinese )  ,  the root of scutellaria baicalensis has been widely used in traditional chinese medicine to treat viral infection related symptoms.']",'Scutellaria baicalensis extract and baicalein inhibit replication of SARS-CoV-2 and its 3C-like protease in vitro','10.1101/2020.04.10.035824',"[[' baicalensis inhibits sars - cov - 2 3clpro activity in vitro and the replication of sars - cov - 2 in vero cells with an ec50 of 0.74 g ml.'], [' baicalensis ,  baicalein strongly inhibits sars - cov - 2 3clpro activity with an ic50 of 0.39 m.']]"
ethanol,[' we found that the ethanol extract of s.'],'Scutellaria baicalensis extract and baicalein inhibit replication of SARS-CoV-2 and its 3C-like protease in vitro','10.1101/2020.04.10.035824',"[[' baicalensis inhibits sars - cov - 2 3clpro activity in vitro and the replication of sars - cov - 2 in vero cells with an ec50 of 0.74 g ml.'], [' baicalensis ,  baicalein strongly inhibits sars - cov - 2 3clpro activity with an ic50 of 0.39 m.']]"
suramin,"[' here we demonstrate that the antiparasitic drug suramin inhibits sars - cov - 2 replication ,  protecting vero e6 cells with an ec50 of [~]20 {micro}m ,  which is well below the maximum attainable level in human serum.', ' suramin also decreased the viral load by 2 - 3 logs when vero e6 cells or cells of a human lung epithelial cell line ( calu - 3 )  were treated.', ' time of addition and plaque reduction assays showed that suramin acts on early steps of the replication cycle ,  possibly preventing entry of the virus.', ' in a primary human airway epithelial cell culture model ,  suramin also inhibited the progression of infection.', ' the results of our preclinical study warrant further investigation and suggest it is worth evaluating whether suramin provides any benefit for covid - 19 patients ,  which obviously requires well - designed ,  properly controlled randomized clinical trials.']",'Suramin inhibits SARS-CoV-2 infection in cell culture by interfering with early steps of the replication cycle','10.1101/2020.05.06.081968',"[[' here we demonstrate that the antiparasitic drug suramin inhibits sars - cov - 2 replication ,  protecting vero e6 cells with an ec50 of [~]20 {micro}m ,  which is well below the maximum attainable level in human serum.']]"
verteporfin,"[' in this study ,  we discovered that protoporphyrin ix and verteporfin ,  two fda - approved drugs for treatment of human diseases ,  had significant antiviral effect against sars - cov - 2 ,  with ec50 values for the reduction of viral rna at nanomolar concentrations.', ' the selection indices of protoporphyrin ix and verteporfin are 952.', ' our finding suggests that protoporphyrin ix and verteporfin might be potential antivirals against sars - cov - 2 infection and also sheds new light on the development of a novel class of small compounds against sars - cov - 2.']",'Potent antiviral effect of protoporphyrin IX and verteporfin on SARS-CoV-2 infection','10.1101/2020.04.30.071290',"[[' in this study ,  we discovered that protoporphyrin ix and verteporfin ,  two fda - approved drugs for treatment of human diseases ,  had significant antiviral effect against sars - cov - 2 ,  with ec50 values for the reduction of viral rna at nanomolar concentrations.']]"
protoporphyrin,"[' in this study ,  we discovered that protoporphyrin ix and verteporfin ,  two fda - approved drugs for treatment of human diseases ,  had significant antiviral effect against sars - cov - 2 ,  with ec50 values for the reduction of viral rna at nanomolar concentrations.', ' the selection indices of protoporphyrin ix and verteporfin are 952.', ' our finding suggests that protoporphyrin ix and verteporfin might be potential antivirals against sars - cov - 2 infection and also sheds new light on the development of a novel class of small compounds against sars - cov - 2.']",'Potent antiviral effect of protoporphyrin IX and verteporfin on SARS-CoV-2 infection','10.1101/2020.04.30.071290',"[[' in this study ,  we discovered that protoporphyrin ix and verteporfin ,  two fda - approved drugs for treatment of human diseases ,  had significant antiviral effect against sars - cov - 2 ,  with ec50 values for the reduction of viral rna at nanomolar concentrations.']]"
chlorpromazine,"[' chlorpromazine ( cpz )  ,  the prototype of typical antipsychotics from the phenothiazine group ,  is known to inhibit clathrin - mediated endocytosis and acts as an antiviral ,  in particular against sars - cov - 1 and mers - cov.']",'Inhibition of the replication of SARS-CoV-2 in human cells by the FDA-approved drug chlorpromazine','10.1101/2020.05.05.079608',"[[' we evidenced an antiviral activity against sars - cov - 2 with an ic50 of [~]10m.', ' because of its high biodistribution in lung ,  saliva and brain ,  such ic50 measured in vitro may translate to cpz dosage used in clinical routine.']]"
phenothiazine,"[' chlorpromazine ( cpz )  ,  the prototype of typical antipsychotics from the phenothiazine group ,  is known to inhibit clathrin - mediated endocytosis and acts as an antiviral ,  in particular against sars - cov - 1 and mers - cov.']",'Inhibition of the replication of SARS-CoV-2 in human cells by the FDA-approved drug chlorpromazine','10.1101/2020.05.05.079608',"[[' we evidenced an antiviral activity against sars - cov - 2 with an ic50 of [~]10m.', ' because of its high biodistribution in lung ,  saliva and brain ,  such ic50 measured in vitro may translate to cpz dosage used in clinical routine.']]"
nafamostat,"[' we previously found that nafamostat mesylate ,  an existing drug used for disseminated intravascular coagulation ( dic )  ,  effectively blocked mers - cov s protein - initiated cell fusion by targeting tmprss2 ,  and inhibited mers - cov infection of human lung epithelium - derived calu - 3 cells.', ' here we established a quantitative fusion assay dependent on sars - cov - 2 s protein ,  ace2 and tmprss2 ,  and found that nafamostat mesylate potently inhibited the fusion while camostat mesylate was about 10 - fold less active.', ' furthermore ,  nafamostat mesylate blocked sars - cov - 2 infection of calu - 3 cells with an ec50 around 10 nm ,  which is below its average blood concentration after intravenous administration through continuous infusion.', ' these findings ,  together with accumulated clinical data regarding its safety ,  make nafamostat a likely candidate drug to treat covid - 19.']",'The anticoagulant nafamostat potently inhibits SARS-CoV-2 infection in vitro: an existing drug with multiple possible therapeutic effects','10.1101/2020.04.22.054981',"[[' furthermore ,  nafamostat mesylate blocked sars - cov - 2 infection of calu - 3 cells with an ec50 around 10 nm ,  which is below its average blood concentration after intravenous administration through continuous infusion.']]"
camostat,"[' here we established a quantitative fusion assay dependent on sars - cov - 2 s protein ,  ace2 and tmprss2 ,  and found that nafamostat mesylate potently inhibited the fusion while camostat mesylate was about 10 - fold less active.']",'The anticoagulant nafamostat potently inhibits SARS-CoV-2 infection in vitro: an existing drug with multiple possible therapeutic effects','10.1101/2020.04.22.054981',"[[' furthermore ,  nafamostat mesylate blocked sars - cov - 2 infection of calu - 3 cells with an ec50 around 10 nm ,  which is below its average blood concentration after intravenous administration through continuous infusion.']]"
sulfate,[' microarray binding experiments using an extensive heparan sulfate ( hs )  oligosaccharide library showed the spike of sars - cov - 2 can bind hs in a length -  and sequence - dependent manner.'],'SARS-CoV-2 spike protein binds heparan sulfate in a length- and sequence-dependent manner','10.1101/2020.05.10.087288',[[' an octasaccharide composed of idoa2s - glcns6s could inhibit spike - heparin interaction with an ic50 of 38 nm.']]
heparin,"[' surface plasma resonance ( spr )  showed the sars - cov - 2 spike protein binds with higher affinity to heparin ( kd 55 nm )  compared to the receptor binding domain ( rbd ,  kd 1 {micro}m )  alone.', ' an octasaccharide composed of idoa2s - glcns6s could inhibit spike - heparin interaction with an ic50 of 38 nm.']",'SARS-CoV-2 spike protein binds heparan sulfate in a length- and sequence-dependent manner','10.1101/2020.05.10.087288',[[' an octasaccharide composed of idoa2s - glcns6s could inhibit spike - heparin interaction with an ic50 of 38 nm.']]
adenosine,"[' we report that remdesivir ( rdv )  ,  a monophosphoramidate prodrug of an adenosine analog ,  potently inhibits sars - cov - 2 replication in human lung cells and primary human airway epithelial cultures ( ec50 = 0.']",'Remdesivir potently inhibits SARS-CoV-2 in human lung cells and chimeric SARS-CoV expressing the SARS-CoV-2 RNA polymerase in mice.','10.1101/2020.04.27.064279',"[[' we report that remdesivir ( rdv )  ,  a monophosphoramidate prodrug of an adenosine analog ,  potently inhibits sars - cov - 2 replication in human lung cells and primary human airway epithelial cultures ( ec50 = 0.01 m ) .', ' weaker activity was observed in vero e6 cells ( ec50 = 1.65 m )  due to their low capacity to metabolize rdv.']]"
remdesivir,"[' we report that remdesivir ( rdv )  ,  a monophosphoramidate prodrug of an adenosine analog ,  potently inhibits sars - cov - 2 replication in human lung cells and primary human airway epithelial cultures ( ec50 = 0.']",'Remdesivir potently inhibits SARS-CoV-2 in human lung cells and chimeric SARS-CoV expressing the SARS-CoV-2 RNA polymerase in mice.','10.1101/2020.04.27.064279',"[[' we report that remdesivir ( rdv )  ,  a monophosphoramidate prodrug of an adenosine analog ,  potently inhibits sars - cov - 2 replication in human lung cells and primary human airway epithelial cultures ( ec50 = 0.01 m ) .', ' weaker activity was observed in vero e6 cells ( ec50 = 1.65 m )  due to their low capacity to metabolize rdv.']]"
licorice,[' liquiritin is abundant in licorice tablet ( ~0.'],'An artificial intelligence system reveals liquiritin inhibits SARS-CoV-2 by mimicking type I interferon','10.1101/2020.05.02.074021',[[' we found liquiritin significantly inhibit replication of sars - cov - 2 in vero e6 cells with ec50 = 2.39 m.']]
liquiritin,"[' we found liquiritin significantly inhibit replication of sars - cov - 2 in vero e6 cells with ec50 = 2.', ' mechanistically ,  we found liquiritin exerts anti - viral function by mimicking type i interferon.', ' upregulated genes induced by liquiritin are enriched in go categories including type i interferon signaling pathway ,  negative regulation of viral genome replication and etc.', ' liquiritin is abundant in licorice tablet ( ~0.', ' together ,  we recommend liquiritin as a competitive candidate for treating covid - 19.', ' we also expect liquiritin to have a broad and potent antiviral function to other viral pathogens ,  like hbv ,  hiv and etc.']",'An artificial intelligence system reveals liquiritin inhibits SARS-CoV-2 by mimicking type I interferon','10.1101/2020.05.02.074021',[[' we found liquiritin significantly inhibit replication of sars - cov - 2 in vero e6 cells with ec50 = 2.39 m.']]
serotonin,"[' fluoxetine is a racemate consisting of both stereoisomers ,  while the s - form is the dominant serotonin reuptake inhibitor.']",'The serotonin reuptake inhibitor Fluoxetine inhibits SARS-CoV-2','10.1101/2020.06.14.150490',"[['8{micro}g ml significantly ,  and the ec50 was determined with 387ng ml.']]"
fluoxetine,"[' in these screenings ,  fluoxetine inhibited sars - cov - 2 at a concentration of 0.', ' fluoxetine is a racemate consisting of both stereoisomers ,  while the s - form is the dominant serotonin reuptake inhibitor.', ' fluoxetine treatment resulted in a decrease in viral protein expression.', ' furthermore ,  fluoxetine inhibited neither rabies virus ,  human respiratory syncytial virus replication nor the human herpesvirus 8 or herpes simplex virus type 1 gene expression ,  indicating that it acts virus - specific.', ' we see the role of fluoxetine in the early treatment of sars - cov - 2 infected patients of risk groups.']",'The serotonin reuptake inhibitor Fluoxetine inhibits SARS-CoV-2','10.1101/2020.06.14.150490',"[['8{micro}g ml significantly ,  and the ec50 was determined with 387ng ml.']]"
remdesivir,"[' in a proof - of - concept screen ,  we found that e64d ,  apilimod ,  eipa and remdesivir can substantially impede sars - cov - 2 replication providing novel insight into viral entry and replication mechanisms.']",'A facile Q-RT-PCR assay for monitoring SARS-CoV-2 growth in cell culture','10.1101/2020.06.26.174698',"[[' hiv - 1 - specific inhibitors nevirapine ( an nnrti )  ,  amprenavir ( a protease inhibitor )  ,  and allini - 2 ( an allosteric integrase inhibitor )  modestly inhibited sars - cov - 2 replication ,  albeit the ic50 values were much higher than that required for hiv - 1.']]"
apilimod,"[' in line with previous studies which has shown that processing of the viral spike protein by cellular proteases and endosomal fusion are required for entry ,  we found that e64d and apilimod potently decreased the amount of sars - cov - 2 rna in cell culture supernatants with minimal cytotoxicity.', ' in a proof - of - concept screen ,  we found that e64d ,  apilimod ,  eipa and remdesivir can substantially impede sars - cov - 2 replication providing novel insight into viral entry and replication mechanisms.']",'A facile Q-RT-PCR assay for monitoring SARS-CoV-2 growth in cell culture','10.1101/2020.06.26.174698',"[[' hiv - 1 - specific inhibitors nevirapine ( an nnrti )  ,  amprenavir ( a protease inhibitor )  ,  and allini - 2 ( an allosteric integrase inhibitor )  modestly inhibited sars - cov - 2 replication ,  albeit the ic50 values were much higher than that required for hiv - 1.']]"
nevirapine,"[' hiv - 1 - specific inhibitors nevirapine ( an nnrti )  ,  amprenavir ( a protease inhibitor )  ,  and allini - 2 ( an allosteric integrase inhibitor )  modestly inhibited sars - cov - 2 replication ,  albeit the ic50 values were much higher than that required for hiv - 1.']",'A facile Q-RT-PCR assay for monitoring SARS-CoV-2 growth in cell culture','10.1101/2020.06.26.174698',"[[' hiv - 1 - specific inhibitors nevirapine ( an nnrti )  ,  amprenavir ( a protease inhibitor )  ,  and allini - 2 ( an allosteric integrase inhibitor )  modestly inhibited sars - cov - 2 replication ,  albeit the ic50 values were much higher than that required for hiv - 1.']]"
amprenavir,"[' hiv - 1 - specific inhibitors nevirapine ( an nnrti )  ,  amprenavir ( a protease inhibitor )  ,  and allini - 2 ( an allosteric integrase inhibitor )  modestly inhibited sars - cov - 2 replication ,  albeit the ic50 values were much higher than that required for hiv - 1.']",'A facile Q-RT-PCR assay for monitoring SARS-CoV-2 growth in cell culture','10.1101/2020.06.26.174698',"[[' hiv - 1 - specific inhibitors nevirapine ( an nnrti )  ,  amprenavir ( a protease inhibitor )  ,  and allini - 2 ( an allosteric integrase inhibitor )  modestly inhibited sars - cov - 2 replication ,  albeit the ic50 values were much higher than that required for hiv - 1.']]"
chloroquine,"[' using this parameter hydroxychloroquine ,  chloroquine ,  mefloquine ,  atazanavir ( boosted with ritonavir )  ,  tipranavir ( boosted with ritonavir )  ,  ivermectin ,  azithromycin and lopinavir ( boosted with ritonavir )  were all predicted to achieve lung concentrations over 10 - fold higher than their reported ec50.']",'Prioritisation of potential anti-SARS-CoV-2 drug repurposing opportunities based on ability to achieve adequate target site concentrations derived from their established human pharmacokinetics','10.1101/2020.04.16.20068379',"[[' moreover ,  most publications have focussed on 50% maximum effective concentrations ( ec50 )  ,  which may be an insufficiently robust indicator of antiviral activity because of marked differences in the slope of the concentration - response curve between drugs.', ' for all drugs reported ,  the unbound lung to plasma tissue partition coefficient ( kpulung )  was also simulated and used along with reported cmax and fraction unbound in plasma to derive a lung cmax ec50 as a better indicator of potential human efficacy ( lung cmax ec90 ratio was also calculable for a limited number of drugs ) .', ' using this parameter hydroxychloroquine ,  chloroquine ,  mefloquine ,  atazanavir ( boosted with ritonavir )  ,  tipranavir ( boosted with ritonavir )  ,  ivermectin ,  azithromycin and lopinavir ( boosted with ritonavir )  were all predicted to achieve lung concentrations over 10 - fold higher than their reported ec50.', ' this analysis was not possible for nelfinavir because insufficient data were available to calculate kpulung but nitozoxanide and sulfadoxine were also predicted to exceed their reported ec50 by 3.1 -  and 1.5 - fold in lung ,  respectively.']]"
tipranavir,"[' a more in - depth assessment of these drugs demonstrated that only nitazoxanide ,  nelfinavir ,  tipranavir ( boosted with ritonavir )  and sulfadoxine achieved plasma concentrations above their anti - sars - cov - 2 activity across their entire approved dosing interval at their approved human dose.', ' using this parameter hydroxychloroquine ,  chloroquine ,  mefloquine ,  atazanavir ( boosted with ritonavir )  ,  tipranavir ( boosted with ritonavir )  ,  ivermectin ,  azithromycin and lopinavir ( boosted with ritonavir )  were all predicted to achieve lung concentrations over 10 - fold higher than their reported ec50.']",'Prioritisation of potential anti-SARS-CoV-2 drug repurposing opportunities based on ability to achieve adequate target site concentrations derived from their established human pharmacokinetics','10.1101/2020.04.16.20068379',"[[' moreover ,  most publications have focussed on 50% maximum effective concentrations ( ec50 )  ,  which may be an insufficiently robust indicator of antiviral activity because of marked differences in the slope of the concentration - response curve between drugs.', ' for all drugs reported ,  the unbound lung to plasma tissue partition coefficient ( kpulung )  was also simulated and used along with reported cmax and fraction unbound in plasma to derive a lung cmax ec50 as a better indicator of potential human efficacy ( lung cmax ec90 ratio was also calculable for a limited number of drugs ) .', ' using this parameter hydroxychloroquine ,  chloroquine ,  mefloquine ,  atazanavir ( boosted with ritonavir )  ,  tipranavir ( boosted with ritonavir )  ,  ivermectin ,  azithromycin and lopinavir ( boosted with ritonavir )  were all predicted to achieve lung concentrations over 10 - fold higher than their reported ec50.', ' this analysis was not possible for nelfinavir because insufficient data were available to calculate kpulung but nitozoxanide and sulfadoxine were also predicted to exceed their reported ec50 by 3.1 -  and 1.5 - fold in lung ,  respectively.']]"
lopinavir,"[' using this parameter hydroxychloroquine ,  chloroquine ,  mefloquine ,  atazanavir ( boosted with ritonavir )  ,  tipranavir ( boosted with ritonavir )  ,  ivermectin ,  azithromycin and lopinavir ( boosted with ritonavir )  were all predicted to achieve lung concentrations over 10 - fold higher than their reported ec50.']",'Prioritisation of potential anti-SARS-CoV-2 drug repurposing opportunities based on ability to achieve adequate target site concentrations derived from their established human pharmacokinetics','10.1101/2020.04.16.20068379',"[[' moreover ,  most publications have focussed on 50% maximum effective concentrations ( ec50 )  ,  which may be an insufficiently robust indicator of antiviral activity because of marked differences in the slope of the concentration - response curve between drugs.', ' for all drugs reported ,  the unbound lung to plasma tissue partition coefficient ( kpulung )  was also simulated and used along with reported cmax and fraction unbound in plasma to derive a lung cmax ec50 as a better indicator of potential human efficacy ( lung cmax ec90 ratio was also calculable for a limited number of drugs ) .', ' using this parameter hydroxychloroquine ,  chloroquine ,  mefloquine ,  atazanavir ( boosted with ritonavir )  ,  tipranavir ( boosted with ritonavir )  ,  ivermectin ,  azithromycin and lopinavir ( boosted with ritonavir )  were all predicted to achieve lung concentrations over 10 - fold higher than their reported ec50.', ' this analysis was not possible for nelfinavir because insufficient data were available to calculate kpulung but nitozoxanide and sulfadoxine were also predicted to exceed their reported ec50 by 3.1 -  and 1.5 - fold in lung ,  respectively.']]"
hydroxychloroquine,"[' using this parameter hydroxychloroquine ,  chloroquine ,  mefloquine ,  atazanavir ( boosted with ritonavir )  ,  tipranavir ( boosted with ritonavir )  ,  ivermectin ,  azithromycin and lopinavir ( boosted with ritonavir )  were all predicted to achieve lung concentrations over 10 - fold higher than their reported ec50.']",'Prioritisation of potential anti-SARS-CoV-2 drug repurposing opportunities based on ability to achieve adequate target site concentrations derived from their established human pharmacokinetics','10.1101/2020.04.16.20068379',"[[' moreover ,  most publications have focussed on 50% maximum effective concentrations ( ec50 )  ,  which may be an insufficiently robust indicator of antiviral activity because of marked differences in the slope of the concentration - response curve between drugs.', ' for all drugs reported ,  the unbound lung to plasma tissue partition coefficient ( kpulung )  was also simulated and used along with reported cmax and fraction unbound in plasma to derive a lung cmax ec50 as a better indicator of potential human efficacy ( lung cmax ec90 ratio was also calculable for a limited number of drugs ) .', ' using this parameter hydroxychloroquine ,  chloroquine ,  mefloquine ,  atazanavir ( boosted with ritonavir )  ,  tipranavir ( boosted with ritonavir )  ,  ivermectin ,  azithromycin and lopinavir ( boosted with ritonavir )  were all predicted to achieve lung concentrations over 10 - fold higher than their reported ec50.', ' this analysis was not possible for nelfinavir because insufficient data were available to calculate kpulung but nitozoxanide and sulfadoxine were also predicted to exceed their reported ec50 by 3.1 -  and 1.5 - fold in lung ,  respectively.']]"
atazanavir,"[' using this parameter hydroxychloroquine ,  chloroquine ,  mefloquine ,  atazanavir ( boosted with ritonavir )  ,  tipranavir ( boosted with ritonavir )  ,  ivermectin ,  azithromycin and lopinavir ( boosted with ritonavir )  were all predicted to achieve lung concentrations over 10 - fold higher than their reported ec50.']",'Prioritisation of potential anti-SARS-CoV-2 drug repurposing opportunities based on ability to achieve adequate target site concentrations derived from their established human pharmacokinetics','10.1101/2020.04.16.20068379',"[[' moreover ,  most publications have focussed on 50% maximum effective concentrations ( ec50 )  ,  which may be an insufficiently robust indicator of antiviral activity because of marked differences in the slope of the concentration - response curve between drugs.', ' for all drugs reported ,  the unbound lung to plasma tissue partition coefficient ( kpulung )  was also simulated and used along with reported cmax and fraction unbound in plasma to derive a lung cmax ec50 as a better indicator of potential human efficacy ( lung cmax ec90 ratio was also calculable for a limited number of drugs ) .', ' using this parameter hydroxychloroquine ,  chloroquine ,  mefloquine ,  atazanavir ( boosted with ritonavir )  ,  tipranavir ( boosted with ritonavir )  ,  ivermectin ,  azithromycin and lopinavir ( boosted with ritonavir )  were all predicted to achieve lung concentrations over 10 - fold higher than their reported ec50.', ' this analysis was not possible for nelfinavir because insufficient data were available to calculate kpulung but nitozoxanide and sulfadoxine were also predicted to exceed their reported ec50 by 3.1 -  and 1.5 - fold in lung ,  respectively.']]"
mefloquine,"[' using this parameter hydroxychloroquine ,  chloroquine ,  mefloquine ,  atazanavir ( boosted with ritonavir )  ,  tipranavir ( boosted with ritonavir )  ,  ivermectin ,  azithromycin and lopinavir ( boosted with ritonavir )  were all predicted to achieve lung concentrations over 10 - fold higher than their reported ec50.']",'Prioritisation of potential anti-SARS-CoV-2 drug repurposing opportunities based on ability to achieve adequate target site concentrations derived from their established human pharmacokinetics','10.1101/2020.04.16.20068379',"[[' moreover ,  most publications have focussed on 50% maximum effective concentrations ( ec50 )  ,  which may be an insufficiently robust indicator of antiviral activity because of marked differences in the slope of the concentration - response curve between drugs.', ' for all drugs reported ,  the unbound lung to plasma tissue partition coefficient ( kpulung )  was also simulated and used along with reported cmax and fraction unbound in plasma to derive a lung cmax ec50 as a better indicator of potential human efficacy ( lung cmax ec90 ratio was also calculable for a limited number of drugs ) .', ' using this parameter hydroxychloroquine ,  chloroquine ,  mefloquine ,  atazanavir ( boosted with ritonavir )  ,  tipranavir ( boosted with ritonavir )  ,  ivermectin ,  azithromycin and lopinavir ( boosted with ritonavir )  were all predicted to achieve lung concentrations over 10 - fold higher than their reported ec50.', ' this analysis was not possible for nelfinavir because insufficient data were available to calculate kpulung but nitozoxanide and sulfadoxine were also predicted to exceed their reported ec50 by 3.1 -  and 1.5 - fold in lung ,  respectively.']]"
nelfinavir,"[' a more in - depth assessment of these drugs demonstrated that only nitazoxanide ,  nelfinavir ,  tipranavir ( boosted with ritonavir )  and sulfadoxine achieved plasma concentrations above their anti - sars - cov - 2 activity across their entire approved dosing interval at their approved human dose.', ' this analysis was not possible for nelfinavir because insufficient data were available to calculate kpulung but nitozoxanide and sulfadoxine were also predicted to exceed their reported ec50 by 3.']",'Prioritisation of potential anti-SARS-CoV-2 drug repurposing opportunities based on ability to achieve adequate target site concentrations derived from their established human pharmacokinetics','10.1101/2020.04.16.20068379',"[[' moreover ,  most publications have focussed on 50% maximum effective concentrations ( ec50 )  ,  which may be an insufficiently robust indicator of antiviral activity because of marked differences in the slope of the concentration - response curve between drugs.', ' for all drugs reported ,  the unbound lung to plasma tissue partition coefficient ( kpulung )  was also simulated and used along with reported cmax and fraction unbound in plasma to derive a lung cmax ec50 as a better indicator of potential human efficacy ( lung cmax ec90 ratio was also calculable for a limited number of drugs ) .', ' using this parameter hydroxychloroquine ,  chloroquine ,  mefloquine ,  atazanavir ( boosted with ritonavir )  ,  tipranavir ( boosted with ritonavir )  ,  ivermectin ,  azithromycin and lopinavir ( boosted with ritonavir )  were all predicted to achieve lung concentrations over 10 - fold higher than their reported ec50.', ' this analysis was not possible for nelfinavir because insufficient data were available to calculate kpulung but nitozoxanide and sulfadoxine were also predicted to exceed their reported ec50 by 3.1 -  and 1.5 - fold in lung ,  respectively.']]"
ritonavir,"[' a more in - depth assessment of these drugs demonstrated that only nitazoxanide ,  nelfinavir ,  tipranavir ( boosted with ritonavir )  and sulfadoxine achieved plasma concentrations above their anti - sars - cov - 2 activity across their entire approved dosing interval at their approved human dose.', ' using this parameter hydroxychloroquine ,  chloroquine ,  mefloquine ,  atazanavir ( boosted with ritonavir )  ,  tipranavir ( boosted with ritonavir )  ,  ivermectin ,  azithromycin and lopinavir ( boosted with ritonavir )  were all predicted to achieve lung concentrations over 10 - fold higher than their reported ec50.']",'Prioritisation of potential anti-SARS-CoV-2 drug repurposing opportunities based on ability to achieve adequate target site concentrations derived from their established human pharmacokinetics','10.1101/2020.04.16.20068379',"[[' moreover ,  most publications have focussed on 50% maximum effective concentrations ( ec50 )  ,  which may be an insufficiently robust indicator of antiviral activity because of marked differences in the slope of the concentration - response curve between drugs.', ' for all drugs reported ,  the unbound lung to plasma tissue partition coefficient ( kpulung )  was also simulated and used along with reported cmax and fraction unbound in plasma to derive a lung cmax ec50 as a better indicator of potential human efficacy ( lung cmax ec90 ratio was also calculable for a limited number of drugs ) .', ' using this parameter hydroxychloroquine ,  chloroquine ,  mefloquine ,  atazanavir ( boosted with ritonavir )  ,  tipranavir ( boosted with ritonavir )  ,  ivermectin ,  azithromycin and lopinavir ( boosted with ritonavir )  were all predicted to achieve lung concentrations over 10 - fold higher than their reported ec50.', ' this analysis was not possible for nelfinavir because insufficient data were available to calculate kpulung but nitozoxanide and sulfadoxine were also predicted to exceed their reported ec50 by 3.1 -  and 1.5 - fold in lung ,  respectively.']]"
ivermectin,"[' using this parameter hydroxychloroquine ,  chloroquine ,  mefloquine ,  atazanavir ( boosted with ritonavir )  ,  tipranavir ( boosted with ritonavir )  ,  ivermectin ,  azithromycin and lopinavir ( boosted with ritonavir )  were all predicted to achieve lung concentrations over 10 - fold higher than their reported ec50.']",'Prioritisation of potential anti-SARS-CoV-2 drug repurposing opportunities based on ability to achieve adequate target site concentrations derived from their established human pharmacokinetics','10.1101/2020.04.16.20068379',"[[' moreover ,  most publications have focussed on 50% maximum effective concentrations ( ec50 )  ,  which may be an insufficiently robust indicator of antiviral activity because of marked differences in the slope of the concentration - response curve between drugs.', ' for all drugs reported ,  the unbound lung to plasma tissue partition coefficient ( kpulung )  was also simulated and used along with reported cmax and fraction unbound in plasma to derive a lung cmax ec50 as a better indicator of potential human efficacy ( lung cmax ec90 ratio was also calculable for a limited number of drugs ) .', ' using this parameter hydroxychloroquine ,  chloroquine ,  mefloquine ,  atazanavir ( boosted with ritonavir )  ,  tipranavir ( boosted with ritonavir )  ,  ivermectin ,  azithromycin and lopinavir ( boosted with ritonavir )  were all predicted to achieve lung concentrations over 10 - fold higher than their reported ec50.', ' this analysis was not possible for nelfinavir because insufficient data were available to calculate kpulung but nitozoxanide and sulfadoxine were also predicted to exceed their reported ec50 by 3.1 -  and 1.5 - fold in lung ,  respectively.']]"
sulfadoxine,"[' a more in - depth assessment of these drugs demonstrated that only nitazoxanide ,  nelfinavir ,  tipranavir ( boosted with ritonavir )  and sulfadoxine achieved plasma concentrations above their anti - sars - cov - 2 activity across their entire approved dosing interval at their approved human dose.', ' this analysis was not possible for nelfinavir because insufficient data were available to calculate kpulung but nitozoxanide and sulfadoxine were also predicted to exceed their reported ec50 by 3.']",'Prioritisation of potential anti-SARS-CoV-2 drug repurposing opportunities based on ability to achieve adequate target site concentrations derived from their established human pharmacokinetics','10.1101/2020.04.16.20068379',"[[' moreover ,  most publications have focussed on 50% maximum effective concentrations ( ec50 )  ,  which may be an insufficiently robust indicator of antiviral activity because of marked differences in the slope of the concentration - response curve between drugs.', ' for all drugs reported ,  the unbound lung to plasma tissue partition coefficient ( kpulung )  was also simulated and used along with reported cmax and fraction unbound in plasma to derive a lung cmax ec50 as a better indicator of potential human efficacy ( lung cmax ec90 ratio was also calculable for a limited number of drugs ) .', ' using this parameter hydroxychloroquine ,  chloroquine ,  mefloquine ,  atazanavir ( boosted with ritonavir )  ,  tipranavir ( boosted with ritonavir )  ,  ivermectin ,  azithromycin and lopinavir ( boosted with ritonavir )  were all predicted to achieve lung concentrations over 10 - fold higher than their reported ec50.', ' this analysis was not possible for nelfinavir because insufficient data were available to calculate kpulung but nitozoxanide and sulfadoxine were also predicted to exceed their reported ec50 by 3.1 -  and 1.5 - fold in lung ,  respectively.']]"
nitazoxanide,"[' a more in - depth assessment of these drugs demonstrated that only nitazoxanide ,  nelfinavir ,  tipranavir ( boosted with ritonavir )  and sulfadoxine achieved plasma concentrations above their anti - sars - cov - 2 activity across their entire approved dosing interval at their approved human dose.']",'Prioritisation of potential anti-SARS-CoV-2 drug repurposing opportunities based on ability to achieve adequate target site concentrations derived from their established human pharmacokinetics','10.1101/2020.04.16.20068379',"[[' moreover ,  most publications have focussed on 50% maximum effective concentrations ( ec50 )  ,  which may be an insufficiently robust indicator of antiviral activity because of marked differences in the slope of the concentration - response curve between drugs.', ' for all drugs reported ,  the unbound lung to plasma tissue partition coefficient ( kpulung )  was also simulated and used along with reported cmax and fraction unbound in plasma to derive a lung cmax ec50 as a better indicator of potential human efficacy ( lung cmax ec90 ratio was also calculable for a limited number of drugs ) .', ' using this parameter hydroxychloroquine ,  chloroquine ,  mefloquine ,  atazanavir ( boosted with ritonavir )  ,  tipranavir ( boosted with ritonavir )  ,  ivermectin ,  azithromycin and lopinavir ( boosted with ritonavir )  were all predicted to achieve lung concentrations over 10 - fold higher than their reported ec50.', ' this analysis was not possible for nelfinavir because insufficient data were available to calculate kpulung but nitozoxanide and sulfadoxine were also predicted to exceed their reported ec50 by 3.1 -  and 1.5 - fold in lung ,  respectively.']]"
azithromycin,"[' using this parameter hydroxychloroquine ,  chloroquine ,  mefloquine ,  atazanavir ( boosted with ritonavir )  ,  tipranavir ( boosted with ritonavir )  ,  ivermectin ,  azithromycin and lopinavir ( boosted with ritonavir )  were all predicted to achieve lung concentrations over 10 - fold higher than their reported ec50.']",'Prioritisation of potential anti-SARS-CoV-2 drug repurposing opportunities based on ability to achieve adequate target site concentrations derived from their established human pharmacokinetics','10.1101/2020.04.16.20068379',"[[' moreover ,  most publications have focussed on 50% maximum effective concentrations ( ec50 )  ,  which may be an insufficiently robust indicator of antiviral activity because of marked differences in the slope of the concentration - response curve between drugs.', ' for all drugs reported ,  the unbound lung to plasma tissue partition coefficient ( kpulung )  was also simulated and used along with reported cmax and fraction unbound in plasma to derive a lung cmax ec50 as a better indicator of potential human efficacy ( lung cmax ec90 ratio was also calculable for a limited number of drugs ) .', ' using this parameter hydroxychloroquine ,  chloroquine ,  mefloquine ,  atazanavir ( boosted with ritonavir )  ,  tipranavir ( boosted with ritonavir )  ,  ivermectin ,  azithromycin and lopinavir ( boosted with ritonavir )  were all predicted to achieve lung concentrations over 10 - fold higher than their reported ec50.', ' this analysis was not possible for nelfinavir because insufficient data were available to calculate kpulung but nitozoxanide and sulfadoxine were also predicted to exceed their reported ec50 by 3.1 -  and 1.5 - fold in lung ,  respectively.']]"
daclatasvir,"[' daclatasvir and sofosbuvir ( sfv )  are clinically approved direct - acting antivirals ( daa )  against hepatitis c virus ( hcv )  ,  with satisfactory safety profile.', ' in the hcv replicative cycle ,  daclatasvir and sfv target the viral enzymes ns5a and ns5b ,  respectively.', ' these characteristics of the hcv and sars - cov - 2 motivated us to further study the activity of daclatasvir and sfv against the new coronavirus.', ' daclatasvir consistently inhibited the production of infectious sars - cov - 2 virus particles in vero cells ,  in the hepatoma cell line huh - 7 and in type ii pneumocytes ( calu - 3 )  ,  with potencies of 0.', ' daclatasvir targeted early events during sars - cov - 2 replication cycle and prevented the induction of il - 6 and tnf -  ,  inflammatory mediators associated with the cytokine storm typical of sars - cov - 2 infection.', ' our data point to additional antiviral candidates ,  in especial daclatasvir ,  among drugs overlooked for covid - 19 ,  that could immediately enter clinical trials.']",'The in vitro antiviral activity of the anti-hepatitis C virus (HCV) drugs daclatasvir and sofosbuvir against SARS-CoV-2','10.1101/2020.06.15.153411',"[[' sofosbuvir ,  although inactive in vero cells ,  displayed ec50 values of 6.2 and 9.5 m in huh - 7 and calu - 3 cells ,  respectively.']]"
sofosbuvir,"[' daclatasvir and sofosbuvir ( sfv )  are clinically approved direct - acting antivirals ( daa )  against hepatitis c virus ( hcv )  ,  with satisfactory safety profile.', ' sofosbuvir ,  although inactive in vero cells ,  displayed ec50 values of 6.']",'The in vitro antiviral activity of the anti-hepatitis C virus (HCV) drugs daclatasvir and sofosbuvir against SARS-CoV-2','10.1101/2020.06.15.153411',"[[' sofosbuvir ,  although inactive in vero cells ,  displayed ec50 values of 6.2 and 9.5 m in huh - 7 and calu - 3 cells ,  respectively.']]"
nafamostat,[' comparative analysis of antiviral activities revealed that nafamostat is the most potent drug in human lung cells ( ic50 = 0.'],'Comparative analysis of antiviral efficacy of FDA-approved drugs against SARS-CoV-2 in human lung cells: Nafamostat is the most potent antiviral drug candidate','10.1101/2020.05.12.090035',[[' comparative analysis of antiviral activities revealed that nafamostat is the most potent drug in human lung cells ( ic50 = 0.0022{micro}m ) .']]
heparin,"[' as the spike protein has previously been shown to bind heparin ,  a soluble glycosaminoglycan ,  we used a flow cytometry assay to determine the effect of heparin on spike protein binding to rt4 cells.', ' unfractionated heparin inhibited spike protein binding with an ic50 value of <0.', '05u ml whereas two low molecular weight heparins were much less effective.', ' this suggests that heparin ,  particularly unfractionated forms ,  could be considered to reduce clinical manifestations of covid - 19 by inhibiting continuing viral infection.', ' despite the sensitivity to heparin ,  we found no evidence that host cell glycosaminoglycans such as heparan and chondroitin sulphates play a major role in spike protein attachment.']",'Unfractionated heparin potently inhibits the binding of SARS-CoV-2 spike protein to a human cell line','10.1101/2020.05.21.107870',[[' unfractionated heparin inhibited spike protein binding with an ic50 value of <0.05u ml whereas two low molecular weight heparins were much less effective.']]
chloroquine,"[' while it is known that chloroquine and hydroxychloroquine ,  extensively explored as clinical agents for covid - 19 ,  have multiple cellular effects including inhibiting autophagy ,  there are also dose - limiting toxicities in patients that make clearly establishing their potential mechanisms - of - action problematic.']",'The SARS-CoV-2 cytopathic effect is blocked with autophagy modulators','10.1101/2020.05.16.091520',"[[' in this work ,  we found that 6 of these compounds blocked the cytopathic effect of sars - cov - 2 in vero - e6 cells with ec50 values ranging from 2.0 to 13 m and selectivity indices ranging from 1.5 to >10 - fold.']]"
hydroxychloroquine,"[' while it is known that chloroquine and hydroxychloroquine ,  extensively explored as clinical agents for covid - 19 ,  have multiple cellular effects including inhibiting autophagy ,  there are also dose - limiting toxicities in patients that make clearly establishing their potential mechanisms - of - action problematic.']",'The SARS-CoV-2 cytopathic effect is blocked with autophagy modulators','10.1101/2020.05.16.091520',"[[' in this work ,  we found that 6 of these compounds blocked the cytopathic effect of sars - cov - 2 in vero - e6 cells with ec50 values ranging from 2.0 to 13 m and selectivity indices ranging from 1.5 to >10 - fold.']]"
angiotensin,"[' sars - cov - 2 relies on its spike protein ,  in particular the receptor binding domain ( rbd )  ,  to bind human cell receptor angiotensin - converting enzyme 2 ( ace2 )  for viral entry ,  and thus targeting rbd holds the promise for preventing sars - cov - 2 infection.']",'Blocking antibodies against SARS-CoV-2 RBD isolated from a phage display antibody library using a competitive biopanning strategy','10.1101/2020.04.19.049643',"[[' it was proved to competitively block the binding of rbd to ace2 protein ,  and potently inhibit sars - cov - 2 pseudovirus infection of ace2 - overexpressing hela cells with ic50 values of 12nm.']]"
boceprevir,"[' using the fret - based enzymatic assay ,  several inhibitors including boceprevir ,  gc - 376 ,  and calpain inhibitors ii ,  and xii were identified to have potent activity with single - digit to submicromolar ic50 values in the enzymatic assay.', ' significantly ,  four compounds ( boceprevir ,  gc - 376 ,  calpain inhibitors ii and xii )  inhibit sars - cov - 2 viral replication in cell culture with ec50 values ranging from 0.', ' notably ,  boceprevir ,  calpain inhibitors ii and xii represent novel chemotypes that are distinct from known mpro inhibitors.']","'Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease'",'10.1101/2020.04.20.051581',"[[' significantly ,  four compounds ( boceprevir ,  gc - 376 ,  calpain inhibitors ii and xii )  inhibit sars - cov - 2 viral replication in cell culture with ec50 values ranging from 0.49 to 3.37 m.'], [' using the fret - based enzymatic assay ,  several inhibitors including boceprevir ,  gc - 376 ,  and calpain inhibitors ii ,  and xii were identified to have potent activity with single - digit to submicromolar ic50 values in the enzymatic assay.']]"
teicoplanin,"[' we previously reported that teicoplanin ,  a glycopeptide antibiotic which has routinely been used in the clinic to treat bacterial infection with low toxicity ,  significantly inhibits the invasion of cells by ebola virus ,  sars - cov and mers - cov ,  via specifically inhibiting the activity of cathepsin l.', ' here ,  we tested the efficacy of teicoplanin against 2019 - ncov virus infection and found that teicoplanin potently prevents the entrance of 2019 - ncov - spike - pseudoviruses into the cytoplasm ,  with an ic50 of 1.', ' although the inhibitory effect upon the replication of wildtype viruses ex vivo and in vivo remains to be determined ,  our preliminary result indicates that the potential antiviral activity of teicoplanin could be applied for the treatment of 2019 - ncov virus infection.']",'Teicoplanin potently blocks the cell entry of 2019-nCoV','10.1101/2020.02.05.935387',"[[' here ,  we tested the efficacy of teicoplanin against 2019 - ncov virus infection and found that teicoplanin potently prevents the entrance of 2019 - ncov - spike - pseudoviruses into the cytoplasm ,  with an ic50 of 1.66 m.']]"
sulfate,"[' in competitive binding studies ,  the ic50 of heparin ,  tri - sulfated non - anticoagulant heparan sulfate ,  and non - anticoagulant low molecular weight heparin against sars - cov - 2 sgp binding to immobilized heparin were 0.', ' finally ,  unbiased computational ligand docking indicates that heparan sulfate interacts with the gag - binding motif at the s1 s2 site on each monomer interface in the trimeric sars - cov - 2 sgp ,  and at another site ( 453 - 459 ( yrlfrks )  )  when the receptor - binding domain is in an open conformation.']",'Glycosaminoglycan binding motif at S1/S2 proteolytic cleavage site on spike glycoprotein may facilitate novel coronavirus (SARS-CoV-2) host cell entry','10.1101/2020.04.14.041459',"[[' in competitive binding studies ,  the ic50 of heparin ,  tri - sulfated non - anticoagulant heparan sulfate ,  and non - anticoagulant low molecular weight heparin against sars - cov - 2 sgp binding to immobilized heparin were 0.056 m ,  0.12 m ,  and 26.4 m ,  respectively.']]"
heparin,"[' using a surface plasmon resonance direct binding assay ,  we found that both monomeric and trimeric sars - cov - 2 spike more tightly bind to immobilized heparin ( kd = 40 pm and 73 pm ,  respectively )  than the sars - cov and mers - cov sgps ( 500 nm and 1 nm ,  respectively ) .', ' in competitive binding studies ,  the ic50 of heparin ,  tri - sulfated non - anticoagulant heparan sulfate ,  and non - anticoagulant low molecular weight heparin against sars - cov - 2 sgp binding to immobilized heparin were 0.']",'Glycosaminoglycan binding motif at S1/S2 proteolytic cleavage site on spike glycoprotein may facilitate novel coronavirus (SARS-CoV-2) host cell entry','10.1101/2020.04.14.041459',"[[' in competitive binding studies ,  the ic50 of heparin ,  tri - sulfated non - anticoagulant heparan sulfate ,  and non - anticoagulant low molecular weight heparin against sars - cov - 2 sgp binding to immobilized heparin were 0.056 m ,  0.12 m ,  and 26.4 m ,  respectively.']]"
lopinavir,"[' therefore ,  it is urgently needed to identify effective antiviral agents for the treatment of this disease ,  and several approved drugs such as lopinavir have been evaluated.', '76 {micro}m respectively ,  the lowest of the nine hiv - 1 protease inhibitors including lopinavir.']",'Nelfinavir inhibits replication of severe acute respiratory syndrome coronavirus 2 in vitro.','10.1101/2020.04.06.026476',"[[' the effective concentrations for 50% and 90% inhibition ( ec50 and ec90 )  of nelfinavir were 1.13 {micro}m and 1.76 {micro}m respectively ,  the lowest of the nine hiv - 1 protease inhibitors including lopinavir.', ' the trough and peak serum concentrations of nelfinavir were three to six times higher than ec50 of this drug.']]"
nelfinavir,"[' here ,  we report that nelfinavir ,  an hiv - 1 protease inhibitor ,  potently inhibits replication of sars - cov - 2.', ' the effective concentrations for 50% and 90% inhibition ( ec50 and ec90 )  of nelfinavir were 1.', ' the trough and peak serum concentrations of nelfinavir were three to six times higher than ec50 of this drug.', ' these results suggest that nelfinavir is a potential candidate drug for the treatment of covid - 19 and should be assessed in patients with covid - 19.']",'Nelfinavir inhibits replication of severe acute respiratory syndrome coronavirus 2 in vitro.','10.1101/2020.04.06.026476',"[[' the effective concentrations for 50% and 90% inhibition ( ec50 and ec90 )  of nelfinavir were 1.13 {micro}m and 1.76 {micro}m respectively ,  the lowest of the nine hiv - 1 protease inhibitors including lopinavir.', ' the trough and peak serum concentrations of nelfinavir were three to six times higher than ec50 of this drug.']]"
teriflunomide,"[' this work demonstrates that both our self - designed candidates and old drugs ( leflunomide teriflunomide )  with dual actions of antiviral and immuno - repression may have clinical potentials not only to influenza but also to covid - 19 circulating worldwide ,  no matter such viruses mutate or not.']","'Novel and potent inhibitors targeting DHODH, a rate-limiting enzyme in de novo pyrimidine biosynthesis, are broad-spectrum antiviral against RNA viruses including newly emerged coronavirus SARS-CoV-2'",'10.1101/2020.03.11.983056',"[[' notably ,  s416 is reported to be the most potent inhibitor with an ec50 of 17nm and si value >5882 in sars - cov - 2 - infected cells so far.']]"
leflunomide,"[' this work demonstrates that both our self - designed candidates and old drugs ( leflunomide teriflunomide )  with dual actions of antiviral and immuno - repression may have clinical potentials not only to influenza but also to covid - 19 circulating worldwide ,  no matter such viruses mutate or not.']","'Novel and potent inhibitors targeting DHODH, a rate-limiting enzyme in de novo pyrimidine biosynthesis, are broad-spectrum antiviral against RNA viruses including newly emerged coronavirus SARS-CoV-2'",'10.1101/2020.03.11.983056',"[[' notably ,  s416 is reported to be the most potent inhibitor with an ec50 of 17nm and si value >5882 in sars - cov - 2 - infected cells so far.']]"
oseltamivir,[' we also proposed the drug combination of daa and hta was a promising strategy for anti - virus treatment and proved that s312 showed more advantageous than oseltamivir to treat advanced influenza diseases in severely infected animals.'],"'Novel and potent inhibitors targeting DHODH, a rate-limiting enzyme in de novo pyrimidine biosynthesis, are broad-spectrum antiviral against RNA viruses including newly emerged coronavirus SARS-CoV-2'",'10.1101/2020.03.11.983056',"[[' notably ,  s416 is reported to be the most potent inhibitor with an ec50 of 17nm and si value >5882 in sars - cov - 2 - infected cells so far.']]"
glutamine,"["" 'the main protease of coronaviruses and the 3c protease of enteroviruses share a similar active - site architecture and a unique requirement for glutamine in the p1 position of the substrate.""]",'Alpha-ketoamides as broad-spectrum inhibitors of coronavirus and enterovirus replication','10.1101/2020.02.10.936898',"[[' the best near - equipotent inhibitors ,  11u ( p2 = cyclopentylmethyl )  and 11r ( p2 = cyclohexylmethyl )  ,  display low - micromolar ec50 values against enteroviruses ,  alphacoronaviruses ,  and betacoronaviruses in cell cultures.']]"
remdesivir,"[' in particular ,  we discovered that lactoferrin is an effective inhibitor of sars - cov - 2 infection with an ic50 of 308 nm and that it potentiates the efficacy of both remdesivir and hydroxychloroquine.']",'Morphological Cell Profiling of SARS-CoV-2 Infection Identifies Drug Repurposing Candidates for COVID-19','10.1101/2020.05.27.117184',"[[' in particular ,  we discovered that lactoferrin is an effective inhibitor of sars - cov - 2 infection with an ic50 of 308 nm and that it potentiates the efficacy of both remdesivir and hydroxychloroquine.']]"
ivermectin,"["" 'introduction: caly ,  druce ( 1 )  reported that ivermectin inhibited sars - cov - 2 in vitro for up to 48 h using ivermectin at 5 um."", ' the concentration resulting in 50% inhibition ( ic50 ,  2 um )  was >35x higher than the maximum plasma concentration ( cmax )  after oral administration of the approved dose of ivermectin when given fasted.', ' method: simulations were conducted using an available population pharmacokinetic model to predict total ( bound and unbound )  and unbound plasma concentration - time profiles after a single and repeat fasted administration of the approved dose of ivermectin ( 200 ug kg )  ,  60 mg ,  and 120 mg.', ' results: plasma ivermectin concentrations of total ( bound and unbound )  and unbound concentrations do not reach the ic50 ,  even for a dose level 10x higher than the approved dose.', ' even with higher exposure in lungs than plasma ,  ivermectin is unlikely to reach the ic50 in lungs after single oral administration of the approved dose ( predicted lung: 0.', ' conclusions: the likelihood of a successful clinical trial using the approved dose of ivermectin is low.']",'The Approved Dose of Ivermectin Alone is not the Ideal Dose for the Treatment of COVID-19','10.1101/2020.04.21.20073262',"[[' the concentration resulting in 50% inhibition ( ic50 ,  2 um )  was >35x higher than the maximum plasma concentration ( cmax )  after oral administration of the approved dose of ivermectin when given fasted.', ' results: plasma ivermectin concentrations of total ( bound and unbound )  and unbound concentrations do not reach the ic50 ,  even for a dose level 10x higher than the approved dose.', ' even with higher exposure in lungs than plasma ,  ivermectin is unlikely to reach the ic50 in lungs after single oral administration of the approved dose ( predicted lung: 0.0857 um )  or at doses 10x higher that the approved dose administered orally ( predicted lung: 0.817 um ) .']]"
ebselen,"["" 'a collection of twelve organoselenium compounds ,  structural analogues of antioxidant drug ebselen were screened for inhibition of the papain - like protease ( plpro )  from the acute respiratory syndrome coronavirus 2 ( sars - cov - 2 ,  cov2 ) .""]",'Discovery of potent inhibitors of PLproCoV2 by screening libraries of selen-containing compounds','10.1101/2020.05.20.107052',"[[' here ,  we identified four strong inhibitors that bind favorably to the plpro cov2 with the ic50 in the nanomolar range.']]"
papain,"["" 'a collection of twelve organoselenium compounds ,  structural analogues of antioxidant drug ebselen were screened for inhibition of the papain - like protease ( plpro )  from the acute respiratory syndrome coronavirus 2 ( sars - cov - 2 ,  cov2 ) .""]",'Discovery of potent inhibitors of PLproCoV2 by screening libraries of selen-containing compounds','10.1101/2020.05.20.107052',"[[' here ,  we identified four strong inhibitors that bind favorably to the plpro cov2 with the ic50 in the nanomolar range.']]"
cysteine,"[' this cysteine protease ,  being responsible for the hydrolysis of peptide bonds between specific amino acids ,  plays a critical role in cov2 replication and in assembly of new viral particles within human cells.']",'Discovery of potent inhibitors of PLproCoV2 by screening libraries of selen-containing compounds','10.1101/2020.05.20.107052',"[[' here ,  we identified four strong inhibitors that bind favorably to the plpro cov2 with the ic50 in the nanomolar range.']]"
hydroxychloroquine,"["" 'chloroquine ( cq )  and hydroxychloroquine ( hcq )  have been used in treating covid - 19 patients recently.""]",'Cytotoxicity evaluation of chloroquine and hydroxychloroquine in multiple cell lines and tissues by dynamic imaging system and PBPK model','10.1101/2020.04.22.056762',"[[' cc50 and the ratio of tissue trough concentrations to cc50 ( rttcc )  were brought into predicted toxicity profiles.', ' the cc50 at 24 h ,  48 h ,  72 h of cq and hcq decreased in the time - dependent manner ,  which indicates the accumulative cytotoxic effect.', ' hcq was found to be less toxic in 7 cell types except cardiomyocytes h9c2 cells ( cc50 - 48 h=29.55 m; cc50 - 72 h=15.26 m ) .']]"
angiotensin,"[' the sars - cov - 2 spike glycoprotein ,  due to its primary interaction with the human angiotensin - converting enzyme 2 ( ace2 )  cell - surface receptor ,  is considered as a potential target for drug development.']",'Bcr-Abl tyrosine kinase inhibitor imatinib as a potential drug for COVID-19','10.1101/2020.06.18.158196',"[[' based on in silico screening followed by in vitro studies ,  here we report that the existing fda - approved bcr - abl tyrosine kinase inhibitor ,  imatinib ,  inhibits sars - cov - 2 with an ic50 of 130 nm.']]"
tyrosine,"[' based on in silico screening followed by in vitro studies ,  here we report that the existing fda - approved bcr - abl tyrosine kinase inhibitor ,  imatinib ,  inhibits sars - cov - 2 with an ic50 of 130 nm.']",'Bcr-Abl tyrosine kinase inhibitor imatinib as a potential drug for COVID-19','10.1101/2020.06.18.158196',"[[' based on in silico screening followed by in vitro studies ,  here we report that the existing fda - approved bcr - abl tyrosine kinase inhibitor ,  imatinib ,  inhibits sars - cov - 2 with an ic50 of 130 nm.']]"
imatinib,"[' based on in silico screening followed by in vitro studies ,  here we report that the existing fda - approved bcr - abl tyrosine kinase inhibitor ,  imatinib ,  inhibits sars - cov - 2 with an ic50 of 130 nm.', ' we provide initial evidence that inhibition of virus fusion may explain the antiviral action of imatinib.', ' to this end ,  we provide evidence that imatinib binds to the receptor - binding domain ( rbd )  of sars - cov - 2 spike protein with an affinity at micromolar ,  i.', ' we also show that imatinib inhibits other coronaviruses ,  sars - cov and mers - cov ,  possibly via fusion inhibition.', ' based on promising in vitro results ,  we propose the abl kinase inhibitor ( atki )  ,  imatinib ,  to be a viable repurposable drug candidate for further clinical validation against covid - 19.']",'Bcr-Abl tyrosine kinase inhibitor imatinib as a potential drug for COVID-19','10.1101/2020.06.18.158196',"[[' based on in silico screening followed by in vitro studies ,  here we report that the existing fda - approved bcr - abl tyrosine kinase inhibitor ,  imatinib ,  inhibits sars - cov - 2 with an ic50 of 130 nm.']]"
velpatasvir,"[' in contrast ,  most of the clinically approved antivirals ,  including tenofovir alafenamide ,  emtricitabine ,  sofosbuvir ,  ledipasvir ,  and velpatasvir were inactive at concentrations up to 10 m.']",'A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19','10.1101/2020.06.22.165712',"[[' when tested against this reporter virus ,  remdesivir exhibited substantially more potent activity in a549 - hace2 cells compared to vero e6 cells ( ec50 0.115 vs 1.28 m )  ,  while this difference was not observed for chloroquine ( ec50 1.32 vs 3.52 m )  ,  underscoring the importance of selecting appropriate cells for antiviral testing.', ' nelfinavir ,  rupintrivir ,  and cobicistat were identified as the most selective inhibitors of sars - cov - 2 - nluc ( ec50 0.77 to 2.74 m ) .']]"
chloroquine,"['28 m )  ,  while this difference was not observed for chloroquine ( ec50 1.']",'A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19','10.1101/2020.06.22.165712',"[[' when tested against this reporter virus ,  remdesivir exhibited substantially more potent activity in a549 - hace2 cells compared to vero e6 cells ( ec50 0.115 vs 1.28 m )  ,  while this difference was not observed for chloroquine ( ec50 1.32 vs 3.52 m )  ,  underscoring the importance of selecting appropriate cells for antiviral testing.', ' nelfinavir ,  rupintrivir ,  and cobicistat were identified as the most selective inhibitors of sars - cov - 2 - nluc ( ec50 0.77 to 2.74 m ) .']]"
ledipasvir,"[' in contrast ,  most of the clinically approved antivirals ,  including tenofovir alafenamide ,  emtricitabine ,  sofosbuvir ,  ledipasvir ,  and velpatasvir were inactive at concentrations up to 10 m.']",'A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19','10.1101/2020.06.22.165712',"[[' when tested against this reporter virus ,  remdesivir exhibited substantially more potent activity in a549 - hace2 cells compared to vero e6 cells ( ec50 0.115 vs 1.28 m )  ,  while this difference was not observed for chloroquine ( ec50 1.32 vs 3.52 m )  ,  underscoring the importance of selecting appropriate cells for antiviral testing.', ' nelfinavir ,  rupintrivir ,  and cobicistat were identified as the most selective inhibitors of sars - cov - 2 - nluc ( ec50 0.77 to 2.74 m ) .']]"
sofosbuvir,"[' in contrast ,  most of the clinically approved antivirals ,  including tenofovir alafenamide ,  emtricitabine ,  sofosbuvir ,  ledipasvir ,  and velpatasvir were inactive at concentrations up to 10 m.']",'A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19','10.1101/2020.06.22.165712',"[[' when tested against this reporter virus ,  remdesivir exhibited substantially more potent activity in a549 - hace2 cells compared to vero e6 cells ( ec50 0.115 vs 1.28 m )  ,  while this difference was not observed for chloroquine ( ec50 1.32 vs 3.52 m )  ,  underscoring the importance of selecting appropriate cells for antiviral testing.', ' nelfinavir ,  rupintrivir ,  and cobicistat were identified as the most selective inhibitors of sars - cov - 2 - nluc ( ec50 0.77 to 2.74 m ) .']]"
remdesivir,"[' when tested against this reporter virus ,  remdesivir exhibited substantially more potent activity in a549 - hace2 cells compared to vero e6 cells ( ec50 0.']",'A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19','10.1101/2020.06.22.165712',"[[' when tested against this reporter virus ,  remdesivir exhibited substantially more potent activity in a549 - hace2 cells compared to vero e6 cells ( ec50 0.115 vs 1.28 m )  ,  while this difference was not observed for chloroquine ( ec50 1.32 vs 3.52 m )  ,  underscoring the importance of selecting appropriate cells for antiviral testing.', ' nelfinavir ,  rupintrivir ,  and cobicistat were identified as the most selective inhibitors of sars - cov - 2 - nluc ( ec50 0.77 to 2.74 m ) .']]"
cobicistat,"[' nelfinavir ,  rupintrivir ,  and cobicistat were identified as the most selective inhibitors of sars - cov - 2 - nluc ( ec50 0.']",'A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19','10.1101/2020.06.22.165712',"[[' when tested against this reporter virus ,  remdesivir exhibited substantially more potent activity in a549 - hace2 cells compared to vero e6 cells ( ec50 0.115 vs 1.28 m )  ,  while this difference was not observed for chloroquine ( ec50 1.32 vs 3.52 m )  ,  underscoring the importance of selecting appropriate cells for antiviral testing.', ' nelfinavir ,  rupintrivir ,  and cobicistat were identified as the most selective inhibitors of sars - cov - 2 - nluc ( ec50 0.77 to 2.74 m ) .']]"
rupintrivir,"[' nelfinavir ,  rupintrivir ,  and cobicistat were identified as the most selective inhibitors of sars - cov - 2 - nluc ( ec50 0.']",'A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19','10.1101/2020.06.22.165712',"[[' when tested against this reporter virus ,  remdesivir exhibited substantially more potent activity in a549 - hace2 cells compared to vero e6 cells ( ec50 0.115 vs 1.28 m )  ,  while this difference was not observed for chloroquine ( ec50 1.32 vs 3.52 m )  ,  underscoring the importance of selecting appropriate cells for antiviral testing.', ' nelfinavir ,  rupintrivir ,  and cobicistat were identified as the most selective inhibitors of sars - cov - 2 - nluc ( ec50 0.77 to 2.74 m ) .']]"
nelfinavir,"[' nelfinavir ,  rupintrivir ,  and cobicistat were identified as the most selective inhibitors of sars - cov - 2 - nluc ( ec50 0.']",'A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19','10.1101/2020.06.22.165712',"[[' when tested against this reporter virus ,  remdesivir exhibited substantially more potent activity in a549 - hace2 cells compared to vero e6 cells ( ec50 0.115 vs 1.28 m )  ,  while this difference was not observed for chloroquine ( ec50 1.32 vs 3.52 m )  ,  underscoring the importance of selecting appropriate cells for antiviral testing.', ' nelfinavir ,  rupintrivir ,  and cobicistat were identified as the most selective inhibitors of sars - cov - 2 - nluc ( ec50 0.77 to 2.74 m ) .']]"
tenofovir,"[' in contrast ,  most of the clinically approved antivirals ,  including tenofovir alafenamide ,  emtricitabine ,  sofosbuvir ,  ledipasvir ,  and velpatasvir were inactive at concentrations up to 10 m.']",'A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19','10.1101/2020.06.22.165712',"[[' when tested against this reporter virus ,  remdesivir exhibited substantially more potent activity in a549 - hace2 cells compared to vero e6 cells ( ec50 0.115 vs 1.28 m )  ,  while this difference was not observed for chloroquine ( ec50 1.32 vs 3.52 m )  ,  underscoring the importance of selecting appropriate cells for antiviral testing.', ' nelfinavir ,  rupintrivir ,  and cobicistat were identified as the most selective inhibitors of sars - cov - 2 - nluc ( ec50 0.77 to 2.74 m ) .']]"
emtricitabine,"[' in contrast ,  most of the clinically approved antivirals ,  including tenofovir alafenamide ,  emtricitabine ,  sofosbuvir ,  ledipasvir ,  and velpatasvir were inactive at concentrations up to 10 m.']",'A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19','10.1101/2020.06.22.165712',"[[' when tested against this reporter virus ,  remdesivir exhibited substantially more potent activity in a549 - hace2 cells compared to vero e6 cells ( ec50 0.115 vs 1.28 m )  ,  while this difference was not observed for chloroquine ( ec50 1.32 vs 3.52 m )  ,  underscoring the importance of selecting appropriate cells for antiviral testing.', ' nelfinavir ,  rupintrivir ,  and cobicistat were identified as the most selective inhibitors of sars - cov - 2 - nluc ( ec50 0.77 to 2.74 m ) .']]"
nafamostat,"[' we demonstrate effectiveness to quantify inhibition down to subnanomolar concentrations by assessing the inhibition of camostat ,  nafamostat and gabexate ,  clinically approved agents in japan for pancreatitis due to their inhibition of trypsin - like proteases.', ' nafamostat and camostat are currently in clinical trials against covid19.', ' the rank order potency for the three inhibitors is: nafamostat ( ic50 = 0.']",'An Enzymatic TMPRSS2 Assay for Assessment of Clinical Candidates and Discovery of Inhibitors as Potential Treatment of COVID-19','10.1101/2020.06.23.167544',"[[' the rank order potency for the three inhibitors is: nafamostat ( ic50 = 0.27 nm )  ,  camostat ( ic50 = 6.2 nm )  and gabexate ( ic50 = 130 nm ) .']]"
camostat,"[' we demonstrate effectiveness to quantify inhibition down to subnanomolar concentrations by assessing the inhibition of camostat ,  nafamostat and gabexate ,  clinically approved agents in japan for pancreatitis due to their inhibition of trypsin - like proteases.', ' nafamostat and camostat are currently in clinical trials against covid19.', '27 nm )  ,  camostat ( ic50 = 6.']",'An Enzymatic TMPRSS2 Assay for Assessment of Clinical Candidates and Discovery of Inhibitors as Potential Treatment of COVID-19','10.1101/2020.06.23.167544',"[[' the rank order potency for the three inhibitors is: nafamostat ( ic50 = 0.27 nm )  ,  camostat ( ic50 = 6.2 nm )  and gabexate ( ic50 = 130 nm ) .']]"
gabexate,"[' we demonstrate effectiveness to quantify inhibition down to subnanomolar concentrations by assessing the inhibition of camostat ,  nafamostat and gabexate ,  clinically approved agents in japan for pancreatitis due to their inhibition of trypsin - like proteases.', '2 nm )  and gabexate ( ic50 = 130 nm ) .']",'An Enzymatic TMPRSS2 Assay for Assessment of Clinical Candidates and Discovery of Inhibitors as Potential Treatment of COVID-19','10.1101/2020.06.23.167544',"[[' the rank order potency for the three inhibitors is: nafamostat ( ic50 = 0.27 nm )  ,  camostat ( ic50 = 6.2 nm )  and gabexate ( ic50 = 130 nm ) .']]"
trypsin,"[' we demonstrate effectiveness to quantify inhibition down to subnanomolar concentrations by assessing the inhibition of camostat ,  nafamostat and gabexate ,  clinically approved agents in japan for pancreatitis due to their inhibition of trypsin - like proteases.']",'An Enzymatic TMPRSS2 Assay for Assessment of Clinical Candidates and Discovery of Inhibitors as Potential Treatment of COVID-19','10.1101/2020.06.23.167544',"[[' the rank order potency for the three inhibitors is: nafamostat ( ic50 = 0.27 nm )  ,  camostat ( ic50 = 6.2 nm )  and gabexate ( ic50 = 130 nm ) .']]"
remdesivir,"[' for the first time ,  our study discovered that pralatrexate is able to potently inhibit sars - cov - 2 replication with a stronger inhibitory activity than remdesivir within the same experimental conditions.']",FDA-approved Pralatrexate and Azithromycin identified by virtual drug screening inhibit SARS-CoV-2 replication in vitro,10.21203/rs.3.rs-36439/v1,"[[' among the four selected fda - approved drug candidates ,  pralatrexate and azithromycin were confirmed to effectively inhibit sars - cov - 2 replication in vitro with ec50 values of 0.008um and 9.453 um ,  respectively.']]"
azithromycin,"[' among the four selected fda - approved drug candidates ,  pralatrexate and azithromycin were confirmed to effectively inhibit sars - cov - 2 replication in vitro with ec50 values of 0.']",FDA-approved Pralatrexate and Azithromycin identified by virtual drug screening inhibit SARS-CoV-2 replication in vitro,10.21203/rs.3.rs-36439/v1,"[[' among the four selected fda - approved drug candidates ,  pralatrexate and azithromycin were confirmed to effectively inhibit sars - cov - 2 replication in vitro with ec50 values of 0.008um and 9.453 um ,  respectively.']]"
pralatrexate,"[' among the four selected fda - approved drug candidates ,  pralatrexate and azithromycin were confirmed to effectively inhibit sars - cov - 2 replication in vitro with ec50 values of 0.', ' for the first time ,  our study discovered that pralatrexate is able to potently inhibit sars - cov - 2 replication with a stronger inhibitory activity than remdesivir within the same experimental conditions.']",FDA-approved Pralatrexate and Azithromycin identified by virtual drug screening inhibit SARS-CoV-2 replication in vitro,10.21203/rs.3.rs-36439/v1,"[[' among the four selected fda - approved drug candidates ,  pralatrexate and azithromycin were confirmed to effectively inhibit sars - cov - 2 replication in vitro with ec50 values of 0.008um and 9.453 um ,  respectively.']]"
serotonin,"[' fluoxetine is a racemate consisting of both stereoisomers ,  while the s - form is the dominant serotonin reuptake inhibitor.']",The serotonin reuptake inhibitor Fluoxetine inhibits SARS-CoV-2,10.1101/2020.06.14.150490,"[['8ug ml significantly ,  and the ec50 was determined with 387ng ml.']]"
fluoxetine,"[' in these screenings ,  fluoxetine inhibited sars - cov - 2 at a concentration of 0.', ' fluoxetine is a racemate consisting of both stereoisomers ,  while the s - form is the dominant serotonin reuptake inhibitor.', ' fluoxetine treatment resulted in a decrease in viral protein expression.', ' furthermore ,  fluoxetine inhibited neither rabies virus ,  human respiratory syncytial virus replication nor the human herpesvirus 8 or herpes simplex virus type 1 gene expression ,  indicating that it acts virus - specific.', ' we see the role of fluoxetine in the early treatment of sars - cov - 2 infected patients of risk groups.']",The serotonin reuptake inhibitor Fluoxetine inhibits SARS-CoV-2,10.1101/2020.06.14.150490,"[['8ug ml significantly ,  and the ec50 was determined with 387ng ml.']]"
serine,"[' the aim of this study was to investigate the molecular interactions between monoterpenoids and spike protein of 2019 - ncov together with the cellular proteases [transmembrane serine protease 2 ( tmprss2 )  ,  cathepsin b ( catb )  ,  and cathepsin l ( catl ) ].']","Interaction of certain monoterpenoid hydrocarbons with the receptor-binding domain of 2019 novel coronavirus (2019-nCoV), transmembrane serine protease 2 (TMPRSS2), cathepsin B, and cathepsin L (CatB/L) and their pharmacokinetic properties",10.3906/biy-2005-46,"[[' as a result of the relative binding capacity index ( rbci )  analysis ,  carvone was found to be the most effective molecule against all targets when binding energy and predicted ( theoretical )  ic50 data were evaluated together.']]"
camostat,"[' compared to the inhibitor camostat mesylate ( 26000 ng ml )  ,  it is 270 times more potent.']","Metadichol a novel nano lipid formulation that inhibits In Vitro, SARS-COV-2 and a multitude of pathological viruses",10.21203/rs.3.rs-34021/v1,"[['\xa0< p><p>\xa0metadichol ,  a nano lipid formulation of long - chain alcohols ,  has been shown to inhibit tmprss2 ( ec50 of 96 ng ml ) .']]"
serine,[' sars - cov - 2 uses the receptor ace2 for entry and the serine protease tmprss2 for s protein priming.'],"Metadichol a novel nano lipid formulation that inhibits In Vitro, SARS-COV-2 and a multitude of pathological viruses",10.21203/rs.3.rs-34021/v1,"[['\xa0< p><p>\xa0metadichol ,  a nano lipid formulation of long - chain alcohols ,  has been shown to inhibit tmprss2 ( ec50 of 96 ng ml ) .']]"
baicalin,"['< p><p><strong>results: < strong>six phytochemicals: baicalin ,  rutin ,  biopterin ,  licoleafol ,  luteolin and quercetin shows stable bonding pattern with the target in compare to known inhibitors as it shows least score in docking ,  forms maximum number of hydrogen bonds with the active residues of the receptor.']",Search for therapeutics against COVID 19 targeting SARS-CoV-2 papain-like protease: an in silico study,10.21203/rs.3.rs-33294/v1,"[[' the predicted ic50 values of the phytochemicals are also better than the known inhibitors.', '< p><p><strong>conclusion: < strong>based on present observation of docking score of both phytochemicals and known inhibitors ,  ic50 value of known inhibitors and predicted ic50 of phytochemicals ,  we suggests above mentioned six phytochemicals may be the papain - like protease ( plpro )  targeted\xa0potent drug leads against covid - 19.']]"
rutin,"['< p><p><strong>results: < strong>six phytochemicals: baicalin ,  rutin ,  biopterin ,  licoleafol ,  luteolin and quercetin shows stable bonding pattern with the target in compare to known inhibitors as it shows least score in docking ,  forms maximum number of hydrogen bonds with the active residues of the receptor.']",Search for therapeutics against COVID 19 targeting SARS-CoV-2 papain-like protease: an in silico study,10.21203/rs.3.rs-33294/v1,"[[' the predicted ic50 values of the phytochemicals are also better than the known inhibitors.', '< p><p><strong>conclusion: < strong>based on present observation of docking score of both phytochemicals and known inhibitors ,  ic50 value of known inhibitors and predicted ic50 of phytochemicals ,  we suggests above mentioned six phytochemicals may be the papain - like protease ( plpro )  targeted\xa0potent drug leads against covid - 19.']]"
cysteine,[' papain - like protease ( plpro )  of sars cov - 2 is an important target of covid - 19 because it is a multifunctional cysteine protease essential for coronaviral replication.'],Search for therapeutics against COVID 19 targeting SARS-CoV-2 papain-like protease: an in silico study,10.21203/rs.3.rs-33294/v1,"[[' the predicted ic50 values of the phytochemicals are also better than the known inhibitors.', '< p><p><strong>conclusion: < strong>based on present observation of docking score of both phytochemicals and known inhibitors ,  ic50 value of known inhibitors and predicted ic50 of phytochemicals ,  we suggests above mentioned six phytochemicals may be the papain - like protease ( plpro )  targeted\xa0potent drug leads against covid - 19.']]"
quercetin,"['< p><p><strong>results: < strong>six phytochemicals: baicalin ,  rutin ,  biopterin ,  licoleafol ,  luteolin and quercetin shows stable bonding pattern with the target in compare to known inhibitors as it shows least score in docking ,  forms maximum number of hydrogen bonds with the active residues of the receptor.']",Search for therapeutics against COVID 19 targeting SARS-CoV-2 papain-like protease: an in silico study,10.21203/rs.3.rs-33294/v1,"[[' the predicted ic50 values of the phytochemicals are also better than the known inhibitors.', '< p><p><strong>conclusion: < strong>based on present observation of docking score of both phytochemicals and known inhibitors ,  ic50 value of known inhibitors and predicted ic50 of phytochemicals ,  we suggests above mentioned six phytochemicals may be the papain - like protease ( plpro )  targeted\xa0potent drug leads against covid - 19.']]"
biopterin,"['< p><p><strong>results: < strong>six phytochemicals: baicalin ,  rutin ,  biopterin ,  licoleafol ,  luteolin and quercetin shows stable bonding pattern with the target in compare to known inhibitors as it shows least score in docking ,  forms maximum number of hydrogen bonds with the active residues of the receptor.']",Search for therapeutics against COVID 19 targeting SARS-CoV-2 papain-like protease: an in silico study,10.21203/rs.3.rs-33294/v1,"[[' the predicted ic50 values of the phytochemicals are also better than the known inhibitors.', '< p><p><strong>conclusion: < strong>based on present observation of docking score of both phytochemicals and known inhibitors ,  ic50 value of known inhibitors and predicted ic50 of phytochemicals ,  we suggests above mentioned six phytochemicals may be the papain - like protease ( plpro )  targeted\xa0potent drug leads against covid - 19.']]"
luteolin,"['< p><p><strong>results: < strong>six phytochemicals: baicalin ,  rutin ,  biopterin ,  licoleafol ,  luteolin and quercetin shows stable bonding pattern with the target in compare to known inhibitors as it shows least score in docking ,  forms maximum number of hydrogen bonds with the active residues of the receptor.']",Search for therapeutics against COVID 19 targeting SARS-CoV-2 papain-like protease: an in silico study,10.21203/rs.3.rs-33294/v1,"[[' the predicted ic50 values of the phytochemicals are also better than the known inhibitors.', '< p><p><strong>conclusion: < strong>based on present observation of docking score of both phytochemicals and known inhibitors ,  ic50 value of known inhibitors and predicted ic50 of phytochemicals ,  we suggests above mentioned six phytochemicals may be the papain - like protease ( plpro )  targeted\xa0potent drug leads against covid - 19.']]"
hydrogen,"['< p><p><strong>results: < strong>six phytochemicals: baicalin ,  rutin ,  biopterin ,  licoleafol ,  luteolin and quercetin shows stable bonding pattern with the target in compare to known inhibitors as it shows least score in docking ,  forms maximum number of hydrogen bonds with the active residues of the receptor.']",Search for therapeutics against COVID 19 targeting SARS-CoV-2 papain-like protease: an in silico study,10.21203/rs.3.rs-33294/v1,"[[' the predicted ic50 values of the phytochemicals are also better than the known inhibitors.', '< p><p><strong>conclusion: < strong>based on present observation of docking score of both phytochemicals and known inhibitors ,  ic50 value of known inhibitors and predicted ic50 of phytochemicals ,  we suggests above mentioned six phytochemicals may be the papain - like protease ( plpro )  targeted\xa0potent drug leads against covid - 19.']]"
papain,"[' papain - like protease ( plpro )  of sars cov - 2 is an important target of covid - 19 because it is a multifunctional cysteine protease essential for coronaviral replication.', ' reported inhibitors of the papain - like protease are taken as control and for qsar study.', ' inhibitors of the papain - like protease were taken from binding database and qsar analysis was performed by using easyqsar software.', '< p><p><strong>conclusion: < strong>based on present observation of docking score of both phytochemicals and known inhibitors ,  ic50 value of known inhibitors and predicted ic50 of phytochemicals ,  we suggests above mentioned six phytochemicals may be the papain - like protease ( plpro )  targeted\xa0potent drug leads against covid - 19.']",Search for therapeutics against COVID 19 targeting SARS-CoV-2 papain-like protease: an in silico study,10.21203/rs.3.rs-33294/v1,"[[' the predicted ic50 values of the phytochemicals are also better than the known inhibitors.', '< p><p><strong>conclusion: < strong>based on present observation of docking score of both phytochemicals and known inhibitors ,  ic50 value of known inhibitors and predicted ic50 of phytochemicals ,  we suggests above mentioned six phytochemicals may be the papain - like protease ( plpro )  targeted\xa0potent drug leads against covid - 19.']]"
vortioxetine,"[' four compounds ,  clomiphene ( citrate )  ,  vortioxetine ,  vortioxetine ( hydrobromide )  and asenapine ( hydrochloride )  ,  showed potent inhibitory effects in both pseudovirus and authentic virus assay.', ' the combination of clomiphene ( citrate )  ,  vortioxetine and asenapine ( hydrochloride )  is much more potent than used alone ,  with ic50 of 0.']",Several FDA-approved drugs effectively inhibit SARS-CoV-2 infection in vitro,10.1101/2020.06.05.135996,"[[' the combination of clomiphene ( citrate )  ,  vortioxetine and asenapine ( hydrochloride )  is much more potent than used alone ,  with ic50 of 0.34 m.']]"
clomiphene,"[' four compounds ,  clomiphene ( citrate )  ,  vortioxetine ,  vortioxetine ( hydrobromide )  and asenapine ( hydrochloride )  ,  showed potent inhibitory effects in both pseudovirus and authentic virus assay.', ' the combination of clomiphene ( citrate )  ,  vortioxetine and asenapine ( hydrochloride )  is much more potent than used alone ,  with ic50 of 0.']",Several FDA-approved drugs effectively inhibit SARS-CoV-2 infection in vitro,10.1101/2020.06.05.135996,"[[' the combination of clomiphene ( citrate )  ,  vortioxetine and asenapine ( hydrochloride )  is much more potent than used alone ,  with ic50 of 0.34 m.']]"
asenapine,"[' four compounds ,  clomiphene ( citrate )  ,  vortioxetine ,  vortioxetine ( hydrobromide )  and asenapine ( hydrochloride )  ,  showed potent inhibitory effects in both pseudovirus and authentic virus assay.', ' the combination of clomiphene ( citrate )  ,  vortioxetine and asenapine ( hydrochloride )  is much more potent than used alone ,  with ic50 of 0.']",Several FDA-approved drugs effectively inhibit SARS-CoV-2 infection in vitro,10.1101/2020.06.05.135996,"[[' the combination of clomiphene ( citrate )  ,  vortioxetine and asenapine ( hydrochloride )  is much more potent than used alone ,  with ic50 of 0.34 m.']]"
ribavirin,"[' it has been shown that the test substance exhibits high antiviral activity against the influenza a virus h1n1 california  07 2009 with effective concentration of ec50 0 , 6 g ml and the selectivity index si > 170 ( for ribavirin si > 160 and amizona si > 2 , 1 ) .']","Synthesis and antiviral activity of 4,6-bis-ethylamino[1,3,5]triazine derivatives for Flu A (H1N1) virus California/07/2009",10.33250/14.02.106,"[[' it has been shown that the test substance exhibits high antiviral activity against the influenza a virus h1n1 california  07 2009 with effective concentration of ec50 0 , 6 g ml and the selectivity index si > 170 ( for ribavirin si > 160 and amizona si > 2 , 1 ) .']]"
acetamide,"[' the aim of research is to synthesize the derivatives of ( 4 , 6 - bis - amino[1 , 3 , 5]triazin - 2 - yl - sulphanyl )  - naryl - acetamide and to study the antiviral activity for flua ( h1n1 )  virus california 07 2009 at primary pharmacological screening stage.', ' the investigated compounds  ( 4 , 6 - bis - amino[1 , 3 , 5]triazin - 2 - yl - sulphanyl )  - n - aryl - acetamide derivatives ,  were synthesized on the basis of 4 , 6 - bis - ethylamino[1 ,  3 , 5]triazin - 2 - tiol.', ' the antiviral activity of ( 4 , 6 - bis - amino[1 , 3 , 5]triazin - 2 - yl - sulphanyl )  - n - ( 2 , 4 , 6 - trichlorphenyl )  - acetamide against the virus flua ( h1n1 )  california 07 2009 was evaluated on mdck cell culture test in vitro.', ' the data obtained substantiate the expediency of further study of derivatives of ( 4 , 6 - diamino[1 , 3 , 5] triazine - 2 - yl - sulphanyl )  - n - aryl - acetamide as potential antiviral agents.']","Synthesis and antiviral activity of 4,6-bis-ethylamino[1,3,5]triazine derivatives for Flu A (H1N1) virus California/07/2009",10.33250/14.02.106,"[[' it has been shown that the test substance exhibits high antiviral activity against the influenza a virus h1n1 california  07 2009 with effective concentration of ec50 0 , 6 g ml and the selectivity index si > 170 ( for ribavirin si > 160 and amizona si > 2 , 1 ) .']]"
auranofin,"[' herein ,  we report that the clinical approved auranofin could perfectly inhibit the activity of 3 - chymotrypsin - like cysteine protease ( mpro or 3clpro )  of sars - cov - 2.', ' for mpro inhibition ,  ic50 of auranofin ,  vitamin k3 ,  phenyl isothiocyanate ,  gold cluster are about 0.', ' especially for fda approved auranofin ,  it is an anti - inflammation drug in clinic ,  thus it may with strong potential to inhibit virus replication and suppress the inflammation damage in covid - 19 patients.']",Molecules inhibit the enzyme activity of 3-chymotrypsin-like cysteine protease of SARS-CoV-2 virus: the experimental and theory studies,10.1101/2020.05.28.120642,"[[' for mpro inhibition ,  ic50 of auranofin ,  vitamin k3 ,  phenyl isothiocyanate ,  gold cluster are about 0.51m ,  7.96m ,  10.13m ,  1.61m ,  respectively.']]"
cysteine,"[' herein ,  we report that the clinical approved auranofin could perfectly inhibit the activity of 3 - chymotrypsin - like cysteine protease ( mpro or 3clpro )  of sars - cov - 2.']",Molecules inhibit the enzyme activity of 3-chymotrypsin-like cysteine protease of SARS-CoV-2 virus: the experimental and theory studies,10.1101/2020.05.28.120642,"[[' for mpro inhibition ,  ic50 of auranofin ,  vitamin k3 ,  phenyl isothiocyanate ,  gold cluster are about 0.51m ,  7.96m ,  10.13m ,  1.61m ,  respectively.']]"
chymotrypsin,"[' herein ,  we report that the clinical approved auranofin could perfectly inhibit the activity of 3 - chymotrypsin - like cysteine protease ( mpro or 3clpro )  of sars - cov - 2.']",Molecules inhibit the enzyme activity of 3-chymotrypsin-like cysteine protease of SARS-CoV-2 virus: the experimental and theory studies,10.1101/2020.05.28.120642,"[[' for mpro inhibition ,  ic50 of auranofin ,  vitamin k3 ,  phenyl isothiocyanate ,  gold cluster are about 0.51m ,  7.96m ,  10.13m ,  1.61m ,  respectively.']]"
cobicistat,"[' methods: prezcobix rezolsta is a fixed - dose combination of 800 mg of the hiv protease inhibitor darunavir ( drv )  and 150 mg cobicistat ,  a cyp3a4 inhibitor ,  which is indicated in combination with other antiretroviral agents for the treatment of hiv infection.', ' there are currently no definitive data on the safety and efficacy of drv cobicistat for the treatment of covid - 19.']",Lack of Antiviral Activity of Darunavir against SARS-CoV-2,10.1016/j.ijid.2020.05.085,"[[' results: drv showed no antiviral activity against sars - cov - 2 at clinically relevant concentrations ( ec50 > 100 m ) .', ' remdesivir ,  used as a positive control ,  demonstrated potent antiviral activity ( ec50 = 0.38 m ) .']]"
darunavir,"[' methods: prezcobix rezolsta is a fixed - dose combination of 800 mg of the hiv protease inhibitor darunavir ( drv )  and 150 mg cobicistat ,  a cyp3a4 inhibitor ,  which is indicated in combination with other antiretroviral agents for the treatment of hiv infection.', ' the in vitro antiviral activity of darunavir against a clinical isolate from a patient infected with sars - cov - 2 was assessed.']",Lack of Antiviral Activity of Darunavir against SARS-CoV-2,10.1016/j.ijid.2020.05.085,"[[' results: drv showed no antiviral activity against sars - cov - 2 at clinically relevant concentrations ( ec50 > 100 m ) .', ' remdesivir ,  used as a positive control ,  demonstrated potent antiviral activity ( ec50 = 0.38 m ) .']]"
remdesivir,"[' remdesivir ,  used as a positive control ,  demonstrated potent antiviral activity ( ec50 = 0.']",Lack of Antiviral Activity of Darunavir against SARS-CoV-2,10.1016/j.ijid.2020.05.085,"[[' results: drv showed no antiviral activity against sars - cov - 2 at clinically relevant concentrations ( ec50 > 100 m ) .', ' remdesivir ,  used as a positive control ,  demonstrated potent antiviral activity ( ec50 = 0.38 m ) .']]"
remdesivir,"[' background: remdesivir is a prodrug of the nucleoside analogue gs - 441524 and is under evaluation for treatment of sars - cov - 2 - infected patients.', ' objectives: to evaluate the pharmacokinetics of remdesivir and gs - 441524 in plasma ,  bronchoalveolar aspirate ( bas )  and csf in two critically ill covid - 19 patients.', ' methods: remdesivir was administered at 200\u2009mg loading dose on the first day followed by 12\u2009days of 100\u2009mg in two critically ill patients.', ' remdesivir and gs - 441524 concentrations were measured in these samples using a validated uhplc - ms ms method.', ' results: we observed higher concentrations of remdesivir at c0 ( 6 -  to 7 - fold higher than ec50 from in vitro studies )  and a notable decay at c1.', ' conclusions: we report the first pharmacokinetic evaluation of remdesivir and gs - 441524 in recovered covid - 19 patients.', ' further study of the pharmacokinetic profile of remdesivir ,  gs - 441524 and the intracellular triphosphate form are required.']",Pharmacokinetics of remdesivir and GS-441524 in two critically ill patients who recovered from COVID-19,10.1093/jac/dkaa239,[[' results: we observed higher concentrations of remdesivir at c0 ( 6 -  to 7 - fold higher than ec50 from in vitro studies )  and a notable decay at c1.']]
chloroquine,"[' they are all old drugs as follows ,  anisomycin ,  antimycin a ,  atovaquone ,  chloroquine ,  conivaptan ,  emetine ,  gemcitabine ,  homoharringtonine ,  niclosamide ,  nitazoxanide ,  oligomycin ,  salinomycin ,  tilorone ,  valinomycin ,  and vismodegib.']",Repurposing old drugs as antiviral agents for coronaviruses,10.1016/j.bj.2020.05.003,"[[' the concentrations ( ec50 )  of each drug necessary to diminish viral activity to 50% of that for the untreated controls were determined.', ' results: fifteen out of the 252 drugs or pharmacologically active compounds screened were found to be active against both fipv and hcov - oc43 ,  with ec50 values ranging from 11\xa0nm to 75\xa0m.']]"
salinomycin,"[' they are all old drugs as follows ,  anisomycin ,  antimycin a ,  atovaquone ,  chloroquine ,  conivaptan ,  emetine ,  gemcitabine ,  homoharringtonine ,  niclosamide ,  nitazoxanide ,  oligomycin ,  salinomycin ,  tilorone ,  valinomycin ,  and vismodegib.']",Repurposing old drugs as antiviral agents for coronaviruses,10.1016/j.bj.2020.05.003,"[[' the concentrations ( ec50 )  of each drug necessary to diminish viral activity to 50% of that for the untreated controls were determined.', ' results: fifteen out of the 252 drugs or pharmacologically active compounds screened were found to be active against both fipv and hcov - oc43 ,  with ec50 values ranging from 11\xa0nm to 75\xa0m.']]"
anisomycin,"[' they are all old drugs as follows ,  anisomycin ,  antimycin a ,  atovaquone ,  chloroquine ,  conivaptan ,  emetine ,  gemcitabine ,  homoharringtonine ,  niclosamide ,  nitazoxanide ,  oligomycin ,  salinomycin ,  tilorone ,  valinomycin ,  and vismodegib.']",Repurposing old drugs as antiviral agents for coronaviruses,10.1016/j.bj.2020.05.003,"[[' the concentrations ( ec50 )  of each drug necessary to diminish viral activity to 50% of that for the untreated controls were determined.', ' results: fifteen out of the 252 drugs or pharmacologically active compounds screened were found to be active against both fipv and hcov - oc43 ,  with ec50 values ranging from 11\xa0nm to 75\xa0m.']]"
homoharringtonine,"[' they are all old drugs as follows ,  anisomycin ,  antimycin a ,  atovaquone ,  chloroquine ,  conivaptan ,  emetine ,  gemcitabine ,  homoharringtonine ,  niclosamide ,  nitazoxanide ,  oligomycin ,  salinomycin ,  tilorone ,  valinomycin ,  and vismodegib.']",Repurposing old drugs as antiviral agents for coronaviruses,10.1016/j.bj.2020.05.003,"[[' the concentrations ( ec50 )  of each drug necessary to diminish viral activity to 50% of that for the untreated controls were determined.', ' results: fifteen out of the 252 drugs or pharmacologically active compounds screened were found to be active against both fipv and hcov - oc43 ,  with ec50 values ranging from 11\xa0nm to 75\xa0m.']]"
niclosamide,"[' they are all old drugs as follows ,  anisomycin ,  antimycin a ,  atovaquone ,  chloroquine ,  conivaptan ,  emetine ,  gemcitabine ,  homoharringtonine ,  niclosamide ,  nitazoxanide ,  oligomycin ,  salinomycin ,  tilorone ,  valinomycin ,  and vismodegib.']",Repurposing old drugs as antiviral agents for coronaviruses,10.1016/j.bj.2020.05.003,"[[' the concentrations ( ec50 )  of each drug necessary to diminish viral activity to 50% of that for the untreated controls were determined.', ' results: fifteen out of the 252 drugs or pharmacologically active compounds screened were found to be active against both fipv and hcov - oc43 ,  with ec50 values ranging from 11\xa0nm to 75\xa0m.']]"
atovaquone,"[' they are all old drugs as follows ,  anisomycin ,  antimycin a ,  atovaquone ,  chloroquine ,  conivaptan ,  emetine ,  gemcitabine ,  homoharringtonine ,  niclosamide ,  nitazoxanide ,  oligomycin ,  salinomycin ,  tilorone ,  valinomycin ,  and vismodegib.']",Repurposing old drugs as antiviral agents for coronaviruses,10.1016/j.bj.2020.05.003,"[[' the concentrations ( ec50 )  of each drug necessary to diminish viral activity to 50% of that for the untreated controls were determined.', ' results: fifteen out of the 252 drugs or pharmacologically active compounds screened were found to be active against both fipv and hcov - oc43 ,  with ec50 values ranging from 11\xa0nm to 75\xa0m.']]"
valinomycin,"[' they are all old drugs as follows ,  anisomycin ,  antimycin a ,  atovaquone ,  chloroquine ,  conivaptan ,  emetine ,  gemcitabine ,  homoharringtonine ,  niclosamide ,  nitazoxanide ,  oligomycin ,  salinomycin ,  tilorone ,  valinomycin ,  and vismodegib.']",Repurposing old drugs as antiviral agents for coronaviruses,10.1016/j.bj.2020.05.003,"[[' the concentrations ( ec50 )  of each drug necessary to diminish viral activity to 50% of that for the untreated controls were determined.', ' results: fifteen out of the 252 drugs or pharmacologically active compounds screened were found to be active against both fipv and hcov - oc43 ,  with ec50 values ranging from 11\xa0nm to 75\xa0m.']]"
conivaptan,"[' they are all old drugs as follows ,  anisomycin ,  antimycin a ,  atovaquone ,  chloroquine ,  conivaptan ,  emetine ,  gemcitabine ,  homoharringtonine ,  niclosamide ,  nitazoxanide ,  oligomycin ,  salinomycin ,  tilorone ,  valinomycin ,  and vismodegib.']",Repurposing old drugs as antiviral agents for coronaviruses,10.1016/j.bj.2020.05.003,"[[' the concentrations ( ec50 )  of each drug necessary to diminish viral activity to 50% of that for the untreated controls were determined.', ' results: fifteen out of the 252 drugs or pharmacologically active compounds screened were found to be active against both fipv and hcov - oc43 ,  with ec50 values ranging from 11\xa0nm to 75\xa0m.']]"
gemcitabine,"[' they are all old drugs as follows ,  anisomycin ,  antimycin a ,  atovaquone ,  chloroquine ,  conivaptan ,  emetine ,  gemcitabine ,  homoharringtonine ,  niclosamide ,  nitazoxanide ,  oligomycin ,  salinomycin ,  tilorone ,  valinomycin ,  and vismodegib.']",Repurposing old drugs as antiviral agents for coronaviruses,10.1016/j.bj.2020.05.003,"[[' the concentrations ( ec50 )  of each drug necessary to diminish viral activity to 50% of that for the untreated controls were determined.', ' results: fifteen out of the 252 drugs or pharmacologically active compounds screened were found to be active against both fipv and hcov - oc43 ,  with ec50 values ranging from 11\xa0nm to 75\xa0m.']]"
nitazoxanide,"[' they are all old drugs as follows ,  anisomycin ,  antimycin a ,  atovaquone ,  chloroquine ,  conivaptan ,  emetine ,  gemcitabine ,  homoharringtonine ,  niclosamide ,  nitazoxanide ,  oligomycin ,  salinomycin ,  tilorone ,  valinomycin ,  and vismodegib.']",Repurposing old drugs as antiviral agents for coronaviruses,10.1016/j.bj.2020.05.003,"[[' the concentrations ( ec50 )  of each drug necessary to diminish viral activity to 50% of that for the untreated controls were determined.', ' results: fifteen out of the 252 drugs or pharmacologically active compounds screened were found to be active against both fipv and hcov - oc43 ,  with ec50 values ranging from 11\xa0nm to 75\xa0m.']]"
emetine,"[' they are all old drugs as follows ,  anisomycin ,  antimycin a ,  atovaquone ,  chloroquine ,  conivaptan ,  emetine ,  gemcitabine ,  homoharringtonine ,  niclosamide ,  nitazoxanide ,  oligomycin ,  salinomycin ,  tilorone ,  valinomycin ,  and vismodegib.']",Repurposing old drugs as antiviral agents for coronaviruses,10.1016/j.bj.2020.05.003,"[[' the concentrations ( ec50 )  of each drug necessary to diminish viral activity to 50% of that for the untreated controls were determined.', ' results: fifteen out of the 252 drugs or pharmacologically active compounds screened were found to be active against both fipv and hcov - oc43 ,  with ec50 values ranging from 11\xa0nm to 75\xa0m.']]"
hydroxychloroquine,"[' translation of in vitro antiviral activity to the in vivo setting is crucial to identify potentially effective dosing regimens of hydroxychloroquine.', ' in vitro ec50 ec90 values for hydroxychloroquine should be compared to the in vivo free extracellular tissue concentration ,  which is similar to the free plasma hydroxychloroquine concentration.']",Connecting hydroxychloroquine in vitro antiviral activity to in vivo concentration for prediction of antiviral effect: a critical step in treating COVID-19 patients,10.1093/cid/ciaa623,"[[' in vitro ec50 ec90 values for hydroxychloroquine should be compared to the in vivo free extracellular tissue concentration ,  which is similar to the free plasma hydroxychloroquine concentration.']]"
nicotianamine,"[' secondary plant metabolites such as polyphenols ( flavonoids ,  coumarins ,  stilbenes )  ,  alkaloids ,  terpenoids ,  organosulfur compounds saponins ,  saikosaponins ,  lectins ,  essential oils ,  nicotianamine and primary metabolites such as vitamins.']",A Comprehensive Review on the Effect of Plant Metabolites on Coronaviruses: Focusing on Their Molecular Docking Score and IC50 Values,10.20944/preprints202005.0295.v1,[[' ic50 value ( the concentration in which there is 50% loss in enzyme activity )  and molecular docking score and binding energy are parameters to understand the metabolites ability to inhibit the specific virus.']]
adenosine,"[' we report that remdesivir ( rdv )  ,  a monophosphoramidate prodrug of an adenosine analog ,  potently inhibits sars - cov - 2 replication in human lung cells and primary human airway epithelial cultures ( ec50 = 0.']",Remdesivir Potently Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice,10.2139/ssrn.3588829,"[[' we report that remdesivir ( rdv )  ,  a monophosphoramidate prodrug of an adenosine analog ,  potently inhibits sars - cov - 2 replication in human lung cells and primary human airway epithelial cultures ( ec50 = 0.01 um ) .', ' weaker activity was observed in vero e6 cells ( ec50 = 1.65 um )  due to their low capacity to metabolize rdv.']]"
remdesivir,"[' we report that remdesivir ( rdv )  ,  a monophosphoramidate prodrug of an adenosine analog ,  potently inhibits sars - cov - 2 replication in human lung cells and primary human airway epithelial cultures ( ec50 = 0.']",Remdesivir Potently Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice,10.2139/ssrn.3588829,"[[' we report that remdesivir ( rdv )  ,  a monophosphoramidate prodrug of an adenosine analog ,  potently inhibits sars - cov - 2 replication in human lung cells and primary human airway epithelial cultures ( ec50 = 0.01 um ) .', ' weaker activity was observed in vero e6 cells ( ec50 = 1.65 um )  due to their low capacity to metabolize rdv.']]"
chlorpromazine,"[' chlorpromazine ( cpz )  ,  the prototype of typical antipsychotics from the phenothiazine group ,  is known to inhibit clathrin - mediated endocytosis and acts as an antiviral ,  in particular against sars - cov - 1 and mers - cov.']",Inhibition of the replication of SARS-CoV-2 in human cells by the FDA-approved drug chlorpromazine,10.1101/2020.05.05.079608,"[[' we evidenced an antiviral activity against sars - cov - 2 with an ic50 of 10m.', ' because of its high biodistribution in lung ,  saliva and brain ,  such ic50 measured in vitro may translate to cpz dosage used in clinical routine.']]"
phenothiazine,"[' chlorpromazine ( cpz )  ,  the prototype of typical antipsychotics from the phenothiazine group ,  is known to inhibit clathrin - mediated endocytosis and acts as an antiviral ,  in particular against sars - cov - 1 and mers - cov.']",Inhibition of the replication of SARS-CoV-2 in human cells by the FDA-approved drug chlorpromazine,10.1101/2020.05.05.079608,"[[' we evidenced an antiviral activity against sars - cov - 2 with an ic50 of 10m.', ' because of its high biodistribution in lung ,  saliva and brain ,  such ic50 measured in vitro may translate to cpz dosage used in clinical routine.']]"
licorice,[' liquiritin is abundant in licorice tablet ( ~0.'],An artificial intelligence system reveals liquiritin inhibits SARS-CoV-2 by mimicking type I interferon,10.1101/2020.05.02.074021,[[' we found liquiritin significantly inhibit replication of sars - cov - 2 in vero e6 cells with ec50 = 2.39 m.']]
liquiritin,"[' we found liquiritin significantly inhibit replication of sars - cov - 2 in vero e6 cells with ec50 = 2.', ' mechanistically ,  we found liquiritin exerts anti - viral function by mimicking type i interferon.', ' upregulated genes induced by liquiritin are enriched in go categories including type i interferon signaling pathway ,  negative regulation of viral genome replication and etc.', ' liquiritin is abundant in licorice tablet ( ~0.', ' together ,  we recommend liquiritin as a competitive candidate for treating covid - 19.', ' we also expect liquiritin to have a broad and potent antiviral function to other viral pathogens ,  like hbv ,  hiv and etc.']",An artificial intelligence system reveals liquiritin inhibits SARS-CoV-2 by mimicking type I interferon,10.1101/2020.05.02.074021,[[' we found liquiritin significantly inhibit replication of sars - cov - 2 in vero e6 cells with ec50 = 2.39 m.']]
verteporfin,"[' here ,  we discovered that protoporphyrin ix ( ppix )  and verteporfin ,  two fda - approved drugs ,  completely inhibited the cytopathic effect produced by sars - cov - 2 infection at 1.', ' the selectivity indices of ppix and verteporfin were 952.', ' importantly ,  ppix and verteporfin prevented sars - cov - 2 infection in mice adenovirally transduced with human ace2.', ' our study suggests that ppix and verteporfin are potent antiviral agents against sars - cov - 2 infection and sheds new light on developing novel chemoprophylaxis and chemotherapy against sars - cov - 2.']",Protoporphyrin IX and verteporfin prevent SARS-CoV-2 infection in vitro and in a mouse model expressing human ACE2,10.1101/2020.04.30.071290,"[['31 m respectively ,  and their ec50 values of reduction of viral rna were at nanomolar concentrations.']]"
protoporphyrin,"[' here ,  we discovered that protoporphyrin ix ( ppix )  and verteporfin ,  two fda - approved drugs ,  completely inhibited the cytopathic effect produced by sars - cov - 2 infection at 1.']",Protoporphyrin IX and verteporfin prevent SARS-CoV-2 infection in vitro and in a mouse model expressing human ACE2,10.1101/2020.04.30.071290,"[['31 m respectively ,  and their ec50 values of reduction of viral rna were at nanomolar concentrations.']]"
andrographolide,"[' <p>andrographolide ( <strong>1< strong> )  a bitter ,  diterpenes lactone is the most biologically active constituent from <em>andrographis paniculata< em>.', ' andrographolide showed <em>in vitro < em>inhibition of the growth of ebola virus ( zaire )  with ec50 \xa0activity of 10 um which is twenty - five - fold the activity of the control favipiravir ( ec50 = 250um )  in the crystal violet ( plaque reduction  neutral red ( toxicity )  assay.', ' andrographolide had an ec50 of 1.']","Antiviral activity of Andrographolide against Ebola virus, Dengue fever and SARS coronavirus",10.21203/rs.3.rs-24311/v1,"[[' andrographolide showed <em>in vitro < em>inhibition of the growth of ebola virus ( zaire )  with ec50 \xa0activity of 10 um which is twenty - five - fold the activity of the control favipiravir ( ec50 = 250um )  in the crystal violet ( plaque reduction  neutral red ( toxicity )  assay.', ' it also showed significant activity against dengue fever virus with ec50 value of 0.56 ug ml in the visual ( cytopathic effect  toxicity )  assay and ec50 of 0.58 ug ml\xa0in the neutral red ( cytopathic effect  toxicity )  assay ( comparable to the values obtained \xa0with 6 - azauridine as the positive control ec50 = 0.32 ug ml and 0.38 ug ml in the respective bioassays; and against sars coronavirus.', ' andrographolide had an ec50 of 1.2 ug ml in the visual ( cytopathic effect toxicity )  assay and 1.1 ug ml in the neutral red ( cytopathic effect toxicity )  assay.']]"
favipiravir,[' andrographolide showed <em>in vitro < em>inhibition of the growth of ebola virus ( zaire )  with ec50 \xa0activity of 10 um which is twenty - five - fold the activity of the control favipiravir ( ec50 = 250um )  in the crystal violet ( plaque reduction  neutral red ( toxicity )  assay.'],"Antiviral activity of Andrographolide against Ebola virus, Dengue fever and SARS coronavirus",10.21203/rs.3.rs-24311/v1,"[[' andrographolide showed <em>in vitro < em>inhibition of the growth of ebola virus ( zaire )  with ec50 \xa0activity of 10 um which is twenty - five - fold the activity of the control favipiravir ( ec50 = 250um )  in the crystal violet ( plaque reduction  neutral red ( toxicity )  assay.', ' it also showed significant activity against dengue fever virus with ec50 value of 0.56 ug ml in the visual ( cytopathic effect  toxicity )  assay and ec50 of 0.58 ug ml\xa0in the neutral red ( cytopathic effect  toxicity )  assay ( comparable to the values obtained \xa0with 6 - azauridine as the positive control ec50 = 0.32 ug ml and 0.38 ug ml in the respective bioassays; and against sars coronavirus.', ' andrographolide had an ec50 of 1.2 ug ml in the visual ( cytopathic effect toxicity )  assay and 1.1 ug ml in the neutral red ( cytopathic effect toxicity )  assay.']]"
chloroquine,"[' these include chloroquine derivatives and remdesivir ,  along with plitidepsin ,  cathepsin inhibitors ,  nelfinavir mesylate hydrate ,  interferon 2 - alpha ,  interferon - gamma ,  fenofibrate and camostat.']",Pre-clinical search of SARS-CoV-2 inhibitors and their combinations in approved drugs to tackle COVID-19 pandemic,10.1101/2020.04.23.055756,"[[' moreover ,  only eight families had an ic50 below 25 um or 10 2 iu ml.']]"
plitidepsin,"[' these include chloroquine derivatives and remdesivir ,  along with plitidepsin ,  cathepsin inhibitors ,  nelfinavir mesylate hydrate ,  interferon 2 - alpha ,  interferon - gamma ,  fenofibrate and camostat.', ' plitidepsin was the only clinically approved drug displaying nanomolar efficacy.']",Pre-clinical search of SARS-CoV-2 inhibitors and their combinations in approved drugs to tackle COVID-19 pandemic,10.1101/2020.04.23.055756,"[[' moreover ,  only eight families had an ic50 below 25 um or 10 2 iu ml.']]"
remdesivir,"[' these include chloroquine derivatives and remdesivir ,  along with plitidepsin ,  cathepsin inhibitors ,  nelfinavir mesylate hydrate ,  interferon 2 - alpha ,  interferon - gamma ,  fenofibrate and camostat.']",Pre-clinical search of SARS-CoV-2 inhibitors and their combinations in approved drugs to tackle COVID-19 pandemic,10.1101/2020.04.23.055756,"[[' moreover ,  only eight families had an ic50 below 25 um or 10 2 iu ml.']]"
fenofibrate,"[' these include chloroquine derivatives and remdesivir ,  along with plitidepsin ,  cathepsin inhibitors ,  nelfinavir mesylate hydrate ,  interferon 2 - alpha ,  interferon - gamma ,  fenofibrate and camostat.']",Pre-clinical search of SARS-CoV-2 inhibitors and their combinations in approved drugs to tackle COVID-19 pandemic,10.1101/2020.04.23.055756,"[[' moreover ,  only eight families had an ic50 below 25 um or 10 2 iu ml.']]"
nelfinavir,"[' these include chloroquine derivatives and remdesivir ,  along with plitidepsin ,  cathepsin inhibitors ,  nelfinavir mesylate hydrate ,  interferon 2 - alpha ,  interferon - gamma ,  fenofibrate and camostat.']",Pre-clinical search of SARS-CoV-2 inhibitors and their combinations in approved drugs to tackle COVID-19 pandemic,10.1101/2020.04.23.055756,"[[' moreover ,  only eight families had an ic50 below 25 um or 10 2 iu ml.']]"
chloroquine,"[' the antimalarial drugs chloroquine phosphate ( cq )  and hydroxychloroquine ( hcq )  impair in vitro the terminal glycosylation of ace2 without significant change of cell - surface ace2 and ,  therefore ,  might be potent inhibitors of sars - cov - 2 infections.']",Hydroxychloroquine as an aerosol might markedly reduce and even prevent severe clinical symptoms after SARS-CoV-2 infection,10.1016/j.mehy.2020.109783,"[[' in addition ,  hcq ,  which is three times more potent than cq in sars - cov - 2 infected cells ( ec50 0.72\xa0um )  ,  was significantly associated with viral load reduction disappearance in covid - 19 patients compared to controls.']]"
hydroxychloroquine,"[' the antimalarial drugs chloroquine phosphate ( cq )  and hydroxychloroquine ( hcq )  impair in vitro the terminal glycosylation of ace2 without significant change of cell - surface ace2 and ,  therefore ,  might be potent inhibitors of sars - cov - 2 infections.']",Hydroxychloroquine as an aerosol might markedly reduce and even prevent severe clinical symptoms after SARS-CoV-2 infection,10.1016/j.mehy.2020.109783,"[[' in addition ,  hcq ,  which is three times more potent than cq in sars - cov - 2 infected cells ( ec50 0.72\xa0um )  ,  was significantly associated with viral load reduction disappearance in covid - 19 patients compared to controls.']]"
phosphate,"[' the antimalarial drugs chloroquine phosphate ( cq )  and hydroxychloroquine ( hcq )  impair in vitro the terminal glycosylation of ace2 without significant change of cell - surface ace2 and ,  therefore ,  might be potent inhibitors of sars - cov - 2 infections.']",Hydroxychloroquine as an aerosol might markedly reduce and even prevent severe clinical symptoms after SARS-CoV-2 infection,10.1016/j.mehy.2020.109783,"[[' in addition ,  hcq ,  which is three times more potent than cq in sars - cov - 2 infected cells ( ec50 0.72\xa0um )  ,  was significantly associated with viral load reduction disappearance in covid - 19 patients compared to controls.']]"
ivermectin,"[' introduction: caly ,  druce ( 1 )  reported that ivermectin inhibited sars - cov - 2 in vitro for up to 48 h using ivermectin at 5 um.', ' the concentration resulting in 50% inhibition ( ic50 ,  2 um )  was >35x higher than the maximum plasma concentration ( cmax )  after oral administration of the approved dose of ivermectin when given fasted.', ' method: simulations were conducted using an available population pharmacokinetic model to predict total ( bound and unbound )  and unbound plasma concentration - time profiles after a single and repeat fasted administration of the approved dose of ivermectin ( 200 ug kg )  ,  60 mg ,  and 120 mg.', ' results: plasma ivermectin concentrations of total ( bound and unbound )  and unbound concentrations do not reach the ic50 ,  even for a dose level 10x higher than the approved dose.', ' even with higher exposure in lungs than plasma ,  ivermectin is unlikely to reach the ic50 in lungs after single oral administration of the approved dose ( predicted lung: 0.', ' conclusions: the likelihood of a successful clinical trial using the approved dose of ivermectin is low.']",The Approved Dose of Ivermectin Alone is not the Ideal Dose for the Treatment of COVID-19,10.1101/2020.04.21.20073262,"[[' the concentration resulting in 50% inhibition ( ic50 ,  2 um )  was >35x higher than the maximum plasma concentration ( cmax )  after oral administration of the approved dose of ivermectin when given fasted.', ' results: plasma ivermectin concentrations of total ( bound and unbound )  and unbound concentrations do not reach the ic50 ,  even for a dose level 10x higher than the approved dose.', ' even with higher exposure in lungs than plasma ,  ivermectin is unlikely to reach the ic50 in lungs after single oral administration of the approved dose ( predicted lung: 0.0857 um )  or at doses 10x higher that the approved dose administered orally ( predicted lung: 0.817 um ) .']]"
chloroquine,[' abstract  chloroquine ( cq )  and hydroxychloroquine ( hcq )  have been used in treating covid - 19 patients recently.'],Cytotoxicity evaluation of chloroquine and hydroxychloroquine in multiple cell lines and tissues by dynamic imaging system and PBPK model,10.1101/2020.04.22.056762,"[[' cc50 and the ratio of tissue trough concentrations to cc50 ( r ttcc  )  were brought into predicted toxicity profiles.', ' the cc50 at 24 h ,  48 h ,  72 h of cq and hcq decreased in the time - dependent manner ,  which indicates the accumulative cytotoxic effect.', ' hcq was found to be less toxic in 7 cell types except cardiomyocytes h9c2 cells ( cc50 - 48 h=29.55 m; cc50 - 72 h=15.26 m ) .']]"
hydroxychloroquine,[' abstract  chloroquine ( cq )  and hydroxychloroquine ( hcq )  have been used in treating covid - 19 patients recently.'],Cytotoxicity evaluation of chloroquine and hydroxychloroquine in multiple cell lines and tissues by dynamic imaging system and PBPK model,10.1101/2020.04.22.056762,"[[' cc50 and the ratio of tissue trough concentrations to cc50 ( r ttcc  )  were brought into predicted toxicity profiles.', ' the cc50 at 24 h ,  48 h ,  72 h of cq and hcq decreased in the time - dependent manner ,  which indicates the accumulative cytotoxic effect.', ' hcq was found to be less toxic in 7 cell types except cardiomyocytes h9c2 cells ( cc50 - 48 h=29.55 m; cc50 - 72 h=15.26 m ) .']]"
chloroquine,"[' using this parameter hydroxychloroquine ,  chloroquine ,  mefloquine ,  atazanavir ( boosted with ritonavir )  ,  tipranavir ( boosted with ritonavir )  ,  ivermectin ,  azithromycin and lopinavir ( boosted with ritonavir )  were all predicted to achieve lung concentrations over 10 - fold higher than their reported ec50.']",Prioritisation of potential anti-SARS-CoV-2 drug repurposing opportunities based on ability to achieve adequate target site concentrations derived from their established human pharmacokinetics,10.1101/2020.04.16.20068379,"[[' moreover ,  most publications have focussed on 50% maximum effective concentrations ( ec50 )  ,  which may be an insufficiently robust indicator of antiviral activity because of marked differences in the slope of the concentration - response curve between drugs.', ' for all drugs reported ,  the unbound lung to plasma tissue partition coefficient ( kpulung )  was also simulated and used along with reported cmax and fraction unbound in plasma to derive a lung cmax ec50 as a better indicator of potential human efficacy ( lung cmax ec90 ratio was also calculable for a limited number of drugs ) .', ' using this parameter hydroxychloroquine ,  chloroquine ,  mefloquine ,  atazanavir ( boosted with ritonavir )  ,  tipranavir ( boosted with ritonavir )  ,  ivermectin ,  azithromycin and lopinavir ( boosted with ritonavir )  were all predicted to achieve lung concentrations over 10 - fold higher than their reported ec50.', ' this analysis was not possible for nelfinavir because insufficient data were available to calculate kpulung but nitozoxanide and sulfadoxine were also predicted to exceed their reported ec50 by 3.1 -  and 1.5 - fold in lung ,  respectively.']]"
tipranavir,"[' a more in - depth assessment of these drugs demonstrated that only nitazoxanide ,  nelfinavir ,  tipranavir ( boosted with ritonavir )  and sulfadoxine achieved plasma concentrations above their anti - sars - cov - 2 activity across their entire approved dosing interval at their approved human dose.', ' using this parameter hydroxychloroquine ,  chloroquine ,  mefloquine ,  atazanavir ( boosted with ritonavir )  ,  tipranavir ( boosted with ritonavir )  ,  ivermectin ,  azithromycin and lopinavir ( boosted with ritonavir )  were all predicted to achieve lung concentrations over 10 - fold higher than their reported ec50.']",Prioritisation of potential anti-SARS-CoV-2 drug repurposing opportunities based on ability to achieve adequate target site concentrations derived from their established human pharmacokinetics,10.1101/2020.04.16.20068379,"[[' moreover ,  most publications have focussed on 50% maximum effective concentrations ( ec50 )  ,  which may be an insufficiently robust indicator of antiviral activity because of marked differences in the slope of the concentration - response curve between drugs.', ' for all drugs reported ,  the unbound lung to plasma tissue partition coefficient ( kpulung )  was also simulated and used along with reported cmax and fraction unbound in plasma to derive a lung cmax ec50 as a better indicator of potential human efficacy ( lung cmax ec90 ratio was also calculable for a limited number of drugs ) .', ' using this parameter hydroxychloroquine ,  chloroquine ,  mefloquine ,  atazanavir ( boosted with ritonavir )  ,  tipranavir ( boosted with ritonavir )  ,  ivermectin ,  azithromycin and lopinavir ( boosted with ritonavir )  were all predicted to achieve lung concentrations over 10 - fold higher than their reported ec50.', ' this analysis was not possible for nelfinavir because insufficient data were available to calculate kpulung but nitozoxanide and sulfadoxine were also predicted to exceed their reported ec50 by 3.1 -  and 1.5 - fold in lung ,  respectively.']]"
lopinavir,"[' using this parameter hydroxychloroquine ,  chloroquine ,  mefloquine ,  atazanavir ( boosted with ritonavir )  ,  tipranavir ( boosted with ritonavir )  ,  ivermectin ,  azithromycin and lopinavir ( boosted with ritonavir )  were all predicted to achieve lung concentrations over 10 - fold higher than their reported ec50.']",Prioritisation of potential anti-SARS-CoV-2 drug repurposing opportunities based on ability to achieve adequate target site concentrations derived from their established human pharmacokinetics,10.1101/2020.04.16.20068379,"[[' moreover ,  most publications have focussed on 50% maximum effective concentrations ( ec50 )  ,  which may be an insufficiently robust indicator of antiviral activity because of marked differences in the slope of the concentration - response curve between drugs.', ' for all drugs reported ,  the unbound lung to plasma tissue partition coefficient ( kpulung )  was also simulated and used along with reported cmax and fraction unbound in plasma to derive a lung cmax ec50 as a better indicator of potential human efficacy ( lung cmax ec90 ratio was also calculable for a limited number of drugs ) .', ' using this parameter hydroxychloroquine ,  chloroquine ,  mefloquine ,  atazanavir ( boosted with ritonavir )  ,  tipranavir ( boosted with ritonavir )  ,  ivermectin ,  azithromycin and lopinavir ( boosted with ritonavir )  were all predicted to achieve lung concentrations over 10 - fold higher than their reported ec50.', ' this analysis was not possible for nelfinavir because insufficient data were available to calculate kpulung but nitozoxanide and sulfadoxine were also predicted to exceed their reported ec50 by 3.1 -  and 1.5 - fold in lung ,  respectively.']]"
hydroxychloroquine,"[' using this parameter hydroxychloroquine ,  chloroquine ,  mefloquine ,  atazanavir ( boosted with ritonavir )  ,  tipranavir ( boosted with ritonavir )  ,  ivermectin ,  azithromycin and lopinavir ( boosted with ritonavir )  were all predicted to achieve lung concentrations over 10 - fold higher than their reported ec50.']",Prioritisation of potential anti-SARS-CoV-2 drug repurposing opportunities based on ability to achieve adequate target site concentrations derived from their established human pharmacokinetics,10.1101/2020.04.16.20068379,"[[' moreover ,  most publications have focussed on 50% maximum effective concentrations ( ec50 )  ,  which may be an insufficiently robust indicator of antiviral activity because of marked differences in the slope of the concentration - response curve between drugs.', ' for all drugs reported ,  the unbound lung to plasma tissue partition coefficient ( kpulung )  was also simulated and used along with reported cmax and fraction unbound in plasma to derive a lung cmax ec50 as a better indicator of potential human efficacy ( lung cmax ec90 ratio was also calculable for a limited number of drugs ) .', ' using this parameter hydroxychloroquine ,  chloroquine ,  mefloquine ,  atazanavir ( boosted with ritonavir )  ,  tipranavir ( boosted with ritonavir )  ,  ivermectin ,  azithromycin and lopinavir ( boosted with ritonavir )  were all predicted to achieve lung concentrations over 10 - fold higher than their reported ec50.', ' this analysis was not possible for nelfinavir because insufficient data were available to calculate kpulung but nitozoxanide and sulfadoxine were also predicted to exceed their reported ec50 by 3.1 -  and 1.5 - fold in lung ,  respectively.']]"
atazanavir,"[' using this parameter hydroxychloroquine ,  chloroquine ,  mefloquine ,  atazanavir ( boosted with ritonavir )  ,  tipranavir ( boosted with ritonavir )  ,  ivermectin ,  azithromycin and lopinavir ( boosted with ritonavir )  were all predicted to achieve lung concentrations over 10 - fold higher than their reported ec50.']",Prioritisation of potential anti-SARS-CoV-2 drug repurposing opportunities based on ability to achieve adequate target site concentrations derived from their established human pharmacokinetics,10.1101/2020.04.16.20068379,"[[' moreover ,  most publications have focussed on 50% maximum effective concentrations ( ec50 )  ,  which may be an insufficiently robust indicator of antiviral activity because of marked differences in the slope of the concentration - response curve between drugs.', ' for all drugs reported ,  the unbound lung to plasma tissue partition coefficient ( kpulung )  was also simulated and used along with reported cmax and fraction unbound in plasma to derive a lung cmax ec50 as a better indicator of potential human efficacy ( lung cmax ec90 ratio was also calculable for a limited number of drugs ) .', ' using this parameter hydroxychloroquine ,  chloroquine ,  mefloquine ,  atazanavir ( boosted with ritonavir )  ,  tipranavir ( boosted with ritonavir )  ,  ivermectin ,  azithromycin and lopinavir ( boosted with ritonavir )  were all predicted to achieve lung concentrations over 10 - fold higher than their reported ec50.', ' this analysis was not possible for nelfinavir because insufficient data were available to calculate kpulung but nitozoxanide and sulfadoxine were also predicted to exceed their reported ec50 by 3.1 -  and 1.5 - fold in lung ,  respectively.']]"
mefloquine,"[' using this parameter hydroxychloroquine ,  chloroquine ,  mefloquine ,  atazanavir ( boosted with ritonavir )  ,  tipranavir ( boosted with ritonavir )  ,  ivermectin ,  azithromycin and lopinavir ( boosted with ritonavir )  were all predicted to achieve lung concentrations over 10 - fold higher than their reported ec50.']",Prioritisation of potential anti-SARS-CoV-2 drug repurposing opportunities based on ability to achieve adequate target site concentrations derived from their established human pharmacokinetics,10.1101/2020.04.16.20068379,"[[' moreover ,  most publications have focussed on 50% maximum effective concentrations ( ec50 )  ,  which may be an insufficiently robust indicator of antiviral activity because of marked differences in the slope of the concentration - response curve between drugs.', ' for all drugs reported ,  the unbound lung to plasma tissue partition coefficient ( kpulung )  was also simulated and used along with reported cmax and fraction unbound in plasma to derive a lung cmax ec50 as a better indicator of potential human efficacy ( lung cmax ec90 ratio was also calculable for a limited number of drugs ) .', ' using this parameter hydroxychloroquine ,  chloroquine ,  mefloquine ,  atazanavir ( boosted with ritonavir )  ,  tipranavir ( boosted with ritonavir )  ,  ivermectin ,  azithromycin and lopinavir ( boosted with ritonavir )  were all predicted to achieve lung concentrations over 10 - fold higher than their reported ec50.', ' this analysis was not possible for nelfinavir because insufficient data were available to calculate kpulung but nitozoxanide and sulfadoxine were also predicted to exceed their reported ec50 by 3.1 -  and 1.5 - fold in lung ,  respectively.']]"
nelfinavir,"[' a more in - depth assessment of these drugs demonstrated that only nitazoxanide ,  nelfinavir ,  tipranavir ( boosted with ritonavir )  and sulfadoxine achieved plasma concentrations above their anti - sars - cov - 2 activity across their entire approved dosing interval at their approved human dose.', ' this analysis was not possible for nelfinavir because insufficient data were available to calculate kpulung but nitozoxanide and sulfadoxine were also predicted to exceed their reported ec50 by 3.']",Prioritisation of potential anti-SARS-CoV-2 drug repurposing opportunities based on ability to achieve adequate target site concentrations derived from their established human pharmacokinetics,10.1101/2020.04.16.20068379,"[[' moreover ,  most publications have focussed on 50% maximum effective concentrations ( ec50 )  ,  which may be an insufficiently robust indicator of antiviral activity because of marked differences in the slope of the concentration - response curve between drugs.', ' for all drugs reported ,  the unbound lung to plasma tissue partition coefficient ( kpulung )  was also simulated and used along with reported cmax and fraction unbound in plasma to derive a lung cmax ec50 as a better indicator of potential human efficacy ( lung cmax ec90 ratio was also calculable for a limited number of drugs ) .', ' using this parameter hydroxychloroquine ,  chloroquine ,  mefloquine ,  atazanavir ( boosted with ritonavir )  ,  tipranavir ( boosted with ritonavir )  ,  ivermectin ,  azithromycin and lopinavir ( boosted with ritonavir )  were all predicted to achieve lung concentrations over 10 - fold higher than their reported ec50.', ' this analysis was not possible for nelfinavir because insufficient data were available to calculate kpulung but nitozoxanide and sulfadoxine were also predicted to exceed their reported ec50 by 3.1 -  and 1.5 - fold in lung ,  respectively.']]"
ritonavir,"[' a more in - depth assessment of these drugs demonstrated that only nitazoxanide ,  nelfinavir ,  tipranavir ( boosted with ritonavir )  and sulfadoxine achieved plasma concentrations above their anti - sars - cov - 2 activity across their entire approved dosing interval at their approved human dose.', ' using this parameter hydroxychloroquine ,  chloroquine ,  mefloquine ,  atazanavir ( boosted with ritonavir )  ,  tipranavir ( boosted with ritonavir )  ,  ivermectin ,  azithromycin and lopinavir ( boosted with ritonavir )  were all predicted to achieve lung concentrations over 10 - fold higher than their reported ec50.']",Prioritisation of potential anti-SARS-CoV-2 drug repurposing opportunities based on ability to achieve adequate target site concentrations derived from their established human pharmacokinetics,10.1101/2020.04.16.20068379,"[[' moreover ,  most publications have focussed on 50% maximum effective concentrations ( ec50 )  ,  which may be an insufficiently robust indicator of antiviral activity because of marked differences in the slope of the concentration - response curve between drugs.', ' for all drugs reported ,  the unbound lung to plasma tissue partition coefficient ( kpulung )  was also simulated and used along with reported cmax and fraction unbound in plasma to derive a lung cmax ec50 as a better indicator of potential human efficacy ( lung cmax ec90 ratio was also calculable for a limited number of drugs ) .', ' using this parameter hydroxychloroquine ,  chloroquine ,  mefloquine ,  atazanavir ( boosted with ritonavir )  ,  tipranavir ( boosted with ritonavir )  ,  ivermectin ,  azithromycin and lopinavir ( boosted with ritonavir )  were all predicted to achieve lung concentrations over 10 - fold higher than their reported ec50.', ' this analysis was not possible for nelfinavir because insufficient data were available to calculate kpulung but nitozoxanide and sulfadoxine were also predicted to exceed their reported ec50 by 3.1 -  and 1.5 - fold in lung ,  respectively.']]"
ivermectin,"[' using this parameter hydroxychloroquine ,  chloroquine ,  mefloquine ,  atazanavir ( boosted with ritonavir )  ,  tipranavir ( boosted with ritonavir )  ,  ivermectin ,  azithromycin and lopinavir ( boosted with ritonavir )  were all predicted to achieve lung concentrations over 10 - fold higher than their reported ec50.']",Prioritisation of potential anti-SARS-CoV-2 drug repurposing opportunities based on ability to achieve adequate target site concentrations derived from their established human pharmacokinetics,10.1101/2020.04.16.20068379,"[[' moreover ,  most publications have focussed on 50% maximum effective concentrations ( ec50 )  ,  which may be an insufficiently robust indicator of antiviral activity because of marked differences in the slope of the concentration - response curve between drugs.', ' for all drugs reported ,  the unbound lung to plasma tissue partition coefficient ( kpulung )  was also simulated and used along with reported cmax and fraction unbound in plasma to derive a lung cmax ec50 as a better indicator of potential human efficacy ( lung cmax ec90 ratio was also calculable for a limited number of drugs ) .', ' using this parameter hydroxychloroquine ,  chloroquine ,  mefloquine ,  atazanavir ( boosted with ritonavir )  ,  tipranavir ( boosted with ritonavir )  ,  ivermectin ,  azithromycin and lopinavir ( boosted with ritonavir )  were all predicted to achieve lung concentrations over 10 - fold higher than their reported ec50.', ' this analysis was not possible for nelfinavir because insufficient data were available to calculate kpulung but nitozoxanide and sulfadoxine were also predicted to exceed their reported ec50 by 3.1 -  and 1.5 - fold in lung ,  respectively.']]"
sulfadoxine,"[' a more in - depth assessment of these drugs demonstrated that only nitazoxanide ,  nelfinavir ,  tipranavir ( boosted with ritonavir )  and sulfadoxine achieved plasma concentrations above their anti - sars - cov - 2 activity across their entire approved dosing interval at their approved human dose.', ' this analysis was not possible for nelfinavir because insufficient data were available to calculate kpulung but nitozoxanide and sulfadoxine were also predicted to exceed their reported ec50 by 3.']",Prioritisation of potential anti-SARS-CoV-2 drug repurposing opportunities based on ability to achieve adequate target site concentrations derived from their established human pharmacokinetics,10.1101/2020.04.16.20068379,"[[' moreover ,  most publications have focussed on 50% maximum effective concentrations ( ec50 )  ,  which may be an insufficiently robust indicator of antiviral activity because of marked differences in the slope of the concentration - response curve between drugs.', ' for all drugs reported ,  the unbound lung to plasma tissue partition coefficient ( kpulung )  was also simulated and used along with reported cmax and fraction unbound in plasma to derive a lung cmax ec50 as a better indicator of potential human efficacy ( lung cmax ec90 ratio was also calculable for a limited number of drugs ) .', ' using this parameter hydroxychloroquine ,  chloroquine ,  mefloquine ,  atazanavir ( boosted with ritonavir )  ,  tipranavir ( boosted with ritonavir )  ,  ivermectin ,  azithromycin and lopinavir ( boosted with ritonavir )  were all predicted to achieve lung concentrations over 10 - fold higher than their reported ec50.', ' this analysis was not possible for nelfinavir because insufficient data were available to calculate kpulung but nitozoxanide and sulfadoxine were also predicted to exceed their reported ec50 by 3.1 -  and 1.5 - fold in lung ,  respectively.']]"
nitazoxanide,"[' a more in - depth assessment of these drugs demonstrated that only nitazoxanide ,  nelfinavir ,  tipranavir ( boosted with ritonavir )  and sulfadoxine achieved plasma concentrations above their anti - sars - cov - 2 activity across their entire approved dosing interval at their approved human dose.']",Prioritisation of potential anti-SARS-CoV-2 drug repurposing opportunities based on ability to achieve adequate target site concentrations derived from their established human pharmacokinetics,10.1101/2020.04.16.20068379,"[[' moreover ,  most publications have focussed on 50% maximum effective concentrations ( ec50 )  ,  which may be an insufficiently robust indicator of antiviral activity because of marked differences in the slope of the concentration - response curve between drugs.', ' for all drugs reported ,  the unbound lung to plasma tissue partition coefficient ( kpulung )  was also simulated and used along with reported cmax and fraction unbound in plasma to derive a lung cmax ec50 as a better indicator of potential human efficacy ( lung cmax ec90 ratio was also calculable for a limited number of drugs ) .', ' using this parameter hydroxychloroquine ,  chloroquine ,  mefloquine ,  atazanavir ( boosted with ritonavir )  ,  tipranavir ( boosted with ritonavir )  ,  ivermectin ,  azithromycin and lopinavir ( boosted with ritonavir )  were all predicted to achieve lung concentrations over 10 - fold higher than their reported ec50.', ' this analysis was not possible for nelfinavir because insufficient data were available to calculate kpulung but nitozoxanide and sulfadoxine were also predicted to exceed their reported ec50 by 3.1 -  and 1.5 - fold in lung ,  respectively.']]"
azithromycin,"[' using this parameter hydroxychloroquine ,  chloroquine ,  mefloquine ,  atazanavir ( boosted with ritonavir )  ,  tipranavir ( boosted with ritonavir )  ,  ivermectin ,  azithromycin and lopinavir ( boosted with ritonavir )  were all predicted to achieve lung concentrations over 10 - fold higher than their reported ec50.']",Prioritisation of potential anti-SARS-CoV-2 drug repurposing opportunities based on ability to achieve adequate target site concentrations derived from their established human pharmacokinetics,10.1101/2020.04.16.20068379,"[[' moreover ,  most publications have focussed on 50% maximum effective concentrations ( ec50 )  ,  which may be an insufficiently robust indicator of antiviral activity because of marked differences in the slope of the concentration - response curve between drugs.', ' for all drugs reported ,  the unbound lung to plasma tissue partition coefficient ( kpulung )  was also simulated and used along with reported cmax and fraction unbound in plasma to derive a lung cmax ec50 as a better indicator of potential human efficacy ( lung cmax ec90 ratio was also calculable for a limited number of drugs ) .', ' using this parameter hydroxychloroquine ,  chloroquine ,  mefloquine ,  atazanavir ( boosted with ritonavir )  ,  tipranavir ( boosted with ritonavir )  ,  ivermectin ,  azithromycin and lopinavir ( boosted with ritonavir )  were all predicted to achieve lung concentrations over 10 - fold higher than their reported ec50.', ' this analysis was not possible for nelfinavir because insufficient data were available to calculate kpulung but nitozoxanide and sulfadoxine were also predicted to exceed their reported ec50 by 3.1 -  and 1.5 - fold in lung ,  respectively.']]"
angiotensin,"[' sars - cov - 2 relies on its spike protein ,  in particular the receptor binding domain ( rbd )  ,  to bind human cell receptor angiotensin - converting enzyme 2 ( ace2 )  for viral entry ,  and thus targeting rbd holds the promise for preventing sars - cov - 2 infection.']",Blocking antibodies against SARS-CoV-2 RBD isolated from a phage display antibody library using a competitive biopanning strategy,10.1101/2020.04.19.049643,"[[' it was proved to competitively block the binding of rbd to ace2 protein ,  and potently inhibit sars - cov - 2 pseudovirus infection of ace2 - overexpressing hela cells with ic50 values of 12nm.']]"
lopinavir,"[' therefore ,  it is urgently needed to identify effective antiviral agents for the treatment of this disease ,  and several approved drugs such as lopinavir have been evaluated.', '76 micro m respectively ,  the lowest of the nine hiv - 1 protease inhibitors including lopinavir.']",Nelfinavir inhibits replication of severe acute respiratory syndrome coronavirus 2 in vitro,10.1101/2020.04.06.026476,"[[' the effective concentrations for 50% and 90% inhibition ( ec50 and ec90 )  of nelfinavir were 1.13 micro m and 1.76 micro m respectively ,  the lowest of the nine hiv - 1 protease inhibitors including lopinavir.', ' the trough and peak serum concentrations of nelfinavir were three to six times higher than ec50 of this drug.']]"
nelfinavir,"[' here ,  we report that nelfinavir ,  an hiv - 1 protease inhibitor ,  potently inhibited replication of sars - cov - 2.', ' the effective concentrations for 50% and 90% inhibition ( ec50 and ec90 )  of nelfinavir were 1.', ' the trough and peak serum concentrations of nelfinavir were three to six times higher than ec50 of this drug.', ' these results suggest that nelfinavir is a potential candidate drug for the treatment of covid - 19 and should be assessed in patients with covid - 19.']",Nelfinavir inhibits replication of severe acute respiratory syndrome coronavirus 2 in vitro,10.1101/2020.04.06.026476,"[[' the effective concentrations for 50% and 90% inhibition ( ec50 and ec90 )  of nelfinavir were 1.13 micro m and 1.76 micro m respectively ,  the lowest of the nine hiv - 1 protease inhibitors including lopinavir.', ' the trough and peak serum concentrations of nelfinavir were three to six times higher than ec50 of this drug.']]"
angiotensin,[' the viral spike glycoprotein is very likely to interact with host angiotensin - converting enzyme 2 ( ace2 )  and transmits its genetic materials and hijacks host machinery with extreme fidelity for self propagation.'],Energetics based epitope screening in SARS CoV-2 (COVID 19) spike glycoprotein by Immuno-informatic analysis aiming to a suitable vaccine development,10.1101/2020.04.02.021725,"[[' we verified their structure quality ( swiss - model ,  phyre2 ,  pymol )  topology ( profunc )  ,  motifs ( meme suite ,  glam2scan )  ,  gene ontology based conserved domain ( interpro database )  and screened several epitopes ( svmtrip )  of sars cov - 2 based on their energetics ,  ic50 and antigenicity with regard to their possible glycosylation and mhc paratopic binding ( vaxigen v2.0 ,  hawkdock ,  zdock server )  effects.', ' we screened here few pairs of spike protein epitopic regions and selected their energetic ,  ic50 ,  mhc ii reactivity and found some of those to be very good target for vaccination.']]"
chloroquine,"[' moreover ,  we have evaluated two of these ,  chloroquine and chlorpromazine ,  in vivo using a mouse - adapted sars - cov model and found both drugs protect mice from clinical disease.']",Broad anti-coronaviral activity of FDA approved drugs against SARS-CoV-2 in vitro and SARS-CoV in vivo,10.1101/2020.03.25.008482,[[' we found that 17 of these inhibit sars - cov - 2 at a range of ic50 values at non - cytotoxic concentrations.']]
chlorpromazine,"[' moreover ,  we have evaluated two of these ,  chloroquine and chlorpromazine ,  in vivo using a mouse - adapted sars - cov model and found both drugs protect mice from clinical disease.']",Broad anti-coronaviral activity of FDA approved drugs against SARS-CoV-2 in vitro and SARS-CoV in vivo,10.1101/2020.03.25.008482,[[' we found that 17 of these inhibit sars - cov - 2 at a range of ic50 values at non - cytotoxic concentrations.']]
chymotrypsin,[' the chymotrypsin - like protease of sars - cov - 2 shares structure similarity with hcv and hiv proteases.'],First Clinical Study Using HCV Protease Inhibitor Danoprevir to Treat Naive and Experienced COVID-19 Patients,10.1101/2020.03.22.20034041,"[[' danoprevir ( ganovo )  is a potent hcv protease ( ns3 4a )  inhibitor ( ic50 = 0.29 nm )  ,  which was approved and marketed in china since 2018 to treat chronic hepatitis c patients.']]"
danoprevir,"[' we reported here the first clinical study using hepatitis c virus ( hcv )  protease inhibitor ,  danoprevir ,  to treat covid - 19 patients.', ' danoprevir ( ganovo )  is a potent hcv protease ( ns3 4a )  inhibitor ( ic50 = 0.', ' ritonavir is a cyp3a4 inhibitor to enhance plasma concentration of danoprevir while it also acts as a human immunodeficiency virus ( hiv )  protease inhibitor at high doses.', ' in the current clinical study (  nct04291729  )  conducted at the nineth hospital of nanchang ,  we evaluated therapeutic effects of danoprevir ,  boosted by ritonavir ,  on treatment nave and experienced covid - 19 patients.', ' the data from this small - sample clinical study showed that danoprevir boosted by ritonavir is safe and well tolerated in all patients.', ' after 4 to 12 - day treatment of danoprevir boosted by ritonavir ,  all eleven patients enrolled ,  two nave and nine experienced ,  were discharged from the hospital as they met all four conditions as follows: ( 1 )  normal body temperature for at least 3 days; ( 2 )  significantly improved respiratory symptoms; ( 3 )  lung imaging shows obvious absorption and recovery of acute exudative lesion; and ( 4 )  two consecutive rt - pcr negative tests of sars - cov - 2 nucleotide acid ( respiratory track sampling with interval at least one day ) .', ' our findings suggest that repurposing danoprevir for covid - 19 is a promising therapeutic option.']",First Clinical Study Using HCV Protease Inhibitor Danoprevir to Treat Naive and Experienced COVID-19 Patients,10.1101/2020.03.22.20034041,"[[' danoprevir ( ganovo )  is a potent hcv protease ( ns3 4a )  inhibitor ( ic50 = 0.29 nm )  ,  which was approved and marketed in china since 2018 to treat chronic hepatitis c patients.']]"
ritonavir,"[' ritonavir is a cyp3a4 inhibitor to enhance plasma concentration of danoprevir while it also acts as a human immunodeficiency virus ( hiv )  protease inhibitor at high doses.', ' in the current clinical study (  nct04291729  )  conducted at the nineth hospital of nanchang ,  we evaluated therapeutic effects of danoprevir ,  boosted by ritonavir ,  on treatment nave and experienced covid - 19 patients.', ' the data from this small - sample clinical study showed that danoprevir boosted by ritonavir is safe and well tolerated in all patients.', ' after 4 to 12 - day treatment of danoprevir boosted by ritonavir ,  all eleven patients enrolled ,  two nave and nine experienced ,  were discharged from the hospital as they met all four conditions as follows: ( 1 )  normal body temperature for at least 3 days; ( 2 )  significantly improved respiratory symptoms; ( 3 )  lung imaging shows obvious absorption and recovery of acute exudative lesion; and ( 4 )  two consecutive rt - pcr negative tests of sars - cov - 2 nucleotide acid ( respiratory track sampling with interval at least one day ) .']",First Clinical Study Using HCV Protease Inhibitor Danoprevir to Treat Naive and Experienced COVID-19 Patients,10.1101/2020.03.22.20034041,"[[' danoprevir ( ganovo )  is a potent hcv protease ( ns3 4a )  inhibitor ( ic50 = 0.29 nm )  ,  which was approved and marketed in china since 2018 to treat chronic hepatitis c patients.']]"
remdesivir,"[' currently clinical trials to repurpose remdesivir ,  a rdrp targeting pro - drug for ebola ,  to covid - 19 is under way.', ' these binding energies were less than the binding energies of the comparison group consisting of prior drugs remdesivir ,  favipiravir ,  and galidesivir.']",Deep learning-based computational drug discovery to inhibit the RNA Dependent RNA Polymerase: application to SARS-CoV and COVID-19,10.31219/osf.io/6kpbg,"[[' to address this need ,  a long short term memory ( lstm )  model from literature was trained to read the smiles fingerprint of a molecule and predict the ic50 of the molecule when binding to an rdrp.', ' this model was trained using ic50 binding data from the pdb database.', ' additionally ,  the 310 , 000 molecules with their predicted ic50s were used to train a generative semi - supervised variational autoencoder ( ssvae )  model from literature.', ' these 10 molecules and the 1025 molecules with the lowest predicted ic50s from the lstm model were docked onto the sars coronavirus ( a virus similar to covid - 19 )  rdrp using autodock vina.']]"
favipiravir,"[' these binding energies were less than the binding energies of the comparison group consisting of prior drugs remdesivir ,  favipiravir ,  and galidesivir.']",Deep learning-based computational drug discovery to inhibit the RNA Dependent RNA Polymerase: application to SARS-CoV and COVID-19,10.31219/osf.io/6kpbg,"[[' to address this need ,  a long short term memory ( lstm )  model from literature was trained to read the smiles fingerprint of a molecule and predict the ic50 of the molecule when binding to an rdrp.', ' this model was trained using ic50 binding data from the pdb database.', ' additionally ,  the 310 , 000 molecules with their predicted ic50s were used to train a generative semi - supervised variational autoencoder ( ssvae )  model from literature.', ' these 10 molecules and the 1025 molecules with the lowest predicted ic50s from the lstm model were docked onto the sars coronavirus ( a virus similar to covid - 19 )  rdrp using autodock vina.']]"
teriflunomide,"[' this work demonstrates that both our self - designed candidates and old drugs ( leflunomide teriflunomide )  with dual actions of antiviral and immuno - repression may have clinical potentials not only to influenza but also to covid - 19 circulating worldwide ,  no matter such viruses mutate or not.']","Novel and potent inhibitors targeting DHODH, a rate-limiting enzyme in de novo pyrimidine biosynthesis, are broad-spectrum antiviral against RNA viruses including newly emerged coronavirus SARS-CoV-2",10.1101/2020.03.11.983056,"[[' notably ,  s416 is reported to be the most potent inhibitor with an ec50 of 17nm and si value >5882 in sars - cov - 2 - infected cells so far.']]"
leflunomide,"[' this work demonstrates that both our self - designed candidates and old drugs ( leflunomide teriflunomide )  with dual actions of antiviral and immuno - repression may have clinical potentials not only to influenza but also to covid - 19 circulating worldwide ,  no matter such viruses mutate or not.']","Novel and potent inhibitors targeting DHODH, a rate-limiting enzyme in de novo pyrimidine biosynthesis, are broad-spectrum antiviral against RNA viruses including newly emerged coronavirus SARS-CoV-2",10.1101/2020.03.11.983056,"[[' notably ,  s416 is reported to be the most potent inhibitor with an ec50 of 17nm and si value >5882 in sars - cov - 2 - infected cells so far.']]"
oseltamivir,[' we also proposed the drug combination of daa and hta was a promising strategy for anti - virus treatment and proved that s312 showed more advantageous than oseltamivir to treat advanced influenza diseases in severely infected animals.'],"Novel and potent inhibitors targeting DHODH, a rate-limiting enzyme in de novo pyrimidine biosynthesis, are broad-spectrum antiviral against RNA viruses including newly emerged coronavirus SARS-CoV-2",10.1101/2020.03.11.983056,"[[' notably ,  s416 is reported to be the most potent inhibitor with an ec50 of 17nm and si value >5882 in sars - cov - 2 - infected cells so far.']]"
chloroquine,"[' chloroquine has been sporadically used in treating sars - cov - 2 infection.', ' hydroxychloroquine shares the same mechanism of action as chloroquine ,  but its more tolerable safety profile makes it the preferred drug to treat malaria and autoimmune conditions.', ' we propose that the immunomodulatory effect of hydroxychloroquine also may be useful in controlling the cytokine storm that occurs late phase in critically ill patients with sars - cov - 2.', ' currently ,  there is no evidence to support the use of hydroxychloroquine in sars - cov - 2 infection.', ' methods: the pharmacological activity of chloroquine and hydroxychloroquine was tested using sars - cov - 2 - infected vero cells.', "" using the pbpk models ,  hydroxychloroquine concentrations in lung fluid were simulated under 5 different dosing regimens to explore the most effective regimen while considering the drug's safety profile."", ' results: hydroxychloroquine ( ec50 = 0.', '72 m )  was found to be more potent than chloroquine ( ec50 = 5.', ' based on pbpk models results ,  a loading dose of 400 mg twice daily of hydroxychloroquine sulfate given orally ,  followed by a maintenance dose of 200 mg given twice daily for 4 days is recommended for sars - cov - 2 infection ,  as it reached 3 times the potency of chloroquine phosphate when given 500 mg twice daily 5 days in advance.', ' conclusions: hydroxychloroquine was found to be more potent than chloroquine to inhibit sars - cov - 2 in vitro.']",In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2),10.1093/cid/ciaa237,[[' results: hydroxychloroquine ( ec50 = 0.72 m )  was found to be more potent than chloroquine ( ec50 = 5.47 m )  in vitro.']]
sulfate,"[' based on pbpk models results ,  a loading dose of 400 mg twice daily of hydroxychloroquine sulfate given orally ,  followed by a maintenance dose of 200 mg given twice daily for 4 days is recommended for sars - cov - 2 infection ,  as it reached 3 times the potency of chloroquine phosphate when given 500 mg twice daily 5 days in advance.']",In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2),10.1093/cid/ciaa237,[[' results: hydroxychloroquine ( ec50 = 0.72 m )  was found to be more potent than chloroquine ( ec50 = 5.47 m )  in vitro.']]
hydroxychloroquine,"[' hydroxychloroquine shares the same mechanism of action as chloroquine ,  but its more tolerable safety profile makes it the preferred drug to treat malaria and autoimmune conditions.', ' we propose that the immunomodulatory effect of hydroxychloroquine also may be useful in controlling the cytokine storm that occurs late phase in critically ill patients with sars - cov - 2.', ' currently ,  there is no evidence to support the use of hydroxychloroquine in sars - cov - 2 infection.', ' methods: the pharmacological activity of chloroquine and hydroxychloroquine was tested using sars - cov - 2 - infected vero cells.', "" using the pbpk models ,  hydroxychloroquine concentrations in lung fluid were simulated under 5 different dosing regimens to explore the most effective regimen while considering the drug's safety profile."", ' results: hydroxychloroquine ( ec50 = 0.', ' based on pbpk models results ,  a loading dose of 400 mg twice daily of hydroxychloroquine sulfate given orally ,  followed by a maintenance dose of 200 mg given twice daily for 4 days is recommended for sars - cov - 2 infection ,  as it reached 3 times the potency of chloroquine phosphate when given 500 mg twice daily 5 days in advance.', ' conclusions: hydroxychloroquine was found to be more potent than chloroquine to inhibit sars - cov - 2 in vitro.']",In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2),10.1093/cid/ciaa237,[[' results: hydroxychloroquine ( ec50 = 0.72 m )  was found to be more potent than chloroquine ( ec50 = 5.47 m )  in vitro.']]
phosphate,"[' based on pbpk models results ,  a loading dose of 400 mg twice daily of hydroxychloroquine sulfate given orally ,  followed by a maintenance dose of 200 mg given twice daily for 4 days is recommended for sars - cov - 2 infection ,  as it reached 3 times the potency of chloroquine phosphate when given 500 mg twice daily 5 days in advance.']",In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2),10.1093/cid/ciaa237,[[' results: hydroxychloroquine ( ec50 = 0.72 m )  was found to be more potent than chloroquine ( ec50 = 5.47 m )  in vitro.']]
dipyridamole,[' we screened an fda approved drug library and found that an anticoagulant agent dipyridamole ( dip )  suppressed hcov - 19 replication at an ec50 of 100 nm in vitro .'],Therapeutic effects of dipyridamole on COVID-19 patients with coagulation dysfunction,10.1101/2020.02.27.20027557,[[' we screened an fda approved drug library and found that an anticoagulant agent dipyridamole ( dip )  suppressed hcov - 19 replication at an ec50 of 100 nm in vitro .']]
lopinavir,"[' for example ,  the ic50 of lopinavir ,  an hiv protease inhibitor ,  against the 3c - like protease is approximately 50 micromolar ,  which is far from ideal.']",Potential COVID-2019 3C-like Protease Inhibitors Designed Using Generative Deep Learning Approaches,10.26434/chemrxiv.11829102.v2,"[[' for example ,  the ic50 of lopinavir ,  an hiv protease inhibitor ,  against the 3c - like protease is approximately 50 micromolar ,  which is far from ideal.']]"
lopinavir,"[' for example ,  the ic50 of lopinavir ,  an hiv protease inhibitor ,  against the 3c - like protease is approximately 50 micromolar.']",Potential 2019-nCoV 3C-like Protease Inhibitors Designed Using Generative Deep Learning Approaches,10.26434/chemrxiv.11829102.v1,"[[' for example ,  the ic50 of lopinavir ,  an hiv protease inhibitor ,  against the 3c - like protease is approximately 50 micromolar.']]"
glutamine,[' the main protease of coronaviruses and the 3c protease of enteroviruses share a similar active - site architecture and a unique requirement for glutamine in the p1 position of the substrate.'],Alpha-ketoamides as broad-spectrum inhibitors of coronavirus and enterovirus replication,10.1101/2020.02.10.936898,"[[' the best near - equipotent inhibitors ,  11u ( p2 = cyclopentylmethyl )  and 11r ( p2 = cyclohexylmethyl )  ,  display low - micromolar ec50 values against enteroviruses ,  alphacoronaviruses ,  and betacoronaviruses in cell cultures.']]"
